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Summary 
 
Gliotoxin is a toxic fungal metabolite that is produced by Aspergillus fumigatus, 
amongst other species. Gliotoxin contains a disulfide bridge that has been significantly 
implicated in its toxicity. Research has demonstrated that gliotoxin displays 
immunomodulating capacity and anti-viral activity, and induces apoptosis and necrosis. 
The gli gene cluster responsible for gliotoxin biosynthesis has recently been identified 
and is continually being further characterised. In this study, evidence is provided that 
strongly suggests gliotoxin exposure causes conditions of oxidative stress in yeast cells. 
Additionally, the GliT gene, which is part of the said gliotoxin biosynthesis cluster, is 
shown to confer resistance to gliotoxin in Saccharomyces cerevisiae. 
Prions are infectious proteins that are known to be responsible for a number of 
neurodegenerative disorders in mammals, such as Creutzfeldt-Jakob Disease (CJD) and 
Bovine Spongiform Encephalopathy (BSE). Fungal prions also exist, which provide a 
useful tool for studying the propagation of these non-mendelian genetic elements. 
Possibly the most widely-studied S. cerevisiae prion is [PSI+], which is the prion form 
of Sup35p, a protein that functions in translation termination. In this study, the effects of 
three prion-curing agents, Tacrine, 6-aminophenanthridine and Guanabenz on [PSI+] 
have been studied. The ability of all three drugs to cure [PSI+] has been demonstrated. 
From investigating the Tacrine mode of action, it appears that this drug may inhibit 
Hsp104p, a chaperone that is involved in prion propagation. Differences in the mode of 
action of Tacrine, compared to 6-aminophenanthridine and Guanabenz have also been 
highlighted. Additional results suggest that Ltv1p and Yar1p, which contribute to 
ribosome stability, are important for regular recovery from heatshock, thus potentially 
implicating them in prion propagation. 
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Chapter 1   Introduction 
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Part 1 Using Saccharomyces cerevisiae as a model organism to 
investigate the eukaryotic response to the toxic fungal metabolite 
gliotoxin 
 
 
 
1.1 Aspergillus fumigatus, a pathogenic fungus 
 
Aspergillus fumigatus, one of the six Aspergillus subgenera, is a ubiquitous, 
saprophytic fungus described in 1863 by Fresenius following isolation from avian lungs 
(Pitt, 1994). Aspergillus species naturally occur in soil and organic matter undergoing 
decomposition and their ability to form spores allows for widespread contamination 
(Hinson et al., 1952). The number of airborne spores has been reported to be more 
elevated in winter, with increase in water presence from rainfall and decay of plant 
vegetation being principal causes suggested for this (Mullins et al., 1976).  
The fact that A. fumigatus spores are just 2.5-3 µm in diameter allows easy 
access to mammalian hosts via inhalation followed by accumulation due to a high level 
of spore thermotolerance (Bateman, 1994). Colonisation by this fungus can give rise to 
a number of different types of host infections (figure 1.1), usually depending on host 
predisposition. Pulmonary migration leading to allergic bronchopulmonary aspergillosis 
(ABPA) has been mainly found to occur in those suffering from pulmonary diseases 
such as cystic fibrosis and prolonged asthma (Bardana et al., 1975, Louridas, 1976, 
Laufer et al., 1984, Soubani and Chandrasekar, 2002). Aspergillomas, fungal masses 
composed of mycelia and mucous, were first described by Deve (1938) and are also 
characteristic of Aspergillus infection. These assemblages form in pre-existing 
pulmonary cavities that are often remnant of tuberculosis infection, sarcoidosis and 
severe pneumonia (Hinson et al., 1952, Tomlinson and Sahn, 1987). Invasive 
aspergillosis (IA) has been found to affect the immunocompromised, including those 
infected with HIV, cancer patients and people who have undergone transplant surgery 
(Meunier-Carpentier, 1983, Weiland et al., 1983, Trull et al., 1985, Marisavljević et al., 
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1989, Rodríguez-Arrondo et al., 1991). IA usually occurs following A. fumigatus entry 
though the respiratory tract, damaged skin, operative wounds, the ear or the cornea 
(Denning, 1998). This is the most deadly form of colonisation and if left untreated can 
result in a mortality rate of almost 100% (Denning, 1996). 
A. fumigatus has the capacity to form biofilm on bronchial epithelial cells and 
this form of growth displays increased resistance to drug treatment (Seidler et al., 2008, 
Beauvais and Müller, 2009, Müller et al., 2011). 
 
     
 
 
 
                     
     
 
 
 
 
 
Figure 1.1 A = Image of A. fumigatus. B = A. fumigatus biofilm on bronchial 
epithelial cells. C = Aspergilloma in lung of child suffering from leukaemia. 
Images from www.aspergillus.org.uk. 
 
A range of secondary metabolites are produced by A. fumigatus that are 
contributory factors to fungal pathogenicity, such as restrictocin, verruculogen, 
fumagillin, helvolic acid, ergot alkaloids, fumitremorgin and importantly, gliotoxin  
(Dagenais and Keller, 2009). It is thought that mycotoxins such as these are produced to 
A B
C
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assist the fungus in evading the host immune system and facilitating colonisation (Latgé, 
1999).  
 
1.2 Gliotoxin 
1.2.1 Structure and description 
Gliotoxin (figure 1.2) is a 326 Da fungal metabolite produced by A. fumigatus, 
in addition to certain strains of Trichoderma and Gliocladium and a number of 
Penicillium and Candida species (Weindling and Emerson, 1936, Shah and Larsen, 
1991, Richard et al., 1994, Kamei and Watanabe, 2005). This highly toxic 
epipolythiodioxopiperazine (ETP) contains a redox-sensitive disulfide bridge, 
characteristic of this group of toxins, which is implicated in A. fumigatus virulence 
(Trown and Bilello, 1972, Müllbacher et al., 1986). Diketopiperazines are the smallest 
cyclic peptides documented, containing a heterocyclic system, and gliotoxin falls into 
this group (Martins and Carvalho, 2007, Gross et al., 2010). The core ETP moiety 
amino acids of this toxin are phenylalanine and serine (Suhadolnik and Chenowith, 
1958, Winstead and Suhadolnik, 1960, Gardiner et al., 2005). 
  
 
 
 
 
 
Figure 1.2 Structure of gliotoxin. Image from www.aspergillus.org.uk. 
This nonribosomal peptide is just one of at least fourteen ETPs documented to 
date (Gardiner et al., 2005). Gliotoxin can occur in the oxidised (natural) form, depicted 
in figure 1.2, or in the reduced (dithiol) form if the disulfide bridge has undergone 
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reduction by a suitable reducing agent such as glutathione, as discussed later (Trown 
and Bilello, 1972, Eichner et al., 1988). 
 
1.2.2 Production 
In addition to A. fumigatus, the species A. niger, A. terrus and A. flavus have 
been reported to produce gliotoxin, although not all Aspergillus species appear to. Of 
these species A. fumigatus was documented as the isolate that consistently produced the 
highest level of the toxin (Lewis et al., 2005, Kupfahl et al., 2008). Gliotoxin appears to 
be heavily involved in A. fumigatus cytotoxicity due to its high production level, 
however, in the other strains mentioned above, the low level of the toxin generated is 
thought to be inadequate to influence cytotoxic effects of the strains (Kupfahl et al., 
2008). 
During biofilm formation, there is a strong increase in the expression of 
gliotoxin by A. fumigatus, while there is a reduction in the level of metabolic activity 
(Bruns et al., 2010). A twelve-gene cluster (gli cluster) has been identified as being 
responsible for gliotoxin production in A. fumigatus, and has similarity to that culpable 
for the generation of another ETP, sirodesmin, in Leptosphaeria maculans (Gardiner et 
al., 2004, Gardiner and Howlett, 2005). This cluster, illustrated in figure 1.3, has been 
predicted to produce a zinc finger transcription factor encoded by gliZ, an 
aminocyclopropane carboxylic acid synthase encoded by gliI, a dipeptidase encoded by 
gliJ, a peptide synthetase encoded by gliP, two cytochrome P450 monooxygenases 
encoded by gliC and gliF, an O-methyl transferase encoded by gliM, a glutathione S-
transferase encoded by gliG, a hypothetical protein encoded by gliK, a transporter 
protein encoded by gliA, a methyl transferase encoded by gliN and a thioredoxin 
reductase encoded by gliT. Interestingly, gliotoxin presence has been shown to induce 
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upregulation of genes belonging to this cluster (Cramer et al., 2006, Schrettl et al., 
2010).  
   
 
 
 
 
 
Figure 1.3 12-gene gliotoxin biosynthetic cluster, gli cluster. Image reproduced from 
Gardiner and Howlett (2005).  
 
There is still much to be elucidated on the subject of gliotoxin biosynthesis and 
release. For gliotoxin to be synthesised in A. fumigatus, GliZp must be present, which is 
responsible for the transcriptional expression of other genes in the gli cluster (Bok et al., 
2006). GliPp has been determined to be a nonribosomal peptide synthetase (NRPS) 
involved in the formation of the gliotoxin diketopiperazine scaffold (Balibar and Walsh, 
2006, Cramer et al., 2006). A shunt metabolite has been identified by Davis et al. (2011) 
that accumulates in the absence of GliGp and lacks sulfur atoms necessary for disulfide 
bridge formation. It has been suggested that the glutathione S-transferase GliGp is 
involved in the addition of sulfur to the precursor of this shunt metabolite, that can 
subsequently be transformed into gliotoxin (Davis et al., 2011). Disruption of either 
GliGp or GliPp renders A. fumigatus unable to produce gliotoxin (Cramer et al., 2006, 
Kupfahl et al., 2006, Davis et al., 2011). Schrettl et al. (2010) predict that prior to efflux, 
gliotoxin may undergo importation into intracellular vesicles for storage.  
Is has been proposed that another protein, LaeAp, plays an important role in 
secondary metabolism regulation in Aspergillus species, impacting on the ability of the 
fungus to colonise the host (Bok and Keller, 2004). A. fumigatus ∆laeA exhibits 
impaired virulence affiliated with loss of gliotoxin production (Bok et al., 2005). 
gliZ gliI gliJ gliP gliC gliM gliKgliG gliA gliN gliF gliT
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1.2.3 General effects of gliotoxin 
There are two principal ways in which gliotoxin has been shown to cause 
deleterious effects in the cell. Firstly, the functionally indispensible disulfide bridge can 
conjugate to proteins that have susceptible thiol residues, leading to protein inactivation 
e.g. the transcription factor NF-kB which plays a key role in immune response (Pahl et 
al., 1996, Gardiner et al., 2005). Secondly, upon cellular uptake of gliotoxin, redox 
cycling can occur, whereby in the presence of a suitable reducing agent the disulfide 
form of the toxin can be processed into the dithiol form. This can then undergo re-
oxidation with the return of the disulfide form (Eichner et al., 1988). One of the main 
initiators of this redox cycling is glutathione and characteristic of this process is the 
production of hydrogen peroxide and superoxide (Waring and Beaver, 1996), as 
illustrated in figure 1.4. Oxidative stress and the generation of reactive oxygen species 
in the presence of gliotoxin is discussed further in section 1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Redox cycling of GT within the cell induces ROS production and 
oxidative stress. 
Oxidised GT
Natural disulfide form
sssHsH
Reductant
e.g. glutathione
O2−
H2o2
production
 7 
The toxicity of gliotoxin is appears to be heavily influenced by the concentration 
of glutathione. Within SH-SY5Y cells, glutathione presence heightens the cytotoxicity 
of gliotoxin (Axelsson et al., 2006).       
Interestingly, gliotoxin has been found at nanomolar concentrations to exhibit 
anti-oxidant and anti-angiogenic activity itself. The metabolite can mimic peroxiredoxin 
function of the thioredoxin redox system whereby it reduces H2O2 to H2O by accepting 
electrons from NADPH (Choi et al., 2007). It has since been suggested that gliotoxin is 
an ‘accidental toxin’ and that it was originally synthesised to protect A. fumigatus 
against oxidative stress, such as is caused by H2O2 (Schrettl et al., 2010).  
 
1.2.4 The effects of gliotoxin on the immune response 
Gliotoxin was first shown three decades ago to have immunosuppressive activity, 
which can aid in host colonisation. This metabolite induces apoptotic cell death in 
macrophages (Waring et al., 1988, Waring, 1990) and represses macrophage function, 
such as phagocytosis, adherence, bactericidal activity and induction of alloreactive 
cytotoxic T cells (Müllbacher and Eichner, 1984, Eichner et al., 1986). Gliotoxin can 
target and kill antigen-presenting cells such as monocytes and dendritic cells, thus 
repressing antigen-presentation and appears to actively inhibit T-cell response (Stanzani 
et al., 2005). NF-kB activation is abrogated in various cell lines under exposure to the 
toxin, preventing the regulation of inflammatory cytokines, growth factors and receptors 
and adhesion molecules (Pahl et al., 1996). It has been reported that gliotoxin hinders 
the ability of polymorphonuclear neutrophils to generate reactive oxygen species and 
carry out phagocytosis (Orciuolo et al., 2007) and also inhibits Langerhans’ cell 
function and cutanaeous foreign antigen response (McMinn et al., 1990).  
Although gliotoxin principally obstructs the host immune response through 
immunosuppression to prevent fungal eradication, the toxin has also been shown  
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to induce inflammation. The presence of a low concentration of gliotoxin has been 
reported to instigate a decrease in host expression of the anti-inflammatory cytokine IL-
10 and an increase in production of the pro-inflammatory cytokine TNF-α (Johannessen 
et al., 2005). 
 
1.2.5 Gliotoxin anti-viral activity 
Many researchers have demonstrated gliotoxin toxicity against various bacteria 
and fungi (McDougall, 1969, Aljofan et al., 2009) but it has long been known that 
gliotoxin also has anti-viral activity, which is attributed to specific inhibition of viral 
RNA replication (Rightsel et al., 1964, Larin et al., 1965, Miller et al., 1968). Some of 
the viruses found to be negatively affected by this toxin are polio virus, herpes simplex 
virus, influenza virus, coxsackie virus, Sendai virus, Newcastle disease virus and 
measles virus (Rightsel et al., 1964, Larin et al., 1965, McDougall, 1969, Aljofan et al., 
2009). It has been demonstrated that reduction of the toxin or removal of the sulphur 
atoms renders gliotoxin unable to inhibit viral RNA synthesis like its natural disulfide 
counterpart (Trown and Bilello, 1972, Rodriguez and Carrasco, 1992). 
 
1.2.6 Gliotoxin-induced apoptosis and necrosis 
Beaver and Waring (1994) demonstrated that concentrations of gliotoxin above 
10 µM favour induction of thymocyte cell death by necrosis, rather than apoptosis, 
which is seen during exposure to relatively lower concentrations. It has since been 
demonstrated that this applies to other cell lines, with hepatic, epithelial, fibroblast and 
macrophage cells undergoing apoptosis or necrosis in the presence of low or high toxin 
concentrations respectively (Kweon et al., 2003, DeWitte-Orr and Bols, 2005). Reports 
have also described how the mode of cell death also may be dependent on the cell type, 
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as it was observed that gliotoxin preferentially kills fibroblasts and epithelial cells via 
necrosis and macrophages via apoptosis (DeWitte-Orr and Bols, 2005).          
 
1.3 GliTp 
GliTp is a FAD-dependent 36 kDa protein that is encoded by a gene that is part 
of the gli cluster, described above (Gardiner and Howlett, 2005, Scharf et al., 2010, 
Schrettl et al., 2010). Loss of GliT in A. fumigatus results in a severe increase in 
sensitivity to gliotoxin, demonstrating the importance of GliTp in protection against this 
endogenous toxin (Scharf et al., 2010, Schrettl et al., 2010). The introduction of GliT 
into the non-gliotoxin producing species Saccharomyces cerevisiae and Aspergillus 
nidulans conferred resistance to exogenous gliotoxin application (Schrettl et al., 2010). 
From work with A. fumigatus, it appears that GliTp is involved in preventing the 
depletion of reduced glutathione in the presence of gliotoxin, as glutathione 
supplementation restored wild-type phenotype in the ∆gliT strain (Schrettl et al., 2010). 
Importantly, another consequence of GliTp absence is the lack of A. fumigatus ability to 
produce gliotoxin (Schrettl et al., 2010). Research has demonstrated that GliTp displays 
gliotoxin reductase activity and it has been suggested that direct gliotoxin reduction 
occurs prior to secretion from A. fumigatus (Schrettl et al., 2010). 
It seems that GliT is differentially expressed relative to the other gli cluster 
genes as GliT expression is induced by gliotoxin, even in the absence of GliZ, encoding 
the transcriptional regulator of the gli cluster. Also, it has been previously shown that 
loss of GliZp abolishes expression of gli cluster genes, except for GliT (Bok et al., 2006, 
Schrettl et al., 2010).  
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1.4 Oxidative stress 
1.4.1 Description  
Growth of organisms in oxygen-containing environments results in the 
generation of reactive oxygen species (ROS) such as the superoxide anion (O2-), 
hydroxyl radical (OH•) and hydrogen peroxide (H2O2), which are formed inadvertently 
when molecular oxygen is reduced during oxidative phosphorylation (Lushchak, 2011). 
OH• is more reactive than H2O2, which in turn is more reactive than O2- (Lushchak, 
2011). O2- can cause enzyme inactivation through oxidising functional iron clusters and 
induces aromatic and sulfur-containing amino acid auxotrophy (Flint et al., 1993, Imlay, 
2003). H2O2 can oxidise sulfur atoms, thereby affecting sulfur-containing amino acids 
such as cysteine and methionine, while OH• can oxidise the majority of organic 
molecules and generate protein and lipid radicals (Slump and Schreuder, 1973, Powell, 
2000, Imlay, 2003).   
Overall, ROS have been shown to display non-specific mutagenic, protein 
modification/damage and lipid peroxidation capacities (Farr et al., 1986, Halliwell, 
1991, Costa et al., 2007). Consistent damage by ROS, accompanied by cellular inability 
to successfully control the causative agents is termed oxidative stress (OS) (Halliwell, 
1994). 
    
1.4.2 Causative agents 
 
Various compounds, such as metals, have the capacity to impose increased 
cellular OS. The presence of metal ions facilitates the oxidative modification of proteins 
by ROS, which is followed by selective degradation by proteases (Stadtman, 1990). Iron 
can reduce oxygen to O2- and catalyse peroxide decomposition resulting in the 
production of OH• (Fraga and Oteiza, 2002). Thus, an organisms ability to regulate the 
separation of iron and molecular oxygen is crucial (Valko et al., 2005). Copper can also 
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catalyse the generation of OH• and, like iron, can cause DNA damage through strand 
breaks (Kawanishi et al., 1989, Kadiiska et al., 1993). Cadmium has also been 
implicated in causing significant levels of cellular OS. The detrimental effects of this 
heavy metal are mediated by ROS and result in the obstruction of oxidative DNA 
damage repair (Filipic and Hei, 2004). The ability of lead to induce OS has been well 
documented and Ercal et al. (2001) evaluated the possible mechanisms employed for 
stress imposition; the effect of the metal on cell membranes, its interaction with 
haemoglobin, its inhibition of heme synthesis regulation and ROS generation and the 
metal’s effect on cellular antioxidant defence. 
There are also non-metal catalysts that exhibit OS-causing capabilities, such as 
quinones and paraquat. Quinones undergo redox cycling whereby they are reduced by 
cellular reductases and then reoxidised, and this process is accompanied by the 
generation of by-products O2- and H2O2 (Brunmark and Cadenas, 1989). Cellular 
exposure to paraquat augments the generation of ROS and induces mitochondrial 
dysfunction (McCarthy et al., 2004). 
          
1.5 S. cerevisiae oxidative stress response 
Due to the damage that can be caused by OS, organisms continually work to 
protect cells and maintain redox state, and yeast are no different employing both 
enzymatic and non-enzymatic processes to do so (Jamieson, 1998). Common yeast 
responses and individual pathways are discussed below in more detail. 
 
1.5.1  Glutathione  
 Glutathione (L-γ-glutamyl-L-cysteinylglycine/GSH) is possibly one of the most 
important molecules produced in response to OS. This tripeptide is a free radical 
scavenger and reduces oxidising species to prevent them causing damage to cellular 
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constituents. Upon reaction, peroxide detoxification leads to the formation of GSSG, the 
oxidised or disulfide form of GSH (Pompella et al., 2003). The GSH sulfhydral or free 
thiol group is thus functionally essential and its ability to confer stability to the thiol has 
been recorded (Meister, 1988). Under normal circumstances, less than 1% of the total 
cellular glutathione content is in the form of GSSG and therefore, measurement of the 
GSH:GSSG ratio has been used for decades as an indication of the level of OS imposed 
on cells (Güntherberg and Rost, 1966, Lauterburg et al., 1984). The enzymatic function 
of NADPH-dependent glutathione reductase is critical for the regeneration of GSH from 
GSSG, to maintain cellular antioxidant capacity (Meldrum and Tarr, 1935, Conn and 
Vennesland, 1951). Glutathione reductase is encoded by GLR1 in S. cerevisiae (Grant et 
al., 1996). In 1951, Mills reported that there is a factor that works in union with GSH to 
abrogate haemoglobin oxidative breakdown. This factor exhibited peroxidase activity 
and employed GSH as hydrogen donor (Mills, 1957). The evaluation of glutathione 
peroxidases has since resulted in the conclusion that these enzymes have cellular 
protective abilites and prevent membrane and protein oxidation by reducing ROS. This 
process involves the exploitation of GSH as a cofactor and its oxidation to GSSG 
(Meister, 1988). Yeast can synthesise three glutathione peroxidases, which are encoded 
by GPX1, GPX2 and GPX3 (Inoue et al., 1999). GSH can also form mixed disulfides 
with cellular protein thiols, a process termed S-glutathionylation, protecting vulnerable 
proteins from oxidation and irreversible damage (Herrero et al., 2008).                     
 
1.5.1.1  Glutathione biosynthesis  
The pathway that leads to the production of this important thiol has been well 
documented to date. Glutathione biosynthesis is dependent on the precursor amino acids 
glutamate, glycine and cysteine, the latter being a product of the superpathway of sulfur 
amino acid biosynthesis (Penninckx, 2002).  
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The sulfur amino acid biosynthesis pathway commences with sulfate 
assimilation and involves subsequent reduction to sulfide involving the formation of a 
number of intermediates. This process is regulated in S. cerevisiae by proteins encoded 
by MET3 (Cherest et al., 1985, Cherest et al., 1987), MET14 (Masselot and De 
Robichon-Szulmajster, 1975, Korch et al., 1991), MET16 (Thomas et al., 1990), MET5 
(Mountain et al., 1991), and MET10 (Hansen et al., 1994). Sulfide is then implicated in 
the generation of homocysteine, which is required for methionine and cysteine 
production. Homoserine, produced from aspartate, is activated through esterification 
resulting in the generation of O-acetylhomoserine which is then sulfhydralased and 
sulfide is incorporated into the carbon chain, giving rise to homocysteine (Thomas and 
Surdin-Kerjan, 1997). This process whereby homoserine and subsequently 
homocysteine are formed is catalysed by enzymes encoded by HOM3 (Rafalski and 
Falco, 1988), HOM2 (Thomas and Surdin-Kerjan, 1989), HOM6 (Yumoto et al., 1991, 
Arévalo-Rodríguez et al., 2004), MET2 (Masselot and De Robichon-Szulmajster, 1975, 
Baroni et al., 1986) and MET17 (Yamagata et al., 1975, D'Andrea et al., 1987, 
Brzywczy and Paszewski, 1993). 
Homocysteine can be metabolised to create methionine, or can act as a key 
protein in the transsulfuration pathway (Finkelstein, 1998). Biosynthesis of the folate 
polyglutamate 5-methyltetrahydrofolate is catalysed by MET7 and prerequisite to 
methionine biosynthesis (Boyer et al., 1996, Cherest et al., 2000, DeSouza et al., 2000). 
The MET6 gene product, methionine synthase, then catalyses the transfer of a methyl 
group to homocysteine, yielding methionine (Csaikl and Csaikl, 1986, González et al., 
1992, Suliman et al., 2005). S-adenosyl-methionine (AdoMet) can be generated from 
methionine by two synthetases encoded by SAM1 and SAM2 (Chiang and Cantoni, 1977, 
Cherest and Surdin-Kerjan, 1978, Thomas and Surdin-Kerjan, 1991). Both methionine 
and AdoMet can then negatively regulate enzymes involved in sulfur assimilation and 
 14 
sulfur amino acid biosynthesis (Cherest et al., 1969). Homocysteine retains a vital 
function in cysteine biosynthesis, in addition to methionine production. The 
transsulfuration pathway in S. cerevisiae involves the interconversion of homocysteine 
and cysteine with the generation of the intermediary, cystathionine (Cherest et al., 1993). 
Cystathionine β-synthase, encoded by CYS4, converts homocysteine to cystathionine, 
which can then be modified to generate cysteine by cystathionine γ-lyase, encoded by 
CYS3 (Ono et al., 1988, Cherest and Surdin-Kerjan, 1992, Ono et al., 1992, Ono et al., 
1994). The opposing side of the transsulfuration pathway sees the generation of 
cystathionine from cysteine, catalysed by cystathionine γ-synthase, encoded by STR2 
and the subsequent regeneration of homocysteine by cystathionine β-lyase, encoded by 
STR3 (Cherest et al., 1993, Hansen and Johannesen, 2000).  
Cysteine and glutamate have the potential to combine to form L-γ-
glutamylcysteine, under the catalytic function of the synthetase encoded by GSH1, the 
first step of glutathione biosynthesis (Ohtake and Yabuuchi, 1991, Wu and Moye-
Rowley, 1994). Thus, the rate-limiting step of cysteine biosynthesis is in itself required 
for protection against oxidative damage (Williamson et al., 1982). Glutathione 
synthetase encoded by GSH2 mediates the formation of glutathione from L-γ-
glutamylcysteine and glycine (Grant et al., 1997, Inoue et al., 1998), facilitating the 
yeast stress response, as described above.   
 
1.5.2  The thioredoxin system 
Thioredoxin is a small protein that can exist in either a reduced or oxidised form, 
due to a redox active disulfide bridge (Söderberg et al., 1978, Holmgren, 1985). In 
combination with thioredoxin reductase (TrxR) and NADPH, thioredoxin (Trx) makes 
up the thioredoxin system, which can act as a hydrogen donor for ribonucleotide 
reductase (Laurent et al., 1964, Berglund et al., 1969). Yeast thioredoxin is in fact 
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involved in sulfate assimilation and thus sulfur amino acid biosynthesis (Gonzalez 
Porqué et al., 1970). TrxR reduces Trx, maintaining it in the sulfhydral state, using 
NADPH. Trx can then reduce other protein disulfides, including GSSG (Nordberg and 
Arnér, 2001). Trx also functions in the reduction of Trx peroxidase (peroxiredoxin). 
Donating electons to Trx peroxidase enables the enzyme to directly reduce peroxides, 
such as H2O2 (Chae et al., 1994, Kang et al., 1998). 
Three S. cerevisiae genes encode thioredoxin, TRX1, TRX2 (both cytoplasmic 
thioredoxins) and TRX3 (a mitochondrial thioredoxin) (Muller, 1991, Muller, 1992, 
Pedrajas et al., 1999). TRR1 encodes a yeast cytoplasmic TrxR, which when absent 
results in hypersensitivity to OS (Chae et al., 1994, Machado et al., 1997). The Trr1p, 
Trx1p, Trx2p defence system is important not only in protecting against OS but also 
against reductive stress (Trotter and Grant, 2002). S. cerevisiae encodes an additional 
TrxR, TRR2, which makes up the mitochondrial thioredoxin system in combination with 
TRX3. This system plays a role in preservation against respiratory metabolism-
generated OS (Pedrajas et al., 1999).      
 
1.5.3  The glutaredoxin system 
The glutaredoxin system comprises GSH, glutaredoxin (Grx), NADPH and the 
already discussed glutathione reductase (Holmgren, 1979). Like thioredoxins, 
glutaredoxins are heat-stable oxidoreductases and play a glutathione-dependent role in 
delivering electrons to ribonucleotide reductase (Holmgren, 1976). As stated before, 
proteins containing cysteine residues are particularly vulnerable to modification during 
OS. As an OS protection mechanism, Grx can induce reversible glutathionylation 
through catalysing mixed disulfide formation between GSH and susceptible protein 
thiols (Yoshitake et al., 1994, Ruoppolo et al., 1997, Shelton et al., 2005). During OS in 
mammalian cell lines, Grx interaction with the Ask1p can be disrupted, activating 
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signalling pathways that lead to cell death, demonstrating the role of Grx in redox-
sensing in addition to cellular protection (Song et al., 2002). Two genes encoding 
dithiol glutaredoxin were initially found to be present in S. cerevisiae, GRX1 and GRX2, 
and were reported to be important in protection against OS. The gene with a more 
prominent role in resisting this stress appears to be GRX2 (Gan et al., 1990, Luikenhuis 
et al., 1998). Following this, a further five genes were identified as monocysteinic 
glutaredoxins, GRX3, GRX4, GRX5, GRX6 and GRX7 (Rodríguez-Manzaneque et al., 
1999, Pujol-Carrion et al., 2006, Izquierdo et al., 2008, Mesecke et al., 2008, Pujol-
Carrion and de la Torre-Ruiz, 2010). An eighth yeast glutaredoxin gene, GRX8 
encoding a third dithiol, has since been documented although it does not appear to 
protect against OS (Mesecke et al., 2008, Eckers et al., 2009). 
 
1.5.4  Superoxide dismutase 
Superoxide dismutases are a group of enzymes that have the capacity to 
dismutate O2- yielding O2 and H2O2 (McCord and Fridovich, 1968, McCord and 
Fridovich, 1969b). Across eukaryotic and prokaryotic species, four main classes of 
superoxide dismutase (SOD) have been recorded to date, with differing cofactors. These 
are manganese-containing SOD (MnSOD), iron-containing SOD (FeSOD), copper- and 
zinc-containing SOD (CuZnSOD) and nickel-containing SOD (NiSOD) (McCord and 
Fridovich, 1969a, Carrico and Deutsch, 1970, Keele et al., 1970, Yost and Fridovich, 
1973, Youn et al., 1996). S. cerevisiae has two SOD genes, SOD1 and SOD2 which 
encode a cytosolic CuZnSOD and a mitochondrial MnSOD respectively (Ravindranath 
and Fridovich, 1975, van Loon et al., 1986, Bermingham-McDonogh et al., 1988, 
Chang et al., 1991, Liu et al., 1992). 
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1.5.5  Catalase 
Catalase was described by Loew (1900) as an enzyme which yielded a high level 
of oxygen under reaction with H2O2, and was thus named. The decomposition of H2O2 
to O2 and H2O by catalase has been well documented to date and reaction is broken 
down into stages, dependent on the type of enzyme (Chelikani et al., 2004). When cells 
find themselves under conditions of OS, H2O2 produced by both redox cycling and the 
reduction of O2- requires detoxification, illustrating the important role of catalase in 
protection against OS (Roos et al., 1980, Kappus, 1987). 
 The S. cerevisiae genome contains two catalase genes, CTA1 encoding the yeast 
peroxisomal catalase A and CTT1 which encodes the yeast cytoplasmic catalase T (Seah 
et al., 1973, Susani et al., 1976, Spevak et al., 1983, Cohen et al., 1985, Hartig and Ruis, 
1986, Cohen et al., 1988). The functions of Cta1p and Ctt1p in surviving exposure to 
H2O2 overlap to some degree with GSH, as it has been demonstrated that the presence of 
these proteins is required to a) prevent the formation of excess GSSG and b) provide 
important resistance against H2O2 in ∆glr1 and ∆gsh1 (Grant et al., 1998). Peroxisomal 
proteins and fatty acids have been shown to induce Cta1p production (Veenhuis et al., 
1987, Skoneczny et al., 1988), which interestingly, can also scavenge mitochondrial-
derived H2O2 and undergo mitochondrial importation (Petrova et al., 2004). CTT1 
expression on the other hand is positively regulated by OS, osmotic stress, heat stress, 
nutrient starvation and heme (Spevak et al., 1986, Bissinger et al., 1989, Belazzi et al., 
1991, Schüller et al., 1994). 
 
1.5.6  Yap1p-regulated transcription 
Yap1p is a transcription factor involved in the regulation of a number of genes 
that are significantly implicated in S. cerevisiae OS defence. Yap1p or yeast AP-1 is so 
called due to the fact that it binds to the mammalian AP-1 recognition element (ARE), 
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and is in fact a homologue of the mammalian protein (Harshman et al., 1988, Moye-
Rowley et al., 1988). AP-1 proteins have the ability to regulate the cell cycle and thus 
mediate cell proliferation and death (Shaulian and Karin, 2001). The yeast ∆yap1 
mutant exhibits increased sensitivity to H2O2 (Schnell et al., 1992). In yeast, Yap1p has 
been shown to regulate the expression of GSH1 and GLR1 (Wu and Moye-Rowley, 
1994, Grant et al., 1996). It is also known that Yap1p interacts with another 
transcription factor Skn7p to control TRX2 and TRR1 (Kuge and Jones, 1994, Morgan et 
al., 1997). Yap1p-mediated upregulation of gene assemblages is induced by OS (Hirata 
et al., 1994, Kuge and Jones, 1994, Kuge et al., 1997, Lee et al., 1999).     
 
 
1.6 Main objectives of this study 
 
As a unicellular eukaryote, S. cerevisiae has long been a useful model organism. 
With a mean generation time of approximately 2 hr. and a fully sequenced genome, this 
species was an ideal organism for employment in this study.            
We initially wanted to analyse the visible effects of gliotoxin on yeast growth 
and investigate the capacity of different strains to withstand deleterious effects of the 
toxin. The principal endeavour was to utilise RNA sequencing technology and 
proteomics to analyse the global response of S. cerevisiae to gliotoxin. From these 
results, we wanted to assess the efficacy and apply functional genetics to further 
investigate the said response and compare it to that induced by typical OS-causing 
agents.  
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Part 2 Investigation into the mode of action of the prion-curing drug 
Tacrine 
 
1.7 Mammalian prions 
The term prion was first coined by Stanley Prusiner (1982) in naming disease-
causing proteinaceous infectious particles. Diseases caused by prions are collectively 
known as transmissible spongiform encephalopathies (TSEs) and one of the earliest 
prion diseases to be documented was scrapie, which affects sheep (Detwiler, 1992). It is 
thought that scrapie, so named due to infected sheep rubbing against stationary objects 
(figure 1.5), was reported in Europe as far back as 1732 (Plummer, 1946). Other TSEs 
include Creutzfeldt–Jakob disease (CJD), Gerstmann–Straussler–Sheinker disease (GSS) 
and Kuru which affect humans, and bovine spongiform encephalopathy (BSE) found in 
cattle (Gerstmann et al., 1936, Gajdusek et al., 1966, Holt and Phillips, 1988, Prusiner, 
1998).   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 A = Comedic advertisement warning against the contraction of Kuru 
which can be transmitted through brain consumption. Image from 
www.bizarremedical.com B = Sponge-like legion in the brain tissue of a CJD 
patient. Image from Centres for Disease Control www.cdc.gov C = Sheep 
displaying weight loss and behaviour characteristic of scrapie infection. Image 
from Ohio State University www.ohioline.osu.edu.com     
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C
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TSEs can also cause chronic wasting disease (CWD) in elk and feline 
spongiform encephalopathy (FSE) in cats (Williams and Young, 1980, Aldhous, 1990). 
Prion diseases are characterised by aggregation of prions within the brain, forming 
amyloid plaques (Prusiner et al., 1983) and lead to fatal neurodegeneration which 
currently cannot be treated (Trevitt and Collinge, 2006). Amyloid plaques are also 
implicit in non-infectious amyloid diseases such as Alzheimer’s Disease and 
Parkinson’s Disease (Lansbury, 1999) and are therefore of major research interest. 
Interestingly, Gimbel et al. (2010) reported that for transgenic Alzheimer mice to 
display memory impairment, the mammalian cellular prion protein must be present.   
 
1.7.1 PrP protein 
Although prion diseases may be contracted sporadically, by infection or through 
inheritance, all involve prion protein (PrP) metabolism and accumulation (McKinley et 
al., 1983, Prusiner, 1991). Prion replication occurs through the cyclic conversion of the 
normal functional PrP protein (PrPC) into a non-functional, disease-causing form (PrPSc) 
(Prusiner, 1998). Devoid of nucleic acid, PrPSc is the only component of the mammalian 
prion (McKinley et al., 1983, Prusiner, 1997). The generation of insoluble protease-
resistant PrPSc is characterised by the refolding of α-helical segments into β-sheets, 
which is a posttranslational event (McKinley et al., 1983, Oesch et al., 1985, Borchelt et 
al., 1990, Pan et al., 1993). This fully supports the “protein-only hypothesis” first put 
forward by Griffith (1967), suggesting that prions are self-replicating.    
PrPC is encoded by the PRNP gene in humans (Kretzschmar et al., 1986). 
Twenty PRNP mutations have been identified that appear to give rise to host prion 
diseases, thus accounting for the fact that ~10% of CJD cases are familial (Prusiner, 
1991, Prusiner, 1997). PrPC, expressed in the brain and spinal chord is a 
sialoglycoprotein and is thought to adhere to the cell surface by its glycolipid (Bolton et 
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al., 1985, Stahl et al., 1987). It it possible that PrPC may function in protecting the cell 
against OS, due to reports that the protein displays superoxide dismutase activity 
(Brown et al., 1999, Brown et al., 2001). It has been demonstrated that PrPC also 
appears to be involved in cell signalling and play a role in cell adhesion (Schmitt-Ulms 
et al., 2001, Gavín et al., 2005).           
 
1.8 Fungal prions 
Prion studies have not been limited to mammals, as fungal prions have also been 
identified. [Het-s] is a prion found in the filamentous fungus Podospora anserina that 
can induce cell death as a protection mechanism to prevent virus transmission, through 
mating incompatibility (Coustou et al., 1997, Wickner, 1997). A number of 
Saccharomyces cerevisiae proteins have the ability to form prions, as listed in table 1.1.   
 
Table 1.1 A selection of S. cerevisiae prions. 
Functional Protein 
 
Function Prion Form Reference 
Sup35p Translation 
termination 
[PSI+] 
 
(Cox, 1965) 
Ure2p Nitrogen 
metabolism 
[URE3] (Wickner, 1994) 
Rnq1p Unknown [PIN+] 
 
(Derkatch et al., 
1997) 
Cyc8p Transcriptional co-
repression 
[OCT+] 
 
(Patel et al., 2009) 
Swi1p Transcription 
regulation 
[SWI+] 
 
(Du et al., 2008) 
New1p ATP-binding 
protein 
[NU+] (Santoso et al., 
2000) 
Sfp1p Transcription 
regulation 
[ISP+] (Rogoza et al., 
2010) 
     
1.8.1 [PSI+] 
 
In yeast, two proteins work in conjunction with one another to control the 
translation termination process. These are Sup35p and Sup45p, which function as 
eukaryotic release factors eRF3 and eRF1 respectively (Frolova et al., 1994, 
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Zhouravleva et al., 1995). Sup45p recognises when a stop codon (TAA, TAG or TGA) 
enters the ribosome, while Sup35p is directly involved in translation termination and 
binds GTP which is required for polypeptide chain release from peptidyl-tRNA 
(Beaudet and Caskey, 1971, Frolova et al., 1994, Zhouravleva et al., 1995). 
In 1965, Brian Cox discovered a non-mendelian genetic element that was 
identified about 30 years later as the yeast prion [PSI+] (Wickner, 1994). [PSI+] is the 
prion form of Sup35p, and thus depends on the SUP35 chromosomal gene (Ter-
Avanesyan et al., 1994, Wickner, 1994). In [PSI+] strains, the spontaneously altered 
prion protein induces the conformation of soluble, functional Sup35p to the prion form, 
resulting in [PSI+] aggregation (Patino et al., 1996). This aggregation and reduction in 
functional Sup35p, leads to suppression of nonsense codons, characteristic of the [PSI+] 
phenotype (Tuite et al., 1987, Cox et al., 1988). [PSI+] confers strength to weak 
nonsense suppressor tRNAs and lethality to strong suppressors (Cox, 1965, Cox, 1971).  
Sup35p is a multidomain protein, containing N-, middle- and C-terminal 
domains (Kushnirov et al., 1988), as illustrated in figure 1.6. 
 
 
 
 
 
Figure 1.6 Structure of the S. cerevisiae Sup35p. The prion determinant is the N-
terminal domain. The charged middle-domain is situated between the N- and C-domains. 
The C-terminal domain responsible for translation termination retains the GTP-binding 
capacity. Image from Lindquist (1997). 
 
The aminoterminal N-domain retains prion activity and is thus referred to as the 
prion domain (PrD) (Derkatch et al., 1996, King et al., 1997). The C-terminal domain is 
responsible for the Sup35p translation termination function and is essential for cell 
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viability (Ter-Avanesyan et al., 1994). The highly charged middle-domain assists in 
maintaining Sup35p solubility and enabling prion and non-prion state interconversion 
(Liu et al., 2002). Like other yeast prions, [PSI+] is inherited by daughter cells in a non-
Mendelian cytoplasmic manner (Lindquist, 1997). [PIN+] ([PSI+] inducible) creates a 
scaffold that must pre-exist to allow the appearance of [PSI+], as the spontaneous 
generation of [PSI+] was observed in [PIN+] cells, but not [pin-] (Derkatch et al., 1997). 
[PIN+] is the prion form of Rnq1p, of which the function is not yet clear. 
 
 
 
                 
 
Figure 1.7 Illustration of aggregated yeast PrD fused to GFP to enable detection in 
a [PSI+] strain. Aggregates are indicated by arrows. Image from Jones and Tuite 
(2005).  
  
Simple colour assays are often used to monitor the presence of [PSI+] in S. 
cerevisiae. The introduction of aberrant stop mutations such as ade2-1 and ade1-14 
confer adenine auxotrophy to cells. These cells subsequently display a red colour which 
represents the build-up of by-products from the adenine biosynthesis pathway. [PSI+] 
can partially suppress the nonsense mutation in the presence of the serine-inserting, 
weak UAA suppressor tRNA SUQ5. This facilitates cellular growth in the absence of 
adenine and eradicates the red pigmentation, allowing growth of white colonies (Cox, 
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1965, Liebman et al., 1975, Ono et al., 1979). This creates an easy way for the presence 
of [PSI+] to be monitored; red cells are [psi-], white cells are [PSI+].      
 
1.8.2 [PSI+] propagation and the importance of chaperone proteins 
 
As briefly stated above, [PSI+] yeast cells typically contain a large amount of 
aggregated insoluble non-functional Sup35p. As opposed to this, the Sup35p in [psi-] 
cells is soluble and functional. The structural change of α-helical content to β-sheets 
characteristic of [PSI+] means protein-folding is inherently associated with prion 
propagation (Glover et al., 1997). In order for the prion to be maintained and passed to 
daughter cells, [PSI+] must be able to propagate efficiently and chaperone proteins play 
a key role in this process. Hsp104p (heat-shock protein 104) is essential for prion 
propagation and maintenance of [PSI+] within a yeast cell line (Chernoff et al., 1995). 
However, close cooperation with other heat-shock proteins, Hsp70p and Hsp40p is 
required for Hsp104p-mediated activity (Glover and Lindquist, 1998). 
  
1.8.2.1 Hsp104p 
Hsp104p is a heat-shock protein that functions in induced cellular 
thermotolerance, enabling yeast cells to survive at high temperatures (Sanchez and 
Lindquist, 1990). It has been shown to play a role in the disaggregation of proteins that 
are heat-damaged (Parsell et al., 1994). Overproduction or absence of Hsp104p 
chaperone activity abolishes [PSI+] (Chernoff et al., 1995). This is because wild-type 
levels of Hsp104p are required for [PSI+] cleavage, leading to the production of prion 
“seeds” which can be passed to daughter cells, enabling prion propagation (Paushkin et 
al., 1996).  
Recent work has raised the possibility that Hsp104p may regulate the 
transmission of propagons to daughter cells. Erjavec et al. (2007) demonstrated that 
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during mitosis, Hsp104p is involved in segregating damaged proteins, preventing them 
from being passed to daughter cells, through a Sir2p-dependent process. This group also 
found that overexpression of Hsp104p improves the retention of damaged proteins. Liu 
et al. (2010) have proposed that rather than simply retaining damaged proteins in the 
mother cell, aggregates are transported to the emerging bud but subsequently translocate 
back to the mother cell, prior to cytokinesis completion. The polarisome machinery has 
been identified as essential for partitioning of damaged proteins and it has been shown 
that this process requires actin cables to act as a scaffold for Hsp104p and associated 
aggregates (Liu et al., 2010). As prions are essentially damaged aggregated proteins, it 
is quite likely that the [psi-] phenotype resulting from Hsp104p overexpression occurs 
due to lack of prion inheritance through retention of aggregates in the mother cells.  
Hsp104p overexpression leads to maintenance of soluble Sup35p, while lack of 
this chaperone activity results in reduced prion forming capacity (Paushkin et al., 1996, 
Wegrzyn et al., 2001). Thus a balance of Hsp104p activity level is essential for prion 
maintenance. [PSI+] curing mediated by Hsp104p overexpression is dependent upon the 
N-terminal domain of the chaperone, although this domain is not required for normal 
levels of [PSI+] propagation (Hung and Masison, 2006). It has also been demonstrated 
that the presence of Sti1p, a Hsp70p and Hsp90p co-chaperone (discussed below), is 
critical for successful [PSI+] curing by excess Hsp104p (Moosavi et al., 2010, Reidy 
and Masison, 2010).  
 
1.8.2.2 Hsp70 protein family 
 
Hsp70, a 70 kDa protein family comprises a complex key molecular chaperone 
group (Ingolia et al., 1982). These proteins have a number of different roles in the cell, 
from folding nascent polypeptide chains to preventing the aggregation of and refolding 
misfolded proteins (Bukau and Horwich, 1998). The Ssa (stress seventy subclass A) and 
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Ssb (stress seventy subclass B) proteins make up cytosolic subfamilies of the Hsp70 
proteins and are themselves composed of Ssa1-4p and Ssb1-2p respectively (Craig et al., 
1993). In addition to these six cytosolic Hsp70 proteins, a further three, Sse1p, Sse2p 
and Ssz1p exist (Ingolia et al., 1982, Craig and Jacobsen, 1984, Craig and Jacobsen, 
1985, Werner-Washburne et al., 1987, Mukai et al., 1993, Gautschi et al., 2001). Three 
mitochondrial Hsp70 proteins Ssc1p, Ssq1p and Ecm10p have also been identified 
(Craig et al., 1987, Craig et al., 1989, Schilke et al., 1996, Baumann et al., 2000), in 
addition to two endoplasmic reticulum-associated Hsp70 proteins Kar2p and Lhs1p 
(Rose et al., 1989, Craven et al., 1996). With reference to yeast prions, the Ssa and Ssb 
proteins are of great interest. 
  The presence of at least one Ssa protein is essential for cell viability (Werner-
Washburne et al., 1989). Ssa1p has been identified as an important protein in prion 
maintenance. Ssa1p prevents the “curing” of [PSI+] mediated by Hsp104p 
overexpression, overexpression of SSA1 increases [PSI+]-regulated nonsense 
suppression and mutations in the SSA1 gene have an antagonistic effect on [PSI+] 
(Newnam et al., 1999, Jung et al., 2000, Jones and Masison, 2003, Loovers et al., 2007). 
In support of these results, Ssa proteins have been shown to induce de novo generation 
of [PSI+] in [psi-] cells, and this appears to be dependent on the peptide-binding domain 
(Allen et al., 2005). Ssb proteins are not required for cell survival (Nelson et al., 1992). 
Conversely to Ssa, there is evidence to suggest that Ssb proteins hinder [PSI+] 
propagation. In ∆ssb1 and ∆ssb2 strains, there is a 10-fold increase in the appearance of 
[PIN+]-dependent spontaneous [PSI+]. Overexpressed Ssbp facilitates [PSI+] curing by 
surplus Hsp104p (Chernoff et al., 1999) and it has been demonstrated that in [psi-] cells, 
diminished levels of Ssbp increases the level of nonsense suppression, albeit modestly 
(Jones et al., 2003).  
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1.8.2.3 The Hsp70p ATPase binding cycle 
 
Hsp70 proteins have two functional domains, an ATPase-binding domain (ABD) 
and a peptide-binding domain (PBD) (Flaherty et al., 1990, Zhu et al., 1996). As 
dictated by ATP hydrolysis, Hsp70p can exist in either a “closed” conformation, 
whereby the substrate is tightly bound to the PBD, or an “open” conformation, 
associated with rapid substrate exchange (Liberek et al., 1991). ATP-binding results in a 
Hsp70p conformational change from a closed to an open state, allowing substrate 
dissociation. Alternatively, the ADP-bound form maintains tight affinity for substrates 
(Schmid et al., 1994). The tight substrate-binding caused by ATP hydrolysis occurs 
through the closing of an α-helical lid domain that is displaced when ATP is bound 
(Zhu et al., 1996). As substrates cycle between the Hsp70p-bound form and the free 
form, the functional activity of Hsp70p can be referred to as the Hsp70p ATPase 
binding cycle (Mayer and Bukau, 2005). This cycle is illustrated in figure 1.8. 
Hsp70 proteins require the cooperation of co-chaperones to function 
successfully. One Hsp70p co-chaperone is Sti1p, a linker protein that forms a scaffold 
between Ssa1p and another chaperone protein Hsp90, which has shown to be a potent 
activator of Ssa1p ATPase activity (Wegele et al., 2003). Like Sti1p, Cns1p acts as a 
co-chaperone for both Hsp70p and Hsp90p. This protein also activates Ssa1p ATPase 
activity through accelerating ATP hydrolysis (Hainzl et al., 2004). Genetic evidence has 
been provided to suggest that another Hsp90p co-chaperone Cpr7p stimulates Hsp70p 
ATPase (Jones and Tuite, 2005). Sis1p, Ydj1p and Apj1p are members of the Hsp40p 
chaperone family and act as cofactors in facilitating Hsp70p activity (Caplan et al., 
1992, Ohba, 1997, Kryndushkin et al., 2002). However, the above named co-
chaperones are not alone in regulating the Hsp70p ATPase binding cycle.  
Nucleotide exchange factors (NEFs) are also involved in the regulation of 
Hsp70p activity. These proteins, such as Fes1p and Sse1p (which is also a member of 
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the Hsp110 family) stimulate an increase in the ADP dissociation time, thus catalysing 
ATP replacement of ADP (Kabani et al., 2002, Raviol et al., 2006, Kabani, 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Proposed model illustrating the importance of Hsp70, co-chaperones 
and NEFs in prion propagation and maintenance within the cell. When ATP is 
bound to the ABD, the PBD exhibits an open conformation and rapid substrate 
exchange occurs. When ADP is bound, the PBD lid closes and substrate is tightly 
affixed. Co-chaperones and NEFs are required for regulation of this cycle. Evidence has 
been provided to suggest that disruption of this cycle leads to impairment of prion 
propagation.  
 
It has been suggested that disruption of this cycle impairs prion propagation 
(Jones and Tuite, 2005). Jung et al. (2000) isolated a yeast mutant, containing a single 
amino acid change within the SSA1 gene, designated SSA1-21. This mutation was found 
in the PBD and significantly weakened [PSI+] stability, through reducing the number of 
prion seeds produced. Subsequent research demonstrated that Sup35p aggregates are 
larger in SSA1-21 cells, probably because they contain more polymers (Song et al., 
2005). This supports previous work in that the loss of Sup35p polymer seeds in SSA1-21 
mutants is due to their employment in the formation of oversized aggregates and 
highlights a role for Ssa1p in prion propagation through prion seed production.   
“OPEN” form (rapid 
substrate exchange)
“CLOSED” form (substrate 
tightly bound)
ATP ADP
Hsp40, Sti1, Cns1
Fes1, Sse1
Hsp70 ATPase binding cycle
Alteration of ATPase cycle to favour ADP bound form appears to 
impair prion propagation
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It has been considered that the SSA1-21 mutation may negatively affect 
communication between the two functional domains of Hsp70p, thus disrupting the 
ATPase cycle (Jones and Tuite, 2005). Mutations were also identified in the Hsp70p 
ABD that impair [PSI+] propagation (Jones and Masison, 2003). This group 
hypothesised that these mutations were modifying ATPase activity that resulted in a 
disruption of the open/closed conformational regulation. Needham and Masison (2008) 
have since generated mutations in the Ssa1p ABD and PBD that disrupt communication 
between that two domains and alter regulation of the cycle, e.g. through hypersensitive 
ATPase activity.   
Interestingly, it appears that alteration of the ATPase-binding cycle to favour the 
ADP-bound form impairs prion propagation. Fes1p deletion has been shown to weaken 
[PSI+] stability, as Fes1p absence decreases the rate of ATP-binding (Jones et al., 2004). 
Loss of [PSI+] has also been found to be a result of Sti1p overexpression, while Sti1p 
and Cpr7p deletion enhances [PSI+] maintenance (Kryndushkin et al., 2002, Jones et al., 
2004). The results described above strongly suggest that Hsp70p and its cooperative 
chaperone machinery assist in the highly sensitive regulation of prion propagation 
(figure 1.9).  
 
1.9 Anti-prion drugs 
Due to the detrimental effects caused to mammals by prion diseases, the 
requirement for efficient prion-curing agents remains urgent. A number of drugs 
possessing mammalian prion-curing ability have been identified and were reviewed by 
Trevitt and Collinge (2006). Yeast models are commonly employed in the search for 
therapeutic drugs, as molecular systems, such as Hsp70p are highly conserved from 
yeast to mammals (Jones and Tuite, 2005). 
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Figure 1.9 Representation of the importance of chaperone activity cooperation in 
prion propagation. Red, green and blue clustered circles represent Hsp40p, Hsp70p 
and other Hsp70p co-chaperones. Gold circles represent soluble Sup35p. Black squares 
represent [PSI+] aggregates.    
      
1.9.1 Guanidine Hydrochloride 
Guanidine Hydrochloride (GdnHCl), a powerful denaturing agent (Levine et al., 
1963) was identified by Tuite et al. (1981) as a [PSI+]-curing compound. GdnHCl 
efficiently cures yeast prions by abrogating prion propagation, leaving the remaining 
prions to be diluted out over time, and eventual [psi-] appearance (Eaglestone et al., 
2000). In agreement with this model and in contrast to earlier work (Wu et al., 2005), 
Byrne et al. (2007) reported that cell division is a certain requirement for GdnHCl-
mediated [PSI+] eradication. [PSI+] elimination occurs through direct inhibition of 
Hsp104p ATPase activity by GdnHCl, although the intracellular level of the chaperone 
protein is not affected (Ferreira et al., 2001, Jung and Masison, 2001, Jung et al., 2002). 
104
Amyloid
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104 104
Hsp40
Hsp70
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Although GdnHCl arrests the cleavage of new prion seeds by Hsp104p in [PSI+] cells, it 
does induce the decomposition of preexisting Sup35p aggregates (Ness et al., 2002).      
 
1.9.2 6-aminophenanthridine      
6-aminophenanthridine is a phenanthridine derivative, that has a modified amino 
group at position 11 that differentiates the two (Bach et al., 2003). Its structure is 
depicted in figure 1.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Structure of 6AP. Image from Tribouillard-Tanvier et al. (2008b). 
 
Bach et al. (2003) identified 6-aminophenanthridine (6AP) as an anti-prion 
agent, using a yeast-based screening assay. They discovered that this drug alone 
inefficiently cures [PSI+], but in combination with relatively low concentrations of 
GdnHCl, 6AP cures [PSI+] very efficiently (figure 1.11). 
Importantly, 6AP has also been shown to be active against the mammalian prion 
(Bach et al., 2003), as illustrated by figure 1.12. 6AP interacts with the ribosome 
through an RNA-dependent process and hinders the rRNA-mediated protein folding 
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activity of the organelle, without affecting protein synthesis (Tribouillard-Tanvier et al., 
2008b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Plate assay showing the effects of different compounds on [PSI+] cells. 
The agar contains 500 µM GdnHCl and other drugs were spotted onto filter paper. The 
red zones represent cured [psi-] cells. Image from Bach et al. (2003).   
 
6AP inhibits ribosomal-mediated protein folding by competing with unfolded 
proteins for ribosome binding (Reis et al., 2011). However, this agent does not directly 
interact with prion proteins (Tribouillard-Tanvier et al., 2008b).  
 
 
 
 
 
 
 
Figure 1.12 Representation of 6AP anti-prion activity. The banding patterns depict 
protease K resistant PrPSc from sheep. It can be seen that with increasing concentrations 
of 6AP, the sheep protein becomes sensitive to protease K digestion as the level of 
soluble PrPC returns. Image from Tribouillard-Tanvier et al. (2008b).  
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1.9.3 Guanabenz 
Guanabenz (GA) is a drug that has been used for decades to treat hypertension 
(McMahon et al., 1974). GA was found to display anti-prion activity in both yeast and 
mammalian systems (Tribouillard-Tanvier et al., 2008a). Although structurally 
unrelated to 6AP, like 6AP, GA does not directly interact with prion proteins, but 
specifically interacts with ribosomal components in an RNA-dependent manner 
(Tribouillard-Tanvier et al., 2008b). As for 6AP, GA does not affect protein synthesis, 
but inhibits rRNA-regulated ribosomal protein folding activity (Tribouillard-Tanvier et 
al., 2008b). Furthermore, both drugs utilise the same binding sites on ribosomal 
components and both impede the action of ribosomal folding modulators (RFMs), 
ribosomal components active in protein folding (Tribouillard-Tanvier et al., 2008b, Reis 
et al., 2011). The structure of GA is depicted in figure 1.13. 
 
 
 
 
 
 
 
 
Figure 1.13 Structure of GA. Image from Tribouillard-Tanvier et al. (2008b). 
   
1.9.4 Tacrine 
Tacrine (1,2,3,4-tetrahydro-9-aminoacridine/THA/TA) is a compound that was 
identified as a prion-curing agent in a yeast-based assay. Although shown to be active 
against yeast prions, TA exhibited no potency against mammalian prions (Tribouillard-
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Tanvier et al., 2008a). It may be the case that TA, the structure of which is shown in 
figure 1.14, targets a yeast pathway too far diverged in mammalian systems. However, 
the fact that prion curing activity in yeast has been demonstrated means TA remains an 
interesting drug for prion researchers.  
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Structure of TA. Image from Tribouillard-Tanvier et al. (2008a). 
 
  
1.9.4.1 Tacrine as a human drug 
TA is a drug which has been prescribed to Alzheimer’s patients, based on 
findings that this compound induces an improvement in memory and relieves symptoms 
of Alzheimer’s dementia (Summers et al., 1981, Summers et al., 1986, Davis et al., 
1992). Although opinion has been divided over the effectiveness of TA and whether or 
not effects of the drug are significantly beneficial (Chatellier and Lacomblez, 1990, 
Molloy et al., 1991, Wilcock et al., 1994), reviewers have concluded that on cognitive 
function, TA has beneficial effects, albeit modest (Byrne and Arie, 1994, Qizilbash et 
al., 1998). 
Since the advent of TA administration, there has been mixed sentiment. 
Concerns were raised regarding TA toxicity when only two months into a clinical trial, 
liver damage was found in one fifth of patients (Marx, 1988). Further to this, many 
groups have demonstrated that hepatotoxicity can result from TA dosage (Forsyth et al., 
1989, Molloy et al., 1991, Lagadic-Gossmann et al., 1998) and that clinical hepatitis 
can subsequently occur (Molloy et al., 1991, O'Brien et al., 1991). However, lack of TA 
 35 
mammalian toxicity has also been documented (Fitten et al., 1987). Accordingly, many 
believe that under careful monitoring and regular enzyme level testing, Alzheimer’s 
sufferers can profit from administration of this drug and to support this belief, in 1993 
TA became “the first FDA-approved treatment for Alzheimer’s disease” (Watkins et al., 
1994, Summers, 2006). 
 
1.9.4.2 Tacrine mode of action 
In 1951, Dr. Adrien Albert published data referencing TA, “aminacrine”, an 
aminoacridine compound as a powerful antiseptic and antibacterial agent. He reported 
on the chemical and biological properties of the aminoacridines, in addition to their 
medicinal functions (Browning and Crawford, 1951). 
TA is an acetylcholinesterase inhibitor and acts through arresting the breakdown 
of acetylcholine (ACh). This in turn prevents decline in cholinergic neurotransmission, 
which is symptomatic of Alzheimer’s disease, and due to it’s high solubility level, TA 
has easy access to the brain (Weinstock, 1995). More recent work has shown that in 
addition to the above, TA, although not an ACh receptor (AChR) agonist, competitively 
binds to agonist AChR sites “stabilising a non-conducting open channel receptor form” 
(Cheffer and Ulrich, 2011). Independent of its acetylcholinesterase inhibitory activity, 
TA can also inhibit the neuronal entry of calcium and can block potassium and sodium 
channels (Davis and Powchik, 1995, Dolezal et al., 1997). 
One of the main characteristics of Alzheimer’s disease is the accumulation of 
amyloid plaques within the brain. These plaques consist of amyloid beta-proteins which 
are derivatives of the secreted beta amyloid precursor proteins (beta APP) (Haass and 
Selkoe, 1993). TA treatment results in a striking inhibition of beta APP secretion and 
also in slightly decreased levels of intracellular beta APP (Lahiri, 1994, Lahiri and 
Farlow, 1996). 
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1.9.4.3 Tacrine and prion proteins 
Recently published data has demonstrated that the mammalian cellular prion 
protein functions as a receptor for amyloid beta-proteins, thus playing a role in synaptic 
dysfunction. In fact, PrP is not required to be in the infectious PrPSc isoform for this 
intercommunication to occur (Laurén et al., 2009). Significantly, it also appears that for 
mammals to show cognitive deficiencies resulting from amyloid beta-protein 
accumulation, PrPC expression is imperative (Gimbel et al., 2010). From this, the link 
between Alzheimer’s disease dysfunction and prions has been strengthened and for 
treatment, TA may be a useful common factor.   
 
1.10 Ribosomal activity as a potential target for prion curing 
Evidence has been provided to suggest that the ribosome may play a role in 
protein folding. Specifically, the domain V of the 23S large ribosomal subunit appears 
to be involved in protein re-and denaturation (Das et al., 2008). As descibed above, 
protein folding is significantly implicated in prion propagation and interestingly, it is 
this domain V that undergoes specific interaction with the prion curing drugs 6AP and 
GA (Tribouillard-Tanvier et al., 2008b). It has been proposed that ribosome-borne 
protein folding activity (RPFA) lies in the preparation of a pre-folded nascent peptide 
that downstream chaperones will alter further (Fåhraeus and Blondel, 2008). Taken 
together, it may be the case that RPFA contributes in some way to priongenesis and 
preservation of the [PSI+] phenotype, and may thus be a potential target for prion curing 
drugs. 
 
1.11 YAR1, LTV1, RPL8A and RPL8B 
YAR1, LTV1, RPL8A and RPL8B are four ribosome-related genes identified as 
potentially important in prion research. ∆yar1, ∆ltv1, ∆rpl8a and ∆rpl8b all contain an 
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imbalance in the relevant ribosomal subunit and can only display weak [PSI+]. 
Interestingly, when these strains are exposed to 6AP or GA, the prion is stabilised (M. 
Blondel, personal communication). YAR1 is not an essential gene but growth of strains 
deleted for this gene is significantly retarded, especially at low temperatures (Lycan et 
al., 1996). In addition to its role in regulating the rate of cellular proliferation, YAR1 
transcription is considerably repressed by heatshock (Lycan et al., 1996). Physical 
interaction between Yar1p and another protein Ltv1p has been documented (Loar et al., 
2004). Evidence suggests that the latter protein may be an assembly factor, involved in 
the processing of pre-ribosomes (Schäfer et al., 2003, Campbell and Karbstein, 2011). 
Overall, it is thought that both Yar1p and Ltv1p distinctly function in 40S subunit 
production (Loar et al., 2004).         
 RPL8A (MAK7) and RPL8B (KRB1) encode the yeast ribosomal protein L4 of 
the of the large 60S subunit (Arevalo and Warner, 1990, Yon et al., 1991, Ohtake and 
Wickner, 1995). The nearly identical RPL8A and RPL8B genes are orthologous to the 
mammalian RPL7A ribosomal protein gene (Yon et al., 1991). The fact that mutants 
deleted for these four genes exhibit a weakened [PSI+] may provide an important link 
between ribosomal function and prion propagation.     
 
1.12 Main aims of this study 
The principal objectives of this study were to assess the yeast prion-curing 
capacites of TA, and to investigate its mode of action. It was anticipated that RNA 
sequencing technology and proteomics would provide insight into the mode of action of 
TA, through analysis of the global S. cerevisiae response to the drug. As TA appears to 
mediate its effects through a different process to 6AP and GA, these drugs were selected 
for employment in a comparative study. It was hypothesised that TA might enhance the 
uptake of GdnHCl and we endeavoured to assess the validity of this supposition. 
  
 
 
 
 
 
 
 
 
 
Chapter 2   Materials and methods 
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Yeast Handling Techniques 
 
2.1 Yeast and bacterial strains used in this study 
2.1.1 Saccharomyces cerevisiae strains  
Listed below in table 2.1 are Saccharomyces cerevisiae strains which were used 
in this study, in addition to genotype description and where strains were sourced. 
  
Table 2.1  S. cerevisiae strains used in this study.      
 
 
Strain name 
 
Genotype 
 
Source 
 
G600 
 
MATa/MATα ade2.1 SUQ5 kar1-1 his3 leu2 
trp1 ura3 
 
Jones et al. 
(2004) 
 
G600 pRS315 
 
MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 pRS315 
 
This study 
 
G600 pRS316 
 
MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 pRS315 
 
This study 
BY4741 MATa his3 leu2 met15 ura3 Euroscarf 
BY4741 ∆cys3 MATa his3 leu2 met15 ura3 cys3::kanMX4 Euroscarf 
BY4741 ∆trr2 MATa his3 leu2 met15 ura3 trr2::kanMX4 Euroscarf 
BY4741 GliT-
pC210 
MATa his3 leu2 met15 ura3 GliT-pC210 This study 
BY4741 pRS315 MATa his3 leu2 met15 ura3 pRS315 This study 
BY4741 ∆cys3 
pRS315 
MATa his3 leu2 met15 ura3 cys3::kanMX4 
pRS315 
This study 
BY4741 ∆cys3 
GliT-pC210 
MATa his3 leu2 met15 ura3 cys3::kanMX4 
GliT-pC210 
This study 
BY4741 pRS316 MATa his3 leu2 met15 ura3 pRS316 This study 
BY4741 GliT-
pYES2 
MATa his3 leu2 met15 ura3 GliT-pYES2 This study 
G600 GliT-pYES2 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 GliT-pC210 
This study 
BY4741 ∆yap1 MATa his3 leu2 met15 ura3 yap1::kanMX4 Euroscarf 
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BY4741 ∆sod1 MATa his3 leu2 met15 ura3 sod1::kanMX4 Euroscarf 
BY4741 ∆gsh1 MATa his3 leu2 met15 ura3 gsh1::kanMX4 Euroscarf 
BY4741 ∆gsh1 
pRS315 
MATa his3 leu2 met15 ura3 gsh1::kanMX4 
pRS315 
This study 
BY4741 ∆gsh1 
GSH1-pRS315 
MATa his3 leu2 met15 ura3 gsh1::kanMX4 
GSH1-pRS315 
This study 
BY4741 ∆cys4 MATa his3 leu2 met15 ura3 cys4::kanMX4 Euroscarf 
BY4741 ∆gpx2 MATa his3 leu2 met15 ura3 gpx2::kanMX4 Euroscarf 
BY4741 ∆frm2 MATa his3 leu2 met15 ura3 frm2::kanMX4 Euroscarf 
BY4741 ∆hxt2 MATa his3 leu2 met15 ura3 hxt2::kanMX4 Euroscarf 
BY4741 ∆met6 MATa his3 leu2 met15 ura3 met6::kanMX4 Euroscarf 
BY4741 ∆met17 MATa his3 leu2 met15 ura3 met17::kanMX4 Euroscarf 
BY4741 ∆met32 MATa his3 leu2 met15 ura3 met32::kanMX4 Euroscarf 
BY4741 ∆ald6 MATa his3 leu2 met15 ura3 ald6::kanMX4 Euroscarf 
BY4741 ∆sam1 MATa his3 leu2 met15 ura3 sam1::kanMX4 Euroscarf 
BY4741 ∆hbn1 MATa his3 leu2 met15 ura3 hbn1::HIS5 This study 
BY4741 
∆frm2∆hbn1 
MATa his3 leu2 met15 ura3 frm2::kanMX4 
hbn1::HIS5 
This study 
G600 ∆sse1 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 sse1::kanMX4 
H. Loovers 
G600 ∆ssa1 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 ssa1::kanMX4 
Jones et al. 
(2004) 
G600 ∆ssa2 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 ssa2::HIS3 
Jones et al. 
(2004) 
G600 ∆ssa1∆ssa2 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 ssa1::kanMX4 ssa2::HIS3 
Jones et al. 
(2004) 
G600 ∆sti1 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 sti1::kanMX4 
Jones et al. 
(2004) 
G600 ∆cpr7 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 cpr7::HIS3 
Jones et al. 
(2004) 
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G600 ∆sti1∆cpr7 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 sti1::kanMX4 cpr7::HIS3 
Jones et al. 
(2004) 
G600 ∆fes1 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 fes1::kanMX4 
Jones et al. 
(2004) 
74D MATa ade1.14 trp1 his3 ura3 leu2 Marc Blondel 
74D ∆yar1 MATa ade1.14 trp1 his3 ura3 leu2 
yar1::HIS5 
Marc Blondel 
74D ∆ltv1 MATa ade1.14 trp1 his3 ura3 leu2 
ltv1::kanMX4 
Marc Blondel 
74D ∆rpl8a MATa ade1.14 trp1 his3 ura3 leu2 
rpl8a::kanMX4 
Marc Blondel 
74D ∆rpl8b MATa ade1.14 trp1 his3 ura3 leu2 
rpl8b::kanMX4 
Marc Blondel 
G600 ∆hsp104 MATa ade2.1 SUQ5 kar1-1 his3 leu2 trp1 
ura3 hsp104::kanMX4 
Yeast Genetics 
74D ∆hsp104 MATa ade1.14 trp1 his3 ura3 leu2 
hsp104::HIS5 
Marc Blondel 
74D ∆ltv1∆hsp104 MATa ade1.14 trp1 his3 ura3 leu2 
ltv1::kanMX4 hsp104::HIS5 
Marc Blondel 
74D ∆yar1∆hsp104 MATa ade1.14 trp1 his3 ura3 leu2 
yar1::HIS5 hsp104::kanMX4 
Marc Blondel 
74D pDCM90 MATa ade1.14 trp1 his3 ura3 leu2 
pDCM90 
This study 
74D ∆hsp104 
pDCM90 
MATa ade1.14 trp1 his3 ura3 leu2 
hsp104::HIS5 pDCM90 
This study 
74D ∆yar1 
pDCM90 
MATa ade1.14 trp1 his3 ura3 leu2 
yar1::HIS5 pDCM90 
This study 
74D ∆ltv1 
pDCM90 
MATa ade1.14 trp1 his3 ura3 leu2 
ltv1::kanMX4 pDCM90 
This study 
74D ∆yar1∆hsp104 
pDCM90 
MATa ade1.14 trp1 his3 ura3 leu2 
yar1::HIS5 hsp104::kanMX4 pDCM90 
This study 
74D ∆ltv1∆hsp104 
pDCM90 
MATa ade1.14 trp1 his3 ura3 leu2 
ltv1::kanMX4 hsp104::HIS5 pDCM90 
This study 
 
Working stocks of regularly used yeast strains were maintained at 4ºC on agar 
plates containing suitable growth media. Approximately every two weeks, these strains 
were sub-cultured onto fresh agar plates. Long-term stocks of all strains were prepared 
by adding a large number of cells to a solution containing 15% glycerol (v/v), 85% 
liquid YPD (v/v). These stocks were stored at -70ºC. 
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2.1.2 Bacterial strain 
DH5α was the only Escherichia coli strain used in this study. Stocks of E. coli 
strain DH5α were stored at -70oC in dH2O or in 20% (v/v) glycerol to 80% (v/v) liquid 
LB. 
  
2.2 Plasmid vectors used in this study 
Listed in table 2.2 are plasmid vectors which were used in this study in addition 
to plasmid description and where plasmids were sourced.  
 
Table 2.2 Plasmid vectors used in this study. 
 
 
Plasmid Name 
 
Description 
 
Source 
 
pRS315 
 
Centromeric Saccharomyces cerevisiae 
shuttle vector LEU2 marker 
 
Sikorshi and 
Hieter (1989) 
 
pRS316 
 
Centromeric Saccharomyces cerevisiae 
shuttle vector URA3 marker 
 
Sikorski and 
Hieter (1989) 
 
pC210 
 
Vector containing SSA1 under control of 
SSA2 promoter LEU2 marker 
 
Schwimmer and 
Masison (2002) 
pUG27 Vector containing Schizosaccharomyces 
pombe HIS5 gene 
Euroscarf 
pYES2 URA3-based plasmid containing inducible 
GAL1 promoter 
Invitrogen 
GliT-pYES2 GliT under control of GAL1 promoter in 
pYES2 vector 
This study 
GliT-pC210 GliT replacing SSA1 in pC210, under 
constitutive SSA2 promoter control 
This study 
YEp13 High-copy plasmid containing gene bank of 
wild-type S. cerevisiae DNA LEU2 marker 
ATCC 
pDCM90 URA3-based single-copy plasmid containing 
a gene for yeast expression of a thermolabile 
bacterial luciferase 
Daniel C. 
Masison 
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2.3 Chemicals and reagents used in this study 
All chemicals, reagents and metabolites were purchased from Sigma-Aldrich 
Chemical Co. Ltd. U.K., unless otherwise stated. 
 
2.4 Drug and metabolite stocks used in this study 
 Tacrine, Guanabenz and 6-aminophenanthridine were provided by Marc Blondel, 
University of Brest, France. 
 
Guanidine Hydrochloride (GdnHCl) 
 100 mM GdnHCl stock was made by adding 0.478 g to 50 ml sterile dH2O. This 
was then separated into 1 ml aliquots and stored at -20ºC. 
 
Tacrine (TA) 
 100 mM TA stocks were prepared by adding 26 mg TA in powder form to 
1106.38 µl DMSO. From this, 10 mM working stocks were aliquoted and stored at -
20ºC. 
 
Guanabenz (GA) 
 100 mM GA stocks were prepared by adding 18.4 mg GA in powder form to 
632.3 µl DMSO. From this, 10 mM working stocks were aliquoted and stored at -20ºC. 
 
6-aminophenanthridine (6AP) 
 100 mM 6AP stocks were prepared by adding 15.6 mg 6AP in powder form to 
804.12 µl DMSO. From this, 10 mM working stocks were aliquoted and stored at -20ºC. 
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Gliotoxin (GT) 
 1 mg/ml gliotoxin stocks were prepared by adding 25 mg of gliotoxin to 25 ml 
of methanol. This was dissolved, aliquoted and stored at -20ºC.   
 
Cystathionine 
 1 mM cystathionine working stocks were made by adding 4.5 mg to 20 ml of 
sterile dH2O. This was stored at -20ºC. 
 
Ampicillin 
 To prepare ampicillin antibiotic stock solutions, 5 g of ampicillin was added to 
100 ml of sterile dH2O to give a concentration of 50 mg/ml. This was dissolved, filter 
sterilized, aliquoted and stored at -20ºC until usage was required.   
 
2.5 Yeast and bacterial growth media 
Bacteriological (bacto-) yeast extract, bacteriological (bacto-) peptone, 
bacteriological (bacto-) agar and yeast nitrogen base (YNB) without amino acids were 
all sourced from Becton, Dickinson and Company, Le Point de Claix, France (BD). 
Petri dishes were sourced from Greiner Bio-One. 
 
2.5.1 Media for culturing yeast 
|Yeast Peptone Dextrose (YPD)  
10 g of bacto-yeast extract, 20 g of bacto-peptone and 20 g of D-glucose were 
added to 1 l of dH2O. This complete media solution was autoclaved and stored at room 
temperature (RT). If solidification was required, 20 g bacto-agar was added to the other 
components described above, solution was autoclaved and allowed to cool. Agar was 
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then poured into sterile petri dishes under sterile conditions and allowed to set. Agar 
plates were stored at 4ºC. 
 
Yeast Peptone Galactose (YPGAL) 
10 g of bacto-yeast extract, 20 g of bacto-peptone and 20 g of galactose were 
added to 1 l of dH2O. The solution was autoclaved stored at RT. If solidification was 
required, 20 g bacto-agar was added to the other components described above, solution 
was autoclaved and allowed to cool. Agar was poured into sterile petri dishes, under 
sterile conditions. Plates were allowed to set and were stored at 4ºC. 
 
YPD-guanidine hydrochloride (GdnHCl) 
YPD was made as described above. After autoclaving, media was allowed to 
cool to approximately 60ºC. GdnHCl stock was added to obtain the required 
concentration (table 2.3).  
 
Table 2.3 Volume of 100 mM GdnHCl stock added to 1 l of YPD to obtain 
concentrations used. 
 
Molarity Required Volume of 100 mM stock added (ml) 
3 mM 30 
200 µM 2 
500 µM 5 
   
If agar had been added, the solution was poured into sterile petri dishes, under sterile 
conditions. Plates were allowed to set and were stored at 4ºC. 
 
YPD-Tacrine/Guanabenz/6-aminophenanthridine 
 YPD was made as described in section above. After autoclaving, the YPD was 
allowed to cool to approximately 60ºC. Tacrine (TA), Guanabenz (GA) or 6-Amino 
phenanthridine (6AP) stock was added to obtain the required concentration (table 2.4).  
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Table 2.4 Volume of 10 mM TA/GA/6AP stock added to 1 l of YPD to obtain 
concentrations used. 
 
Molarity Required 
 
Volume of 10 mM stock added (ml) 
5 µM 0.5 
10 µM 1 
15 µM 1.5 
20 µM 2 
25 µM 2.5 
100 µM 10 
 
If agar had been added, the solution was poured into sterile petri dishes, under sterile 
conditions. Plates were allowed to set and were stored at 4ºC. 
 
YPD-GdnHCl-TA/GA/6AP 
 When a combination of both GdnHCl and TA/GA/6AP was required, 
appropriate volumes of both compounds, described above were added simultanaeously 
to YPD. E.g. to make 200 µM GdnHCl-20 µM 6AP media, 2 ml of 100 mM GdnHCl 
stock and  2 ml 10 mM 6AP stock were added to 1 l of YPD. 
 
Synthetic Complete (SC) 
6.7 g of YNB without amino acids, 20 g of glucose and 2 g of dropout mixture 
(table 2.5) were added to 1 l of dH2O, This solution was then supplemented, depending 
on growth requirements of the strain, with required amino acids (table 2.6), autoclaved 
and stored at RT. If solidification was required, 20 g of bacto-agar was added to the 
other components described above, solution was autoclaved and allowed to cool. The 
agar was poured into sterile petri dishes, under sterile conditions. Plates were allowed to 
set and were stored at 4ºC.  
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Table 2.5 Composition of dropout mixture. The components below were added 
together, ground using a pestle and mortar and stored at RT. 
 
Component 
 
Quantity (g) 
Alanine 2 
Arginine 2 
Asparagine 2 
Aspartic Acid 2 
Cysteine 2 
Glutamic Acid 2 
Glutamine 2 
Glycine 2 
Isoleucine 2 
Lysine 2 
Methionine 2 
Phenylalanine 2 
Proline 2 
Serine 2 
Threonine 2 
Tyrosine 2 
Valine 2 
Para-aminobenzoic Acid 2 
Inositol 2 
 
Table 2.6 Amino acid stock concentrations and final concentration of amino acids 
supplemented into SC media. 
 
Amino 
acid 
 
 
Amino acid quantity 
added to 
100 ml dH2O to make 
stock solutions (g) 
Volume of stock 
added to 1 l SC 
media (ml) 
 
Final amino acid 
concentration in 1 l 
SC media (µg/ml) 
Leucine 1 10 100 
Adenine 0.2 10 20 
Histidine 1 2 20 
Tryptophan 1 2 20 
Uracil 0.2 10 20 
 
SC Galactose (SCGal) 
6.7 g of YNB without amino acids, 20 g of galactose and 2 g of dropout mixture 
(table 2.5) were added to 1 l of dH2O, This solution was then supplemented, depending 
on growth requirements of the strain, with required amino acids (table 2.6), autoclaved 
and stored at RT. If solidification was required, 20 g of bacto-agar was added to the 
other components described above, solution was autoclaved and allowed to cool. The 
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agar was poured into sterile petri dishes, under sterile conditions. Plates were allowed to 
set and were stored at 4ºC.  
 
 
YPD/SC-Gliotoxin  
YPD or SC was made as described above. After autoclaving, the media was 
allowed to cool to approximately 60ºC. Gliotoxin stock was added to obtain the required 
concentration (table 2.7)  
 
Table 2.7 Volume of 1 mg/ml gliotoxin stock added to 30 ml SC. This made enough 
for one agar plate. 
 
Concentration required (µg/ml) 
 
Volume of 1 mg/ml stock added (µl) 
2 60 
4 120 
8 240 
12 360 
16 480 
32 960 
64 1920 
 
If agar had been added, the solution was poured into sterile petri dishes, under sterile 
conditions. Plates were allowed to set and were stored at 4ºC. 
 
SC-cystathionine 
SC was made as described above. After autoclaving, the media was allowed to 
cool to approximately 60ºC. Cystathionine stock was added to obtain the required 
concentration (table 2.8). If agar had been added, the solution was poured into sterile 
petri dishes, under sterile conditions. Plates were allowed to set and were stored at 4ºC. 
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Table 2.8 Volume of 1 mM cystathionine stock added to 30 ml SC. This made 
enough for one agar plate. 
 
Concentration required (µM) 
 
Volume of 1 mM stock added (ml) 
100 3 
250 7.5 
350 10.5 
 
SC-cystathionine-gliotoxin 
 When a combination of both gliotoxin and cystathionine was required, 
appropriate volumes of both compounds, described above were added simultanaeously 
to SC. E.g. to make 16 µg/ml GT-100 µM cystathionine media, 480 µl of 1 mg/ml 
gliotoxin stock and 3 ml of 1 mM cystathionine stock were added to 30 ml SC. 
 
SC-H2O2 
SC was made as described above. After autoclaving, the media was allowed to 
cool to approximately 60ºC. H2O2 (30 % (w/w) in H2O) was added at the required 
concentration (table 2.9). 
 
Table 2.9 Volume of 30 % H2O2 added to 250 ml SC. 
 
Concentration Required (mM) 
 
Volume of 1 mM stock added (µl) 
1 21 
2 42 
3 63 
4 84 
5 105 
 
2.5.2 Media for culturing E. coli 
Luria Broth (LB) 
 20 g of Luria bertani broth was added to 1 l of dH2O, autoclaved and stored at 
RT. If solidification was required, 20 g of bacto-agar was added to the luria broth, the 
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solution was autoclaved and allowed to cool. The agar was poured into sterile petri 
dishes, under sterile conditions. Plates were allowed to set and were stored at 4ºC. 
 
LB-ampicillin 
LB was made as described above and after cooling media, the antibiotic 
ampicillin was added. In LB-ampicillin, only bacterial strains containing an ampicillin 
resistance marker can survive. This enables selection of E. coli cells into which an 
ampicillin-resistance conferring plasmid has integrated. 1 ml of 50 mg/ml ampicillin 
stock was added to 999 ml of LB, resulting in LB with an ampicillin concentration of 50 
µg/ml.  
 
2.6 Sterilisation techniques 
 Sterilisation of growth media and materials required for aseptic techniques was 
achieved by autoclaving at 121oC for 15 min. Any solutions that were susceptible to 
decomposition during autoclaving were filter sterilised using 0.22 µm Millipore 
membrane filters. All worktops and benches were washed with 70% (v/v) ethanol prior 
to carrying out experiments. 
 
2.7 Yeast and bacterial culture conditions 
2.7.1 Conditions for yeast liquid culture 
 Yeast strains required for an experiment were freshly cultured on suitable agar 
plates and grown at 30ºC (BD series Binder incubator, Mason Technology) for 48 hr. 
From these plates, liquid cultures were inoculated in 5 ml suitable media (in 14 ml 
round bottom falcon tubes, BD) unless otherwise stated. Cultures were incubated 
overnight at 30ºC, 200 rpm (Innova 4000 Orbital Shaker, New Brunswick Scientific, 
UK). 
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2.7.2 Conditions for E. coli liquid culture 
 E. coli required was freshly cultured on LB-ampicillin agar plates and grown at 
37ºC for 24 hr., prior to inoculation of liquid culture. Liquid LB-ampicillin was 
inoculated with a single E. coli colony to obtain a 5 ml culture, unless otherwise stated. 
These cultures were incubated overnight at 37ºC, 200 rpm (Innova 44 Orbital Shaker, 
New Brunswick Scientific, UK). 
 
2.7.3 Harvesting yeast and E. coli from liquid cultures 
 Yeast and E. coli were harvested from liquid cultures by centrifugation for five 
min. at 1258 x g and 3220 x g respectively (Centrifuge 5810R, Eppendorf). 
  
2.8 Determination of yeast cell density 
Yeast overnight cultures were diluted 1/100 with sterile dH2O and counted using 
a haemocytometer (Bright Line, Hausser Scientific). The cells were counted using a 
light microscope (INGENIUS, Bio imaging Syngene) at a magnification of X 100. 
Other experiments required O.D. values of yeast growth over a certain time period. In 
this case cell concentration was determined using a spectrophotometer (Eppendorf) at 
OD600nm. 
 
2.9 Yeast comparative growth analysis 
 Yeast were cultured overnight at 30oC (200 rpm) in 5 ml selective media. The 
following morning the cultures were diluted back to OD600nm= 0.1 in 5 ml of fresh 
media and incubated at 30oC shaking until the cells reached a concentration of 3x106 
cells/ml. The cells were harvested by centrifugation and resuspended in selective media 
to a final concentration of 5x106 cells/ml. 200 µl of cultures were placed in wells in 
column 1 in a 96 well plate (Starstedt) and 160 µl of media was added to wells in 
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columns 2-6. A 1/5 serial dilution was performed on the cells using a multichannel 
pipette e.g. by removing and adding 20 µl of culture from well A1 through to A6. Using 
a 96 well metal replicator (Sigma), cells were transferred as spots onto appropriate agar 
plates and left to dry on the bench. The plates were incubated at 30oC and in the case of 
temperature-sensitive tests plates were also incubated at 37oC and 39oC. The plates were 
incubated for 48 hr. and growth was monitored over that time. 
 
2.10 Yeast transformation 
In provision for this technique,  
a) 1 M Lithium acetate was prepared by dissolving 10.2 g of Lithium acetate in 100 
ml of dH2O, followed by autoclaving the mixture. 100 mM Lithium acetate was 
prepared by mixing 1 ml of 1 M Lithium acetate with 9 ml of sterile dH2O. 
Stocks were stored at RT. 
b) 50% (w/v) polyethylene glycol (PEG) stock solutions were prepared by mixing 
50 g PEG with 50 ml of dH2O and adjusting it to a final volume of 100 ml with 
dH2O, followed by autoclaving. PEG Stocks were stored at RT. 
c) Carrier DNA was prepared by adding 200 mg of single stranded DNA into 100 
ml of 10 mM Tris/1 mM EDTA solution. This gave a final carrier DNA 
concentration of 2 mg/ml. The 100 ml stocks were separated into 1 ml volumes 
in fresh 1.5 ml microfuge tubes (Eppendorf) and boiled at 100oC for 5 min. on 
an Accublock Digital Dry Bath (Labnet International.Inc). The tubes were 
subsequently cooled on ice and stored at -20oC.  
d) DNA mix was prepared, for transformation into the competent yeast cells. For 
plasmid DNA transformations, 5 µl plasmid was added to 45 µl molecular H2O. 
For cloning an insert into a vector, various volumes of both insert and vector 
DNA were added together for transformation.  
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e) 10 mM Tris/1 mM EDTA solutions in which the carrier cDNA was dissolved 
were prepared by making a 100X stock concentration. 12.14 g Tris and 2.92 g 
EDTA were added together and adjusted to 100 ml with dH2O. The pH was 
adjusted to 7.5. The solution was autoclaved and 1 ml was removed and added 
to 99 ml sterile dH2O to give a final concentration of 10 mMTris/1 mM EDTA. 
 
2.10.1 Preparation of competent yeast 
 Yeast strains were inoculated as previously described in section 2.7.1. The 
following morning, the 5 ml overnight cultures were added to 50 ml fresh suitable liquid 
media. Yeast cultures were incubated at 30oC shaking for a further 3-5 hr. until cell 
concentrations reached 1-2 x 107cells/ml. The cells were harvested by centrifugation at 
1258 x g, washed in 25 ml of sterile dH2O and centrifuged again. The supernatants were 
disposed of and pellets were resuspended in 1 ml of 100 mM Lithium acetate. The cells 
were transferred to microfuge tubes and pelleted in a table top centrifuge (Centrifuge 
5415D, Eppendorf AG, Hamburg) at 15700 x g for 5 sec. and resuspended in 500 µl of 
100 mM Lithium acetate. These cells could be stored at 4oC for 1-2 weeks or used 
immediately for transformation. 
 
2.10.2 Transformation of competent yeast with DNA 
 50 µl aliquots of competent yeast cell suspensions were added to fresh 
microfuge tubes and pelleted for 5 sec. Residual lithium acetate was removed. The 
following components were added to each microfuge tube in the order listed: 
        240 µl 50% (w/v) PEG  
        36 µl 1 M Lithium acetate 
        25 µl single stranded carrier DNA (taken from 2 mg/ml stock)  
        50 µl mix of molecular H2O and desired DNA  
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The cell suspensions were mixed and incubated at 30oC for 30 min. The mixtures were 
then heat-shocked at 42oC in an Accublock Digital Dry Bath (Labnet International.Inc) 
for 20-25 min. The microfuge tubes were centrifuged at 15700 x g for 15 sec. and the 
pellets were resuspended in 200 µl of dH2O and plated onto selective agar plates. These 
plates were incubated at 30oC for 2-3 days. 
 
2.11 E. coli transformation 
2.11.1 Preparation of competent E. coli 
E. coli DH5α were inoculated in 10 ml of LB media and incubated overnight at 
37ºC 200 rpm. The following day, the 10 ml culture was added to 1 l of LB media and 
incubated for 2 hr. at 37oC (200 rpm). This culture was split into 4 x 250 ml 
centrifugation tubes and chilled on ice for 10 min. The cells were centrifuged at 5000 
rpm for 10 min. at 4ºC, in a GSA rotor. The pellets were resuspended in 10 ml RF1 
Buffer (table 2.10) and kept on ice for 30 min. The cells were then centrifuged at 3220 x 
g for 10 min. at 4ºC and each pellet was resuspended in 3.2 ml RF2 Buffer (table 2.11). 
The tubes were kept on ice for 15 min. 100 µl aliquots were transferred into pre-cooled 
1.5 ml microfuge tubes and the cells were stored at -70oC.  
 
Table 2.10 Components of buffer RF1 used in the preparation of competent E. coli. 
 
Component 
 
Amount added Final concentration/volume 
K-Acetate 1.47 g 30 mM 
CaCl2.2H2O (dihydrate) 5 ml 1 M 10 mM 
Glycerol 7.5 ml 15% 
dH2O  Adjusted to 450 ml* 
RbCl 6 g 100 mM 
MnCl2.4H2O 
(tetrahydrate) 
4.95 g 50 mM 
dH2O  Adjusted to 500 ml 
* At this point, solution was adjusted to pH 5.92 with 0.2 M acetic acid (0.2 M = 3 g in 
250 ml dH2O). 
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Table 2.11 Components of buffer RF2 used in the preparation of competent E. coli. 
 
Component Amount added Final 
concentration/volume 
RbCl 5 ml 1 M 10 mM 
CaCl2.2H2O 
 
5.5. g 75 mM 
dH2O  Adjusted to 500 ml 
 
All chemicals and solutions were added in consecutive order from top to bottom, as 
illustrated in the table. Both RF1 and RF2 buffers were filter sterilised and stored at 4ºC 
prior to use. 
 
2.11.2 E. coli transformation (long method) 
1-20 µl (approximately 1 µg) of plasmid DNA was added to 100 µl competent E. 
coli and incubated on ice for 30 min. The cells were subjected to 42ºC for 1 min. on a 
digital dry bath followed by immediate recovery by adding 1 ml of liquid LB to each 
1.5 microfuge tube. The tubes were incubated at 37oC shaking for 1 hr. and then plated 
onto LB-amp agar. These plates were incubated overnight at 37oC. 
 
2.11.3 E. coli transformation (5 min. method) 
 To ensure optimum conditions for efficient transformation, LB-amp plates were 
incubated at 37ºC for approximately 1 hr. prior to transformation. 50 µl of competent E. 
coli were thawed on ice and 1-5 µl plasmid DNA was added. These mixes were 
maintained on ice for 5 min., then plated onto warm LB-amp plates and incubated at 
37ºC overnight.     
 
2.12 Yeast genomic DNA isolation 
In provision for this technique, 
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a) 1 M sorbitol/100 mM EDTA solutions were prepared by dissolving 18.2 g of 
sorbitol in 20 ml warm dH2O and adding 2.92 g of EDTA. The solutions were 
adjusted to 100 ml with dH2O, autoclaved and stored at RT. 
b) Zymolase stocks were prepared by adding 500 mg of zymolase (Sigma) to 100 
ml of dH2O and filter sterilising. The stocks were aliquoted into 1 ml volumes 
and stored at -20oC. 
c) 1 M Tris/100 mM EDTA solutions were prepared by dissolving 2.92 g of EDTA 
and 12.1 g of Tris in 20 ml of dH2O and adjusting the final volume to 100 ml 
with dH2O. The solutions were autoclaved and stored at RT. 
d) 10% (w/v) Sodium dodecyl sulfate (SDS) solutions were prepared by dissolving 
10 g of SDS in 20 ml of dH2O and adjusting the final volume to 100 ml with 
dH2O. The solutions were autoclaved and stored at RT. 
e) 5 M potassium acetate (KAc) solutions were prepared by dissolving 49 g of KAc 
in 20 ml of dH2O and adjusting the final volume to 100 ml with dH2O. The 
solutions were autoclaved and stored at RT. 
 
 To isolate genomic DNA from a desired strain, yeast were inoculated in 2 ml 
YPD and incubated overnight shaking at 30°C. The cells were pelleted at 1258 x g for 5 
min. and pellets were resuspended in 150 µl of 1 M sorbitol/100 mM EDTA and 
transferred to 1.5 ml microfuge tubes. 12 µl of 5 mg/ml zymolase was added to each set 
of cells and the tubes were incubated for 1 hour at 37°C. The mixtures were centrifuged 
at 15700 x g for 5 sec. and resupended in 150 µl of 1 M Tris/100 mM EDTA. 15 µl of 
10% (w/v) SDS was mixed with the cell suspensions and solutions were incubated at 
65°C for 30 min. 60 µl of 5 M KAc was added to each tube and tubes were chilled on 
ice for 1 hr. The resulting mixtures were centrifuged at 15700 x g for 5 min. and the 
supernatants were retained. 195 µl of Isopropanol was added to each su
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tubes were maintained for 5 min. at RT, to allow precipitation of DNA. The tubes were 
then centrifuged at 15700 x g for 10 sec., supernatants were removed and pellets were 
allowed to air dry. The DNA pellets were resuspended in 45 µl dH2O and stored at  
-20°C. 
 
2.13 Isolation of plasmid DNA from yeast 
To isolate plasmid DNA from yeast, cells were inoculated overnight in 5 ml 
selective media at 30ºC, 200 rpm. The cells were harvested by centrifugation at 1258 x 
g for 5 min. All buffers used in this procedure were purchased in a plasmid miniprep kit 
from QIAGEN. The cell pellets were resuspended in 250 µl Resuspension Buffer in 1.5 
ml microfuge tubes and approximately 200 µl of 0.5 mm soda lime glass beads (Biospec 
products Inc.) were added to the cell suspensions. The cells were vortexed (Vortex-2 
Gene, Scientific Industries) for 5 min. at maximum speed. At this stage the glass beads 
were at the bottom of the microfuge tubes and the liquid cell mixtures were carefully 
removed. 250 µl of Lysis Buffer followed by 350 µl of Neutralising Buffer were added 
to the cells, mixed well and centrifuged for 10 min. at 15700 x g. The supernatants were 
then removed and transferred to DNA binding columns (QIAGEN) where they were 
centrifuged for 1 min. at 15700 x g. Flow-through into the catchment tubes were 
discarded and 750 µl of Wash Buffer was added to each column, this was followed by 
centrifugation for 1 min. at 15700 x g. Flow-through was discarded and columns were 
centrifuged for an additional min. to remove any residual buffer from the binding 
column. DNA was eluted by adding 50 µl of Elution Buffer directly into the binding 
columns and allowing them to sit for 1-2 min. The binding columns were transferred to 
fresh 1.5 ml microfuge tubes and plasmid DNA was isolated by a final 1 min. 
centrifugation at 15700 x g. 
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To ensure plasmid DNA was at an ideal concentration for further experimentation (ideal 
amount is 100-500 ng/µl), 17 µl of each DNA elution was transformed into E. coli by 
the ‘long’ method of transformation (section 2.11.2). Plasmid DNA was finally isolated 
by additional steps that will be discussed in section 2.14. 
  
2.14 Isolation of plasmid DNA from E. coli 
Following transformation of plasmid DNA into E. coli, individual bacterial 
colonies were isolated from the LB-amp plates. To isolate this DNA, a single colony 
was inoculated in 5 ml of LB-amp liquid and grown overnight at 37°C 200 rpm. The 
next day, cells were harvested by centrifugation for 5 min. at 3220 x g. All buffers used 
in this procedure were purchased in a plasmid miniprep kit from QIAGEN. The cell 
pellets were resuspended in 250 µl Resuspension Buffer. 250 µl of Lysis Buffer 
followed by 350 µl of Neutralising Buffer were added to the cells, mixed well and 
centrifuged for 10 min. at 15700 x g. The supernatants were then removed and 
transferred to DNA binding columns where they were centrifuged for 1 min. at 15700 x 
g. Flow-through in catchment tubes was discarded and 750 µl of Wash Buffer was 
added to each column, this was followed by centrifugation for 1 min. at 15700 x g. 
Flow-through was discarded again and columns were centrifuged for an additional 1 
min. to remove any residual buffer from the binding column. DNA was eluted by 
adding 50 µl of Elution Buffer directly into the binding columns and allowing it sit for 
1-2 min. The binding columns were transferred to fresh 1.5 ml microfuge tubes and 
plasmid DNA was isolated by a centrifugation at 15700 x g. Plasmid DNA was stored at 
-20°C. 
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2.15 Monitoring the presence of the prion [PSI+] in S. cerevisiae 
 
 The presence or absence of the [PSI+] prion can be monitored in yeast strains by 
a simple colour assay (figure 2.1). 
 
                                           
 
Figure 2.1 Monitoring the presence/absence of [PSI+] using a simple colour assay. 
[PSI+] cells grow as white colonies on media containing limited adenine, while [psi-] 
cells grow as red colonies.   
 
It can thus be determined whether or not the cells contain the prion ([PSI+] cells) 
or do not ([psi-] cells). The strains that we use to carry out experiments involving the 
monitoring of [PSI+] contain an ochre mutation (ade2.1) in a gene responsible for 
adenine biosynthesis. Sup35p is a S. cerevisiae protein involved in translation 
termination and when in its fully functional state, halts translation at this premature stop 
codon, leading to the build-up of a red pigment in the cells. These cells are clearly seen 
as red when grown with limiting amounts of adenine. When Sup35p aggregates into a 
non-functional form it is called [PSI+], and there is subsequently reduced translation 
termination of the ade2 gene and cells appear white on limiting adenine media (figure 
2.2).    
A second way of monitoring the presence of [PSI+] is by growth of yeast cells 
on medium lacking adenine. [PSI+] cells grow on medium lacking adenine whereas [psi-] 
cells do not. This is because [PSI+] cells produce functional Ade2p which is involved in 
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the adenine biosynthesis pathway. In [psi-] cells the adenine biosynthesis pathway is 
disrupted and cells require supplemented adenine for normal growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Consequences of [PSI+]. Non-functional, aggregated Sup35p [PSI+] allows 
readthrough of the ade2-1 mutation.  
 
2.16 Thermotolerance Assay 
 Yeast strains were prepared for comparative growth analysis as described in 
section 2.9. On the second day, after cultures were grown and resuspended to a final 
concentration of 5x106 cells/ml in 14 ml round-bottom tubes, cells were exposed to a 
temperature of 39ºC (200 rpm) for 1 hr.  This temperature exposure can result in the 
induction of Hsp104p, which is important in conferring cellular thermotolerance, 
preventing denaturation of proteins when cells are undergoing heat stress. Subsequent to 
this, cell aliquots were maintained at 52ºC (200 rpm) for 0, 10, 20, 30 and 40 min., or 0, 
2, 4, 6, 8, and 10 min., with cells undergoing heat-shock. Cells were immediately 
transferred to ice when removed from incubation. Comparative growth analyses were 
then carried out by making a 1/5 serial dilution as described in section 2.9. Cells were 
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plated on various plates dicatated by the nature of the experiment and incubated for 48 
hr. at 30oC. 
 
2.17 Luciferase Assay 
Prior to carrying out the luciferase assay, strains to be tested were transformed 
with the pDCM90 plasmid, following the method described in section 2.10. 1 mg/ml 
cycloheximide stocks were prepared by adding 5 mg of cycloheximide to 5 ml of sterile 
dH2O. These were aliquoted and stored at -20oC.    
To perform the luciferase assay, yeast strains were cultured overnight in 5 ml of 
SC –uracil media to select for cells containing the plasmid. The following morning, 
cultures were diluted back to OD600 0.2 and incubated for 1 hr. at 37oC, 200 rpm, to 
induce expression of heat-shock proteins. Cellular luciferase activity of each strain was 
then measured in triplicate, by adding 10 µl of decanal to 200 µl of culture in 5 ml 
rohren tubes (Sarstedt). An FB 12 Luminometer (Berthold Detection Systems) was used 
to obtain the luciferase activity readings, which were taken as 100% activity readings. 
Cells were then incubated at 45ºC (200 rpm) for 50 min., after which cycloheximide 
was added at a concentration of 10 µg/ml to prevent protein synthesis activity and de 
novo synthesis of heatshock proteins. Cultures were then incubated at 45ºC for a further 
10 min. After this 1 hr. heatshock, cellular luciferase activity of each strain was 
measured as before, in triplicate. If heatshock worked successfully, readings were at 
most 10% of those recorded as 100% activity levels. 
Cultures were then shifted to 25ºC to let the cells recover from heatshock. After 
30 min. at 25ºC, luciferase activity readings were taken again, as before, followed by 
readings after 60, 90, 120 and 150 min. at 25ºC. 
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When testing the effects of drugs on luciferase activity and recovery, cells were 
pre-exposed to the drug(s) at an appropriate concentration for 1 hr. at 30ºC (200 rpm), 
prior to the 1 hr. 37ºC incubation. 
 
2.18 Carbon-14 [14C]-GdnHCl uptake assay 
 All work requiring the use of [14C] was carried out in a certified radiation suite. 
In   preparation for [14C] work, the workstation was decontaminated using 2% (v/v) 
Decon. A portable Geiger counter (Mini Instruments, Series 900 EP15 contamination 
meter, Perspective Instruments) was placed beside the workstation to record any 
airborne radiation. A personal Geiger counter (Perspective Instruments) was also worn 
to record personal radiation exposure.   
 Yeast strains were cultured overnight in 10 ml YPD. The following morning, 
cultures were diluted to OD600 0.2 in 40 ml fresh YPD. 1 mM GdnHCl was added to the 
cultures (50 µl of 100 mM GdnHCl stock) and cultures were transferred to sterile flasks. 
To these flasks, [14C]-labelled GdnHCl (American Radiolabeled Chemicals, Inc.) was 
added at a concentration of 0.05 µCi/ml from a 0.1 mCi/ml stock. At this point (T=0), in 
duplicate, 5 ml samples were removed from flasks and and transferred to 14 ml round-
bottom tubes. Samples were centrifuged for 5 min. (1258 x g) and 1 ml of supernatants 
were removed to 1.5 ml microfuge tubes. The remaining supernatants were discarded 
and pellets were washed and resuspended in 1 ml sterile dH2O. Both pellets and 
supernatants were stored at 4ºC until readings were taken. The flasks were incubated at 
30ºC in a hybaid oven contained within in a fume hood. 5 ml samples were taken in 
duplicate after 2 and 4 hr. and prepared in the same way as before. Prior to sampling, 
OD600 was measured using a spectrophotometer. When all samples were prepared, 
[14C]-labelled GdnHCl readings were made of all pellets and supernatants using a 
Beckman Scintillation Counter. 
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Molecular Techniques 
2.19 Polymerase Chain Reaction (PCR) analysis 
2.19.1 PCR amplification 
All primers were purchased from Sigma in the de-salted powder from. The 
primers were dissolved in molecular-grade H2O to give a final 100 µM concentration. 
The volume of water to be added was indicated on the specific primer sticker, as 
provided by Sigma. From these, 10 µM working stocks were made up by adding 10 µl 
of 100 µM stock to 90 µl molecular-grade H2O (1/10 dilution). All primer stocks were 
stored at -20ºC. Two enzymes were used, depending on the experiment being carried 
out, taq polymerase or Platinum/High-Fidelity taq. PCR cycle conditions were thus 
adjusted accordingly. PCRs were carried out using a Peltier Thermal cycler (MJ 
Research) in sterile PCR tubes (Starstedt). Table 2.12 lists the specific PCR reaction 
mixtures and cycle conditions for the appropriate product. Tables 2.13-2.17 list primers 
used for PCR. 
 
Table 2.12 PCR reaction mixtures and PCR cycles. 
 
PCR PCR mixture 
component 
Volume added 
(µl) 
PCR cycle 
conditions 
 
PCR for diagnostic 
tests 
Taq Buffer (New 
England Biolabs, 
NEB) 
dNTP mix (Sigma) 
Forward primer 
Reverse primer 
MgCl2 (NEB) 
Template DNA 
Taq Polymerase 
(NEB) 
Molecular-grade 
water 
 
2 
 
 
1 
1 
1 
1 
2 
0.5 
 
11.5 
94oC 4 min. 
94oC 1 min. 
55oC 1 min. 
72oC 1 min. per kb 
Cycle to step 2 x 30 
times 
72oC 6 min. 
4oC overnight 
 
PCR of template 
DNA for 
cloning/genomic 
knockout 
Platinum/High 
Fidelity Taq Buffer 
(Invitrogen) 
dNTP mix 
Forward primer 
5 
 
 
2 
2 
94oC 2 min. 
94oC 30 sec. 
55oC 30 sec. 
68oC 1 min. per kb 
Cycle to step 2 x 30 
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Reverse primer 
MgSO4 (Invitrogen) 
Template DNA 
HF Taq Polymerase 
(Invitrogen) 
Molecular-grade 
water 
 
2 
2 
2 
0.5 
 
34.5 
times 
72oC 6 min. 
4oC overnight 
 
 
   
 Table 2.13 Primers for GliT cloning. 
 
Primer Oligonucletide sequence 
 
Cloning GliT into pC210 F AGATTTTATACAGAAATATTTAT
ACATATGATGTCGATCGGCAAAC
TACTCTCCAAC 
Cloning GliT into pC210 R TTCCTGATTAAACAGGAAGACAA
AGCATGCCTATAGCTCCTGATCG
AGACGAAAC 
Cloning GliT into pYES2 F CTGTAATACGACTCACTATAGGG
AATATTAATGTCGATCGGCAAAC
TACT 
Cloning GliT into pYES2 R CATGATGCGGCCCTCTAGATGCA
TGCTCGACTATAGCTCCTGATCG
AGAC 
 
 
Table 2.14 Primers for qPCR. Primers anneal within gene sequence. 
 
Gene name 
 
Oligonucleotide sequence 
ERG9 F GACTTATTTGGCCGGTATCCA 
ERG9 R GCGACACAGCCACGCAAAGTCC 
VMA6 F GGGGATTTTTGGAGACTGGT 
VMA6 R GTGCGATACATTCTGCAATCCAGG 
MET7 F CTAAGTGGGAAGGCAGATGTCAAG 
MET7 R TCTGGCGAAACAGATGAGTACAGG 
SAM1 F TGCCTTCTCCGGTAAGGACTACTCT 
SAM1 R AGACTTGGTCGCAGTACCATAGGTG 
MET6 F ATTCAACAAGGGCACCATCTCTG 
MET6 R TGGTCTGGACAAGTCACCAACAA 
MET16 F CAATTGGACGTTCGAGCAGGTTA 
MET16 R CCCTTCCATCTTCCTGCTCTCTC 
MET17 F TCAACTACACGCCGGCCAAGAGA 
MET17 R AAACAGCCAAAGCAGCAGCACCA 
MET2 F ATTGAATCTCCCGAAGGCCACGA 
MET2 R TTCGGCCTCACCAAAGACAGACG 
MET14 F TGGTGACAACATTCGTTTTGGATTGA 
MET14 R GGGTCCCTTTGCTCAGCGACTTC 
MET22 F GGCAACGTTATTGTCCATGAAGC 
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MET22 R CGCATGATGTAGACACCACCAAG 
HBN1 F CTAGTTTCGCGGACCATACCTC 
HBN1 R GGTCCAAGACTCAGGGATTTTG 
JEN1 F GTGTCTTTGGTGTCTGGGGTATC 
JEN1 R AGAGCACCAGAGGCATCTCTTT 
SIP18 F CATGGACATGGGTATGGGTCAT 
SIP18 R ATCGTTCGCAATTCCTCTGC 
BDH2 F CATGTGCTACACACACCACGAT 
BDH2 R CTCCGTGATTGTTTGGAGTCAG 
SDH2 F AAGGATGGAACGGAAGTGCTAC 
SDH2 R TGTTCTTGGTTCCACCAGTACG 
MLS1 F GTTGCAGTACATGGAAGCTTGG 
MLS1 R GGACTTGCCTTAGACAGTCTTTCC 
 
 
Table 2.15 Primers for cloning GSH1. 
 
Primer 
 
Oligonucleotide sequence 
Cloning GSH1 into pRS315 F GGTGGCGGCCGCTCTAGAACTAGTGG 
ATCCGCTCTTGAATGGCGACAGCC 
Cloning GSH1 into pRS315 R CCCCTCGAGGTCGACGGTATCGATAA 
GCTTTTAACATTTGCTTTCTATTG 
 
 
Table 2.16 Primers for HBN1 knockout HBN1::HIS5. 
 
Primer 
 
Oligonucleotide sequence 
HBN1 knockout in wildtype F AGACTGAAGTATCCTATATCAACA
TATATACAAAAAAACAATCCAATA
TCATGCAGCTGAAGCTTCG 
HBN1 knockout in wildtype R GACGTTCGCATTTAATCTATACCTA
TAATTCTGTACTTATATACTGTTCC
TTAGCATAGGCCACTAGTGGATCT
G 
HBN1 knockout in ∆frm2 F CCGCTCCTTCTCCTAACATCAA 
HBN1 knockout in ∆frm2 R TACGAGCCTAGATTGACAGACG 
Diagnostic HBN1 knockout F CTAGGGTCTTGGCATTTGCAC 
Diagnostic HBN1 knockout R CGATGGATGGTGTCTGGTAGAA 
HIS5 internal F GGGTAGGAGGGCTTTTGTAGAA 
HIS5 internal R GCGCTTTCAGCACGATGATGGT 
 
 
Table 2.17 Primers for sequencing YEp13. 
 
Primer 
 
Oligonucleotide sequence 
Sequencing primer F GCCAGTCACTATGGCGTGCTGC 
Sequencing primer R CGCCGAAACAAGCGCTCATGAG 
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2.19.2 Agarose gel electrophoresis 
PCR products were resolved on 0.8% (w/v) agarose gel at 90 V for 45 min. in a 
Biorad electrophoresis power-pack. 0.8% (w/v) agarose was dissolved in 50 ml of 1X 
TAE Buffer (Millipore), boiled and allowed to cool. Once cooled, 1 µl of a 10 mg/ml 
ethidium bromide solution was added to make a final concentration of 0.2 µg/ml. Care 
was taken when handling the carcinogen ethidium bromide. All materials that were in 
contact with the agent were disposed of in a separate ethidium bromide waste container. 
The molten agarose was poured into a casting rig and allowed to set. PCR products (3 µl) 
were mixed with 1 µl of 6X Blue Loading Dye (NEB) and 2 µl of dH2O. When set, the 
gel was submerged in 1X TAE Buffer and the PCR products were added to the wells 
alongside a 1 kb molecular grade marker (NEB), which had been as prepared in the 
same way as the PCR products. 
 
2.20 DNA sequence analysis 
 Yeast genomic or plasmid DNA was prepared as described in sections 2.12 and 
2.13. DNA concentrations were measured using a Nanodrop Spectrophotometer  
(Nanodrop 1000, Thermo Scientific). It was ensured that the DNA concentrations were 
not less than 200 ng/ml. For each piece of DNA to undergo sequence analysis, 3 µl of 
DNA and 4 µl forward primer were added to 3 µl molecular H2O in a microfuge tube, 
giving a final volume of 10 µl. This was then repeated using the reverse primer. 
Microfuge tubes were tagged with a prepaid barcode and samples were sent to Agowa 
Sequencing Services Berlin, Germany. DNA was sequenced by dye-terminator 
sequencing and results were available on the Agowa website. Sequencing results were 
analysed using the BLAST function on NCBI. 
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2.21 Cloning DNA into plasmid vector by homologous recombination 
 To clone genes into plasmids, yeast were employed to do so by homologous 
recombination/gap repair. In this study, three plasmid clones were created, GliT-pC210, 
GliT-pYES2 and GSH1-pRS315. 
 
2.21.1 Creating DNA fragment for cloning 
 Firstly, primers were designed to PCR amplify the region of interest to be cloned 
into a plasmid e.g. PCR reaction was set up to amplify GliT from the topovector 
plasmid. Primers were designed to create the product with overhangs both up- and 
downstream which were homologous to regions of the plasmid, into which the gene 
would be cloned. These primers annealed to approximately 30 bp of the gene of interest 
coding regions and incorporated approximately 30-40 bp of DNA sequence from the 
plasmid vector as overhangs. The PCR cycle used is described in table 2.12 and primers 
are listed in tables 2.13 and 2.15. HF Taq has better proof-reading than Taq and so was 
used for cloning. The PCR product sizes were confirmed by gel electrophoresis. 
 
2.21.2 Restriction digest of plasmid DNA 
 Prior to digestion, plasmid DNA was prepared as described in section 2.14. 
When a high concentration of plasmid DNA was obtained (ideally over 200 ng/µl), 
restriction digests of the plasmids were set up. 
 pC210 vector DNA was digested with enzymes NdeI and SphI (both NEB) in 
order to linearise the DNA and remove the SSA1 gene. 4 µg plasmid was digested using 
2 µl of each enzyme. 5 µl of NEB buffer 4 was added to this reaction and the volume 
was brought to 50 µl total with molecular-grade H2O. pRS315 was digested with 
BamHI and HindIII (both NEB) to linearise the plasmid. 4 µg plasmid DNA was 
digested using 2 µl of each enzyme, 5 µl of NEB buffer 2 was added and the reaction 
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volume was adjusted to 50 µl with molecular-grade H2O. pYES2 was digested with 
XhoI and HindIII to linearise the plasmid. 4 µg of plasmid DNA was digested using 2 µl 
of each enzyme, 5 µl of NEB buffer 2 was added and the reaction volume was adjusted 
to 50 µl with molecular-grade H2O. For digestion to occur, reaction mixes were 
incubated in 1.5 ml microfuge tubes at 37ºC for approximately 3 hr. 
 
2.21.3 Gel extraction and purification of digested plasmid DNA 
 After plasmids were digested, loading dye was added to the whole digestion 
reaction and run on an agarose gel (as described in section 2.19.2). The gel was then 
viewed under ultra-violet light to determine whether or not the digestion had been 
successful. After pC210 digestion with NdeI and SphI, the products visible under UV 
light were of approximately 2.2 kb and 6.7 kb. This demonstrated that SSA1 had been 
removed from the rest of the plasmid, with a linear product remaining. The remaining 
plasmid fragments were removed for cloning. When pRS315 was digested successfully 
with BamhI and HindIII, bands of approximately 6 kb was seen under UV light. These 
bands were excised from the gel. When pYES2 was digested using XhoI and HindIII, 
products of approximately 5.9 kb were seen and gel extracted. 
 Fragments were excised from the gel under UV light using a clean scalpel. The 
pieces of gel were added to 1.5 ml microfuge tubes and weighed on a fine balance. If 
the agarose gel weighed more than 400 mg then it was split into two microfuge tubes. 
Using a QIAGEN gel extraction kit, 3 volumes of Buffer QG was added to 1 volume of 
gel. The gels were then dissolved in the QG Buffer at 50oC for 10 min. The dissolved 
samples were applied to QIAquick spin columns and centrifuged for 1 min. at 15700 x g. 
The flow-through was discarded and 750 µl Buffer PE was added to each column. The 
columns were centrifuged for 1 min., flow-through discarded and centrifuged for an 
additional min. 50 µl of Buffer EB was added to the columns and left to stand for 1 min. 
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DNA was eluted by centrifugation for 1 min. 3 µl of sample was analysed by agarose 
gel electrophoresis to confirm the presence of DNA. 
  
2.21.4 Homologous recombination of vector and DNA fragment 
 Prior to cloning, yeast cells were prepared for transformation as described in 
section 2.10.1. The cells acted as vehicles for the cloning to occur. Figure 2.3 illustrates 
the methodology behind cloning by homologous recombination. Four DNA samples 
were prepared as follows: (a) 15 µl digested vector/35 µl insert, (b) 5 µl digested 
vector/20 µl insert (c) 10 µl digested vector/20 µl insert and (d) 5 µl digested vector/20 
µl molecular-grade H2O. Each DNA mix was transformed into separate yeast cell 
aliquots as described in section 2.10.2. The cells were selected on SC-leucine (pRS315, 
pC210) and -uracil (pYES2). Any colonies that grew on these plates should have had an 
intact plasmid being expressed, as the wildtype cells used in this study cannot grow in 
the absence of these amino acids. When cloning worked successfully, there were 
colonies on plates a, b and c and there were no colonies on plated, as it had no intact 
vector.  
 
 
 
 
 
 
 
 
Figure 2.3 Cloning GliT into pC210. The SSA1 gene which is found in the plasmid 
between the NdeI and SphI restriction sites was first digested and removed from the 
plasmid. Then the GliT gene with 5’ and 3’ overhangs was cloned into the plasmid by 
homologous recombination. 
GliT from topo vector
SSA1
5’ overhang 3’ overhang
pC210
vector
 69 
Colonies from cloning plates a, b and/or c were replated onto fresh selective plates. 
After 48 hr., plasmids were extracted as described in section 2.13. These were then 
transformed into E. coli and isolated as described in sections 2.11 and 2.14. Each 
plasmid was enzyme digested as described in section 2.21.2 and examined by agarose 
gel electrophoresis. Potential clones should have at least two DNA bands, one 
corresponding to the linearised vector and the other the size of the gene cloned. This 
depends on where and how often the enzyme cuts.  
 The plasmids were sent to Agowa for sequencing to confirm the presence of the 
gene of interest. Figure 2.3 illustrates the methodology behind cloning by homologous 
recombination. 
 
    
2.22 Knockout of genomic DNA by homologous recombination 
Certain yeast knockout strains used in this study were purchased from 
EUROSCARF. All other strains were made in the laboratory. Yeast knockout strains 
were made by homologous recombination. This involves creating a gene disruption 
cassette that encodes a selectable marker. Located at either side of the selectable marker 
are segments of DNA homologous to the gene being knocked out. The knockout 
cassette incorporates itself into the genome at the corresponding chromosomal locus by 
homologous recombination. Genomic HBN1 was knocked out in the wildtype BY4741 
and ∆frm2 backgrounds using the selectable marker HIS5. To replace HBN1 with HIS5 
in the wild-type background, the HIS5 gene, in addition to its promoter and terminator 
regions, was isolated from the pUG27 plasmid by PCR. These PCR products were 
created with overhangs homolgous to flanking regions of the gene to be knocked out, in 
this case HBN1. Conditions, reagents and primers are documented in tables 2.12 and 
2.16. These products (50 µl) were then transformed into competent BY4741 cells, 
which were plated on synthetic complete plates lacking histidine (SC –histidine) to 
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select for mutants that can survive in the absence of exogenous histidine, i.e. cells in 
which HBN1 was replaced by HIS5. Molecular-grade H2O was also transformed into 
BY4741 as a negative control. Figure 2.4 represents this method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Method used to knock out genomic HBN1 in BY4741 with HIS5. It was 
then possible to select for knockouts on –histidine plates. 
 
To knock out HBN1 in the BY4741 ∆frm2 background, a similar method was 
employed. This time, the HIS5 cassette was isolated from the BY4741 ∆hbn1 strain by 
PCR. Primers were designed that annealed 343 and 264 bp up- and downstream of the 
HIS5 region respectively (table 2.16). These products (50 µl) were transformed into 
competent BY4741 ∆frm2 cells along with a molecular-grade H2O negative control and 
selected on –histidine plates. Figure 2.5 illustates this method.   
 
HIS5 cassette
Flanking region 
of HBN1
Flanking region 
of HBN1
HBN1
Genomic DNA
HIS5 Cassette
pUG27
vector
PCR
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Figure 2.5 Method used to knock out genomic HBN1 in BY4741 ∆frm2 with HIS5. 
Knockouts were selected for on –histidine plates. 
 
2.23 Real-time/quantitative PCR 
Prior to RNA extraction, G600 cells were cultured overnight in 5 ml YPD. 1.5 
ml of overnight cultures was added to 500 µl fresh YPD and gliotoxin was added at 
concentrations of 16 µg/ml and 64 µg/ml (32 µl and 128 µl of 1 mg/ml gliotoxin stock 
respectively). Cultures were exposed to gliotoxin for 1 hr. at 30°C, 200 rpm. 
  
2.23.1 RNA extraction 
Following 1 hr. gliotoxin exposure, RNA was extracted using the Qiagen 
RNeasy kit. Cells were harvested by centrifugation at 4°C (1258 x g, 5 min.). Cell 
pellets were resuspended in 600 µl Buffer RLT and transferred to 1.5 ml microfuge 
tubes. 0.5 mm soda lime glass beads were added at the same volume and the microfuge 
tubes were vortexed for 30 sec. and left on ice for 30 sec. This was repeated 5 times. 
Samples were then centrifuged at 4°C (700 x g, 3 min.) and supernatants were 
transferred to new 1.5 ml microfuge tubes. One volume of 70% (v/v) molecular ethanol 
(Merck) was added to lysates, mixed, transferred to spin columns and centrifuged at 4°C 
(9300 x g, 15 sec). 700 µl Buffer RW1 was added to columns and samples were 
centrifuged again at 4°C (9300 x g, 15 sec). 500 µl Buffer RPE was added to columns 
and centrifuged as above. Further 500 µl Buffer RPE was added to columns and 
HIS5 cassetteHBN1 flanking region
HBN1
PCR from BY4741 ∆hbn1 HBN1 flanking region
Primer 5’-3’ Primer 3’-5’
BY4741 ∆frm2
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centrifuged at 4°C (9300 x g, 2 min.). RNA was eluted from columns in molecular H2O 
through centrifugation (9300 x g, 1 min.).  
 
2.23.2 RNA quantification 
RNA concentrations were measured using NanoDrop 1000 Spectrophotometer 
(Mason Technologies). 
 
2.23.3 DNAse treatment 
DNA was removed using DNase I kit (Sigma). 1 µl 10X buffer and 1 µl DNase I 
were added to 1 µg RNA and volumes were brought to 10 µl with molecular H2O. 
Solutions were incubated at RT for 15 min. Reactions were stopped by adding 1 µl 
EDTA solution and heated at 70ºC for 10 min. 
 
2.23.4 RT-cDNA synthesis 
cDNA was synthesized using Superscript III First-Strand Synthesis System 
(Invitrogen). To 8 µl DNase-treated RNA (from above reaction), 1 µl 50 µM oligo dT 
and 1 µl 10 mM dNTP were added. Solutions were incubated at 65ºC for 5 min., then 
chilled on ice. 10 µl reaction mix (2 µl RT buffer, 4 µl 25 mM MgCl2, 2 µl 0.1M DTT, 
1 µl RNase out, µl SSIII) was added and solutions were incubated at 50ºC for 50 min. 
Reactions were stopped by incubation at 85ºC for 5 min. Solutions were then chilled on 
ice. 1 µl RNase H was added to solutions, followed by incubation at 37ºC for 20 min. 
cDNA was then stored at -20ºC. 
 
2.23.5 qPCR reaction 
For each gene, both references and targets, a standard curve was first constructed. 
Five-sample serial dilutions (1:4) of the control cDNA (from non-treated cells) were 
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made and these were used as reaction template. Reaction mixes were prepared by 
combining 1 µl template cDNA, 1 µl forward primer, 1 µl reverse primer, 1 µl 
molecular H2O (Roche) and 5 µl SYBR Green I Master reaction mix (Roche). These 
reactions were prepared in triplicate and loaded onto 96-well plates (Roche). For these 
standard samples, concentrations were assigned (table 2.18) and absolute quantification 
analysis using Lightcycler 480 (Roche) was performed, where only the fluorescence 
values measured in the exponentially growing phase of the PCR were taken into account 
during analysis. This analysis was then used to create a standard curve where the 
efficiency of the amplification reaction was calculated. When this data was generated, 
relative quantification analysis was carried out using experimental cDNA from cells 
exposed to 0, 16 and 64 µg/ml gliotoxin, in order to compare the level of expression of 
the gene in question. For this analysis, reaction efficiency was considered which had 
been calculated from the standard curve, as this maintains accuracy of the experiment. 
Before preparing reaction mixes using experimental cDNA, all cDNA was first diluted 
1:1 to ensure that values would fall within standard values. Reaction samples were then 
prepared as before for standards, in triplicate and loaded onto 96-well plate. Absolute 
quantification and relative quantification analyses were carried out according to 
manufacturer’s specifications. PCR conditions used are illustrated in table 2.19. Figure 
2.6 depicts a typical example of how a 96-well plate may be laid out.      
 
 
Table 2.18 Concentrations assigned to standards. 
 
Standard number 
 
Concentration 
1 1000 
2 250 
3 62.5 
4 15.625 
5 3.90 
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Figure 2.6 Example of how qPCR 96-well plate may be laid out. 
 
 
Table 2.19 qPCR conditions. Conditions below are those used for MET7, SAM1, 
MET22, MET6, MET16, MET17, MET2 and MET14. Annealing temperature 55ºC was 
changed to 56ºC for JEN1, SIP18 and BDH1. Annealing temperature 55ºC was changed 
to 57ºC for SDH2, MLS1 and HBN1.  
 
Programme 
 
No. Cycles Temperature Time 
Pre-incubation 1 95ºC 10 min. 
    
Amplification 55 95ºC 10 sec. 
  55ºC 20 sec. 
  72ºC 10 sec. 
    
Melting Curve 1 95ºC 5 sec. 
  65ºC 1 min. 
    
Cooling 1 37ºC 1 sec. 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
MET7
standards
SAM1
standards
MET7
experimental 
cDNA
SAM1
experimental 
cDNA
0 µg/ml GT exposure
0 µg/ml GT exposure
16 µg/ml GT exposure
16 µg/ml GT exposure
64 µg/ml GT exposure
64 µg/ml GT exposure
MET7 Negative 
Control
SAM1 Negative 
Control
Negative 
Control
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Proteomic Techniques 
2.24 Western blot analysis 
2.24.1 Preparation of cell lysates 
Yeast strains were cultured overnight in 5 ml YPD or selective media The 
following morning, cells were diluted in 25 ml fresh YPD to an OD600 0.1-0.2 and 
incubated as before, until an OD600 0.6-0.8 was reached. Cells were harvested by 
centrifugation at 4ºC (5 min., 1258 x g)
 
and pellets were immediately placed on ice.
 
Pellets were resuspended in 750 µl cell lysis reagent and transferred to chilled 2 ml 
capped microcentrifuge tubes (Sarstedt) containing 0.5 mm soda lime glass beads. 
Tubes were inverted to remove air and additional lysis reagent was added if space 
remained. Cells were then bead-beated using a mini-beater (Biospec products) for 20 
sec. and chilled on ice. This was repeated three times and tubes were then centrifuged 
(10 min., 4300 x g). Supernatants were transferred to pre-chilled 1.5 ml microfuge tubes 
and stored at -20ºC.  
 
2.24.2 Protein quantification 
5 µl thawed lysates and 5 µl cell lysis reagent (to provide blank) were added to 
500 µl Bradford reagent (Quickstart Bradford dry reagent 1X, Biorad) and incubated at 
RT for approximately 20 min. Protein concentrations were determined using a 
Nanodrop spectrophotometer, Bradford Assay, following manufacturer’s 
recommendations. 
 
2.24.3 Preparation of Sodium Dodecyl Sulphate-Poly acrylamide (SDS-PAGE) 
gels 
 
12.5% SDS-PAGE gels were prepared by mixing components listed in tables 
2.20 and 2.21. Running gels were prepared first and allowed to set between two clean 
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glass plates (approximately 70% capacity of plates). 100% (v/v) isopropanol was added 
after running gel to ensure gel solidified with a level surface. Stacking gels were 
subsequently prepared and allowed to set between plates, above running gels, after 
isopropanol was discarded. Combs were placed between plates directly after stacking 
gel was added to create wells into which protein samples were placed. 
 
Table 2.20 Composition of polyacrylamide running gel. All components of running 
gel stored at RT with the exception of 10% (w/v) APS (4ºC). 
 
Reagents and quantities for 1 gel 
 
Reagents and quantities for 2 gels 
2.5 ml 4X Running Buffer (34.75 g Tris 
base and 4 g SDS dissolved in 
500 ml dH2O and adjusted to pH8) 
3.75 ml 4X Running Buffer (34.75 g Tris 
base and 4 g SDS dissolved in 
500 ml distilled H2O and adjusted to pH8) 
3.3 ml dH2O 4.95 ml dH2O 
4.15 ml Protogel 6.225 ml Protogel 
100 µl 10% Ammonium persulfate 150 µl 10% Ammonium persulfate 
10 µl TeMed 15 µl TeMed 
 
 
Table 2.21 Composition of polyacrylamide stacking gel. All components of 
stacking gel stored at RT with the exception of 10% (w/v) APS (4ºC). 
 
Reagents and quantities for 1 gel Reagents and quantities for 2 gels 
 
1.25 ml 2X Stacking buffer (15 g Tris 
Base and 0.2 g SDS dissolved in 
500 ml dH20 and adjust to pH 6.8) 
2.5 ml 2X Stacking buffer (15 g Tris Base 
and 0.2 g SDS dissolved in 
500 ml dH20 and adjust to pH 6.8) 
0.825 ml dH20 1.65 ml dH20 
400 µl Protogel 800 µl Protogel 
25 µl 10% Ammonium persulfate 50 µl 10% Ammonium persulfate 
2.5 µl TeMed 5 µl TeMed 
 
2.24.4 SDS-PAGE 
4X protein sample buffer (PSB) was made by mixing 625 µl of 10 mM Tris (pH 
6.8), 500 µl of 200 mM EDTA, 15 ml of 20% (w/v) SDS, 10 ml of 100% (w/v) glycerol 
and a pinch of bromophenol blue. This was adjusted to 50 ml dH20. 10X protein gel 
buffer was made by combining 15 g of Tris, 72 g of Glycine, 5 g of SDS and adjusting 
to 500 ml with dH20. 
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PSB was added to required concentration of protein and boiled at 100ºC for 5 
min. in a digital dry bath. The prepared protein gels were placed in an electrophoresis 
tank (Biorad) which was filled to appropriate level with 1X protein gel buffer made 
from 10X protein gel buffer. Combs were gently removed from gels and 10 µg of 
protein samples were loaded onto gel along with protein ladder (Page ruler plus 
prestained protein ladder 10-250 kDa, Fermentas, Life Sciences). Electric current (100 
V, 50 mA/gel) was applied to gels (Biorad Powerpac Basic). 
 
2.24.5 Protein transfer to PVDF membrane 
Transfer Buffer was prepared by adding 3.03 g of Tris, 14.4 g of glycine and 
200 ml of methanol, and adjusting to 1 l with dH20. This was stored at -20ºC for 
approximately 1 hr. 
For each protein gel, a PVDF membrane and four sheets of Whatman paper were 
cut to a similar size of the protein gel. PVDF membranes were soaked in 100% (v/v) 
methanol for a few seconds and then in dH20 for 1 min. Membrane, Whatman paper and 
transfer sponges were all soaked in ice-cold transfer buffer for approximately 5 min. For 
each transfer, sponges were placed on each side of transfer case, followed by two sheets 
of Whatman paper on each side. The membrane was then placed on the clear side of the 
transfer case and the gel was placed on top of the membrane. The transfer case was 
closed, ensuring that no air bubbles were present and placed in the transfer tank 
(Biorad), with the clear side of the transfer case to the red side of the tank. The tank was 
filled with ice-cold transfer buffer, followed by addition of an ice block and a magnetic 
stirrer bar. An electric current was applied (100 V/ 350 mA/gel) for precisely 1 hr. while 
the buffer was stirred (Stuart Scientific magnetic Stirrer). 
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2.24.6 Protein detection using antibodies 
10X TBS was formulated from 100 mM Tris pH 7.5, 1 M NaCl. From this, 
TBS-t was prepared by adding 50 ml of 10X TBS, 450 ml of sterile dH2O and 500 µl of 
Tween. Both 10X TBS and TBS-t were stored at RT. Blocking solution consisted of 5% 
(w/v) Marvel milk powder in TBS-t. 
The membranes were washed twice, at 5 min. intervals in 20 ml TBS-t and then 
blocked by incubation for 1-2 hr. at RT in 40 ml blocking solution. Following this, the 
membranes were incubated overnight, rocking (Rocker 35A, Labnet), with the primary 
antibody, diluted in 10 ml TBS-t according to manufacturer’s recommendations (table 
2.22). The membranes were subsequently washed three times, as before and then 
incubated with alkaline phosphatase-labelled secondary antibodies which were diluted 
in 10 ml of TBS-t according to manufacturer’s recommendations (table 2.23). The 
membranes were probed with the secondary antibody for approximately 1-2 hr., rocking 
at RT. Following this, the membranes were washed three times, as before. 
 
Table 2.22 Primary antibodies used in this study. 
 
Name of Antibody Animal of Origin Source Dilution 
 
Hsp70 SPA-822 Mouse Stressgen 
(Victoria, BC, 
Canada) 
1/2,000 
Hsp104 Rabbit John Glover 
(University of 
Toronto) 
1/150,000 
 
 
Table 2.23 Secondary antibodies used in this study. 
 
Name of Antibody Animal of Origin Source Dilution 
 
Anti-Mouse IgG (Fab 
specific) – Alkaline 
Phosphatase antibody 
Goat Sigma-Aldrich 
Chemical Co. Ltd. 
U.K. 
1/2,000 
Anti-Rabbit IgG 
(whole molecule) – 
Alkaline Phosphatase 
antibody 
Goat Sigma-Aldrich 
Chemical Co. Ltd. 
U.K. 
1/2,000 
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2.24.7 Chemiluminescence and developing 
The membranes were covered in 5 ml of Chemiluminescence substrate CDP-star 
(PerkinElmer) and rocked for 5 min. at RT. The membranes were then placed between 
two acetate sheets and in darkness, placed in an autoradiography cassette (FBAC 810 
FisherBiotech). Kodak film (PerkinElmer) was placed on top of the membranes and the 
cassette was shut for varying times. The film was immediately transferred to developer 
(25 ml Kodak developer and 100 ml of dH2O) for approximately 10 sec., or until image 
began to appear. The film was then washed in dH2O and transferred to fixer (25 ml 
Kodak fixing solution and 100 ml of dH2O) for approximately 30 sec. The film was 
washed in dH2O and allowed to dry. 
 
2.24.8 Stripping membrane  
In order to probe a membrane with a second primary antibody, it was necessary 
to ‘strip’ the membrane to remove traces of the first antibodies used. The membranes 
were firstly washed twice for 5 min. with 5 ml of dH2O, followed by 5 ml of TBS-t. 
This was followed by membrane incubation with 0.2 M sodium hydroxide for 5 min., 
rocking at RT. Sodium hydroxide was removed by washing with 5 ml of dH2O for 5 
min. 
 
2.24.9 Coomassie staining of protein gels  
Following electrophoresis, polyacrylamide gels were transferred to coomassie 
brilliant blue stain shaking, overnight at RT. The gels were washed with dH2O and then 
incubated with destain solution (10% (v/v) Ethanol, 10% (v/v) Acetic acid and 80% (v/v) 
dH2O) for 2 hr., or until enough stain was removed resulting in a clear band pattern. 
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2.24.10 Amido black staining of membrane 
PVDF membranes were stained in 10 ml of amido black stain (0.1% (w/v) 
Naphthol blue black dissolved in 2% (v/v) acetic acid and 45% (v/v) MeOH) for 1 min. 
The membrane were then washed in dH2O and incubated with destain (2% (v/v) acetic 
acid and 45% (v/v) Methanol) until a clear banding pattern appeared. 
 
2.25 Two-dimensional gel electrophoresis (2D-GE) 
2.25.1 Buffer preparation 
 In preparation for 2D-GE, buffers were prepared as below (tables 2.24-2.27) 
 
Table 2.24 IEF Buffer constituents. The following were added together and IEF 
buffer was stored at -20ºC. 
 
Component 
 
Concentration Quantity in 50 ml 
Urea 8 M 24.024 g 
Thiourea 2 M 7.612 g 
CHAPS 4% 2 g 
Triton X-100 1% 500 µl 
Tris Base 10 mM 0.0606 g 
 
 
Table 2.25 Rehydration Buffer (RB) constituents. The following were added together 
and rehydration buffer was stored at -20ºC. 
 
Component 
 
Concentration Quantity in 50 ml 
Urea 8 M 24.024 g 
CHAPS 0.5% 0.25 g 
Dithiothreitol (DTT) 0.2% 0.1 g 
Ampholytes (GE 
Healthcare) 
0.2% 100 µl 
 
 
Table 2.26 IPG Equilibration Buffer constituents. The following were added 
together and IPG equilibration buffer was adjusted to pH 6.8 and stored at -20ºC. 
 
Component Concentration Quantity in 500 ml 
Glycerol 30% 150 ml 
SDS 2% 10 g 
Urea 6 M 180 g 
Tris 50 mM 3.03 g 
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Table 2.27 10X SDS Buffer constituents. The following were added together and 10X 
SDS buffer was stored at RT.  
 
Component Concentration Quantity in 2 l 
 
Tris 25 mM 60.57 g 
Glycine 192 mM 288.82 g 
SDS 0.1% 20 g 
 
2.25.2 Trichloroacetic acid (TCA) protein precipitation 
 Lysates were extracted as described in section 2.24.1. One volume of TCA was 
added to four volumes of thawed lysate in 1.5 ml microfuge tubes and incubated at 4°C 
for 10 min. Samples were then centrifuged at 15700 x g, for 7 min. and supernatants 
were removed. Protein pellets were washed in ice-cold acetone by resuspending in 200 
µ acetone, followed by centrifugation for 7 min. at 15700 x g and removal of acetone. 
This wash step was repeated 3 times. Pellets were then dried by placing in a digital dry 
bath at 95ºC for 5-10 min., driving off acetone. Appropriate volumes of IEF buffer were 
thawed and DTT and ampholytes were added at concentrations of 65 mM and 0.8% (v/v) 
respectively. This was then used to resuspend pellets. 
 Precipitated proteins were quantified (section 2.24.2) and 10 µg of proteins were 
run under SDS-PAGE, followed by coomassie staining (2.24.9) to check for equal 
loading. It was ensured that the proteins had been quantified accurately and that equal 
loading was obtained before proceeding. 
 
2.25.3 IPG strip rehydration 
 400-800 µg of precipitated proteins were added to thawed RB to give a total of 
450 µl, e.g. if protein concentration was 4880 µg/ml, 122.95 µl (600 µg) was added to 
327.05 µl RB to give a total of volume 450 µl. It was ensured that the exact same 
protein concentration, e.g. 600 µg was added for each sample to be run. A pinch of 
bromophenol blue was added to these protein samples, which were then pipetted into 
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lanes in an IPG strip rehydration tray (GE Healthcare). The plastic backing was 
removed from IPG strips (Immobiline Drystrip, pH3-10, 24 cm, GE Healthcare) which 
were then placed, gel-side down into the lanes containing protein samples. The strip 
codes were recorded to later identify protein samples. Cover fluid (GE Healthcare) was 
added to the lanes in the tray until the the strips were covered fully, to prevent strip 
dessication and the lid was closed tightly on the tray. The tray was incubated at RT for 
approximately 20 hr. Following this incubation, the strips immediately underwent 
isoelectric focusing. 
 
2.25.4 Isoelectric focusing (IEF), first dimension 
 IEF was carried out on protein samples using Ettan IPGphor 3 IEF system (GE 
Healthcare), in which up to 12 strips could be run simultaneously. 108 ml of mineral oil 
(GE Healthcare) was added to the IEF tray in the IEF machine. The rehydrated strips 
were placed into the lanes of the IEF tray with gel sides facing up, ensuring that the 
strips were between lane notches and the positive strip ends were at the top of the tray. 
Electrode wicks (GE Healthcare) were soaked in MilliQ H2O and placed touching both 
strip ends in between lane notches. Electrodes were fixed onto the tray, in contact with 
wicks and the machine lid was closed. The IEF instrument was closed and programme 
was run under conditions in table 2.28. 
 
Table 2.28 IEF conditions. 
 
Volts (V) Time (hr.) 
 
100 2 
500 1.5 
1000 1 
2000 1 
4000 1 
6000 2 
8000 3 
500 4 
8000 4 
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2.25.5 Preparation of 12% gels 
12% gels were prepared by adding 280 ml of Protogel (National Diagnostics), 
182 ml of Resolving Buffer (National Diagnostics), 230.3 ml of sterile dH2O and 2.8 ml 
of 10% (w/v) APS. Glass plates (27 x 21 cm, GE Healthcare) were cleaned with 70% 
(v/v) ethanol, paired and placed into a gel casting system (GE Healthcare) with plastic 
spacers between plate pairs and filling casting cassette. The casting system was sealed 
tightly and clamped to prevent leakage. Immediately before casting, 280 µl of Temed 
was added to 12% gel solution and mixed gently. The gel was poured slowly into the 
caster and 0.1% 10X SDS buffer was sprayed on top to prevent bubble formation. The 
casting cassette was sealed with clingfilm and left overnight to allow gel solidification.   
  
2.25.6 Gel electrophoresis, second dimension 
 In preparation for second dimension protein separation by electrophoresis, the 
IPG strips were equilibrated. Appropriate volumes of IPG equilibration buffer were 
thawed and Equilibration Buffer A was made by adding 2% (w/v) DTT while 
Equilibration Buffer B was prepared by adding 2.5% (w/v) Idoacetamide. A small 
amount of bromophenol blue was added to both buffers to act as a tracking dye. The 
strips were incubated in equilibration buffer A for 15 min., rocking, followed by 
equilibration buffer B for 15 min., rocking. Agarose sealing solution was then prepared, 
by combining 1.5 g of Trizma Base, 7.2 g of glycine, 0.5 g of SDS, 80 ml of dH2O, 0.5 
g of agarose (Electran), adjusting to 100 ml with dH2O and adding a pinch of 
bromophenol blue. Each equilibrated strip was placed horizontally on top of a solidified 
12% gel, gel-side facing backwards and positive side to the left. The agarose sealing 
solution was boiled and pipetted on to cover the strip completely, sealing it to the gel.  
 The Ettan DALTtwelve Separation unit (GE Healthcare) was used for second 
dimension protein separation by electrophoresis. The DALT was set to system circular 
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and 7.5 l of 1X SDS (made from the 10X stock) was added. When all gels and strips 
were prepared in the above described way, the gels were arranged in the DALT and 
spaces were filled using plastic spacers. 2.5 l of 2X SDS (made from the 10X stock) 
was poured into the filled DALT and the machine was closed tightly. The gels were run 
at 0.5 watt per gel for the first hour and 5 watt per gel for rest of programme, until the 
blue line from the tracking dye was no longer visible. 
  
2.25.7 Coomassie staining (colloidal method) 
 A colloidal coomassie method was employed to stain the gels after 
electrophoresis. Immediately after the gels were removed from the electrophoresis tank, 
they were placed in coomassie staining solution made from 80 ml of stock A (table 
2.29), 2 ml of stock B (table 2.30) and 20 ml of methanol. 
 
Table 2.29 Constituents of coomassie stock A. Stock A was stored at RT following 
preparation. 
 
Component Concentration % Amount added before 
adjusting to 1 l with 
dH2O 
Ammonium sulfate 10 100 g 
Phosphoric Acid 2 20 ml 
 
 
Table 2.30 Constituents of coomassie stock B. Stock B was stored at RT following 
preparation. 
 
Component Concentration % Amount added before 
adjusting to 100 ml with 
dH2O 
Coomassie (Brilliant Blue 
G250, Serva) 
5 5 g 
 
The gels were incubated in the staining solution overnight, rocking at RT. The 
following day, the gels were removed from the staining solution and transferred to 
neutralisation buffer (table 2.31) for 1-3 min. and then washed in 25% (v/v) methanol 
for less than 1 min. 
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Table 2.31 Preparation of neutralisation buffer. Buffer was adjusted to pH 6.5 with 
phosphoric acid prior to use and stored at RT. 
 
Component Concentration Amount added before 
adjusting to 1 l with 
dH2O 
Tris base 0.1 M 12.114 g 
 
After the methanol wash, the gels were incubated in fixation solution (table 2.32) 
overnight, rocking at RT. 
 
Table 2.32 Preparation of fixation solution. Solution was stored at RT following 
preparation. 
 
Component Concentration Amount added before 
adjusting to 1 l with 
dH2O 
Ammonium sulfate 20% 200 g 
 
This proceedure was repeated 3 times, after which the gels were placed between two 
sheets of acetate and scanned to record images. 
 
2.26 Progenesis 
 Separated proteins were analysed using ProgenesisTM same spot software. 
Protein spots were identified that showed differential expression resulting from different 
treatments. 
 
2.27 Mass spectrometry (LC-MS) 
2.27.1 Gel plug extraction 
 Gels of interest were placed on a clean, illuminated lightbox (A3 Lightbox, 
Hancock) and spots to be analysed were exised from the gels using a clean sharp scalpel. 
These gel plugs were placed in clean 1.5 ml microfuge tubes that were pre-cleaned 
using acetonitrile (ACN). 
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2.27.2 Gel destain 
 395 mg of ammonium bicoarbonate (AB) was added to 50 ml of HPLC-grade 
H2O to prepare 100 mM ammonium bicarbonate solution. 5 ml was added to 5 ml ACN 
(1:1) and each gel plug was incubated in 100 µl of this with occasional vortexing at RT 
for approximately 30 min., until the stain was removed. 
 
2.27.3 Tryptic digestion 
20 µg of Trypsin (Promega) was reconstituted in 100 µl of reconstitution buffer 
(Promega). Aliquots were made and stored at -20ºC. 
For trypsin digestion, 50 mM AB was prepared by adding 40 mg AB to 10 ml HPLC-
grade H2O. 500 µl was combined with 10 µl of reconstituted trypsin and this was added 
to each destained gel plug in the 1.5 ml microfuge tube. The plugs were then incubated 
at 4ºC for 30 min., after which additional AB was added, ensuring the plugs were 
covered. The plugs were then incubated for a further 90 min. at 4ºC, allowing diffusion 
of trypsin into the gel pieces. To ensure efficient tryptic digestion, the gel pieces were 
incubated at 37ºC overnight. 
 
2.27.4 Peptide recovery 
 Microfuge tubes were centrifuged for 10 min. (9300 x g) and supernatants were 
transferred to new 1.5 ml tubes. Extraction buffer was prepared by adding one volume 
of 5% (v/v) formic acid to 2 volumes of ACN and (1:2). 100 µl of extraction buffer was 
added to each gel piece and the plugs were incubated at 37ºC for 15 min. (90 rpm 
approx.) Following this, the gel samples were centrifuged for 10 min. (9300 x g) and 
supernatants were added to supernatants isolated at the initial peptide recovery step. The 
extracts were dried overnight in a vacuum centrifuge (Eppendorf) and subsequently 
stored at -20ºC. 
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2.27.5 LC-MS preparation 
Immediately prior to Mass Spectrometry analysis, the dried peptides were 
resuspended in 20 µl of 0.1% (v/v) formic acid and placed in a sonication bath for 5 min. 
The resuspended peptides were added to 0.22 µm centrifuge tube filters (Costar) and 
centrifuged for 15 min. (9300 x g) at 4°C to remove impurities. 20 µl of purified 
peptides were placed in mass spectrometry vials (Agilent) for analysis, which was 
achieved using an Agilent 6340 Ion Trap Liquid Chromatography Mass Spectrometer. 
     
2.28 Enzymatic assay of gliotoxin reductase activity 
2.28.1 Buffer preparation 
 Prior to performing this assay, buffers were prepared, filter sterilised and stored 
at 4°C, unless otherwise stated. 500 mM potassium phosphate buffer was prepared by 
adding 8.71 g and adjusting the volume to 100 ml dH2O. The pH was adjusted to 7.5. 
100 mM EDTA was made by combining 0.372 g with 10 ml dH2O. 7 mM β-
nicotinamide adenine dinucleotide phosphate (reduced form of β-NADPH) was 
prepared by adding 8 mg to 1 ml dH2O. This was protected from light and stored at -
20ºC. 0.5% (w/v) bovine serum albumin (BSA) was made by combining 25 mg and 5 
ml dH2O. 0.5 mg/ml gliotoxin was prepared in methanol by adding 5 ml methanol to 5 
mg gliotoxin. The principal reaction buffer was made as described in table 2.33. 
 
Table 2.33 Principal buffer constituents. This buffer was filter sterilised before use 
and stored at 4°C. 
 
Component 
 
Volume added (ml) 
500 mM potassium phosphate 14 
100 mM EDTA 7 
0.5% BSA 2 
dH2O 26.5 
 
Lysis buffer was prepared as described in table 2.34. 
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Table 2.34 Lysis buffer constituents. Lysis buffer was stored at -20°C following 
preparation.  
 
Component 
 
Stock Concentration Amount added to make 
lysis buffer (µl) 
Tris HCl 1 M (1.21 g in 10 ml 
dH2O) pH 7.5 
250 
Potassim chloride 1 M (0.74 g in 10 ml 
dH2O) 
125 
Magnesium chloride 1 M (2.03 g in 10 ml 
dH2O) 
50 
RNase A 10 g/ml (10 g in 1 ml 
dH2O) 
100 
Phenylmethylsulfonyl 
fluoride (PMSF) 
200 mM (0.35 g in 10 ml 
ethanol) 
50 
Protease inhibitor cocktail - 10 
 
2.28.2 Assay procedure 
Yeast strains were cultured overnight and lysates were extracted as described in 
section 2.24.1, using pre-prepared ice-cold lysis buffer (table 2.34) in the place of 
Sigma cell lysis reagent. Proteins were quantified as described in section 2.24.2 and 
appropriate dilutions were made to bring all samples to the same protein concentration. 
Per assay, into a glass cuvette 624 µl of the principal buffer was added, followed by 6 µl 
of gliotoxin and 50 µl of lysate. This was mixed by inversion and measured at 340 nm 
using a spectrophotometer. The reading was monitored until stable and recorded. 20 µl 
of β-NADPH was added, mixed by inversion and the decrease in absorbance at 340 nm 
was recorded over 3 min. This decrease represented GliTp activity through measuring 
the oxidation of β-NADPH to β-NADP(+). 
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3.1 Introduction 
Gliotoxin is an epipolythiodioxopiperazine (ETP) that was first isolated in 1936 
by Weindling and Emerson, who recorded its potent antimicrobial activity. Gliotoxin 
was soon shown to be toxic in higher mammals and Aspergillus fumigatus was 
identified as one of the strains responsible for its production. Of the three metabolites 
known to be produced by this fungal species by the 1940s, gliotoxin was documented as 
being the most active compound, the most toxic to animals and effective against the 
widest range of bacteria (Dutcher, 1941, Menzel et al., 1944, Waksman and Geiger, 
1944). Structurally characterised by Bell in 1958, gliotoxin and other ETPs have been 
well studied to date (Gardiner et al., 2005). Characteristic of its toxin class, gliotoxin 
has an internal disulfide bridge that plays a critical role in many deleterious effects 
imposed by gliotoxin. An example of this is inhibition of NADPH oxidase activation, 
leading to suppression of superoxide production by neutrophils (Yoshida et al., 2000, 
Tsunawaki et al., 2004). Superoxide plays an important role in the eradication of 
microorganisms, thus abrogation of this response can result in a struggle by the host to 
efficiently deal with A. fumigatus (Miyasaki et al., 1986, Clark, 1990). The disulfide 
linkage can also conjugate with free thiols on proteins forming mixed disulfides which 
can in turn result in protein inactivation and depletion (Hurne et al., 2000, Bernardo et 
al., 2001). 
Gliotoxin has been shown to elicit immunomodulation in mammalian tissue, 
contributing significantly to A. fumigatus pathogenicity (Müllbacher and Eichner, 1984). 
Gliotoxin disrupts the antigen-presenting process by detecting and eradicating antigen-
presenting cells such as dendritic cells and monocytes (Stanzani et al., 2005) and in B 
and T cell lines, gliotoxin specifically suppresses NF-κB activation (Pahl et al., 1996). 
This inhibitory effect on NF-κB is also seen in vivo, along with that imposed on IL-1α, 
resulting in disruption of the natural inflammatory response (Herfarth et al., 2000). 
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Gliotoxin can cause damage to eukaryotic macrophage DNA through seemingly 
random fragmentation, but which is in fact symbolic of apoptosis-associated cleavage 
and independent of protein synthesis (Eichner et al., 1988, Waring et al., 1988, Waring, 
1990). 
The internal disulfide bond is also key in the ability of gliotoxin to undergo 
redox cycling, in doing so producing reactive oxygen species (ROS) (Munday, 1982, 
Waring et al., 1995). Natural gliotoxin in the disulfide form can undergo reduction 
giving rise to the dithiol form, which can then in turn reoxidise with the reappearance of 
the disulfide bridge. Characteristic of this redox cycle is the production of hydrogen 
peroxide and superoxide (Eichner et al., 1988, Waring and Beaver, 1996). As 
accumulation of ROS through this process can induce cellular oxidative stress (OS) 
(Freeman and Crapo, 1982, Nakano, 1992, Sies and de Groot, 1992), the stimulants 
which facilitate this cycle are vitally important.  
Glutathione (GSH/L-γ-glutamyl-L-cysteinylglycine) has long been known to be 
important in protection against OS and in detoxification (Spielberg et al., 1979, 
Kaplowitz, 1981, Schulz et al., 2000). Glutathione can exist in the cell in the reduced 
form, GSH, or the oxidised form, GSSG, which is generated when GSH sulfhydral 
groups interact with oxidants in an attempt to destroy free radicals. Glutathione 
reductase is then responsible for regeneration of GSH and maintenance of the 
appropriate GSH:GSSG ratio (Stephen and Jamieson, 1996, Penninckx, 2000). The 
synthesis of this tripeptide, as illustrated in figure 3.1, requires glutamate and cysteine 
which combine to form L-γ-glutamylcysteine, a process mediated in S. cerevisiae by γ-
glutamylcysteine synthetase (Gsh1p) followed by the addition of glycine. Glutathione 
synthetase (Gsh2p) subsequently catalyses glutathione formation from glycine and L-γ-
glutamylcysteine (Penninckx, 2002). 
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Figure 3.1 Glutathione biosynthesis pathway in yeast. Reproduced from Penninckx 
(2002).  
 
Bernardo et al. (2001, 2003) reported that for uptake of gliotoxin by macrophage 
cells to occur, there must be glutathione present and only the disulfide form of the toxin 
can pass through the cell membrane. Inside the cell, the disulfide form is actively 
converted through reduction to the dithiol form by glutathione, and as a consequence of 
gliotoxin uptake, GSH levels are reduced and ROS are produced (Eichner et al., 1988, 
Waring and Beaver, 1996).  
Thioredoxins are oxidoreductases that function in redox regulation and 
protection against OS (Laurent et al., 1964, Arnér and Holmgren, 2000). Interestingly, 
the sulfur amino acid biosynthesis pathway which gives rise to cysteine biosynthesis is 
linked to thioredoxin function. Thioredoxin has been found to activate APS kinase, a 
function carried out by the yeast Met14p which is necessary for sulfate assimilation so 
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that sulfur amino acids can be synthesised (Schriek and Schwenn, 1986, Thomas and 
Surdin-Kerjan, 1997). 
There are many ways in which yeast respond to OS. The way in which yeast 
respond to other oxidative stressors such as hydrogen peroxide and copper has been 
well documented to date. The transcription factor Yap1p (yeast AP-1) plays a role in the 
regulation of genes that encode proteins involved in the OS response, such as TRX2 
which encodes thioredoxin, GSH1, which was discussed above and GLR1, a gene 
encoding glutathione reductase that is involved in maintaining intracellular supplies of 
reduced glutathione (Moye-Rowley et al., 1989, Kuge and Jones, 1994, Wu and Moye-
Rowley, 1994, Grant et al., 1996). Yap1p also mediates the transcription of HSP31, 
which encodes a heat-shock protein that may function in scavenging ROS, and 
cooperates with the Skn7p transcription factor to regulate induction of TRR1 which 
encodes a thioredoxin reductase (Morgan et al., 1997, Skoneczna et al., 2007). In 
response to OS, yeast also increase expression of superoxide dismutase, encoded by 
SOD genes, which disproportionates superoxide to H2O2 and dioxygen (Ravindranath 
and Fridovich, 1975, Fridovich, 1978, Bermingham-McDonogh et al., 1988). 
The generation of cysteine which is required for glutathione biosynthesis is 
dependent on the sulfur amino acid biosynthesis pathway. Transsulfuration plays a 
major part in this process, whereby proteins such as Cys3p, Cys4p, Str2p and Str3p 
regulate the interconversion of cysteine and homocysteine with cystathionine 
intermediate formation (Cherest et al., 1993, Thomas and Surdin-Kerjan, 1997). Genes 
such as MET1, MET4, MET8, MET18, MET19 and MET22 encode products that are 
involved in the regulation of the sulfur amino acid biosynthesis pathway (Masselot and 
De Robichon-Szulmajster, 1975, Thomas et al., 1992a). 
To prevent damage by endogenous gliotoxin, the A. fumigatus genome encodes 
a protein, GliTp, which confers resistance to the organism. Research has demonstrated 
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that the absence of the GliT gene not only renders the fungus susceptible to the 
destructive capacities of the toxin, but also prevents gliotoxin production, highlighting 
the two-fold function of GliTp, protection and biosynthesis (Scharf et al., 2010, Schrettl 
et al., 2010). 
Other fungal metabolites also appear to induce conditions of OS in groups of 
cells. Citrinin is a fungal mycotoxin produced by a variety of Aspergillus and 
Penicillium species (Bennett and Klich, 2003). Utilisation of DNA microarray and 
subsequent analysis revealed citrinin to induce OS-mediated toxicity in yeast, and 
activate methionine and glutathione biosynthetic pathways to counteract these effects 
(Iwahashi et al., 2007). Similarly to citrinin, patulin is a fungal food contaminant that 
has been found to induce an increase in expression of sulfur amino acid biosynthesis 
genes by DNA microarray analysis (Sweeney and Dobson, 1998, Iwahashi et al., 2006). 
However, patulin was also noted to stimulate proteolytic activity and other antioxidant 
defence systems (Iwahashi et al., 2006). Yu et al. (2010) used a similar method to 
assess the yeast response induced by allicin, a biologically active compound isolated 
from garlic to which many anti-microbial characteristics have been attributed 
(Raghunandana Rao et al., 1946, Ankri and Mirelman, 1999). It has been reported that 
allicin can interact with thiol containing proteins an interaction which in itself generates 
a product that exhibits clear antioxidant properties (Rabinkov et al., 1998, Rabinkov et 
al., 2000). Yu et al. (2010) discovered that yeast sulfur amino acid biosynthesis 
pathway genes undergo elevated transcription in response to allicin treatment, in 
addition to many other transcriptional changes that suggest allicin may exhibit some 
level of toxicity. In 1948, Dunlop reported that under acidic conditions, degradation of 
xylose can produce furfural (Palmqvist et al., 1999). Furfural was shown using 
microarray to stimulate an upregulation of genes involved in the OS response, although 
not those that play a role in sulfur amino acid biosynthesis. In the same study, the toxin 
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was found to impede the metabolism of a number of chemicals essential in viable cells 
(Li and Yuan, 2010). 
The main aim of the work described in this chapter was to gain insight into the 
mode of action of gliotoxin, using Saccharomyces cerevisiae as a tool. To address the 
question of how yeast respond to gliotoxin, advanced genetics, transcriptomics and 
proteomics were applied. Previous work has suggested that gliotoxin imposes OS in 
various cell lines, thus we endeavoured to determine if such conditions were induced in 
our yeast strains. 
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Section 1: Genetic and biochemical analysis of gliotoxin using S. 
cerevisiae as a model organism 
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3.2 Assessing the ability of gliotoxin to inhibit wild-type yeast growth 
3.2.1 The effect of gliotoxin on wild-type yeast cell growth on solid medium  
The first experiments performed in this study involved assessing the growth of 
wild-type S. cerevisiae in the presence of gliotoxin. As a model organism, S. cerevisiae 
is commonly employed to study many aspects of the biology of eukaryotes (Botstein et 
al., 1997). The genome is fully sequenced and data, along with resources and tools are 
readily available on Saccharomyces Genome Database (www.yeastgenome.org). For 
these assays, yeast were grown on different types of media containing gliotoxin, to 
assess the ability of gliotoxin to inhibit yeast growth. Additionally, two different wild-
type strains were tested to determine the most useful for future assays (figure 3.2). 
 
 
 
 
 
       
    
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Gliotoxin inhibits the growth of S. cerevisiae. Cells were grown in culture 
to OD600 0.2 and 200 µl of each culture was plated on YPD and SC plates containing 0 
and 8 µg/ml gliotoxin. The images above are sections of these plates after 48 hr. at 30ºC. 
 
 
YPD + 0 µg/ml GT
YPD + 8 µg/ml GT
SC + 0 µg/ml GT
SC + 8 µg/ml GT
BY4741 G600
g/ml GT
g/ml GT
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Results from single colony assays depicted in figure 3.2 show that gliotoxin can 
exhibit an inhibitory affect on yeast growth at a concentration of 8 µg/ml, and S. 
cerevisiae growth is considerably retarded under exposure to gliotoxin.  
The G600 background strain generally did not grow as well as the BY4741 
strain and appeared to be more easily inhibited by gliotoxin. From these results, it was 
decided that for the majority of future gliotoxin plate assays, BY4741 and mutants in 
this background would be employed. YPD is a nutrient-rich broth, while synthetic 
complete (SC) has minimal nutrients and amino acids required for growth. It soon 
became clear that SC would be the medium of choice for gliotoxin assays, as inhibition 
of both wild-type strains was seen to a greater degree on SC medium than YPD, thus 
lower concentrations of gliotoxin would be needed to yield results (figure 3.2).   
Comparative growth analysis was performed (figure 3.3) in addition to the 
single colony assays. Growth of S. cerevisiae was inhibited by gliotoxin, again 
illustrating the detrimental effects the toxic metabolite gliotoxin has on yeast cell 
growth.  
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Gliotoxin suppresses yeast growth. Comparative growth analysis assays 
were carried out using the wild-type BY4741 strain. The cells were plated on 0 and 8 
µg/ml gliotoxin SC plates to compare growth. The above images represent cellular 
growth after 48 hr. at 30ºC. 
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SC + 8 µg/ml GT
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3.2.2 The effect of gliotoxin on wild-type yeast cell growth in liquid culture 
The question of whether gliotoxin has a similar affect on yeast growth in liquid 
culture was also addressed. Gliotoxin was added to BY4741 and G600 cultures at 
concentrations of 0, 16 and 64 µg/ml. These concentrations were used due to their 
significant inhibitory effects documented in previous plate assays, results as shown in 
figure 3.4.  
 
 
      
 
 
 
 
 
Figure 3.4 Inhibitory effect of 16 and 64 µg/ml gliotoxin on BY4741 growth. Results 
indicated that on SC medium, 16 µg/ml gliotoxin is sufficient to inhibit yeast growth 
and on YPD medium 64 µg/ml gliotoxin yields the same result. The above images 
represent cellular growth after 48 hr. at 30ºC.   
 
The cultures were incubated at 30ºC and samples were taken and OD600 
determined every 30 min. over a total 180 min. Figure 3.5 shows that BY4741 
consistently grows more efficiently than G600 in liquid culture, in both the absence and 
presence of gliotoxin. At an exposure level of 64 µg/ml, neither strain undergoes growth 
to any significant extent over a period of 3 hr. After 3 hr. exposure to 16 µg/ml gliotoxin, 
BY4741 has almost doubled, while G600 has grown at a considerably slower rate. 
The toxicity of gliotoxin can clearly be seen in figure 3.5 from 60 min. onwards. There 
is an extensive difference between the growth in the control cultures and that in the 
gliotoxin cultures.    
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Figure 3.5 Growth of wild-type strains in liquid culture containing gliotoxin. 
Throughout the experiment, BY4741 grew better than G600. There is an severe 
inhibition of growth in general by gliotoxin and this is more acute at a concentration of 
64µg/ml than 16µg/ml. 
   
 The experiment illustrated in figure 3.6 depicts the rapid cell death induced by 
gliotoxin. Cells incubated with 16 and 64 µg/ml gliotoxin for 1 hr. give rise to a much 
smaller number of colonies than untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 The ability of BY4741 to grow after gliotoxin exposure in liquid culture. 
BY4741 was cultured in liquid YPD containing 0, 16 and 64 µg/ml gliotoxin. After a 1 
hr. incubation at 30ºC, 200 µl of cells were plated on YPD, along with 200 µl of the pre-
exposed culture. It should be noted that the 0 µg/ml sample gave rise to an unusually 
high number of colonies after 1 hr. incubation, which may indicate an inaccuracy in the 
assay results.  
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3.3 Investigation into the importance of oxidative stress response genes in yeast  
growth under gliotoxin exposure  
 
 
3.3.1 Comparative growth analysis of BY4741, ∆cys3, ∆yap1 and ∆sod1 
Previous studies have reported that gliotoxin causes OS through the generation 
of ROS (Eichner et al., 1988, Waring et al., 1988, Zhou et al., 2000, Orr et al., 2004). 
Chamilos et al. (2008) carried out a genome-wide screen in an attempt to pinpoint yeast 
genes involved in conferring increased sensitivity or increased resistance to gliotoxin. 
One of the genes they found to be important in protection against gliotoxin was CYS3, 
when this gene was disrupted the resultant phenotype showed increased sensitivity to 
the metabolite. The CYS3 gene encodes the cystathionine γ-lyase enzyme which plays a 
role in the transsulfuration pathway that is characterised by an interconversion of 
cysteine and homocysteine (Ono et al., 1984, Ono et al., 1992). Cysteine plays an 
essential role in the biosynthesis of glutathione, along with the other amino acids 
glycine and glutamate. As glutathione plays a critical part in maintaining an appropriate 
redox state and preventing oxidative damage, it can be said that the CYS3 gene has a 
valuable part to play in protection against OS, through its production of cysteine (Ono et 
al., 1992, Penninckx, 2002).  
In agreement with Chamilos et al. (2008) it was determined from comparative 
growth analysis (figure 3.7) of BY4741 and the isogenic ∆cys3 strain, that ∆cys3 is 
indeed more sensitive to gliotioxin exposure than wild-type. This illustrates the 
importance of Cys3p in protection against gliotoxin exposure and suggests that the toxin 
may be eliciting effects through OS.  
Both Yap1p and Sod1p play key roles in modulating yeast resistance to OS. 
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Figure 3.7 Comparative growth analysis of BY4741 and ∆cys3. ∆cys3 is more 
sensitive to gliotoxin than wild-type. The above images represent cellular growth after 
48 hr. at 30ºC. 
 
Yap1p is a transcription factor which upon activation, undergoes relocation from 
the cytoplasm to the nucleus and regulates the expression of a number of genes that 
contribute to stress tolerance, including GSH1 (Wu and Moye-Rowley, 1994, Kuge et 
al., 1997). The SOD1 product is a copper, zinc-superoxide dismutase, involved in the 
conversion of superoxide radicals to oxygen and hydrogen peroxide which in turn can 
be rendered harmless to the cell (Fridovich, 1978, Bermingham-McDonogh et al., 1988, 
Gralla and Kosman, 1992). Given that gliotoxin has been reported to induce cellular OS, 
the sensitivity of YAP1 and SOD1 deletion strains to gliotoxin was tested. In figure 3.8 
it can be seen that both ∆sod1 and ∆yap1 show increased sensitivity to gliotoxin, in 
comparison to wild-type.      
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Figure 3.8 Comparative growth analysis of BY4741, ∆yap1 and ∆sod1. At 8 µg/ml 
gliotoxin exposure, both mutants are more sensitive to gliotoxin than wild-type. ∆yap1 
is the most sensitive strain. The above images represent cellular growth after 72 hr. at 
30ºC. 
 
3.3.2 Analysis of ∆gsh1 sensitivity to gliotoxin 
3.3.2.1 Comparative growth analysis of BY4741 and ∆gsh1  
As previously discussed, CYS3 is involved in the superpathway of sulfur amino 
acid biosynthesis, that can lead to the production of glutathione. As suggested by 
Williamson et al. (1982), the principal contributing factor to ∆cys3 sensitivity may be 
absence of glutathione, through disruption of the said pathway. This group illustrated 
that increased cysteine results in a higher level of toxin protection through boosting 
glutathione concentration. Thus, we decided to assess the growth in the presence of 
gliotoxin of a yeast strain unable to produce glutathione, ∆gsh1. The GSH1 gene is vital 
for glutathione synthesis, as the first functional enzyme in the biosynthesis pathway 
(Grant, 2001). Surprisingly, comparative growth analysis showed the BY4741 ∆gsh1 
strain to be more resistant to gliotoxin than wild-type, it grew better at 16 µg/ml 
gliotoxin than BY4741.       
 
3.3.2.2 Complementation study 
To confirm that this result was real we performed a complementation study that 
demonstrated how the re-introduction of GSH1 into BY4741 ∆gsh1 restored the wild-
type phenotype (figure 3.9). The 2,036 bp GSH1 region, plus 500 bp upstream 
BY4741
∆sod1
∆yap1
SC + 0 µg/ml GT SC + 8 µg/ml GT
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containing the promoter sequence, was amplifed from BY4741 via PCR. The 2.5 kb 
GSH1 amplicon, depicted in figure 3.9, contained at both 5’ and 3’ ends overhangs 
homologous to regions within pRS315.   
 
 
 
 
 
 
 
 
 
Figure 3.9 PCR amplified GSH1. GSH1 was amplified from BY4741 by PCR for 
cloning into pRS315. 
 
The GSH1 gene sequence and promoter region were cloned by homologous 
recombination into the pRS315 vector, which contains the LEU2 gene marker. To 
achieve this, pRS315 was digested using the BamHI and HindIII restriction enzymes, 
giving a linear product of approximately 6 kb. The regions immediately up- and 
downstream of the cleavage sites were homologous to the sequence at the ends of the 
GSH1 amplicon. Therefore, when both digested vector and insert were transformed into 
BY4741 simultanaeously, homologous recombination occurred, giving rise to colonies 
containing the new GSH1-pRS315 plasmid. The new construct was extracted and a 
diagnostic PCR was carried out to ensure that GSH1 had been cloned into the said 
plasmid effectively. PCR amplified a fragment of approximately 2.5 kb (as seen for that 
in figure 3.9) from the vector, a region which in normal pRS315 is occupied by 24 bp, 
demonstrating that GSH1 had been cloned efficiently. Figure 3.10 illustrates the plasmid 
maps for pRS315 and GSH1-pRS315. 
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Figure 3.10 Plasmid maps constructed for pRS315 and GSH1-pRS315. pRS315 was 
digested using BamHI and HindIII. 30 bp were removed and the GSH1 coding sequence 
and promoter were cloned into the plasmid by homologous recombination. Both 
plasmids contain leucine and ampicillin resistance marker genes and a number of 
restriction sites as depicted above. 
  
 Comparative growth analysis confirmed that the absence of GSH1 confers 
increased yeast resistance to gliotoxin and revealed that ∆gsh1 complementation 
restores wild-type phenotype (figure 3.11) 
 
 
 
 
 
 
 
Figure 3.11 Comparative growth analysis of BY4741, ∆gsh1 and ∆gsh1 GSH1-
pRS315. BY4741 and ∆gsh1 harbour the pRS315 vector. ∆gsh1 GSH1-pRS315 is the 
mutant complemented with GSH1 within the pRS315 vector. The absence of GSH1 
confers increased resistance to BY4741. When this gene is re-introduced on a plasmid 
to the deletion strain, wild-type phenotype is restored. The above images represent 
cellular growth after 72 hr. at 30ºC. 
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3.3.3 Summary of mutant phenotypic response to gliotoxin exposure 
Previous proteomic studies in Prof. S. Doyle’s laboratory, NUIM (Carberry, 
2008) using A. fumigatus resulted in the identification of a number of proteins that are 
differentially expressed in the presence of gliotoxin. In the absence of exogenous 
application of the toxin, Sod1p was undetectable. Conversely, when gliotoxin was 
added to cultures, there was a significant increase in production of this protein as Sod1p 
was expressed at a detectable level. This data supports our results, highlighting the 
importance of SOD1 in gliotoxin resisitance.  
Similar trends were seen for Tef (translation elongation factor) proteins in A. 
fumigatus. TEF3 and TEF4 are S. cerevisiae genes with homology to those encoding 
Tef proteins in A. fumigatus and so we tested the sensitivity to gliotoxin of single 
mutants lacking these genes. The yeast TEF3 and TEF4 genes encode a translation 
elongation factor eEF1Bγ, although Tef3p and Tef4p do not function in the same 
manner suggesting that they encode different isoforms with different specialised 
capacities (Kinzy et al., 1994, Jeppesen et al., 2003). eEF1B has been shown to be 
involved in the OS response and it appears that downregulation of TEF3 and TEF4 is 
important in the OS response (Godon et al., 1998, Olarewaju et al., 2004, Carberry et 
al., 2006). However, our ∆tef3 and ∆tef4 strains exhibited a wildtype phenotype (data 
not shown). 
Work in Prof. Doyles’ laboratory also documented the decrease in A. fumigatus 
mycelial catalase I in the presence of gliotoxin (Carberry, 2008). The yeast CTT1 gene 
is the equivalent homologue and encodes a cytosolic catalase T which functions in the 
detoxification of H2O2 (Hartig and Ruis, 1986, Grant et al., 1998). From the data 
obtained from A. fumigatus work, it was hypothesised that without Ctt1p, there would 
be less gliotoxin reduction leading to free radical production and therefore a phenotype 
displaying increased resistance to the toxin. Despite this, when the S. cerevisiae mutant 
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∆ctt1 was grown in the presence of gliotoxin, it grew in a similar manner to wild-type 
(figure 3.12).  
Growth of the yeast strain ∆trx2 was also assessed in the presence of gliotoxin. 
Thioredoxin encoded by TRX2 functions in the stress response through repairing 
proteins which have been damaged by OS and regulating sulfur metabolism (Kuge and 
Jones, 1994, Grant, 2001) TRR1, a thioredoxin reductase which plays an essential role 
in facilitating thioredoxin function, is induced by Yap1p under OS (Morgan et al., 1997, 
Pedrajas et al., 1999). Although TRX2 appears considerably influential in the OS 
response, the deletion strain grew as wild-type under gliotoxin exposure, suggesting 
Trx2p is not essential in survival in the presence of this toxin. 
Ace2p was an additional protein identified in Prof. Doyles’ laboratory as being 
key in A. fumigatus response to exogenous gliotoxin. This protein is involved in 
delaying daughter cells in G1 prior to entering S phase of the cell cycle (Laabs et al., 
2003), and in its absence, yeast cells displayed no change in sensitivity to gliotoxin. 
Other strains that underwent phenotypic analysis were those deleted for glutathione 
synthetase GSH2 and the glutathione reductase GLR1, which function in the final step 
of glutathione synthesis and maintaining a high level of intracellular reduced GSH 
respectively (Grant et al., 1996, Grant et al., 1997, Inoue et al., 1998, Grant, 2001). In 
this study both ∆gsh2 and ∆glr1 were found to exhibit a wild-type phenotype under 
gliotoxin exposure.  
In figure 3.12 the ∆ctt1, ∆ace2, ∆gsh2, ∆glr1 and ∆trx2 phenotypic responses to 
gliotoxin can be seen. The variety of deletions strains tested for sensitivity to gliotoxin  
and their respective phenotypes are depicted in table 3.1.  
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Figure 3.12 Comparative growth analysis of BY4741, ∆ctt1, ∆ace2, ∆gsh2, ∆glr1 
and ∆trx2 under gliotoxin exposure. The above images represent cellular growth after 
72 hr. at 30ºC. 
  
 
Table 3.1 Summary of strains tested through comparative growth analysis for 
altered phenotype under gliotoxin exposure. IR indicates increased resistance. IS 
indicates increased sensitivity. 
Strain Phenotype 
∆gsh1 IR 
∆sod1 IS 
∆yap1 IS 
∆gsh2 WT 
∆ace2 WT 
∆ctt1 WT 
∆glr1 WT 
∆trx2 WT 
∆tef3 WT 
∆tef4 WT 
 
3.3.4 Comparison of mutant response to gliotoxin and hydrogen peroxide 
As a comparison, the mutants which showed a divergent phenotype to that of 
wild-type on gliotoxin plates were assessed under the exposure of another common 
BY4741
∆ctt1
∆ace2
∆gsh2
∆glr1
∆trx2
SC + 8 µg/ml gliotoxin
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oxidative stressor. Growth of BY4741, ∆gsh1, ∆yap1 and ∆sod1 was assessed in the 
presence of 0, 1, and 3 mM H2O2 (figure 3.13). Under 1 mM H2O2 exposure there was a 
clear difference in growth capacities of the strains. While wild-type is virtually 
unaffected by this concentration, ∆yap1 cannot grow at all and the growth ability of 
∆gsh1 is clearly impaired. However, ∆sod1 does not appear to be greatly inhibited by 1 
mM H2O2. 3 mM H2O2 considerably inhibits wild-type growth, ∆gsh1 and ∆yap1 cannot 
grow in the presence of this concentration and ∆sod1 grows to a small degree.   
 
 
    
 
 
 
 
 
 
Figure 3.13 Comparative growth analsysis of BY4741, ∆gsh1, ∆yap1 and ∆sod1 in 
response to various concentrations of H2O2. The above images represent cellular 
growth after 72. hr at 30ºC.   
 
 
3.4 Conferring S. cerevisiae resistance to gliotoxin by expressing the Aspergillus 
fumigatus GliT gene  
 
3.4.1 Cloning of GliT into pC210 
 GliT is a gene found in Aspergillus fumigatus. It is part of a biosynthetic 12-gene 
cluster that was identified due to its high level of sequence conservation with that of the 
Leptosphaeria maculans biosynthetic gene cluster (Gardiner et al., 2004, Gardiner and 
Howlett, 2005, Gardiner et al., 2005). Using the CADRE resource described by Mabey 
et al. (2004) http://www.cadre.man.ac.uk, the GliT gene has been annotated as 1005 bp 
in length (figure 3.14) and the 334 amino acid GliTp is 36 kDA in weight. This gene has 
been shown to be paramount in enabling A. fumigatus to protect itself from exogenous 
gliotoxin (Schrettl et al., 2010). 
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SC + 0 mM H2O2 SC + 1 mM H2O2 SC + 3 mM H2O2
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ATGTCGATCGGCAAACTACTCTCCAACGGAGCCCTGCTCGTCGACGTGCTCATCATCGG
CGCCGGTCCCGCTGGTCTCTCGACAGCCACCGGCCTGGCCCGTCAACTGCACACGGCAG
TCGTCTTCGACTCTGGCGTCTACCGCAATGCAAAGACCCAGCACATGCACAACGTCCTC
GGATGGGACCACCGCAACCCGGCCGAGCTGCGCGCCGCGGGTCGCGCCGACCTGACCAC
CCGCTACTCCACCATCCAGTTCCAGAACAGCACGATCGAGGCGATCCGCCAGGTCGAGA
CCAACCAGCTGTTCGAGGCGCGCGACAACGAGGGCCACAGCTGGTACGGTCGCAAGGTC
GTGCTGGCGACCGGCGTCCGCGACATCCCCCTCGACATCGAGGGATACTCGGAGTGCTG
GGCGAACGGCATCTACCACTGTCTCTTCTGCGACGGCTACGAGGAACGTGGCCAGGAGA
CCGTGGGTGTCCTGGCTCTGGGGCCCATCGCGAACCCTGCGCGCGCTCTGCATTTGGCT
CGCATGGCCCTCCGGCTTTCCGAGTCCGTCACCATCTACACGAATGGCAATGAGCAGCT
GGCCAAGGAGATCCAGCAGGCCGCCGAGGAATCCCCTGTCGGTGCCTCGGGACTGAAAT
TCGAGGCTCGACCCATCCGGCGATTCGAAAAGGGCGATGTCGCCAAGACCGTCATTGTT
CATCTTGGGGAGTCGGAGTCGAAAACGGAGGGCTTTTTGGTACGTTGTCCAGTTTACTC
GACAGAGATATCCTTGCTAACCGCGGCAAACCGCTCAGGTGTACAACCCCCAAACGGAG
GTCAATGGACCGTTTGCCAAGCAGCTCGCCTTGAATATGACAGAAGGAGGGGATATCCT
GACCACGCCGCCCTTCTATGAGACCAGTGTGCCCGGAGTATTTGCCGTGGGGGATTGTG
CCACGCCGTTAAAGGCCGTCACGCCCGCGGTGTCGATGGGATCTTTGGCCGCTGGCGGT
CTCGTGGCTCAGCTGCAGGCTCAGGCATTGCCGGAGTTTCGTCTCGATCAGGAGCTATA
G 
 
Figure 3.14 Genomic sequence of GliT. This gene is made up of two exons, separated 
by a 58 bp intron. Blue depicts coding region. Red depicts intron. 
 
 GliT was cloned by homologous recombination into pC210 yeast vector. pC210 
is a plasmid  8,928 bp in size containing a leucine marker, the LEU2 gene. It contains 
the yeast SSA1 gene, under the control of the constitutive SSA2 promoter. Prior to 
cloning, the plasmid was digested at sites surrounding SSA1, using NdeI and SphI. The 
digested plasmid was run on an agarose gel and the remaining vector, lacking the 2,210 
bp SSA1 gene plus terminator region, was gel extracted and purified. GliT cDNA within 
TOPOvector® was obtained from Dr. Markus Schrettl and was amplified by PCR, with 
overhangs homologous to regions within pC210 up- and downstream of where the 
plasmid had been cut. Subsequent transformation of both GliT and digested pC210 
simultanaeously led to recombination and the formation of a new vector, containing 
constitutively expressed GliT. Cells containing the new construct were selected on SC 
plates lacking leucine and plasmids from the selected clonies were isolated to confirm 
presence of GliT-pC210. Figure 3.15 illustrates the plasmid maps for pC210 and GliT-
pC210.  
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Figure 3.15 Plasmid maps constructed for pC210 and GliT-pC210. pC210 was 
digested using NdeI and SphI. The SSA1 region including terminator sequence was 
digested from pC210 and replaced with GliT. Both plasmids contain leucine and 
ampicillin marker genes and a number of restriction sites as depicted above. 
    
 To confirm that GliT had been cloned into pC210, the plasmid was digested 
using NdeI and SphI resulting in fragments of approximately 6.7 kb and 1 kb, pC210 
and GliT respectively. This provided evidence that GliT had been successfully cloned. 
 
 
 
 
 
 
 
 
 
Figure 3.16 Agarose gel illustrating GliT cloned into pC210 vector. The new 
construct was digested yielding products of approximately 7 kb and 1 kb, pC210 and 
GliT respectively.  
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 To obtain further proof that GliT was cloned and also to check for mutations 
within the GliT sequence, the plasmid was sequenced (figure 3.17). 
 
CCATTTCCTACGCATCGAGGTTTTGACGACATTTCATTCTTAAGCACTATGGGAAGGTG
TGGACGAATTGTTATATATAAGCCGCAATTGGGCTGGGTTTTCTCCAAAAAATGTTGAA
AATATAATACTCTCTTATTTAAGTTACTTCTATTCTTCAATTGATTAATTCCAACAGAT
CAAGCAGATTTTTATACAGAAATATTTATACATATGATGTCGATCGGCAAACTACTCTC
CAACGGAGCCCTGCTCGTCGACGTGCTCATCATCGGCGCCGGTCCCGCTGGTCTCTCGA
CAGCCACCGGCCTGGCCCGTCAACTGCACACGGCAGTCGTCTTCGACTCTGGCGTCTAC
CGCAATGCAAAGACCCAGCACATGCACAACGTCCTCGGATGGGACCACCGCAACCCGGC
CGAGCTGCGCGCCGCGGGTCGCGCCGACCTGACCACCCGCTACTCCACCATCCAGTTCC
AGAACAGCACGATCGAGGCGATCCGCCAGGTCGAGACCAACCAGCTGTTCGAGGCGCGC
GACAACGAGGGCCACAGCTGGTACGGTCGCAAGGTCGTGCTGGCGACCGGCGTCCGCGA
CATCCCCCTCGACATCGAGGGATACTCGGAGTGCTGGGCGAACGGCATCTACCACTGTC
TCTTCTGCGACGGCTACGAGGAACGTGGCCAGGAGACCGTGGGTGTCCTGGCTCTGGGG
CCCATCGCGAACCCTGCGCGCGCTCTGCATTTGGCTCGCATGGCCCTCCGGCTTTCCGA
GTCCGTCACCATCTACACGAATGGCAATGAGCAGCTGGCTAAGGAGATCCAGCAGGCCG
CCGAGGAATCCCCTGTCGGTGCCTCGGGACTGAAATTCGAGGCTCGACCCATCCGGCGA
TTCGAAAAGGGCGATGTCGCCAAGACCGTCATTGTTCATCTTGGGGAGTCGGAGTCGAA
AACGGAGGGCTTTTTGGTGTACAACCCCCAAACGGAGGTCAATGGACCGTTTGCCAAGC
AGCTCGCCTTGAATATGACAGAAGGAGGGGATATCCTGACCACGCCGCCCTTCTATGAG
ACCAGTGTGCCCGGAGTATTTGCCGTGGGGGATTGTGCCACGCCGTTAAAGGCCGTCAC
GCCCGCGGTGTCGATGGGATCTTTGGCCGCTGGCGGTCTCGTGGCTCAGCTGCAGGCTC
AGGCATTGCCGGAGTTTCGTCTCGATCAGGAGCTATAGGCATGCTTTGTCTTCCTGTTT
AATCAGGAAGTCGCCCAAAGCGAGAATCATACCACTAGACCACACGCCCGTACTAATTG
ATGTCTTCCTTTTCGGATAGATGTATATATATACAAATTGGTCAGATTGCTTTTGGCTC
CCTTTCGTACGTAACTCATTTAGACTACGAAGCTTATCGATACCGTCGACCTCGAGGGA
CTTTGACCCA 
 
Figure 3.17 Agowa sequencing result. The start and stop codons are highlighted in 
purple. The result revealed one mutation, C→T at position 594, highlighted in yellow. 
When translated, this mutation was shown not to alter the GliTp amino acid sequence 
and was therefore suitable to use in experimentation.  
 
3.4.2 The effects of constitutive GliT expression on yeast growth 
 To assess the effects of constitutive GliT expression on the growth of both wild-
type and mutant yeast strains, the newly created construct described above containing 
the GliT gene was transformed into BY4741 and ∆cys3 and comparative growth 
analysis was carried out on these strains in the presence of gliotoxin. As controls, the 
pRS315 plasmid containing the LEU2 gene was transformed into the two strains to 
enable an accurate growth comparison to be made on SC –LEU gliotoxin plates. At a 
concentration of 16 µg/ml, gliotoxin completely inhibited the growth of both wild-type 
and ∆cys3. However, when these strains expressed GliTp, a significant increase in 
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resistance to the toxin was observed (figure 3.18). It was thus concluded that 
constitutive expression of the GliT gene confers resistance to gliotoxin in S. cerevisiae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Comparative growth analysis of BY4741 and ∆cys3 under gliotoxin 
exposure. The presence of GliT conferred resistance in both strains. SC plates lacking 
leucine were used to select for cells containing the pC210 plasmid and thus those 
expressing GliT. The above images represent cellular growth after 36 hr. at 30ºC. 
 
 This result was further verified by assessing single colony growth under 
exposure to gliotoxin. Figure 3.19 illustrates this gliotoxin resistance afforded by GliT 
expression and shows the considerable increase in cellular survival when cells express 
GliTp. 
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Figure 3.19 Single colony growth assay of BY4741 under gliotoxin exposure. There 
is increased survival under gliotoxin exposure of cells expressing GliTp. The above 
images represent cellular growth on SC –Leu media after 48 hr. at 30ºC.  
 
3.4.3 Detecting GliTp when constitutively expressed 
 Due to the fact that the presence of GliT under a constitutive promoter conferred 
gliotoxin resistance to S. cerevisiae, an attempt was made to detect GliTp production in 
yeast cells.  
  
3.4.3.1 Coomassie stain of SDS-PAGE gel (GliT-pC210) 
 Lysates were extracted from BY4741 GliT-pC210, BY4741 pRS315, G600 
GliT-pC210, G600 pRS315, BY4741 ∆cys3 GliT-pC210 and BY4741 ∆cys3 pRS315. 
10 µg of each lysate sample was run on a SDS-PAGE gel and coomassie stained in an 
attempt to observe possible GliTp bands in the protein samples from strains containing 
the GliT gene (figure 3.20). 
 
 
 
 
 
BY4741 pRS315
BY4741 GliT
0 µg/ml GT 12 µg/ml GT
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Figure 3.20 Coomassie stain of SDS-PAGE gel with protein from strains 
containing GliT-pC210. 1 = BY4741 GliT-pC210; 2 = BY4741 pRS315; 3 = G600 
GliT-pC210; 4 = G600 pRS315; 5 = BY4741 ∆cys3 GliT-pC210; 6 = BY4741 ∆cys3 
pRS315. No discrepancy in band intensity at 36 kDA. 
 
GliTp has a molecular mass of 36 kDa, however no bands representative of this 
protein were visible. Coomassie-stained 1-dimensional gels do not reveal differences 
between proteins from yeast strains without GliT and GliT transformant strains. 
  
3.4.3.2 Enzymatic assay of gliotoxin reductase activity (GliT-pC210) 
Gliotoxin can cause an inhibition of NADPH oxidase activity (Yoshida et al., 
2000, Tsunawaki et al., 2004). Schrettl et al. (2010) demonstrated the ability of GliTp to 
cleave the gliotoxin disulfide bridge (gliotoxin reductase activity), which has been 
shown to play a key role in the deleterious activity exhibited by the toxin (Trown and 
Bilello, 1972, Müllbacher et al., 1986). Thus, NADPH oxidase activity can be used as 
an indirect measure of gliotoxin activity. This NADPH assay was carried out in an 
attempt to observe a difference in NADPH oxidase activity inhibition by gliotoxin, in 
the absence and presence of GliTp. The assay was carried out as described in section 
2.28 and comparisons were made between BY4741 and BY4741 GliT, and G600 and 
G600 GliT. Figure 3.21 represents a typical graph observed from the data obtained.  
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1 2 3 4 5 6
~40 kDa
~30 kDa
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Figure 3.21 NADPH oxidase activity in BY4741 when GliT is present. This graph is 
representative of the typical trend seen over time. 
 
 To enable more accurate comparisons to be made, the absorbance figures 
obtained during the 3 min. following NADPH addition were converted to percentages of 
the initial reading. This allowed us to examine the oxidase activity in each sample 
relative to the others (figure 3.22).   
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Figure 3.22 NADPH oxidase activity in BY4741 and G600 (GliT-pC210)  
 
 
 The results from this assay show that expression of GliTp impairs the ability of 
gliotoxin to inhibit NADPH oxidase activity. In both BY4741 and G600, when GliT is 
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present along with gliotoxin, there is more rapid oxidation of NADPH. It appears based 
on the observations in figure 3.22 that the GliTp is inactivating gliotoxin to some extent, 
probably by exhibiting gliotoxin reductase activity, thus alleviating the toxin’s 
inhibition of NADPH oxidase activity. This suggests that there is GliTp production 
within GliT transformant cells, albeit a low level.  
 Further to this, we wanted to quantify the amount of GliTp in the cell lysates. 
From here, gliotoxin reductase activity, and subsequent inability of the toxin to inhibit 
NADPH oxidase activity, was taken to represent GliTp. We used the formula below and 
figures recorded in this assay to calculate the units of NADPH oxidase per mg of 
protein. 
Units/ml enzyme = (∆A340 nm Sample – ∆A340 nm Blank)(0.7)/(6.22)(0.05) 
0.7 = volume of assay (ml) 
6.22 = extinction coefficient of β-NADPH 
0.05 = volume of enzyme added (ml) 
 
Units/mg = Units per ml enzyme/mg protein per ml enzyme 
 
For each sample, the assay was performed in triplicate. Units of NADPH oxidase per µg 
of protein were calculated using the equation above and the average value of the three 
was taken. These values are shown in table 3.2.  
Table 3.2 Calculated units of NADPH oxidase representing the estimated amount 
of gliotoxin reductase/GliTp, per µg of protein for BY4741 and G600 samples. 
 
Sample Units NADPH oxidase/µg of protein 
BY4741 pRS315 3.08 
BY4741 GliT-pC210 6.74 
G600 pRS315 10.59 
G600 GliT-pC210 19.63 
 
 Table 3.2 shows that in GliT transformants there is a higher level of NADPH 
oxidase and thus gliotoxin reductase activity. BY4741 and G600 constitutively 
expressing GliT exhibit approximately double the gliotoxin reductase than wild-type.  
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3.5 Assessing GliT expression in yeast under an inducible promoter 
3.5.1 Cloning GliT into pYES2 
 After the discovery that constitutive expression of the A. fumigatus GliT gene 
confers increased resistance to gliotoxin in yeast, we wanted to increase the level of 
GliTp in vivo by galactose induction. To this end, we cloned the GliT gene by 
homologous recombination into the pYES2 vector which contains a GAL1 promoter and 
the URA3 gene marker. pYES2 was digested using the XhoI and HindIII restriction 
enzymes, gel electrophoresed and extracted. GliT was amplified, as before, from 
topovector with overhangs homologous to regions approaching the cleavage sites of 
pYES2. Simultanaeous transformation of linear pYES2 and GliT followed by selection 
on SC plates lacking uracil resulted in colonies containing GliT-pYES2. Figure 3.23 
represents the plasmid maps constructed for pYES2 and GliT-pYES2.     
  
 
 
 
 
 
 
 
 
 
 
Figure 3.23 Plasmid maps constructed for pYES2 and GliT-pYES2. pYES2 was 
digested using HindIII and XhoI. 82 bp was removed and GliT was cloned into the 
plasmid by homologous recombination. Both plasmids contain uracil markers and a 
number of restriction sites as depicted above. 
 
XhoI
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 To confirm that cloning had been achieved, PCR was performed on the plasmid, 
the results are shown in figure 3.24. The primers used bound to pYES2 30 bp up- and 
downstream of GliT, resulting in a product of 1,065 bp (lane 1). No product was 
observed for the negative control, in which digested pYES2 was used as template DNA. 
As the primers contained sequence homologous to GliT, GliT was amplified from GliT-
pC210 as a positive control giving a product of 1 kb (lane 3).  
 
 
 
 
 
 
 
    
 
 
 
 
Figure 3.24 Diagnostic PCR depicting the cloning of GliT into pYES2. 1 = GliT-
pYES2; 2 = pYES2; 3 = GliT-pC210 
 
 The PCR product amplified from the new construct was sent to Agowa for 
sequencing to check for mutations. The sequencing data retrieved depicted the GliT 
sequence containing the same mutation as was seen for GliT-pC210 (section 3.4.1). No 
other mutations were found. 
 
3.5.2 Examining the effects of galactose-induced GliT expression on yeast growth 
To assess the effects of galactose-induced GliTp on the growth of S. cerevisiae, 
we transformed the new construct of GliT under the control of the inducible GAL1 
promoter in pYES2 into BY4741 and G600. We selected for cells containing the 
plasmid on SC plates lacking uracil and used both glucose and galactose for metabolism. 
1kb
1 2 3
 119 
Gliotoxin was added to these plates enabling us to compare and contrast a) the cellular 
growth when different carbohydrate sources were used and b) the protective abilities of 
GliT in response to gliotoxin when induced by galactose metabolism. As a control, an 
empty pYES2 vector was used to allow comparative growth. Figure 3.25 reveals how 
BY4741 utilises galactose much more efficiently than G600.  
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Comparative growth analysis of wild-type strains during metabolism 
of glucose and galactose (48 hr. 30ºC). G600 cannot metabolise galactose as 
efficiently as glucose. 
 
In figure 3.26 it can be seen that at 8 µg/ml gliotoxin exposure, BY4741 grew 
notably better than G600. When glucose was metabolised and cells were exposed to 8 
µg/ml gliotoxin, GliT-pYES2 transformants grew as wild-type, as GliT expression was 
not induced. Under 8 µg/ml gliotoxin exposure when galactose was used as a 
carbohydrate source, overall growth was largely diminished and GliT expression, rather 
than exhibiting protective effects actually appeared to confer an increase in sensitivity to 
gliotoxin in yeast. The cells containing the empty pYES2 vector grew more efficiently 
than those expressing galactose inducible GliT. 
These plates were incubated at room temperature for a further 48 hours after 
which a clearer difference in growth of BY4741 GliT-pYES2 and pYES2 was observed 
(figure 3.27). The strain containing the empty vector grew better than the GliT 
BY4741 GliT-pYES2
BY4741 pYES2
G600 pYES2
G600 GliT-pYES2
-URA -URA gal
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transformant, suggesting galactose induction of GliT increasingly sensitises yeast to 
gliotoxin. 
 
 
 
 
 
 
 
 
 
Figure 3.26 Comparative growth analysis of wild-type strains during metabolism 
of glucose and galactose with 8 µg/ml gliotoxin addition (48 hr. 30ºC).  8 µg/ml 
gliotoxin caused a strong inhibition of G600 when glucose was metabolised. On 8 
µg/ml gliotoxin galactose plates, G600 does not grow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27 Comparative growth analysis of BY4741 during galactose metabolism 
with 8 µg/ml gliotoxin addition (48 hr. 30ºC + 48 hr. RT). Galactose induction of 
GliT appeared to further sensitise yeast to gliotoxin. 
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3.5.3 Detecting GliTp under galactose induction 
Following the findings described above, we attempted to detect GliTp levels in 
cell lysates. Our results demonstrated that the GliT gene displays different effects in 
yeast, depending on regulation of its expression, thus we wanted to assess levels of 
GliTp that could be detected when induced by galactose. 
 
3.5.3.1 Coomassie stain of SDS-PAGE gel (GliT-pYES2) 
To investigate if controlled induction time is relevant to GliTp production, the 
levels of detectable GliTp was assessed after chronic and acute galactose exposure. 
SDS-PAGE and coomassie staining was performed as described in section 3.4.3.1. For 
chronically galactose-exposed lysates, cells were cultured in SC –URA gal liquid media 
overnight and grown in the same liquid media on the day of lysate extraction. For 
acutely exposed lysates, cells were cultured in SC –URA overnight and SC –URA gal 
on the day of lysate extraction. This allowed us to compare how chronic and acute 
metabolism of galactose (and thus induction of GliT expression) impact on the ability to 
detect GliTp (figure 3.28). 
 
 
 
 
 
 
 
 
 
 
Figure 3.28 Coomassie stain of SDS-PAGE gel with protein from BY4741 
containing GliT-pYES2 and pYES2 (chronic and acute galactose metabolism) 1 = 
GliT-pYES2 (acute); 2 = pYES2 (acute); 3 = GliT-pYES2 (chronic); 4 = pYES2 
(chronic). 
~36 kDa
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10 µg of each lysate sample was run on a SDS-PAGE gel and coomassie stained 
in an attempt to observe possible GliTp bands in the protein samples from strains 
containing the GliT gene. Figure 3.28 showns that there was no protein expression at 36 
kDa, therefore GliTp detection in yeast appears to be difficult. Regardless of chronic or 
acute galactose metabolism and controlled induction of GliT expression, GliTp could 
not be identified. 
 
3.5.3.2 Enzymatic assay of gliotoxin reductase activity (GliT-pYES2) 
Again we wanted to compare GliTp detection after chronic and acute galactose 
metabolism. The enzymatic gliotoxin reductase assay was performed as described in 
section 3.4.3.2. For chronically galactose-exposed lysates, cells were cultured in SC –
URA gal liquid media overnight and grown in the same liquid media on the day of 
lysate extraction. For acutely exposed lysates, cells were cultured in SC –URA 
overnight and SC –URA gal on the day of lysate extraction. This allowed us to compare 
how chronic and acute metabolism of galactose (and thus induction of GliT expression) 
impact on GliTp detection (figure 3.29).     
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Figure 3.29 NADPH oxidase activity in BY4741 (GliT-pYES2).  
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There is no clear trend seen in figure 3.29. After three minutes, the highest level of 
NADPH oxidase activity is seen for the pYES2 acute galactose metabolism sample. The 
GliT-pYES2 acute galactose metabolism sample showed the second highest level of 
activity and both the chronic galactose metabolism samples showed lower levels of 
NADPH oxidase activity. However, these results were not consistent at all time points 
during the three minutes. Thus, due to the lack of consistency within this graph, no 
accurate conclusions can be made about the detectable level of GliTp. 
We calculated the units of NADPH oxidase as before and these values are presented in 
table 3.3. It is again clear from this table that there is no specific trend, GliT under 
controlled galactose induction does not produce a detectable level of GliTp. The same 
was apparent for both chronic and acute galactose-induced expression.      
 
Table 3.3 Calculated units of NADPH oxidase representing the estimated amount 
of GliTp, per µg of protein from BY4741 samples. 
 
Sample Units of NADPH oxidase/µg of protein 
 
pYES2 chronic gal 13.96 
 
GliT-pYES2 chronic gal 21.27 
 
pYES2 acute gal 30.39 
 
GliT-pYES2 acute gal 17.78 
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Section 2: Investigation into the global response to gliotoxin exhibited 
by S. cerevisiae 
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3.6 Investigation into the global response of S. cerevisiae to gliotoxin 
To gain further insight into the deleterious effects caused by gliotoxin, we 
investigated the global yeast response to the toxin. To do this, we applied transcriptomic 
and proteomic techniques, RNA sequencing analysis and two-dimensional gel 
electrophoresis respectively. 
  
3.6.1  Using transcriptomics to explore the mechanism of action of gliotoxin 
 G600 wild-type yeast were exposed to gliotoxin at concentrations of 0, 16 and 
64 µg/ml for 1 hr., RNA was extracted from the cells and residual DNA was removed. 
Approximately 8 mg of total RNA from each sample underwent sequenced using 
Illumina® technology, whereby the total RNA was converted into a library of template 
molecules which were quantified to give figures representative of expression levels of 
genes. Thus, for each treatment, data was obtained listing any gene that was transcribed 
and its expression level detected. 
On retrieval of transcriptome data for each treatment, comparisons were made 
between the data from samples that were exposed to a) 0 and 16 µg/ml gliotoxin, and b) 
0 and 64 µg/ml gliotoxin. The genes from lists returned were first grouped into those 
upregulated and downregulated, and then sub-grouped depending on their fold change. 
The groups that underwent further analysis were those that had more than 2-fold 
increase or decrease in expression.  
 
3.6.1.1 Analysis of the effect of 16 µg/ml gliotoxin exposure on global transcription 
in yeast cells 
 
In response to 16 µg/ml gliotoxin exposure, 172 genes showed increased 
expression of more than 3-fold and 423 2-3-fold. From this, analysis was performed on 
the 595 genes that underwent more than 2-fold upregulation in response to 16 µg/ml 
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gliotoxin exposure. In contrast, 318 and 335 genes underwent more than 3-fold and 2-3-
fold downregulation repectively, thus 653 genes which exhibited more than 2-fold 
downregulation were analysed. 
Each of these genes that showed a noteworthy change in the level of 
transcription was assigned GO Identities reflective of the gene function. Most genes 
were designated more than one GO Identity due to multiple functions. There are three 
GO Identity categories which were used, Molecular Function, Biological Process and 
Cellular Component, see table 3.4. 
Table 3.4 GO Identity terms used to characterise genes and proteins (taken from 
Saccharomyces Genome Database). 
 
Biological Process Terms Molecular Function Terms Cellular Component Terms 
None None None 
Biological process unknown Molecular function unknown Cellular component unknown 
DNA metabolic processes DNA binding Golgi apparatus 
RNA metabolic processes RNA binding Cell cortex 
Cell budding Enzyme regulator activity Cell wall 
Cell cycle Helicase activity Cellular bud 
Cellular amino acid metabolic processes Hydrolase activity Chromosome 
Cellular aromatic compound metabolic 
processes 
Isomerase activity Cytoplasm 
Cellular carbohydrate metabolic processes Ligase activity Cytoplasmid membrane-bounded 
vesicle 
Cellular component morphogenesis Lipid binding Cytoskeleton 
Cellular homeostasis Lyase activity Endomembrane system 
Cellular lipid metabolic process Motor activity Endoplasmic reticulum 
Cellular membrane organization Neucleotidyltransferase activity Extracellular region membrane 
Cellular protein catabolic process Oxidoreductase activity Membrane fraction 
Cellular respiration Peptidase activity Microtubule organising centre 
Chromosome organization Phosphoprotein phosphatase 
activity 
Mitochondrial envelope 
Chromosome segregation Protein binding Mitochondrion 
Cofactor metabolic process Protein kinase activity Nucleolus 
Conjugation Signal transducer activity Nucleus 
Cytokinesis Structural molecule activity Peroxisome 
Cytoskeleton organization Transcription regulator activity Plasma membrane 
Cell wall organization Transferase activity Ribosome 
Generation of precursor metabolites and 
energy 
Translation regulator activity Site of polarized growth 
Heterocycle metabolic process Transporter activity Vacuole 
Meiosis Triplet codon-amino acid 
adaptor activity 
 
Mitochondrion organization   
Nucleus organization   
Peroxisome organization   
Protein complex biogenesis   
Protein folding   
Protein modification process   
Pseudohyphal growth   
Response to chemical stimulus   
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Response to stress   
Ribosome biogenesis   
Signaling   
Sporulation   
Transcription   
Translation   
Transport   
Transposition   
Vacuole organization   
Vesicle organization   
Vesicle-mediated transport   
Vitamin metabolic process   
 
Thus, each gene was categorised respective to its biological and molecular functions, in 
addition to the cellular component affected by the expression of the gene. For both up- 
and downregulated genes, the number of genes in each category was then expressed as a 
percentage of the total transcriptional changes. For example, genes that underwent a 
more than 2-fold increase in transcription were classified based on their molecular 
function. Four genes were found to have helicase activity, ergo these genes occupy 
0.7% of the total molecular function activity carried out by the said genes. 
 It must be noted however that there are limitations in analysing gene percentages 
in each of the three categories. For example, the proportion of cytoplasm- and vacuole-
associated genes that exist may not be the same across the genome. Thus, the percentage 
change outcomes are likely to be skewed to reflect the proportions of genes in the entire 
genome that are associated with a particular component/function/process.  
 
Summary of the overall effects of gene upregulation on cells 
Figures 3.30-3.32 illustrate the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 16 µg/ml gliotoxin exposure.  
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Figure 3.30 The percentage of each cellular component category (16 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned cellular 
component categories. The number of genes in each category was expressed as a 
percentage of the number of total genes.   
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Figure 3.31 The percentage of each molecular function category (16 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned  molecular 
function categories. The number of genes in each category was expressed as a 
percentage of the number of total genes.  
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Figure 3.32 The percentage of each biological process category (16 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned biological 
process categories. The number of genes in each category was expressed as a percentage 
of the number of total genes.  
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 In order to further analyse the cellular response to gliotoxin, the five most highly 
upregulated biological processes, molecular functions and associated cellular 
components were further examined. These are illustrated in figures 3.33-3-35. 
 
Cellular Components
0
50
100
150
200
250
300
350
400
450
cytoplasm nucleus ribosome membrane mitochondrion
Associated Component
N
u
m
be
r 
o
f g
en
es
 
w
ith
 
>
2-
fo
ld
 
in
cr
ea
se
 
in
 
tr
a
n
sc
ri
pt
io
n
 
Figure 3.33 The five associated cellular components most highly upregulated by 
exposure to 16 µg/ml gliotoxin. 
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Figure 3.34 The five molecular functions most highly upregulated by exposure to 
16 µg/ml gliotoxin. 
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Figure 3.35 The five biological processes most highly upregulated by exposure to 
16 µg/ml gliotoxin. 
 
 Table 3.5 lists the fifty genes, and their respective functions, that underwent the 
highest increase in transcription in response to 16 µg/ml gliotoxin. 
Table 3.5 The fifty genes most highly upregulated in response to 16 µg/ml gliotoxin 
exposure. Gene functions were obtained from www.yeastgenome.org (SGD). 
 
Gene Fold Change Gene Function 
 
MET3 11.70 ATP sulfurylase, catalyzes the primary step of intracellular 
sulfate activation, essential for assimilatory reduction of sulfate 
to sulfide, involved in methionine metabolism 
RPS29B 9.36 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps29Ap and has similarity to rat S29 and E. coli 
S14 ribosomal proteins 
BTN2 9.13 v-SNARE binding protein that facilitates specific protein 
retrieval from a late endosome to the Golgi; modulates arginine 
uptake, possible role in mediating pH homeostasis between the 
vacuole and plasma membrane H(+)-ATPase 
MET14 7.44 Adenylylsulfate kinase, required for sulfate assimilation and 
involved in methionine metabolism 
RPL28 6.64 Ribosomal protein of the large (60S) ribosomal subunit, has 
similarity to E. coli L15 and rat L27a ribosomal proteins; may 
have peptidyl transferase activity; can mutate to cycloheximide 
resistance 
RPS9B 5.98 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps9Ap and has similarity to E. coli S4 and rat S9 
ribosomal proteins 
RNR1 5.86 One of two large regulatory subunits of ribonucleotide-
diphosphate reductase; the RNR complex catalyzes rate-limiting 
step in dNTP synthesis, regulated by DNA replication and DNA 
damage checkpoint pathways via localization of small subunits 
RPL2B 5.67 Protein component of the large (60S) ribosomal subunit, 
identical to Rpl2Ap and has similarity to E. coli L2 and rat L8 
ribosomal proteins; expression is upregulated at low 
temperatures 
RPL31A 5.61 Protein component of the large (60S) ribosomal subunit, nearly 
 132 
identical to Rpl31Bp and has similarity to rat L31 ribosomal 
protein; associates with the karyopherin Sxm1p; loss of both 
Rpl31p and Rpl39p confers lethality 
RPP1B 5.55 Ribosomal protein P1 beta, component of the ribosomal stalk, 
which is involved in interaction of translational elongation 
factors with ribosome; accumulation is regulated by 
phosphorylation and interaction with the P2 stalk component 
MET17 5.54 Methionine and cysteine synthase (O-acetyl homoserine-O-
acetyl serine sulfhydrylase), required for sulfur amino acid 
synthesis 
YFR032C 5.42 Putative protein of unknown function; non-essential gene 
identified in a screen for mutants with increased levels of rDNA 
transcription; expressed at high levels during sporulation 
RPS26B 5.17 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps26Ap and has similarity to rat S26 ribosomal 
protein 
RPL8A 4.99 Ribosomal protein L4 of the large (60S) ribosomal subunit, 
nearly identical to Rpl8Bp and has similarity to rat L7a 
ribosomal protein; mutation results in decreased amounts of free 
60S subunits 
RPL34B 4.98 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl34Ap and has similarity to rat L34 ribosomal 
protein 
RPS30B 4.94 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps30Ap and has similarity to rat S30 ribosomal 
protein 
PAU18 4.91 Protein of unknown function, member of the seripauperin 
multigene family encoded mainly in subtelomeric regions; 
identical to Pau6p 
PAU6 4.91 Member of the seripauperin multigene family encoded mainly in 
subtelomeric regions, active during alcoholic fermentation, 
regulated by anaerobiosis, negatively regulated by oxygen, 
repressed by heme; identical to Pau18p 
SPH1 4.87 Protein involved in shmoo formation and bipolar bud site 
selection; homologous to Spa2p, localizes to sites of polarized 
growth in a cell cycle dependent- and Spa2p-dependent manner, 
interacts with MAPKKs Mkk1p, Mkk2p, and Ste7p 
RPL6B 4.80 Protein component of the large (60S) ribosomal subunit, has 
similarity to Rpl6Ap and to rat L6 ribosomal protein; binds to 
5.8S rRNA 
RPS24B 4.77 Protein component of the small (40S) ribosomal subunit; 
identical to Rps24Ap and has similarity to rat S24 ribosomal 
protein 
RPL17A 4.70 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl17Bp and has similarity to E. coli L22 and rat 
L17 ribosomal proteins; copurifies with the Dam1 complex (aka 
DASH complex) 
TOS3 4.67 Protein kinase, related to and functionally redundant with Elm1p 
and Sak1p for the phosphorylation and activation of Snf1p; 
functionally orthologous to LKB1, a mammalian kinase 
associated with Peutz-Jeghers cancer-susceptibility syndrome 
RPL2A 4.67 Protein component of the large (60S) ribosomal subunit, 
identical to Rpl2Bp and has similarity to E. coli L2 and rat L8 
ribosomal proteins 
RPL26B 4.66 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl26Ap and has similarity to E. coli L24 and rat 
L26 ribosomal proteins; binds to 5.8S rRNA 
MET16 4.63 3'-phosphoadenylsulfate reductase, reduces 3'-phosphoadenylyl 
sulfate to adenosine-3',5'-bisphosphate and free sulfite using 
reduced thioredoxin as cosubstrate, involved in sulfate 
assimilation and methionine metabolism 
RPS24A 4.62 Protein component of the small (40S) ribosomal subunit; 
identical to Rps24Bp and has similarity to rat S24 ribosomal 
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protein 
ZPS1 4.61 Putative GPI-anchored protein; transcription is induced under 
low-zinc conditions, as mediated by the Zap1p transcription 
factor, and at alkaline pH 
RPS10A 4.60 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps10Bp and has similarity to rat ribosomal protein 
RPL26A 4.58 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl26Bp and has similarity to E. coli L24 and rat 
L26 ribosomal proteins; binds to 5.8S rRNA 
RPS28B 4.56 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps28Ap and has similarity to rat S28 ribosomal 
protein 
MCD4 4.52 Protein involved in glycosylphosphatidylinositol (GPI) anchor 
synthesis; multimembrane-spanning protein that localizes to the 
endoplasmic reticulum; highly conserved among eukaryotes 
RPP2A 4.39 Ribosomal protein P2 alpha, a component of the ribosomal stalk, 
which is involved in the interaction between translational 
elongation factors and the ribosome; regulates the accumulation 
of P1 (Rpp1Ap and Rpp1Bp) in the cytoplasm 
RPL34A 4.38 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl34Bp and has similarity to rat L34 ribosomal 
protein 
RPL8B 4.37 Ribosomal protein L4 of the large (60S) ribosomal subunit, 
nearly identical to Rpl8Ap and has similarity to rat L7a 
ribosomal protein; mutation results in decreased amounts of free 
60S subunits 
RPS0B 4.33 Protein component of the small (40S) ribosomal subunit, nearly 
identical to Rps0Ap; required for maturation of 18S rRNA along 
with Rps0Ap; deletion of either RPS0 gene reduces growth rate, 
deletion of both genes is lethal 
BNA3 4.33 Kynurenine aminotransferase, catalyzes formation of kynurenic 
acid from kynurenine; potential Cdc28p substrate 
RPS0A 4.32 Protein component of the small (40S) ribosomal subunit, nearly 
identical to Rps0Bp; required for maturation of 18S rRNA along 
with Rps0Bp; deletion of either RPS0 gene reduces growth rate, 
deletion of both genes is lethal 
VEL1 4.32 Protein of unknown function; highly induced in zinc-depleted 
conditions and has increased expression in NAP1 deletion 
mutants 
MET10 4.30 Subunit alpha of assimilatory sulfite reductase, which converts 
sulfite into sulfide 
RPS29A 4.30 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps29Bp and has similarity to rat S29 and E. coli 
S14 ribosomal proteins 
RPS7B 4.27 Protein component of the small (40S) ribosomal subunit, nearly 
identical to Rps7Ap; interacts with Kti11p; deletion causes 
hypersensitivity to zymocin; has similarity to rat S7 and 
Xenopus S8 ribosomal proteins 
RPL16A 4.26 N-terminally acetylated protein component of the large (60S) 
ribosomal subunit, binds to 5.8 S rRNA; has similarity to 
Rpl16Bp, E. coli L13 and rat L13a ribosomal proteins; 
transcriptionally regulated by Rap1p 
RPL7B 4.21 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl7Ap and has similarity to E. coli L30 and rat L7 
ribosomal proteins; contains a conserved C-terminal Nucleic 
acid Binding Domain (NDB2) 
GAT4 4.21 Protein containing GATA family zinc finger motifs 
RPL37A 4.19 Protein component of the large (60S) ribosomal subunit, has 
similarity to Rpl37Bp and to rat L37 ribosomal protein 
RPL15A 4.18 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl15Bp and has similarity to rat L15 ribosomal 
protein; binds to 5.8 S rRNA 
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RPS9A 4.17 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps9Bp and has similarity to E. coli S4 and rat S9 
ribosomal proteins 
RPL13B 4.17 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl13Ap; not essential for viability; has similarity to 
rat L13 ribosomal protein 
RPS5 4.16 Protein component of the small (40S) ribosomal subunit, the 
least basic of the non-acidic ribosomal proteins; phosphorylated 
in vivo; essential for viability; has similarity to E. coli S7 and rat 
S5 ribosomal proteins 
 
 One of the first significant observations made was that out of 172 genes that 
underwent a more than 3-fold increase in transcription, 107 were noted to encode 
components of either the small or large subunit of the ribosome. It was also discovered 
that many genes involved in sulfur amino acid and glutathione biosynthesis were 
upregulated in response to gliotoxin, in addition to a number of genes involved in 
glucose fermentation. These will be discussed in detail later.   
 
Summary of the overall effects of gene downregulation on cells 
Genes which were transcriptionally repressed under 16 µg/ml gliotoxin exposure 
were subsequently assessed. Figures 3.36-3.38 illustrate the overall effects on cells 
induced by genes downregulated more than 2-fold in response to 16 µg/ml gliotoxin 
exposure.   
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Figure 3.36 The percentage of each cellular component category (16 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
cellular component categories. The number of genes in each category was expressed as 
a percentage of the number of total genes.  
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Figure 3.37 The percentage of each molecular function category (16 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
molecular function categories. The number of genes in each category was expressed as a 
percentage of the number of total genes. 
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Figure 3.38 The percentage of each biological process category (16 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
biological process categories. The number of genes in each category was expressed as a 
percentage of the number of total genes. 
 
As for the transcriptionally upregulated genes, the the five most transcriptionally 
repressed biological processes, molecular functions and associated cellular components 
were investigated. These results can be observed in figures 3.39-3.41. 
 137 
 
  
Cellular Components
0
50
100
150
200
250
300
350
400
450
cytoplasm mitochondrion membrane mitochondrial
envelope
nucleus
Associated Component
N
u
m
be
r 
o
f g
en
es
 
w
ith
 
>
2-
fo
ld
 
de
cr
ea
se
 
in
 
tr
a
n
sc
rip
tio
n
 
Figure 3.39 The five associated cellular components most highly downregulated by 
exposure to 16 µg/ml gliotoxin. 
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Figure 3.40 The five molecular functions most highly downregulated by exposure 
to 16 µg/ml gliotoxin. 
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Figure 3.41 The five biological processes most highly downregulated by exposure 
to 16 µg/ml gliotoxin. 
 
 Table 3.6 lists the fifty genes, and their respective functions, that underwent the 
highest decrease in transcription in response to 16 µg/ml gliotoxin. 
Table 3.6 The fifty genes most highly downregulated in response to 16 µg/ml 
gliotoxin exposure. Gene functions were obtained from www.yeastgenome.org (SGD). 
 
Gene Fold Change Gene Function 
 
YIL057C -204.79 Protein of unknown function involved in energy metabolism 
under respiratory conditions; expression induced under carbon 
limitation and repressed under high glucose 
YDR119W-
A 
-186.53 Putative protein of unknown function; may interact with 
respiratory chain complexes III (ubiquinol-cytochrome c 
reductase) or IV (cytochrome c oxidase) 
SPG1 -136.45 Protein required for survival at high temperature during 
stationary phase; not required for growth on nonfermentable 
carbon sources; the authentic, non-tagged protein is detected in 
highly purified mitochondria in high-throughput studies 
YIG1 -106.67 Protein that interacts with glycerol 3-phosphatase and plays a 
role in anaerobic glycerol production; localizes to the nucleus 
and cytosol 
SFC1 -67.46 Mitochondrial succinate-fumarate transporter, transports 
succinate into and fumarate out of the mitochondrion; required 
for ethanol and acetate utilization 
SIP18 -62.65 Phospholipid-binding protein; expression is induced by osmotic 
stress 
SPG4 -50.52 Protein required for survival at high temperature during 
stationary phase; not required for growth on nonfermentable 
carbon sources 
YGR067C -36.99 Putative protein of unknown function; contains a zinc finger 
motif similar to that of Adr1p 
MLS1 -34.38 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in peroxisomes 
during growth in oleic acid medium 
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ACH1 -33.96 Protein with CoA transferase activity, particularly for CoASH 
transfer from succinyl-CoA to acetate; has minor acetyl-CoA-
hydrolase activity; phosphorylated; required for acetate 
utilization and for diploid pseudohyphal growth 
JEN1 -33.65 Lactate transporter, required for uptake of lactate and pyruvate; 
phosphorylated; expression is derepressed by transcriptional 
activator Cat8p during respiratory growth, and repressed in the 
presence of glucose, fructose, and mannose 
SDH2 -33.01 Iron-sulfur protein subunit of succinate dehydrogenase (Sdh1p, 
Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate 
to the transfer of electrons to ubiquinone as part of the TCA 
cycle and the mitochondrial respiratory chain 
YMR175W-
A 
-31.16 Putative protein of unknown function 
ADY2 -30.94 Acetate transporter required for normal sporulation; 
phosphorylated in mitochondria 
HXT5 -26.87 Hexose transporter with moderate affinity for glucose, induced 
in the presence of non-fermentable carbon sources, induced by a 
decrease in growth rate, contains an extended N-terminal 
domain relative to other HXTs 
SDH1 -23.57 Flavoprotein subunit of succinate dehydrogenase (Sdh1p, 
Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate 
to the transfer of electrons to ubiquinone as part of the TCA 
cycle and the mitochondrial respiratory chain 
POT1 -21.95 3-ketoacyl-CoA thiolase with broad chain length specificity, 
cleaves 3-ketoacyl-CoA into acyl-CoA and acetyl-CoA during 
beta-oxidation of fatty acids 
GRE1 -20.69 Hydrophilin of unknown function; stress induced (osmotic, 
ionic, oxidative, heat shock and heavy metals); regulated by the 
HOG pathway 
CSM4 -19.85 Protein required for accurate chromosome segregation during 
meiosis; involved in meiotic telomere clustering (bouquet 
formation) and telomere-led rapid prophase movements 
YNL195C -17.62 Putative protein of unknown function; shares a promoter with 
YNL194C; the authentic, non-tagged protein is detected in 
highly purified mitochondria in high-throughput studies 
CAT2 -17.44 Carnitine acetyl-CoA transferase present in both mitochondria 
and peroxisomes, transfers activated acetyl groups to carnitine 
to form acetylcarnitine which can be shuttled across membranes 
FMP43 -17.03 Putative protein of unknown function; expression regulated by 
osmotic and alkaline stresses; the authentic, non-tagged protein 
is detected in highly purified mitochondria in high-throughput 
studies 
IDP2 -16.68 Cytosolic NADP-specific isocitrate dehydrogenase, catalyzes 
oxidation of isocitrate to alpha-ketoglutarate; levels are elevated 
during growth on non-fermentable carbon sources and reduced 
during growth on glucose 
YAT1 -16.51 Outer mitochondrial carnitine acetyltransferase, minor ethanol-
inducible enzyme involved in transport of activated acyl groups 
from the cytoplasm into the mitochondrial matrix; 
phosphorylated 
ACS1 -15.69 Acetyl-coA synthetase isoform which, along with Acs2p, is the 
nuclear source of acetyl-coA for histone acetlyation; expressed 
during growth on nonfermentable carbon sources and under 
aerobic conditions 
NDE2 -15.18 Mitochondrial external NADH dehydrogenase, catalyzes the 
oxidation of cytosolic NADH; Nde1p and Nde2p are involved 
in providing the cytosolic NADH to the mitochondrial 
respiratory chain 
FBP1 -14.95 Fructose-1,6-bisphosphatase, key regulatory enzyme in the 
gluconeogenesis pathway, required for glucose metabolism; 
undergoes either proteasome-mediated or autophagy-mediated 
degradation depending on growth conditions; interacts with 
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Vid30p 
YGL188C -14.63 Putative protein of unknown function; YMR206W is not an 
essential gene 
RIP1 -13.42 Ubiquinol-cytochrome-c reductase, a Rieske iron-sulfur protein 
of the mitochondrial cytochrome bc1 complex; transfers 
electrons from ubiquinol to cytochrome c1 during respiration 
YNL194C -13.09 Integral membrane protein required for sporulation and plasma 
membrane sphingolipid content; has sequence similarity to 
SUR7 and FMP45; GFP-fusion protein is induced in response to 
the DNA-damaging agent MMS 
YML087C -12.53 Putative protein of unknown function, highly conserved across 
species and orthologous to human CYB5R4; null mutant 
displays reduced frequency of mitochondrial genome loss 
SDH4 -12.15 Membrane anchor subunit of succinate dehydrogenase (Sdh1p, 
Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate 
to the transfer of electrons to ubiquinone as part of the TCA 
cycle and the mitochondrial respiratory chain 
CRC1 -12.10 Mitochondrial inner membrane carnitine transporter, required 
for carnitine-dependent transport of acetyl-CoA from 
peroxisomes to mitochondria during fatty acid beta-oxidation 
COX5A -11.78 Subunit Va of cytochrome c oxidase, which is the terminal 
member of the mitochondrial inner membrane electron transport 
chain; predominantly expressed during aerobic growth while its 
isoform Vb (Cox5Bp) is expressed during anaerobic growth 
YAT2 -11.07 Carnitine acetyltransferase; has similarity to Yat1p, which is a 
carnitine acetyltransferase associated with the mitochondrial 
outer membrane 
NDI1 -10.41 NADH:ubiquinone oxidoreductase, transfers electrons from 
NADH to ubiquinone in the respiratory chain but does not pump 
protons, in contrast to the higher eukaryotic multisubunit 
respiratory complex I; phosphorylated; homolog of human 
AMID 
ODC1 -10.27 Mitochondrial inner membrane transporter, exports 2-
oxoadipate and 2-oxoglutarate from the mitochondrial matrix to 
the cytosol for lysine and glutamate biosynthesis and lysine 
catabolism; suppresses, in multicopy, an fmc1 null mutation 
CBP4 -10.14 Mitochondrial protein required for assembly of ubiquinol 
cytochrome-c reductase complex (cytochrome bc1 complex); 
interacts with Cbp3p and function is partially redundant with 
that of Cbp3p 
SDH3 -9.77 Cytochrome b subunit of succinate dehydrogenase (Sdh1p, 
Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate 
to the transfer of electrons to ubiquinone as part of the TCA 
cycle and the mitochondrial respiratory chain 
FOX2 -9.72 Multifunctional enzyme of the peroxisomal fatty acid beta-
oxidation pathway; has 3-hydroxyacyl-CoA dehydrogenase and 
enoyl-CoA hydratase activities 
GLG2 -9.63 Self-glucosylating initiator of glycogen synthesis, also 
glucosylates n-dodecyl-beta-D-maltoside; similar to mammalian 
glycogenin 
CAT8 -9.51 Zinc cluster transcriptional activator necessary for derepression 
of a variety of genes under non-fermentative growth conditions, 
active after diauxic shift, binds carbon source responsive 
elements 
OM45 -9.06 Protein of unknown function, major constituent of the 
mitochondrial outer membrane; located on the outer (cytosolic) 
face of the outer membrane 
CYT1 -9.02 Cytochrome c1, component of the mitochondrial respiratory 
chain; expression is regulated by the heme-activated, glucose-
repressed Hap2p/3p/4p/5p CCAAT-binding complex 
HXT6 -8.94 High-affinity glucose transporter of the major facilitator 
superfamily, nearly identical to Hxt7p, expressed at high basal 
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levels relative to other HXTs, repression of expression by high 
glucose requires SNF3 
HXT7 -8.88 High-affinity glucose transporter of the major facilitator 
superfamily, nearly identical to Hxt6p, expressed at high basal 
levels relative to other HXTs, expression repressed by high 
glucose levels 
RPM2 -8.63 Protein subunit of mitochondrial RNase P, has roles in nuclear 
transcription, cytoplasmic and mitochondrial RNA processing, 
and mitochondrial translation; distributed to mitochondria, 
cytoplasmic processing bodies, and the nucleus 
HAP4 -8.62 Subunit of the heme-activated, glucose-repressed 
Hap2p/3p/4p/5p CCAAT-binding complex, a transcriptional 
activator and global regulator of respiratory gene expression; 
provides the principal activation function of the complex 
YKL187C -8.61 Putative protein of unknown function; the authentic, non-tagged 
protein is detected in a phosphorylated state in highly purified 
mitochondria in high-throughput studies 
COX4 -8.53 Subunit IV of cytochrome c oxidase, the terminal member of the 
mitochondrial inner membrane electron transport chain; 
precursor N-terminal 25 residues are cleaved during 
mitochondrial import; phosphorylated; spermidine enhances 
translation 
 
3.6.1.2 Analysis of the effect of 64 µg/ml gliotoxin exposure on global transcription 
in yeast cells 
 
In response to 64 µg/ml gliotoxin exposure, 246 and 493 genes underwent more 
than 3-fold and 2-3-fold upregulation respectively. Thus, analysis was performed on the 
739 genes that underwent more than 2-fold upregulation in response to 64 µg/ml 
gliotoxin exposure. In contrast, 475 and 530 genes underwent more than 3-fold and 2-3-
fold downregulation repectively, and these 1,005 genes which exhibited more than 2-
fold downregulation were analysed. The same procedure was carried out on these genes, 
as for the previous set. These genes were allocated GO Identities and categorised under 
the headings of Molecular Function, Biological Process and Cellular Component, see 
table 3.4. Gene number in each category was subsequently expressed as a percentage of 
the total transcriptional changes, as before.  
 
Summary of the overall effects of gene upregulation on cells 
Figures 3.42-3.44 illustrate the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 64 µg/ml gliotoxin exposure. 
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Figure 3.42 The percentage of each cellular component category (64 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned cellular 
component categories. The number of genes in each category was expressed as a 
percentage of the number of total genes.  
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Figure 3.43 The percentage of each molecular function category (64 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned molecular 
function categories. The number of genes in each category was expressed as a 
percentage of the number of total genes.  
 143 
1.47
16.33
0.39
2.94
6.73
1.86
2.09
0.46
0.54
1.32
1.16
0.93
0.15
1.55
0.23
1.86
1.01
0.93
0.77
1.01
1.47
4.26
0.77
0.46
0.31
2.32
0.08
0.70
1.08
2.09
0.31
2.63
3.48
12.93
0.85
0.70
4.80
8.36
6.58
0.54
0.08
1.01
0.46
0 2 4 6 8 10 12 14 16 18
DNA metabolic process
RNA metabolic process
cell budding
cell cycle
cellular amino acid metabolic process
cellular aromatic compound metabolic process
cellular carbohydrate metabolic process
cellular component morphogenesis
cellular homeostasis
cellular lipid metabolic process
cellular membrane organization
cellular protein catabolic process
cellular respiration
chromosome organization
chromosome segregation
cofactor metabolic process
conjugation
cytokinesis
cytoskeleton organization
fungal-type cell wall organization
generation of precursor metabolites and energy
heterocycle metabolic process
meiosis
mitochondrion organization
nucleus organization
other
peroxisome organization
protein complex biogenesis
protein folding
protein modification process
pseudohyphal growth
response to chemical stimulus
response to stress
ribosome biogenesis
signaling
sporulation resulting in formation of a cellular spore
transcription
translation
transport
vacuole organization
vesicle organization
vesicle-mediated transport
vitamin metabolic process
Bi
o
lo
gi
ca
l P
ro
ce
ss
% Total Expression
 
 
Figure 3.44 The percentage of each biological process category (64 µg/ml 
upregulated genes). Genes upregulated more than two-fold were assigned biological 
process categories. The number of genes in each category was expressed as a percentage 
of the number of total genes.  
 
 To further analyse the cellular response to the toxin in question, the five most 
highly upregulated biological processes, molecular functions and associated cellular 
components were examined. These are illustrated in figures 3.45-3.47. 
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Figure 3.45 The five associated cellular components most highly upregulated by 
exposure to 64 µg/ml gliotoxin. 
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Figure 3.46 The five molecular functions most highly upregulated by exposure to 
64 µg/ml gliotoxin. 
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Figure 3.47 The five biological processes most highly upregulated by exposure to 
64 µg/ml gliotoxin. 
 
 Table 3.7 lists the fifty genes, and their respective functions, that underwent the 
highest increase in transcription in response to 64 µg/ml gliotoxin. 
 
Table 3.7 The fifty genes most highly upregulated in response to 64 µg/ml gliotoxin 
exposure. Gene functions were obtained from www.yeastgenome.org (SGD). 
 
Gene Fold Change Gene Function 
 
CUP1-2 171.19 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
CUP1-1 171.19 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
YFR032C 18.63 Putative protein of unknown function; non-essential gene 
identified in a screen for mutants with increased levels of rDNA 
transcription; expressed at high levels during sporulation 
FRM2 15.75 Protein of unknown function, involved in the integration of lipid 
signaling pathways with cellular homeostasis; expression 
induced in cells treated with the mycotoxin patulin; has 
similarity to bacterial nitroreductases 
MET16 13.57 3'-phosphoadenylsulfate reductase, reduces 3'-phosphoadenylyl 
sulfate to adenosine-3',5'-bisphosphate and free sulfite using 
reduced thioredoxin as cosubstrate, involved in sulfate 
assimilation and methionine metabolism 
MET14 13.56 Adenylylsulfate kinase, required for sulfate assimilation and 
involved in methionine metabolism 
MET3 13.15 ATP sulfurylase, catalyzes the primary step of intracellular 
sulphate activation, essential for assimilatory reduction of sulfate 
to sulfide, involved in methionine metabolism 
HBN1 11.00 Putative protein of unknown function; similar to bacterial 
nitroreductases; green fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and nucleus; protein becomes 
insoluble upon intracellular iron depletion 
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YMR001C-
A 
9.94 Putative protein of unknown function 
IMD2 9.88 Inosine monophosphate dehydrogenase, catalyzes the rate-
limiting step in GTP biosynthesis, expression is induced by 
mycophenolic acid resulting in resistance to the drug, expression 
is repressed by nutrient limitatio 
NRG2 9.71 Transcriptional repressor that mediates glucose repression and 
negatively regulates filamentous growth; has similarity to Nrg1p 
SAM1 9.48 S-adenosylmethionine synthetase, catalyzes transfer of the 
adenosyl group of ATP to the sulfur atom of methionine; one of 
two differentially regulated isozymes (Sam1p and Sam2p) 
HXT2 8.80 High-affinity glucose transporter of the major facilitator 
superfamily, expression is induced by low levels of glucose and 
repressed by high levels of glucose 
YPR160C-
A 
8.78 Identified by gene-trapping, microarray-based expression 
analysis, and genome-wide homology searching 
MET6 8.75 Cobalamin-independent methionine synthase, involved in 
methionine biosynthesis and regeneration; requires a minimum 
of two glutamates on the methyltetrahydrofolate substrate, 
similar to bacterial metE homologs 
STR3 8.67 Cystathionine beta-lyase, converts cystathionine into 
homocysteine 
ICY2 8.54 Protein of unknown function; mobilized into polysomes upon a 
shift from a fermentable to nonfermentable carbon source; 
potential Cdc28p substrate 
YKL071W 8.52 Putative protein of unknown function; expression induced in 
cells treated with the mycotoxin patulin, and also the quinone 
methide triterpene celastrol; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm 
NRD1 8.51 RNA-binding protein that interacts with the C-terminal domain 
of the RNA polymerase II large subunit (Rpo21p), preferentially 
at phosphorylated Ser5; required for transcription termination 
and 3' end maturation of nonpolyadenylated RNAs 
MET17 8.49 Methionine and cysteine synthase (O-acetyl homoserine-O-
acetyl serine sulfhydrylase), required for sulfur amino acid 
synthesis 
CYS3 8.03 Cystathionine gamma-lyase, catalyzes one of the two reactions 
involved in the transsulfuration pathway that yields cysteine 
from homocysteine with the intermediary formation of 
cystathionine 
SER33 7.77 3-phosphoglycerate dehydrogenase, catalyzes the first step in 
serine and glycine biosynthesis; isozyme of Ser3p 
RPS29B 6.72 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps29Ap and has similarity to rat S29 and E. coli 
S14 ribosomal proteins 
YDR524W-
C 
6.57 Putative protein of unknown function; small ORF identified by 
SAGE; deletion strains are moderately sensitive to the 
radiomimetic drug bleomycin 
BIO2 6.47 Biotin synthase, catalyzes the conversion of dethiobiotin to 
biotin, which is the last step of the biotin biosynthesis pathway; 
complements E. coli bioB mutant 
GPX2 6.43 Phospholipid hydroperoxide glutathione peroxidase induced by 
glucose starvation that protects cells from phospholipid 
hydroperoxides and nonphospholipid peroxides during oxidative 
stress 
ALD5 5.87 Mitochondrial aldehyde dehydrogenase, involved in regulation 
or biosynthesis of electron transport chain components and 
acetate formation; activated by K+; utilizes NADP+ as the 
preferred coenzyme; constitutively expressed 
MUP3 5.83 Low affinity methionine permease, similar to Mup1p 
HOF1 5.78 Bud neck-localized, SH3 domain-containing protein required for 
cytokinesis; regulates actomyosin ring dynamics and septin 
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localization; interacts with the formins, Bni1p and Bnr1p, and 
with Cyk3p, Vrp1p, and Bni5p 
ADH6 5.73 NADPH-dependent medium chain alcohol dehydrogenase with 
broad substrate specificity; member of the cinnamyl family of 
alcohol dehydrogenases; may be involved in fusel alcohol 
synthesis or in aldehyde tolerance 
OYE2 5.56 Conserved NADPH oxidoreductase containing flavin 
mononucleotide (FMN), homologous to Oye3p with different 
ligand binding and catalytic properties; may be involved in sterol 
metabolism, oxidative stress response, and programmed cell 
death 
SAM2 5.55 S-adenosylmethionine synthetase, catalyzes transfer of the 
adenosyl group of ATP to the sulfur atom of methionine; one of 
two differentially regulated isozymes (Sam1p and Sam2p) 
TRR1 5.50 Cytoplasmic thioredoxin reductase, key regulatory enzyme that 
determines the redox state of the thioredoxin system, which acts 
as a disulfide reductase system and protects cells against both 
oxidative and reductive stress 
MET8 5.48 Bifunctional dehydrogenase and ferrochelatase, involved in the 
biosynthesis of siroheme, a prosthetic group used by sulfite 
reductase; required for sulfate assimilation and methionine 
biosynthesis 
YLR460C 5.46 Member of the quinone oxidoreductase family, up-regulated in 
response to the fungicide mancozeb; possibly up-regulated by 
iodine 
MMT1 5.42 Putative metal transporter involved in mitochondrial iron 
accumulation; closely related to Mmt2p 
DBP2 5.41 Essential ATP-dependent RNA helicase of the DEAD-box 
protein family, involved in nonsense-mediated mRNA decay and 
rRNA processing 
YKL070W 5.38 Putative protein of unknown function; expression induced in 
cells treated with mycotoxins patulin or citrinin; the authentic, 
non-tagged protein is detected in highly purified mitochondria in 
high-throughput studies 
RPL29 5.25 Protein component of the large (60S) ribosomal subunit, has 
similarity to rat L29 ribosomal protein; not essential for 
translation, but required for proper joining of the large and small 
ribosomal subunits and for normal translation rate 
ADE5 5.21 Bifunctional enzyme of the 'de novo' purine nucleotide 
biosynthetic pathway, contains aminoimidazole ribotide 
synthetase and glycinamide ribotide synthetase activities 
YGR271C-
A 
5.15 Essential protein required for maturation of 18S rRNA; null 
mutant is sensitive to hydroxyurea and is delayed in recovering 
from alpha-factor arrest; green fluorescent protein (GFP)-fusion 
protein localizes to the nucleolus 
PHO89 5.04 Na+/Pi cotransporter, active in early growth phase; similar to 
phosphate transporters of Neurospora crassa; transcription 
regulated by inorganic phosphate concentrations and Pho4p 
ILV3 5.03 Dihydroxyacid dehydratase, catalyzes third step in the common 
pathway leading to biosynthesis of branched-chain amino acids 
SAH1 4.99 S-adenosyl-L-homocysteine hydrolase, catabolizes S-adenosyl-
L-homocysteine which is formed after donation of the activated 
methyl group of S-adenosyl-L-methionine (AdoMet) to an 
acceptor 
ECM17 4.96 Sulfite reductase beta subunit, involved in amino acid 
biosynthesis, transcription repressed by methionine 
YAP7 4.94 Putative basic leucine zipper (bZIP) transcription factor 
MFA1 4.91 Mating pheromone a-factor, made by a cells; interacts with alpha 
cells to induce cell cycle arrest and other responses leading to 
mating; biogenesis involves C-terminal modification, N-terminal 
proteolysis, and export; also encoded by MFA2 
YLR146W- 4.87 Putative protein of unknown function 
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A 
PHO12 4.78 One of three repressible acid phosphatases, a glycoprotein that is 
transported to the cell surface by the secretory pathway; nearly 
identical to Pho11p; upregulated by phosphate starvation 
MET22 4.73 Bisphosphate-3'-nucleotidase, involved in salt tolerance and 
methionine biogenesis; dephosphorylates 3'-phosphoadenosine-
5'-phosphate and 3'-phosphoadenosine-5'-phosphosulfate, 
intermediates of the sulfate assimilation pathway 
 
Summary of the overall effects of gene downregulation on cells 
 Genes which underwent more than 2-fold transcriptional repression as a result of 
exposure to 64 µg/ml gliotoxin were also assessed. Figures 3.48-3.50 illustrate the 
overall effects on cells induced by genes downregulated more than 2-fold in response to 
64 µg/ml gliotoxin exposure. 
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Figure 3.48 The percentage of each cellular component category (64 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
cellular component categories. The number of genes in each category was expressed as 
a percentage of the number of total genes.  
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Figure 3.49 The percentage of each molecular function category (64 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
molecular function categories. The number of genes in each category was expressed as a 
percentage of the number of total genes. 
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Figure 3.50 The percentage of each biological process category (64 µg/ml 
downregulated genes). Genes downregulated more than two-fold were assigned 
biological process categories. The number of genes in each category was expressed as a 
percentage of the number of total genes. 
 
 The five most common functions in each GO Identity category of these genes 
downregulated at a high degree were assessed (figures 3.51-3.53).  
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Figure 3.51 The five associated cellular components most highly downregulated by 
exposure to 64 µg/ml gliotoxin. 
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Figure 3.52 The five molecular functions most highly downregulated by exposure 
to 64 µg/ml gliotoxin. 
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Figure 3.53 The five biological processes most highly downregulated by exposure 
to 64 µg/ml gliotoxin. 
 
 The fifty genes that underwent the highest level of downregulation are illustrated 
in table 3.8 
 
Table 3.8 The fifty genes most highly downregulated in response to 64 µg/ml 
gliotoxin exposure. Gene functions were obtained from www.yeastgenome.org (SGD). 
 
Gene Fold Change Gene Function 
 
SIP18 -131.20 Phospholipid-binding protein; expression is induced by 
osmotic stress 
SPG1 -124.46 Protein required for survival at high temperature during 
stationary phase; not required for growth on nonfermentable 
carbon sources; the authentic, non-tagged protein is detected 
in highly purified mitochondria in high-throughput studies 
YIL057C -92.27 Protein of unknown function involved in energy metabolism 
under respiratory conditions; expression induced under 
carbon limitation and repressed under high glucose 
SPG4 -70.25 Protein required for survival at high temperature during 
stationary phase; not required for growth on nonfermentable 
carbon sources 
GRE1 -50.50 Hydrophilin of unknown function; stress induced (osmotic, 
ionic, oxidative, heat shock and heavy metals); regulated by 
the HOG pathway 
YMR175W-
A 
-49.45 Putative protein of unknown function 
SFC1 -44.99 Mitochondrial succinate-fumarate transporter, transports 
succinate into and fumarate out of the mitochondrion; 
required for ethanol and acetate utilization 
YGR067C -44.01 Putative protein of unknown function; contains a zinc finger 
motif similar to that of Adr1p 
NDE2 -43.64 Mitochondrial external NADH dehydrogenase, catalyzes the 
oxidation of cytosolic NADH; Nde1p and Nde2p are 
involved in providing the cytosolic NADH to the 
mitochondrial respiratory chain 
YDR119W-
A 
-43.47 Putative protein of unknown function; may interact with 
respiratory chain complexes III (ubiquinol-cytochrome c 
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reductase) or IV (cytochrome c oxidase) 
FMP45 -43.06 Integral membrane protein localized to mitochondria 
(untagged protein); required for sporulation and maintaining 
sphingolipid content; has sequence similarity to SUR7 and 
YNL194C 
HXT5 -41.98 Hexose transporter with moderate affinity for glucose, 
induced in the presence of non-fermentable carbon sources, 
induced by a decrease in growth rate, contains an extended 
N-terminal domain relative to other HXTs 
YIG1 -41.75 Protein that interacts with glycerol 3-phosphatase and plays a 
role in anaerobic glycerol production; localizes to the nucleus 
and cytosol 
POT1 -39.33 3-ketoacyl-CoA thiolase with broad chain length specificity, 
cleaves 3-ketoacyl-CoA into acyl-CoA and acetyl-CoA 
during beta-oxidation of fatty acids 
ECM13 -33.03 Non-essential protein of unknown function; induced by 
treatment with 8-methoxypsoralen and UVA irradiation 
JEN1 -32.82 Lactate transporter, required for uptake of lactate and 
pyruvate; phosphorylated; expression is derepressed by 
transcriptional activator Cat8p during respiratory growth, and 
repressed in the presence of glucose, fructose, and mannose 
PCK1 -32.46 Phosphoenolpyruvate carboxykinase, key enzyme in 
gluconeogenesis, catalyzes early reaction in carbohydrate 
biosynthesis, glucose represses transcription and accelerates 
mRNA degradation, regulated by Mcm1p and Cat8p, located 
in the cytosol 
ADY2 -30.61 Acetate transporter required for normal sporulation; 
phosphorylated in mitochondria 
HSP12 -29.47 Plasma membrane localized protein that protects membranes 
from desiccation; induced by heat shock, oxidative stress, 
osmostress, stationary phase entry, glucose depletion, oleate 
and alcohol; regulated by the HOG and Ras-Pka pathways 
YNL195C -27.34 Putative protein of unknown function; shares a promoter with 
YNL194C; the authentic, non-tagged protein is detected in 
highly purified mitochondria in high-throughput studies 
ACH1 -26.62 Protein with CoA transferase activity, particularly for 
CoASH transfer from succinyl-CoA to acetate; has minor 
acetyl-CoA-hydrolase activity; phosphorylated; required for 
acetate utilization and for diploid pseudohyphal growth 
YAL018C -26.38 Putative protein of unknown function 
CRC1 -24.63 Mitochondrial inner membrane carnitine transporter, required 
for carnitine-dependent transport of acetyl-CoA from 
peroxisomes to mitochondria during fatty acid beta-oxidation 
YER053C-
A 
-24.00 Putative protein of unknown function; green fluorescent 
protein (GFP)-fusion protein localizes to the endoplasmic 
reticulum 
YAT1 -22.93 Outer mitochondrial carnitine acetyltransferase, minor 
ethanol-inducible enzyme involved in transport of activated 
acyl groups from the cytoplasm into the mitochondrial 
matrix; phosphorylated 
YRO2 -22.66 Putative protein of unknown function; the authentic, non-
tagged protein is detected in a phosphorylated state in highly 
purified mitochondria in high-throughput studies; 
transcriptionally regulated by Haa1p 
CAT2 -21.61 Carnitine acetyl-CoA transferase present in both 
mitochondria and peroxisomes, transfers activated acetyl 
groups to carnitine to form acetylcarnitine which can be 
shuttled across membranes 
NQM1 -21.32 Transaldolase of unknown function; transcription is 
repressed by Mot1p and induced by alpha-factor and during 
diauxic shift 
ACS1 -19.01 Acetyl-coA synthetase isoform which, along with Acs2p, is -
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the nuclear source of acetyl-coA for histone acetlyation; 
expressed during growth on nonfermentable carbon sources 
and under aerobic conditions 
YMR118C -18.66 Protein of unknown function with similarity to succinate 
dehydrogenase cytochrome b subunit; YMR118C is not an 
essential gene 
GLG2 -18.58 Self-glucosylating initiator of glycogen synthesis, also 
glucosylates n-dodecyl-beta-D-maltoside; similar to 
mammalian glycogenin 
YNL194C -18.55 Integral membrane protein required for sporulation and 
plasma membrane sphingolipid content; has sequence 
similarity to SUR7 and FMP45; GFP-fusion protein is 
induced in response to the DNA-damaging agent MMS 
HSP30 -18.46 Hydrophobic plasma membrane localized, stress-responsive 
protein that negatively regulates the H(+)-ATPase Pma1p; 
induced by heat shock, ethanol treatment, weak organic acid, 
glucose limitation, and entry into stationary phase 
POX1 -18.40 Fatty-acyl coenzyme A oxidase, involved in the fatty acid 
beta-oxidation pathway; localized to the peroxisomal matrix 
FMP16 -18.28 Putative protein of unknown function; proposed to be 
involved in responding to conditions of stress; the authentic, 
non-tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
YMR206W -18.27 Putative protein of unknown function; YMR206W is not an 
essential gene 
SDH2 -18.19 Iron-sulfur protein subunit of succinate dehydrogenase 
(Sdh1p, Sdh2p, Sdh3p, Sdh4p), which couples the oxidation 
of succinate to the transfer of electrons to ubiquinone as part 
of the TCA cycle and the mitochondrial respiratory chain 
MLS1 -17.93 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in 
peroxisomes during growth in oleic acid medium 
HBT1 -17.74 Substrate of the Hub1p ubiquitin-like protein that localizes to 
the shmoo tip (mating projection); mutants are defective for 
mating projection formation, thereby implicating Hbt1p in 
polarized cell morphogenesis 
YKL065W-
A 
-17.37 Putative protein of unknown function 
RTN2 -16.36 Protein of unknown function; has similarity to mammalian 
reticulon proteins; member of the RTNLA (reticulon-like A) 
subfamily 
GUT2 -16.17 Mitochondrial glycerol-3-phosphate dehydrogenase; 
expression is repressed by both glucose and cAMP and 
derepressed by non-fermentable carbon sources in a Snf1p, 
Rsf1p, Hap2/3/4/5 complex dependent manner 
YDR018C -14.94 Probable membrane protein with three predicted 
transmembrane domains; homologous to Ybr042cp, similar 
to C. elegans F55A11.5 and maize 1-acyl-glycerol-3-
phosphate acyltransferase 
RIP1 -14.94 Ubiquinol-cytochrome-c reductase, a Rieske iron-sulfur 
protein of the mitochondrial cytochrome bc1 complex; 
transfers electrons from ubiquinol to cytochrome c1 during 
respiration 
IDP2 -14.87 Cytosolic NADP-specific isocitrate dehydrogenase, catalyzes 
oxidation of isocitrate to alpha-ketoglutarate; levels are 
elevated during growth on non-fermentable carbon sources 
and reduced during growth on glucose 
NCE102 -14.78 Protein of unknown function; contains transmembrane 
domains; involved in secretion of proteins that lack classical 
secretory signal sequences; component of the detergent-
insoluble glycolipid-enriched complexes (DIGs) 
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FMP43 -14.70 Putative protein of unknown function; expression regulated 
by osmotic and alkaline stresses; the authentic, non-tagged 
protein is detected in highly purified mitochondria in high-
throughput studies 
PHM7 -14.54 Protein of unknown function, expression is regulated by 
phosphate levels; green fluorescent protein (GFP)-fusion 
protein localizes to the cell periphery and vacuole 
COX4 -14.46 Subunit IV of cytochrome c oxidase, the terminal member of 
the mitochondrial inner membrane electron transport chain; 
precursor N-terminal 25 residues are cleaved during 
mitochondrial import; phosphorylated; spermidine enhances 
translation 
MSC1 -14.35 Protein of unknown function; mutant is defective in directing 
meiotic recombination events to homologous chromatids; the 
authentic, non-tagged protein is detected in highly purified 
mitochondria and is phosphorylated 
 
3.6.1.3 Comparison of the yeast transcriptomic response to 16 and 64 µg/ml  
gliotoxin exposure 
 
 It would be reasonable to expect a similar yeast response to 16 and 64 µg/ml 
gliotoxin exposure, to some degree. If these reactions are real, there should be overlap 
in the data when comparing the response to 16 and 64 µg/ml gliotoxin. To investigate if 
this is the case, correlation was searched for by comparing and contrasting the five most 
highly up- and downregulated molecular functions, biological processes and associated 
cellular components. Figures 3.54-3.59 illustrate these comparisons. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.54 Comparison of the five most common biological processes performed 
by genes with >2-fold upregulation. 
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 From the above figure it can be seen that four out of the top five most common 
upregulated biological processes characteristic of response to gliotoxin are induced by 
the two concentrations, these are RNA metabolic process, ribosome biogenesis, 
translation and transport. However, the response to stress is one of the most common 
processes performed by cells under 16 µg/ml gliotoxin exposure, but not 64 µg/ml. At 
the same time, cellular amino acid metabolic process is highly stimulated by the latter 
concentration but not the former.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.55 Comparison of the five most common associated cellular components 
of genes with >2-fold upregulation. 
 
Under exposure to both concentrations of gliotoxin, genes associated with the 
cytoplasm, ribosome, mitochondrion and nucleus are all highly upregulated (figure 
3.55). Membrane-associated genes fall into the most commonly upregulated category 
only under exposure to 16 µg/ml gliotoxin, not under 64 µg/ml. On the other hand, 
genes associated with the nucleolus were upregulated to a high degree when cell were 
treated with 64 µg/ml gliotoxin, but not with the lower concentration. 
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Figure 3.56 Comparison of the five most common molecular functions performed 
by genes with >2-fold upregulation. 
 
In relation to molecular function, protein binding was one of the highest functions to be 
stimulated by the lower concentration of gliotoxin, but not by the higher. In contrast, 
oxidoreductase activity was very highly stimulated by 64 µg/ml gliotoxin exposure, but 
not by 16 µg/ml. Transferase activity, structural molecule activity, RNA binding 
activity and hydrolase activity were all stimulated to the highest degree under exposure 
to the toxin at both concentations (figure 3.56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.57 Comparison of the five most common biological processes performed 
by genes with >2-fold downregulation. 
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 Downregulated gene GO identities were also compared and contrasted. Of all 
the biological processes inhibited by exposure to 16 µg/ml gliotoxin, only one, the 
cellular carbohydrate metabolic process was unique to this concentration, the rest were 
shared with the response to 64 µg/ml exposure; transport, translation, mitochondrion 
organisation, generation of precursor metabolites and energy. Protein modification 
process genes were strongly repressed by exposure to the higher concentration of 
gliotoxin, but not to the lower (figure 3.57).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.58 Comparison of the five most common associated cellular components 
of genes with >2-fold downregulation. 
 
Figure 3.58 outlines how the five most common cellular components associated with 
>2-fold downregulated genes are highly transcriptionally repressed under exposure to 
both gliotoxin concentrations. The cellular components inhibited by the toxin are the 
cytoplasm, mitochondrion, membrane, mitochondrial envelope and nucleus. 
 Regarding molecular function, the five most common transcriptionally inhibited 
categories were identical when considering gliotoxin exposure levels of 16 and 64 
µg/ml. Structural molecule activity, oxidoreductase activity, transporter activity, 
transferase activity and hydrolase activity were all extremely repressed. 
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  Overall, good correlation of GO identities indicating the yeast response to two 
different gliotoxin exposure concentrations was observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.59 Comparison of the five most common molecular functions performed 
by genes with >2-fold downregulation. 
 
3.6.1.4 Exploration for pathways transcriptionally altered by gliotoxin exposure 
Organisation and categorisation of data allowed us to examine the overall effects 
that gliotoxin imposes on S. cerevisiae. Further to this I was able to compare and 
constrast the cellular transcriptional responses to different concentrations of the toxin. In 
addition, the data was examined in an attempt to pinpoint pathways directly induced or 
repressed by gliotoxin. One such pathway identified was the superpathway of sulfur 
amino acid biosynthesis. All but one gene in this pathway was found to be transcribed at 
an elevated level in response to gliotoxin. As depicted by figure 3.60, the superpathway 
of sulfur amino acid biosynthesis begins with a sulphate ion. Following the formation of 
four intermediates, the resultant hydrogen sulfide combines with O-Acetyl-L-
homoserine to form homocysteine (Thauer et al., 1977, Setya et al., 1996, Berndt et al., 
2004). Homocysteine goes on to play a role in methionine biosynthesis but can also 
enter the transsulfuration pathway. This involves the interconversion of cysteine and 
16 µg/ml GT 64 µg/ml GT 
Oxidoreductase Activity
Transporter Activity
Hydrolase Activity
Transferase Activity
Structural Molecule Activity
The Five Most Common Molecular Functions 
Carried out by Genes with >2-fold Downregulation
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homocysteine with cystathionine acting as an intermediate (Thomas and Surdin-Kerjan, 
1997, Finkelstein, 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.60 The superpathway of sulfur amino acid and glutathione biosynthesis 
(reproduced from SGD). Gene names are depicted in red. These represent the enzymes 
involved in conversion of one intermediate to another.   
 
L-cysteine produced from the transsulfuration pathway is then utilised, along with L-
glycine and L-glutamate, in glutathione biosynthesis. This makes cysteine a potential 
rate-limiting amino acid in the OS response (Arrick et al., 1982, Williamson et al., 1982, 
Anderson, 1998, Dickinson and Forman, 2002). Furthermore, it has been demonstrated 
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that the sulfur amino acid biosynthesis structural system must be functional before 
GSH1 can be expressed under OS (Dormer et al., 2000).    
Every gene illustrated above, with the exception of STR2, undergoes an increase in 
transcription level when yeast cells are exposed to gliotoxin. The fold change in level of 
transcription is outlined in table 3.9. 
 
Table 3.9 Fold change in level of transcription of genes involved in sulfur amino 
acid and glutathione biosynthesis in response to two concentrations of gliotoxin. Ø 
depicts no increase in transcription level.  
  
Gene Name Fold increase in level of 
transcription under 16 µg/ml 
gliotoxin exposure 
Fold increase in level of 
transcription under 64 µg/ml 
gliotoxin exposure 
 
MET7 1.5 1.5 
MET3 11.7 13.2 
MET14 7.4 13.6 
MET16 4.6 13.6 
MET5 (ECM17) 3.9 4.9 
MET10 4.3 3.5 
MET17 5.5 8.5 
HOM3 2.4 4.1 
HOM2 1.7 2.3 
HOM6 1.9 1.5 
MET2 2.9 4.2 
STR3 4 8.7 
STR2 Ø Ø 
CYS3 4.1 8 
CYS4 1.6 3.8 
MET6 2.9 8.7 
SAM2 3.8 5.6 
SAM1 1.8 9.5 
GSH1 Ø 2.2 
GSH2 1.2 1.8 
 
 This demonstrates that under the stress imposed on cells by the gliotoxin, S. 
cerevisiae cells rapidly upregulate the transcription of genes involved in sulfur amino 
acid and glutathione biosynthesis. Other genes exist that encode proteins that play a role 
in mediation of the sulfur amino acid biosynthesis pathway. The MET1, MET4, MET8, 
MET18, MET19 and MET22 , MET28, MET30, MET31, MET32 gene products are 
involved in this regulation (Masselot and De Robichon-Szulmajster, 1975, Thomas et 
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al., 1992a). MET1 and MET8 and MET18 encode proteins that have been shown to 
exhibit sulfite reductase activity, in the same manner as MET5 and MET10, depicted in 
figure 3.60 (Masselot and De Robichon-Szulmajster, 1975, Thomas et al., 1992a). 
Met4p modulates transcriptional activation of the pathway (Thomas et al., 1992b). 
Met19p is required for functional sulfur amino acid biosynthesis as the null mutant 
depends on organic sulfur supplementation for survival and MET19 deletion has led to 
increased sensitivity to OS (Thomas et al., 1991, Krems et al., 1995). The MET22 gene 
product is also required for sulfate assimilation in addition to playing a role in salt 
tolerance (Gläser et al., 1993, Murguía et al., 1995). MET22 deletion gives rise to 
methionine auxotrophs (Masselot and De Robichon-Szulmajster, 1975). Met31p and 
Met32p are additional transcription factors involved in the regulation of said pathway 
and the transcription of MET3 and MET14 is dependent on the presence of at least one 
of these proteins (Blaiseau et al., 1997). In contrast, Met30p negatively regulates the 
sulfur amino acid biosynthesis pathway, through repressing Met19p and the 
transcriptional activities of Met4p in the presence of high S-adenosyl-L-methionine 
(SAM/AdoMet) levels, a product of the said pathway (Thomas et al., 1995). Expression 
of the above mentioned genes in response to two concentrations of gliotoxin is 
illustrated in table 3.10. MET4, MET19 and MET30 are not upregulated in response to 
gliotoxin exposure, unlike MET1, MET8, MET18, MET22, MET31 and MET32. 
Upregulation of these genes has been observed in response to two concentrations of 
gliotoxin, demonstrating overlap and supporting results and conclusions that can 
subsequently be made.   
 Genes involved in glucose fermentation were also seen to be upregulated in the 
presence of gliotoxin. Depending on the availability of oxygen, yeast metabolise 
glucose by fermentation or respiration. From the RNA sequencing data, it became 
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apparent that gliotoxin exposure induces increased transcription of most genes involved 
in the glucose fermentation pathway.  
Fermentation, illustrated in figure 3.61, involves the formation of pyruvate, which is 
then converted to acetaldehyde under the control of pyruvate decarboxylase (Pdc) 
(Zhang et al., 1995, Bongers et al., 2005).        
 
Table 3.10 Fold change in level of transcription of genes involved in regulation of 
the sulfur amino acid biosynthesis pathway in response to two concentrations of 
gliotoxin. Ø depicts no increase in transcription level. N/A depicts no test result 
 
Gene Name Fold increase in level of 
transcription under 16 µg/ml 
gliotoxin exposure 
Fold increase in level of 
transcription under 64 µg/ml 
gliotoxin exposure 
 
MET1 2.5 3.8 
MET4 Ø Ø 
MET8 3.1 5.5 
MET18 1.3 1.5 
MET19 Ø Ø 
MET22 2.9 4.7 
MET28 N/A N/A 
MET30 Ø Ø 
MET31 1.7 2.0 
MET32 1.6 2.9 
  
Although not all genes involved in the glucose fermentation pathway were upregulated 
under gliotoxin exposure, the majority did undergo an increase in transcription. Five 
genes, HXK1, GLK1, PYK2, PDC6 and ALD4 were downregulated to some degree by 
the presence of gliotoxin. 
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Figure 3.61 Glucose fermentation pathway (reproduced from SGD). Gene names are 
depicted in red. These represent the enzymes involved in conversion of one intermediate 
to another.   
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Table 3.11 Fold change in level of transcription of genes involved in glucose 
fermentation in response to two concentrations of gliotoxin. Ø depicts no increase in 
transcription level. 
 
Gene Name Fold increase in level of 
transcription under 16 µg/ml 
gliotoxin exposure 
Fold increase in level of 
transcription under 64 µg/ml 
gliotoxin exposure 
 
HXK1 Ø Ø 
HXK2 2.3 2.5 
GLK1 Ø Ø 
PGI1 1.9 2.1 
PFK1 1.9 1.9 
PFK2 1.9 1.9 
FBA1 1.7 2.8 
TPI1 2.5 2.7 
TDH1 1.9 1.9 
TDH2 2.9 3.4 
TDH3 2.7 2.2 
PGK1 2.5 2.2 
GPM1 2.3 2.8 
ENO1 1.9 2.2 
ENO2 2.6 3.4 
PYK2 Ø Ø 
CDC19 2.6 3.3 
PDC6 Ø Ø 
PDC5 3.0 2.3 
PDC1 3.2 1.9 
ADH5 Ø 1.7 
ADH4 1.4 Ø 
ADH3 Ø 1.1 
ADH2 1.5 2.8 
ADH1 1.7 3.0 
ALD4 Ø Ø 
ALD5 1.8 5.9 
ALD6 1.1 3.8 
 
 Gluconeogenesis, the synthesis of glucose is fundamentally the opposite of 
glycolysis, an intricate part of the fermentation process and genes involved in this 
process are listed in table 3.12 
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Table 3.12 Fold change in level of transcription of genes involved in 
gluconeogenesis in response to two concentrations of gliotoxin. Ø depicts no 
decrease in transcription level. 
 
Gene Name Fold decrease in level of 
transcription under 16 µg/ml 
gliotoxin exposure 
Fold decrease in level of 
transcription under 64 µg/ml 
gliotoxin exposure 
 
MAE1 1.2 Ø 
MDH2 4.7 10.5 
PYC1 6.9 5.9 
PYC2 1.7 1.1 
PCK1 80.1 32.5 
ENO1 Ø Ø 
ENO2 Ø Ø 
GPM1 Ø Ø 
PGK1 Ø Ø 
TDH1 Ø Ø 
TDH2 Ø Ø 
TDH3 Ø Ø 
FBA1 Ø Ø 
FBP1 14.9 13.2 
PGI1 Ø Ø 
 
 Many of the genes involved in gluconeogenesis also play a role in glucose 
fermentation and these are transcribed at a higher level in the presence of gliotoxin as 
this toxin appears to “switch on” the latter pathway. Interestingly, the other genes 
involved in gluconeogenesis are all transcriptionally downregulated. Our data suggests 
these two antithetical processes are both affected by cellular exposure to gliotoxin in 
that the glucose fermentation pathway is “switched on” and gluconeogenesis is 
“switched off”.  
 
3.6.1.5 Comparative evaluation of the effects of gliotoxin and other mycotoxins 
Previous studies have utilised S. cerevisiae to investigate the global expressional 
response to other toxins, including mycotoxins. Transcriptomic data, representing the 
global response to gliotoxin was compared and contrasted with that for citrinin, patulin, 
allicin and furfural obtained from Iwahashi et al. (2007), Iwahashi et al. (2006), Yu et al. 
(2010) and Li & Yuan (2010) respectively. Genes which undergo an increase or 
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decrease in transcription in response to the mycotoxins were compared and similarities 
were investigated. Table 3.13 illustrates the upregulated genes of interest. 
Table 3.14 lists the downregulated genes of interest. Tables 3.13 and 3.14 demonstrate 
significant overlap in genes that undergo up- and downregulation in response to the 
different toxins listed above. Analysis of results using other mycotoxins may help us 
build a bigger picture of the yeast response to gliotoxin. Discrepancies in genes up- and 
downregulated were also investigated and are listed in table 3.15. This contrast could 
provide insight into differences in mycotoxin targets etc. For example, ARO9 is 
upregulated in response to gliotoxin, furfural and allicin exposure. Conversely, it is 
downregulated when cells are exposed to citrinin. Thus, the former three toxins may 
exert a particular type of stress on the cell that requires Aro9p response to resist the 
toxin, the same stress may not be elicited by citrinin. 
 
3.6.1.6 Utilisation of quantitative PCR to confirm transcriptome data 
To assess the efficacy of our RNA sequencing expression data, quantitative PCR 
(qPCR) was performed. Total RNA was extracted from yeast cultures exposed to 0, 16 
and 64 µg/ml gliotoxin. cDNA was synthesised as described in section 2.23.4 and was 
used as reaction template for qPCR. The expression level of fourteen genes in response 
to gliotoxin exposure was analysed. Genes were chosen based on their importance in 
pathways identified and also due to pronounced up- or downregulation recorded in 
transcriptomic data. 
VMA6 and ERG9 were selected as reference genes based on the fact that the 
RNA sequencing data did not record a significant change in their transcription levels in 
response to gliotoxin exposure.
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Table 3.13 Comparison of genes that are upregulated in the presence of the respective compound. X denotes upregulation. Gene function data 
was recorded from SGD. Genes listed show an upregulation in response to one or more toxins. 
Gene Citrinin Patulin Allicin Furfural Gliotoxin Gene Function 
FRM2 X X   X Protein of unknown function, involved in the integration of lipid signaling pathways with cellular homeostasis; expression 
induced in cells treated with the mycotoxin patulin; has similarity to bacterial nitroreductases 
AAD16 X X X   Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
AAD6 X X X   Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase, involved in the oxidative 
stress response; expression induced in cells treated with the mycotoxin patulin 
AAD4 X X    Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase, involved in the oxidative 
stress response; expression induced in cells treated with the mycotoxin patulin 
FLR1 X X X   Plasma membrane multidrug transporter of the major facilitator superfamily, involved in efflux of fluconazole, diazaborine, 
benomyl, methotrexate, and other drugs; expression induced in cells treated with the mycotoxin patulin 
OYE3 X X X   Conserved NADPH oxidoreductase containing flavin mononucleotide (FMN), homologous to Oye2p with different ligand 
binding and catalytic properties; has potential roles in oxidative stress response and programmed cell death 
AAD15 X X    Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
AAD10 X X    Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
AAD14 X X X   Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
GRE2 X X X   3-methylbutanal reductase and NADPH-dependent methylglyoxal reductase (D-lactaldehyde dehydrogenase); stress induced 
(osmotic, ionic, oxidative, heat shock and heavy metals); regulated by the HOG pathway 
AAD3 X X    Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium aryl-alcohol dehydrogenase; mutational analysis has not 
yet revealed a physiological role 
YLL056C X X    Putative protein of unknown function, transcription is activated by paralogous transcription factors Yrm1p and Yrr1p and genes 
involved in pleiotropic drug resistance (PDR); expression is induced in cells treated with the mycotoxin patulin 
GTT2 X X    Glutathione S-transferase capable of homodimerization; functional overlap with Gtt2p, Grx1p, and Grx2p 
ECM4 X X    Omega class glutathione transferase; not essential; similar to Ygr154cp; green fluorescent protein (GFP)-fusion protein localizes 
to the cytoplasm 
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YKL070W X X    Putative protein of unknown function; expression induced in cells treated with mycotoxins patulin or citrinin; the authentic, non-
tagged protein is detected in highly purified mitochondria in high-throughput studies 
MET1 X X X  X S-adenosyl-L-methionine uroporphyrinogen III transmethylase, involved in the biosynthesis of siroheme, a prosthetic group used 
by sulfite reductase; required for sulfate assimilation and methionine biosynthesis 
MET10 X X X  X Subunit alpha of assimilatory sulfite reductase, which converts sulfite into sulphide 
MET14 X X X  X Adenylylsulfate kinase, required for sulphate assimilation and involved in methionine metabolism 
MET16 X X X  X 3'-phosphoadenylsulfate reductase, reduces 3'-phosphoadenylyl sulfate to adenosine-3',5'-bisphosphate and free sulfite using 
reduced thioredoxin as cosubstrate, involved in sulfate assimilation and methionine metabolism 
MET17 X X X  X Methionine and cysteine synthase (O-acetyl homoserine-O-acetyl serine sulfhydrylase), required for sulfur amino acid synthesis 
MET2 X X X   L-homoserine-O-acetyltransferase, catalyzes the conversion of homoserine to O-acetyl homoserine which is the first step of the 
methionine biosynthetic pathway 
MET22 X X X  X Bisphosphate-3'-nucleotidase, involved in salt tolerance and methionine biogenesis; dephosphorylates 3'-phosphoadenosine-5'-
phosphate and 3'-phosphoadenosine-5'-phosphosulfate, intermediates of the sulfate assimilation pathway 
MET3 X X X  X ATP sulfurylase, catalyzes the primary step of intracellular sulfate activation, essential for assimilatory reduction of sulfate to 
sulfide, involved in methionine metabolism 
MET30 X X    F-box protein containing five copies of the WD40 motif, controls cell cycle function, sulfur metabolism, and methionine 
biosynthesis as part of the ubiquitin ligase complex; interacts with and regulates Met4p, localizes within the nucleus 
MET32 X X    Zinc-finger DNA-binding protein, involved in transcriptional regulation of the methionine biosynthetic genes, similar to Met31p 
MET8 X X   X Bifunctional dehydrogenase and ferrochelatase, involved in the biosynthesis of siroheme, a prosthetic group used by sulfite 
reductase; required for sulfate assimilation and methionine biosynthesis 
CYS3 X X   X Cystathionine gamma-lyase, catalyzes one of the two reactions involved in the transsulfuration pathway that yields cysteine from 
formation of cystathionine 
CYS4 X X   X Cystathionine beta-synthase, catalyzes synthesis of cystathionine from serine and homocysteine, the first committed step in 
cysteine biosynthesis; responsible for hydrogen sulfide generation; mutations in human ortholog cause homocystinuria 
SNQ2 X X    Plasma membrane ATP-binding cassette (ABC) transporter, multidrug transporter involved in multidrug resistance and resistance 
to singlet oxygen species 
ARN1 X  X  X Transporter, member of the ARN family of transporters that specifically recognize siderophore-iron chelates; responsible for 
uptake of iron bound to ferrirubin, ferrirhodin, and related siderophores 
TRX2 X X    Cytoplasmic thioredoxin isoenzyme of the thioredoxin system which protects cells against oxidative and reductive stress, forms 
LMA1 complex with Pbi2p, acts as a cofactor for Tsa1p, required for ER-Golgi transport and vacuole inheritance 
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MXR1 X X    Methionine-S-sulfoxide reductase, involved in the response to oxidative stress; protects iron-sulfur clusters from oxidative 
inactivation along with MXR2; involved in the regulation of lifespan 
PST2 X X    Protein with similarity to members of a family of flavodoxin-like proteins; induced by oxidative stress in a Yap1p dependent 
manner; the authentic, non-tagged protein is detected in highly purified mitochondria in high-throughput studies 
RAD59 X X X  X Protein involved in the repair of double-strand breaks in DNA during vegetative growth via recombination and single-strand 
annealing; anneals complementary single-stranded DNA; homologous to Rad52p 
UBC13 X X    Ubiquitin-conjugating enzyme involved in the error-free DNA postreplication repair pathway; interacts with Mms2p to assemble 
ubiquitin chains at the Ub Lys-63 residue; DNA damage triggers redistribution from the cytoplasm to the nucleus 
MAG1 X X X   3-methyl-adenine DNA glycosylase involved in protecting DNA against alkylating agents; initiates base excision repair by 
removing damaged bases to create abasic sites that are subsequently repaired 
HPA2 X X    Tetrameric histone acetyltransferase with similarity to Gcn5p, Hat1p, Elp3p, and Hpa3p; acetylates histones H3 and H4 in vitro 
and exhibits autoacetylation activity 
RPT1 X X    One of six ATPases of the 19S regulatory particle of the 26S proteasome involved in the degradation of ubiquitinated substrates; 
required for optimal CDC20 transcription; interacts with Rpn12p and Ubr1p; mutant has aneuploidy tolerance 
DDR48 X X   X DNA damage-responsive protein, expression is increased in response to heat-shock stress or treatments that produce DNA 
lesions; contains multiple repeats of the amino acid sequence NNNDSYGS 
RFA1 X X X   Subunit of heterotrimeric Replication Protein A (RPA), which is a highly conserved single-stranded DNA binding protein 
involved in DNA replication, repair, and recombination 
DDC1 X X    DNA damage checkpoint protein, part of a PCNA-like complex required for DNA damage response, required for pachytene 
checkpoint to inhibit cell cycle in response to unrepaired recombination intermediates; potential Cdc28p substrate 
TRX1 X X   X Cytoplasmic thioredoxin isoenzyme of the thioredoxin system which protects cells against oxidative and reductive stress, forms 
LMA1 complex with Pbi2p, acts as a cofactor for Tsa1p, required for ER-Golgi transport and vacuole inheritance 
RAD23 X X    Protein with ubiquitin-like N terminus, subunit of Nuclear Excision Repair Factor 2 (NEF2) with Rad4p that recognizes and 
binds damaged DNA; enhances protein deglycosylation activity of Png1p; homolog of human HR23A and HR23B 
RFA2 X X    Subunit of heterotrimeric Replication Protein A (RPA), which is a highly conserved single-stranded DNA binding protein 
involved in DNA replication, repair, and recombination 
SSL2 X X    Component of the holoenzyme form of RNA polymerase transcription factor TFIIH, has DNA-dependent ATPase/helicase 
activity and is required, with Rad3p, for unwinding promoter DNA; involved in DNA repair; homolog of human ERCC3 
RAD7 X X    Protein that recognizes and binds damaged DNA in an ATP-dependent manner (with Rad16p) during nucleotide excision repair; 
subunit of Nucleotide Excision Repair Factor 4 (NEF4) and the Elongin-Cullin-Socs (ECS) ligase complex 
RAD52 X X    Protein that stimulates strand exchange by facilitating Rad51p binding to single-stranded DNA; anneals complementary single-
stranded DNA; involved in the repair of double-strand breaks in DNA during vegetative growth and meiosis 
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MND2 X X    Subunit of the anaphase-promoting complex (APC); necessary for maintaining sister chromatid cohesion in prophase I of meiosis 
by inhibiting premature ubiquitination and subsequent degradation of substrates by the APC(Ama1) ubiquitin ligase 
RAD50 X X X   Subunit of MRX complex, with Mre11p and Xrs2p, involved in processing double-strand DNA breaks in vegetative cells, 
initiation of meiotic DSBs, telomere maintenance, and nonhomologous end joining 
CSM1 X X    Nucleolar protein that forms a complex with Lrs4p and then Mam1p at kinetochores during meiosis I to mediate accurate 
homolog segregation; required for condensin recruitment to the replication fork barrier site and rDNA repeat segregation 
NCA3  X X   Protein that functions with Nca2p to regulate mitochondrial expression of subunits 6 (Atp6p) and 8 (Atp8p ) of the Fo-F1 ATP 
synthase; member of the SUN family; expression induced in cells treated with the mycotoxin patulin 
RPT2  X X   One of six ATPases of the 19S regulatory particle of the 26S proteasome involved in the degradation of ubiquitinated substrates; 
required for normal peptide hydrolysis by the core 20S particle 
RPN6  X X   Essential, non-ATPase regulatory subunit of the 26S proteasome lid required for the assembly and activity of the 26S 
proteasome; the human homolog (S9 protein) partially rescues Rpn6p depletion 
MGT1  X X   DNA repair methyltransferase (6-O-methylguanine-DNA methylase) involved in protection against DNA alkylation damage 
SAM2 X    X S-adenosylmethionine synthetase, catalyzes transfer of the adenosyl group of ATP to the sulfur atom of methionine; one of two 
differentially regulated isozymes (Sam1p and Sam2p) 
STR3 X    X Cystathionine beta-lyase, converts cystathionine into homocysteine 
PDR16 X    X Phosphatidylinositol transfer protein (PITP) controlled by the multiple drug resistance regulator Pdr1p, localizes to lipid particles 
and microsomes, controls levels of various lipids, may regulate lipid synthesis, homologous to Pdr17p 
AHP1  X   X Thiol-specific peroxiredoxin, reduces hydroperoxides to protect against oxidative damage; function in vivo requires covalent 
conjugation to Urm1p 
TSA1  X   X Thioredoxin peroxidase, acts as both a ribosome-associated and free cytoplasmic antioxidant; self-associates to form a high-
molecular weight chaperone complex under oxidative stress; deletion results in mutator phenotype 
LAP4  X   X Vacuolar aminopeptidase yscI; zinc metalloproteinase that belongs to the peptidase family M18; often used as a marker protein in 
studies of autophagy and cytosol to vacuole targeting (CVT) pathway 
PRE6  X   X Alpha 4 subunit of the 20S proteasome; may replace alpha 3 subunit (Pre9p) under stress conditions to create a more active 
proteasomal isoform; GFP-fusion protein relocates from cytosol to the mitochondrial surface upon oxidative stress 
TRP3   X  X Bifunctional enzyme exhibiting both indole-3-glycerol-phosphate synthase and anthranilate synthase activities, forms 
multifunctional hetero-oligomeric anthranilate synthase:indole-3-glycerol phosphate synthase enzyme complex with Trp2p 
TRP5   X  X Tryptophan synthase, catalyzes the last step of tryptophan biosynthesis; regulated by the general control system of amino acid 
biosynthesis 
ILS1   X  X Cytoplasmic isoleucine-tRNA synthetase, target of the G1-specific inhibitor reveromycin A 
ARO8   X  X Aromatic aminotransferase I, expression is regulated by general control of amino acid biosynthesis 
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SER33   X  X 3-phosphoglycerate dehydrogenase, catalyzes the first step in serine and glycine biosynthesis; isozyme of Ser3p 
HOM3   X  X Aspartate kinase (L-aspartate 4-P-transferase); cytoplasmic enzyme that catalyzes the first step in the common pathway for 
methionine and threonine biosynthesis; expression regulated by Gcn4p and the general control of amino acid synthesis 
THR4   X  X Threonine synthase, conserved protein that catalyzes formation of threonine from O-phosphohomoserine; expression is regulated 
by the GCN4-mediated general amino acid control pathway 
FTR1   X  X High affinity iron permease involved in the transport of iron across the plasma membrane; forms complex with Fet3p; expression 
is regulated by iron 
FET3   X  X Ferro-O2-oxidoreductase required for high-affinity iron uptake and involved in mediating resistance to copper ion toxicity, 
belongs to class of integral membrane multicopper oxidases 
TIS11   X  X mRNA-binding protein expressed during iron starvation; binds to a sequence element in the 3'-untranslated regions of specific 
mRNAs to mediate their degradation; involved in iron homeostasis 
PRE2   X  X Beta 5 subunit of the 20S proteasome, responsible for the chymotryptic activity of the proteasome 
EPT1    X X sn-1,2-diacylglycerol ethanolamine- and cholinephosphotranferase; not essential for viability 
YBR096W    X X Putative protein of unknown function; green fluorescent protein (GFP)-fusion protein localizes to the ER 
 
Table 3.14 Comparison of genes that are downregulated in the presence of the respective compound. X denotes upregulation. Gene function data 
was recorded from SGD. Genes listed show a downregulation in response to one or more toxins. 
Gene Citrinin Patulin Allicin Furfural Gliotoxin Gene Function 
ATP4   X X X Subunit b of the stator stalk of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme complex 
required for ATP synthesis; phosphorylated 
ADE17 X    X Enzyme of ‘de novo’ purine biosynthesis containing both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and 
inosine monophosphate cyclohydrolase activities, isozyme of Ade16p; ade16 ade17 mutants require adenine and histidine 
SSU1 X    X Plasma membrane sulfite pump involved in sulfite metabolism and required for efficient sulfite efflux; major facilitator 
superfamily protein 
LEU1   X  X Isopropylmalate 
uinine
e, catalyzes the second step in the leucine biosynthesis pathway 
GLT1   X  X NAD(+)-dependent glutamate synthase (GOGAT), synthesizes glutamate from glutamine and alpha-ketoglutarate; with Gln1p, 
forms the secondary pathway for glutamate biosynthesis from ammonia; expression regulated by nitrogen source 
AGX1   X  X Alanine:glyoxylate aminotransferase (AGT), catalyzes the synthesis of glycine from glyoxylate, which is one of three 
pathways for glycine biosynthesis in yeast; has similarity to mammalian and plant alanine:glyoxylate aminotransferases 
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LPD1   X  X Dihydrolipoamide dehydrogenase, the lipoamide dehydrogenase component (E3) of the pyruvate dehydrogenase and 2-
oxoglutarate dehydrogenase multi-enzyme complexes 
NDE1   X  X Mitochondrial external NADH dehydrogenase, a type II NAD(P)H:
uinine oxidoreductase that catalyzes the oxidation of 
cytosolic NADH; Nde1p and Nde2p provide cytosolic NADH to the mitochondrial respiratory chain 
NDI1   X  X NADH:ubiquinone oxidoreductase, transfers electrons from NADH to ubiquinone in the respiratory chain but does not pump 
protons, in contrast to the higher eukaryotic multisubunit respiratory complex I; phosphorylated; homolog of human AMID 
SDH1   X  X Flavoprotein subunit of succinate dehydrogenase (Sdh1p, Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate to 
the transfer of electrons to ubiquinone as part of the TCA cycle and the mitochondrial respiratory chain 
SDH2   X  X Iron-sulfur protein subunit of succinate dehydrogenase (Sdh1p, Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of 
succinate to the transfer of electrons to ubiquinone as part of the TCA cycle and the mitochondrial respiratory chain 
SDH3   X  X Cytochrome b subunit of succinate dehydrogenase (Sdh1p, Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of succinate to 
the transfer of electrons to ubiquinone as part of the TCA cycle and the mitochondrial respiratory chain 
SDH4   X  X Membrane anchor subunit of succinate dehydrogenase (Sdh1p, Sdh2p, Sdh3p, Sdh4p), which couples the oxidation of 
succinate to the transfer of electrons to ubiquinone as part of the TCA cycle and the mitochondrial respiratory chain 
COR1   X  X Core subunit of the ubiquinol-cytochrome c reductase complex (bc1 complex), which is a component of the mitochondrial 
inner membrane electron transport chain 
CYT1   X  X Cytochrome c1, component of the mitochondrial respiratory chain; expression is regulated by the heme-activated, glucose-
repressed Hap2p/3p/4p/5p CCAAT-binding complex 
QCR2   X  X Subunit 2 of the ubiquinol cytochrome-c reductase complex, which is a component of the mitochondrial inner membrane 
electron transport chain; phosphorylated; transcription is regulated by Hap1p, Hap2p/Hap3p, and heme 
QCR6   X  X Subunit 6 of the ubiquinol cytochrome-c reductase complex, which is a component of the mitochondrial inner membrane 
electron transport chain; highly acidic protein; required for maturation of cytochrome c1 
QCR7   X  X Subunit 7 of the ubiquinol cytochrome-c reductase complex, which is a component of the mitochondrial inner membrane 
electron transport chain; oriented facing the mitochondrial matrix; N-terminus appears to play a role in complex assembly 
QCR8   X  X Subunit 8 of ubiquinol cytochrome-c reductase complex, which is a component of the mitochondrial inner membrane electron 
transport chain; oriented facing the intermembrane space; expression is regulated by Abf1p and Cpf1p 
QCR9   X  X Subunit 9 of the ubiquinol cytochrome-c reductase complex, which is a component of the mitochondrial inner membrane 
electron transport chain; required for electron transfer at the ubiquinol oxidase site of the complex 
RIP1   X  X Ubiquinol-cytochrome-c reductase, a Rieske iron-sulfur protein of the mitochondrial cytochrome bc1 complex; transfers 
electrons from ubiquinol to cytochrome c1 during respiration 
CYC1   X  X Cytochrome c, isoform 1; electron carrier of the mitochondrial intermembrane space that transfers electrons from ubiquinone-
cytochrome c oxidoreductase to cytochrome c oxidase during cellular respiration 
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COX4   X  X Subunit IV of cytochrome c oxidase, the terminal member of the mitochondrial inner membrane electron transport chain; 
precursor N-terminal 25 residues are cleaved during mitochondrial import; phosphorylated; spermidine enhances translation 
COX5A   X  X Subunit Va of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain; predominantly expressed during aerobic growth while its isoform Vb (Cox5Bp) is expressed during anaerobic growth 
COX6   X  X Subunit VI of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain; expression is regulated by oxygen levels 
COX7   X  X Subunit VII of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain 
COX8   X  X Subunit VIII of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain 
COX9   X  X Subunit VIIa of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain 
COX12   X  X Subunit Vib of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain; required for assembly of cytochrome c oxidase but not required for activity after assembly; phosphorylated 
COX13   X  X Subunit Via of cytochrome c oxidase, which is the terminal member of the mitochondrial inner membrane electron transport 
chain; not essential for cytochrome c oxidase activity but may modulate activity in response to ATP 
ATP3   X  X Gamma subunit of the F1 sector of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme 
complex required for ATP synthesis 
ATP5   X  X Subunit 5 of the stator stalk of mitochondrial F1F0 ATP synthase, which is an evolutionarily conserved enzyme complex 
required for ATP synthesis; homologous to bovine subunit OSCP (oligomycin sensitivity-conferring protein); phosphorylated 
ATP7   X  X Subunit d of the stator stalk of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme complex 
required for ATP synthesis 
ATP14   X  X Subunit h of the F0 sector of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme complex 
required for ATP synthesis 
ATP16   X  X Delta subunit of the central stalk of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme 
complex required for ATP synthesis; phosphorylated 
ATP17   X  X Subunit f of the F0 sector of mitochondrial F1F0 ATP synthase, which is a large, evolutionarily conserved enzyme complex 
required for ATP synthesis 
ATP20   X  X Subunit g of the mitochondrial F1F0 ATP synthase; reversibly phosphorylated on two residues; unphosphorylated form is 
required for dimerization of the ATP synthase complex 
FRE2   X  X Ferric reductase and cupric reductase, reduces siderophore-bound iron and oxidized copper prior to uptake by transporters; 
expression induced by low iron levels but not by low copper levels 
MEF2   X  X Mitochondrial elongation factor involved in translational elongation 
TEC1    X X Transcription factor required for full Ty1 expression, Ty1-mediated gene activation, and haploid invasive and diploid 
pseudohyphal growth; TEA/ATTS DNA-binding domain family member 
MIH1    X X Protein tyrosine phosphatase involved in cell cycle control; regulates the phosphorylation state of Cdc28p; homolog of S. 
pombe cdc25 
YBR225W    X X Putative protein of unknown function; non-essential gene identified in a screen for mutants affected in 
mannosylphophorylation of cell wall components 
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Table 3.15 Discrepancies in transcription trends in response to the different compounds. Gene function data was recorded from SGD. Genes 
listed show differences in expression trends in response to one or more toxins.U indicates the upregulation and D the downregulation of the gene in 
response to exposure of the respective toxin. 
Gene Citrinin Patulin Allicin Furfural Gliotoxin Gene Function 
PDR5 U  D   Plasma membrane ATP-binding cassette (ABC) transporter, multidrug transporter actively regulated by Pdr1p; also involved in 
steroid transport, cation resistance, and cellular detoxification during exponential growth 
ARO10 D   U  Phenylpyruvate decarboxylase, catalyzes decarboxylation of phenylpyruvate to phenylacetaldehyde, which is the first specific 
step in the Ehrlich pathway 
ARO9 D  U U U Aromatic aminotransferase II, catalyzes the first step of tryptophan, phenylalanine, and tyrosine catabolism 
BNA4 D   U  Kynurenine 3-mono oxygenase, required for the de novo biosynthesis of NAD from tryptophan via kynurenine; expression 
regulated by Hst1p; putative therapeutic target for Huntington disease 
MET28 U U D   Basic leucine zipper (bZIP) transcriptional activator in the Cbf1p-Met4p-Met28p complex, participates in the regulation of 
sulfur metabolism 
MET31  D    Zinc-finger DNA-binding protein, involved in transcriptional regulation of the methionine biosynthetic genes, similar to Met32p 
MET4  U    Leucine-zipper transcriptional activator, responsible for the regulation of the sulfur amino acid pathway, requires different 
combinations of the auxiliary factors Cbf1p, Met28p, Met31p and Met32p 
MET6 U D   U Cobalamin-independent methionine synthase, involved in methionine biosynthesis and regeneration; requires a minimum of two 
glutamates on the methyltetrahydrofolate substrate, similar to bacterial metE homologs 
RAD54  U    DNA-dependent ATPase, stimulates strand exchange by modifying the topology of double-stranded DNA; involved in the 
recombinational repair of double-strand breaks in DNA during vegetative growth and meiosis; member of the SWI/SNF family 
AHC1  U   D Subunit of the Ada histone acetyltransferase complex, required for structural integrity of the complex 
MCM6  U    Protein involved in DNA replication; component of the Mcm2-7 hexameric complex that binds chromatin as a part of the pre-
replicative complex 
PHB2  U    Subunit of the prohibitin complex (Phb1p-Phb2p), a 1.2 MDa ring-shaped inner mitochondrial membrane chaperone that 
stabilizes newly synthesized proteins; determinant of replicative life span; involved in mitochondrial segregation 
HSP12 D U   D Plasma membrane localized protein that protects membranes from desiccation; induced by heat shock, oxidative stress, 
osmostress, stationary phase entry, glucose depletion, oleate and alcohol; regulated by the HOG and Ras-Pka pathways 
PRP12 D U    Integral inner mitochondrial membrane protein with a role in maintaining mitochondrial nucleoid structure and number; mutants 
exhibit an increased rate of mitochondrial DNA escape; shows some sequence similarity to exonucleases 
RAD14 D U    Protein that recognizes and binds damaged DNA during nucleotide excision repair; subunit of Nucleotide Excision Repair Factor 
1 (NEF1); contains zinc finger motif; homolog of human XPA protein 
HST1 D U    NAD(+)-dependent histone deacetylase; essential subunit of the Sum1p/Rfm1p/Hst1p complex required for ORC-dependent 
silencing and mitotic repression; non-essential subunit of the Set3C deacetylase complex; involved in telomere maintenance 
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MAG2  U    Cytoplasmic protein of unknown function; induced in response to mycotoxin patulin; ubiquitinated protein similar to the human 
ring finger motif protein RNF10; predicted to be involved in repair of alkylated DNA due to interaction with MAG1 
RDH54  U   U DNA-dependent ATPase, stimulates strand exchange by modifying the topology of double-stranded DNA; involved in 
recombinational repair of DNA double-strand breaks during mitosis and meiosis; proposed to be involved in crossover 
interference 
SHP1   U D  UBX (ubiquitin regulatory X) domain-containing protein that regulates Glc7p phosphatase activity and interacts with Cdc48p; 
interacts with ubiquitylated proteins in vivo and is required for degradation of a ubiquitylated model substrate 
YLR346C U    D Putative protein of unknown function found in mitochondria; expression is regulated by transcription factors involved in 
pleiotropic drug resistance, Pdr1p and Yrr1p; YLR346C is not an essential gene 
HO D    U Site-specific endonuclease required for gene conversion at the MAT locus (homothallic switching) through the generation of a 
ds DNA break; expression restricted to mother cells in late G1 as controlled by Swi4p-Swi6p, Swi5p and Ash1p 
SAM4 D    U S-adenosylmethionine-homocysteine methyltransferase, functions along with Mht1p in the conversion of S-adenosylmethionine 
(AdoMet) to methionine to control the methionine/AdoMet ratio 
YHK8 U    D Presumed antiporter of the DHA1 family of multidrug resistance transporters; contains 12 predicted transmembrane spans; 
expression of gene is up-regulated in cells exhibiting reduced susceptibility to azoles 
PRX1 U U   D Mitochondrial peroxiredoxin (1-Cys Prx) with thioredoxin peroxidase activity, has a role in reduction of hydroperoxides; 
reactivation requires Trr2p and glutathione; induced during respiratory growth and oxidative stress; phosphorylated 
PUG1 U    D Plasma membrane protein with roles in the uptake of protoprophyrin IX and the efflux of heme; expression is induced under 
both low-heme and low-oxygen conditions; member of the fungal lipid-translocating exporter (LTE) family of proteins 
RIM4 U U   D Putative RNA-binding protein required for the expression of early and middle sporulation genes 
EAF3 U U   D Esa1p-associated factor, nonessential component of the NuA4 acetyltransferase complex, homologous to Drosophila dosage 
compensation protein MSL3; plays a role in regulating Ty1 transposition 
SPS100  U   D Protein required for spore wall maturation; expressed during sporulation; may be a component of the spore wall; expression also 
induced in cells treated with the mycotoxin patulin 
YJL045W  U   D Minor succinate dehydrogenase isozyme; homologous to Sdh1p, the major isozyme reponsible for the oxidation of succinate and 
transfer of electrons to ubiquinone; induced during the diauxic shift in a Cat8p-dependent manner 
SRX1  U  U D Sulfiredoxin, contributes to oxidative stress resistance by reducing cysteine-sulfinic acid groups in the peroxiredoxin Tsa1p, 
which is formed upon exposure to oxidants; conserved in higher eukaryotes 
GRE1  U   D Hydrophilin of unknown function; stress induced (osmotic, ionic, oxidative, heat shock and heavy metals); regulated by the 
HOG pathway 
SOD2  U   D Mitochondrial superoxide dismutase, protects cells against oxygen toxicity; phosphorylated 
OXR1  U   D Protein of unknown function required for normal levels of resistance to oxidative damage, null mutants are sensitive to hydrogen 
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peroxide; member of a conserved family of proteins found in eukaryotes 
ATG8  U  U D Component of autophagosomes and Cvt vesicles; undergoes conjugation to phosphatidylethanolamine (PE); Atg8p-PE is 
anchored to membranes, is involved in phagophore expansion, and may mediate membrane fusion during autophagosome 
formation 
PAI3  U   D Cytoplasmic proteinase A (Pep4p) inhibitor, dependent on Pbs2p and Hog1p protein kinases for osmotic induction; intrinsically 
unstructured, N-terminal half becomes ordered in the active site of proteinase A upon contact 
ATG1  U   D Protein ser/thr kinase required for vesicle formation in autophagy and the cytoplasm-to-vacuole targeting (Cvt) pathway; 
structurally required for phagophore assembly site formation; during autophagy forms a complex with Atg13p and Atg17p 
YHR138C  U   D Putative protein of unknown function; has similarity to Pbi2p; double null mutant lacking Pbi2p and Yhr138p exhibits highly 
fragmented vacuoles 
ECM29  U U  D Major component of the proteasome; tethers the proteasome core particle to the regulatory particle, and enhances the stability of 
the proteasome 
SER3   U  D 3-phosphoglycerate dehydrogenase, catalyzes the first step in serine and glycine biosynthesis; isozyme of Ser33p 
MDM34   U  D Mitochondrial component of the ERMES complex that links the ER to mitochondria and may promote inter-organellar calcium 
and phospholipid exchange as well as coordinating mitochondrial DNA replication and growth 
ISU1   U  D Conserved protein of the mitochondrial matrix, performs a scaffolding function during assembly of iron-sulfur clusters, interacts 
physically and functionally with yeast frataxin (Yfh1p); isu1 isu2 double mutant is inviable 
PYC1   U  D Pyruvate carboxylase isoform, cytoplasmic enzyme that converts pyruvate to oxaloacetate; highly similar to isoform Pyc2p but 
differentially regulated; mutations in the human homolog are associated with lactic acidosis 
MIS1    D U Mitochondrial C1-tetrahydrofolate synthase, involved in interconversion between different oxidation states of tetrahydrofolate 
(THF); provides activities of formyl-THF synthetase, methenyl-THF cyclohydrolase, and methylene-THF dehydrogenase 
RHR2    D U Constitutively expressed isoform of DL-glycerol-3-phosphatase; involved in glycerol biosynthesis, induced in response to both 
anaerobic and, along with the Hor2p/Gpp2p isoform, osmotic stress 
CTA1    U D Catalase A, breaks down hydrogen peroxide in the peroxisomal matrix formed by acyl-CoA oxidase (Pox1p) during fatty acid 
beta-oxidation 
GRX5    U D Hydroperoxide and superoxide-radical responsive glutathione-dependent oxidoreductase; mitochondrial matrix protein involved 
in the synthesis/assembly of iron-sulfur centers; monothiol glutaredoxin subfamily member along with Grx3p and Grx4p 
CYC7    U D Cytochrome c isoform 2, expressed under hypoxic conditions; electron carrier of the mitochondrial intermembrane space that 
transfers electrons from ubiquinone-cytochrome c oxidoreductase to cytochrome c oxidase during cellular respiration 
EMG1    D U Member of the alpha/beta knot fold methyltransferase superfamily; required for maturation of 18S rRNA and for 40S ribosome 
production; interacts with RNA and with S-adenosylmethionine; associates with spindle/microtubules; forms homodimers 
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GAR1    D U Protein component of the H/ACA snoRNP pseudouridylase complex, involved in the modification and cleavage of the 18S pre-
rRNA 
ZUO1    D U Ribosome-associated chaperone, functions in ribosome biogenesis and, in partnership with Ssz1p and SSb1/2, as a chaperone for 
nascent polypeptide chains; contains a DnaJ domain and functions as a J-protein partner for Ssb1p and Ssb2p 
YNL305C    U D Putative protein of unknown function; green fluorescent protein (GFP)-fusion protein localizes to the vacuole; YNL305C is not 
an essential gene 
MPM1    U D Mitochondrial membrane protein of unknown function, contains no hydrophobic stretches 
YKL091C    U D Putative homolog of Sec14p, which is a phosphatidylinositol/phosphatidylcholine transfer protein involved in lipid metabolism; 
localizes to the nucleus 
CRC1    U D Mitochondrial inner membrane carnitine transporter, required for carnitine-dependent transport of acetyl-CoA from peroxisomes 
to mitochondria during fatty acid beta-oxidation 
UBX6    U D UBX (ubiquitin regulatory X) domain-containing protein that interacts with Cdc48p, transcription is repressed when cells are 
grown in media containing inositol and choline 
YPL189C-A      Cytochrome oxidase assembly factor; null mutation results in respiratory deficiency with specific loss of cytochrome oxidase 
activity; functions downstream of assembly factors Mss51p and Coa1p and interacts with assembly factor Shy1p 
YER053C-
A 
     Putative protein of unknown function; green fluorescent protein (GFP)-fusion protein localizes to the endoplasmic reticulum 
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The RNA sequencing data values obtained for these genes are depicted in table 3.16. 
Table 3.16 Transcript levels of reference genes used for qPCR obtained from RNA 
sequencing data. 
 
Gene Trancription level 
value under 0 
µg/ml gliotoxin 
exposure 
Trancription level 
value under 16 
µg/ml gliotoxin 
exposure 
Trancription level 
value under 64 
µg/ml gliotoxin 
exposure 
 
VMA6 273.08 
 
292.57 
 
258.41 
 
ERG9 234.67 
 
222.58 
 
262.58 
 
  
As the transcript levels of VMA6 and ERG9 remain relatively stable when yeast 
cells are exposed to the two concentrations of gliotoxin, these genes were ideal for use 
as references. Before proceeding with qPCR for the fourteen genes chosen (listed in 
table 3.17), standard curves were constructed for these two reference genes. Standard 
curves were subsequently constructed for the fourteen genes of interest. The production 
of standard curves allowed the PCR reaction efficiency to be considered in the 
generation of results, as the multiplication factor is not always two after each PCR cycle. 
The fourteen genes of interest and their fold change according to the RNA sequencing 
data are listed in table 3.17. 
 qPCR was carried out using primers for these genes and methodology described 
in sections 2.19.1 and 2.23.5. To make the analyses more accurate, advanced relative 
quantification was performed to compare transcript levels of a specific gene when cells 
are exposed to the concentrations of the toxin described above. This involved 
importation of reference gene transcript levels and standard curves, which were used in 
generation of results. 
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Table 3.17 Fold change recorded in RNA sequencing data of fourteen genes used 
for qPCR. + indicates upregulation and – indicates downregulation. 
 
Gene Name Fold change when 
exposed to 16 µg/ml 
gliotoxin 
Fold change when 
exposed to 64 µg/ml 
gliotoxin 
 
MET7 +1.5 +1.5 
SAM1 +1.8 +9.5 
MET6 +2.9 +8.7 
MET16 +4.6 +13.6 
MET17 +5.5 +8.5 
MET2 +2.9 +4.2 
MET14 +7.4 +13.6 
MET22 +2.98 +4.8 
HBN1 +3.9 +11.0 
JEN1 -33.7 -32.8 
SIP18 -62.7 -131.2 
BDH2 -6.3 -10.2 
SDH2 
-33.0 -18.2 
MLS1 -34.4 -17.9 
 
Figures 3.62-3.68 illustrate the comparison of transcript levels of genes involved in the 
sulfur amino acid biosynthesis pathway (figure 3.60), identified from transcriptomic 
data as a process upregulated by gliotoxin exposure. 
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Figure 3.62 Fold changes in the level of transcription of MET7 in response to 16 
and 64 µg/ml gliotoxin exposure.  
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In figure 3.62 it can be observed that when cells are exposed to 16 µg/ml gliotoxin, 
there is a 2.095-fold increase in the level of transcription of MET7. However under 
exposure to 64 µg/ml gliotoxin, the cellular MET7 RNA level decreases to 0.4524 of the 
level seen without gliotoxin exposure. This is equivalent to a 2.2-fold decrease in the 
level of transcription. 
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Figure 3.63 Fold changes in the level of transcription of SAM1 in response to 16 
and 64 µg/ml gliotoxin exposure.  
 
It can be seen in the figure above that under 16 µg/ml gliotoxin exposure, the 
transcription level of SAM1 increases 2.595-fold. Under an exposure concentration of 
64 µg/ml, there is an increase to 12.94-fold observed in wild-type. 
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Figure 3.64 Fold changes in the level of transcription of MET6  in response to 16 
and 64 µg/ml gliotoxin exposure. 
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The transcription level of MET6 increases significantly in the presence of both 
concentrations of the metabolite under investigation. There is a 4.284-fold increase at 
the lower concentration of gliotoxin and a 3.587-fold increase at the higher 
concentration, as illustrated by figure 3.64. 
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Figure 3.65 Fold changes in the level of transcription of MET16  in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
Figure 3.65 presents the upregulation of MET16 when cells are treated with gliotoxin. In 
the presence of 16 µg/ml and 64 µg/ml gliotoxin, the transcription level of MET16 
increases 4.158-fold and 1.238-fold respectively. 
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Figure 3.66 Fold changes in the level of transcription of MET17  in response to 16 
and 64 µg/ml gliotoxin exposure. 
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It can be seen above that there is an 8.808-fold increase in MET17 transcription under 
the lower gliotoxin concentration and an increase of 2.387-fold under the higher 
concentration.   
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Figure 3.67 Fold changes in the level of transcription of MET2  in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
When cells are exposed to 16 µg/ml gliotoxin, the level of MET2 transcription increases 
1.434-fold and under 64 µg/ml exposure, 1.886-fold. This data is presented in the above 
figure. 
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Figure 3.68 Fold changes in the level of transcription of MET14  in response to 16 
and 64 µg/ml gliotoxin exposure. 
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 Figure 3.68 depicts that under 16 and 64 µg/ml gliotoxin, MET14 is transcribed 
at levels 5.398- and 1.886-fold higher than normal respectively. 
These results, presented in figures 3.62-3.68 demonstrate that gliotoxin does indeed 
induce a general increase in transcription of many genes involved in the sulfur amino 
acid biosynthesis pathway. A comparison of RNA sequencing data and qPCR data is 
depicted in figure 3.69. All changes are documented as fold-change. 
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Figure 3.69 Fold change in transcription of sulfur amino acid biosynthesis genes 
under gliotoxin exposure documented from RNA sequencing and qPCR. Blue 
pattern represents 16 µg/ml and orange represents 64 µg/ml.   
 
The above figure shows that both the RNA sequencing data and qPCR data support one 
another. The two methods of analysis demonstrate the upregulation of genes involved in 
sulfur amino acid biosynthesis. Discrepancy in the degree of upregulation is likely to be 
due to complications linked to a high level of cell death, particularly in the presence of 
64 µg/ml gliotoxin. 
 In addition to the sulfur amino acid biosynthesis genes, advanced relative 
quantification PCR was also carried out on some genes found to be highly up- and 
downregulated transcriptionally under gliotoxin exposure. Figures 3.70-3.71 illustrate 
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the comparison of transcription of genes identified from transcriptomic data as being 
upregulated by gliotoxin exposure. 
 
Figure 3.70 Fold changes in the level of transcription of HBN1 in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
HBN1 was selected for qPCR as it was identified from RNA sequencing data as a gene 
that is highly upregulated in response to gliotoxin exposure. qPCR illustrated this gene 
to be upregulated 6.212-fold in the presence of the lower toxin concentration and 1.886-
fold in the presence of the higher. 
 
 
Figure 3.71 Fold changes in the level of transcription of MET22 in response to 16 
and 64 µg/ml gliotoxin exposure. 
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Relative analysis was carried out on MET22 due to its involvement in sulfur amino acid 
biosynthesis regulation. qPCR results showed that it undergoes a 4.213- and 1.986-fold 
increase in transcription under exposure to 16 and 64 µg/ml gliotoxin respectively, this 
is shown in the above figure.   
 Again, we graphically presented qPCR and RNA sequencing data together in 
order to make an accurate comparison. This is depicted in figure 3.72, and good 
correlation is seen again. 
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Figure 3.72 Fold change in transcription of MET22 and HBN1 under gliotoxin 
exposure documented from RNA sequencing and qPCR. Blue pattern represents 16 
µg/ml and orange represents 64 µg/ml.  
 
 Figures 3.73-3.77 illustrate the comparison of transcription of genes identified 
from transcriptomic data as being downregulated by gliotoxin exposure. 
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Figure 3.73 Fold changes in the level of transcription of JEN1 in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
The qPCR data reflected an 1.302-fold increase in the transcription of JEN1 in response 
to 16 µg/ml gliotoxin and a 1.609-fold decrease in response to 64 µg/ml gliotoxin 
exposure. 
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Figure 3.74 Fold changes in the level of transcription of SIP18 in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
In the above figure, it can be seen that the SIP18 transcription level documented from 
qPCR does not correlate with that of the RNA sequencing analysis. qPCR depicted 
1.219- and 3.437-fold increases in SIP18 transcription in response to 16 and 64 µg/ml 
gliotoxin respectively.    
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Figure 3.75 Fold changes in the level of transcription of BDH2 in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
The BDH2 qPCR data from also contradicted transcriptome data as increases in 
transcription of 1.851- and 1.574-fold were seen in the presence of lower and higher 
gliotoxin levels respectively. 
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Figure 3.76 Fold changes in the level of transcription of SDH2 in response to 16 
and 64 µg/ml gliotoxin exposure. 
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Similar discrepancies in results from the two methods of analysis were observed for 
SDH2. SDH2 qPCR demonstrated a 1.428-fold increase in transcription in the presence 
of 16 µg/ml gliotoxin and 1.886-fold in the under 64 µg/ml exposure.   
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Figure 3.77 Fold changes in the level of transcription of MLS1 in response to 16 
and 64 µg/ml gliotoxin exposure. 
 
As was seen for the other genes in this category, MLS1 qPCR illustrated an unexpected 
increase in transcription of 1.428- and 1.886-fold under 16 and 64 µg/ml gliotoxin 
exposure respectively. 
Figure 3.78 shows the comparison of the two modes of analysis and their respective 
results. These genes were analysed based on the fact that RNA sequencing data 
determined them to be downregulated in response to gliotoxin exposure. However, 
JEN1, SIP18, BDH2, SDH2 and MLS1 were shown to be upregulated under gliotoxin 
exposure by qPCR, thus a lack of correlation was seen in the assessment of these genes.  
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Figure 3.78 Comparison of expression levels of JEN1, SIP18, BDH2, SDH2 and 
MLS1 in response to gliotoxin exposure using data from RNA sequencing and 
qPCR. Blue pattern represents 16 µg/ml and orange represents 64 µg/ml.  
 
3.6.2 Using proteomics to explore the mechanism of action of gliotoxin 
 We employed two-dimensional gel electrophoresis to explore the global 
proteomic yeast response to gliotoxin. Wild-type G600 yeast were cultured and exposed 
to gliotoxin at concentrations of 0, 16 and 64 µg/ml (as for transcriptome analysis) for 1 
hr. before lysates were extracted. Proteins were precipitated using trichloroacetic acid 
(TCA), quantified and were isoelectrically focused on 24 cm, pH 3-10 IPG strips. After 
focusing, protein was separated based on weight by gel electrophoresis, followed by 
colloidal coomassie staining and ProgenesisTM same spot software analysis. This 
programme identified protein spots showing alterations in expression levels under 
different gliotoxin treatments. Protein from cells exposed to 0 and 16 µg/ml gliotoxin 
were compared and those exposed to 0 and 64 µg/ml. Subsequent to this, protein spots 
of interest were excised and Liquid Chromatography Mass Spectrometry (LC-MS) was 
used to identify proteins extracted. This process allowed us to examine the overall 
response to gliotoxin initiated by yeast via the production of specific proteins. 
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3.6.2.1 Analysis of the effect of 16 µg/ml gliotoxin exposure on global protein 
expression in yeast cells 
 
Separated proteins isolated from cells that were exposed to 16 µg/ml gliotoxin 
were compared to wild-type proteins using ProgenesisTM same spot software. 500 µg of 
protein was analysed for each sample in duplicate. 29 protein spots were identified 
based on their differential expression level induced by exposure to 16 µg/ml gliotoxin. 
Figure 3.79 illustrates the pattern of peptide spots typically seen on one of the gels 
containing two-dimensionally separated proteins. Circled spots are proteins identified as 
differentially expressed, either up- or downregulated in response to 16 µg/ml gliotoxin 
exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.79 2-D gel electrophoresis separated proteins from G600 cells. Spots 
circled represent proteins that undergo an increase or decrease in level of expression in 
response to 16 µg/ml gliotoxin exposure. 
 
The protein spots circled were then excised from the above gel, prepared as described in 
section 2.27, and sequenced using LC-MS. Mascot search engine was subsequently 
used to identify these yeast proteins, percentage coverage was calculated and identity 
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scores were assigned. Table 3.18 outlines details relating to the expression of the 
proteins of interest and compares results to transcriptome data analysed previously. 
From table 3.18 it can be seen that yeast global proteomic responses generally 
correlate well with data obtained from transcriptome analysis. Of significant note, 
Cys3p and Cys4p were expressed more than 2-fold higher than normal when cells were 
treated with 16 µg/ml gliotoxin. Under the same treatment, the genes CYS3 and CYS4 
that encode these proteins were found to be upregulated 4.1- and 1.6-fold. Not only 
were the sulfur amino acid and closely linked glutathione biosynthesis pathways 
discovered to be upregulated at both the RNA and protein level, the same was 
ascertained for the glucose fermentation pathway. In response to the lower level of 
gliotoxin used, Fba1p was increased 2.7-fold and transcriptionally 1.7-fold. Tdh1p was 
upregulated at the protein and RNA level 3-fold and 1.9-fold respectively. Mascot 
identified three upregulated proteins as Tdh3p isoforms. Taking the average value 
representing an increase in Tdh3p expression, it can be said that this protein is 
upregulated 2.5-fold under exposure to 16 µg/ml gliotoxin and 2.7-fold from 
transcriptomic reports. Additionally, three different upregulated proteins were identified 
as Pgk1p isoforms. For this protein, the average increase was seen to be 2.2-fold and 
this correlated with the RNA sequencing result which showed a 2.5-fold increase. Eight 
proteins were identified by Mascot as being Eno2p protein, of which seven were 
upregulated. Of these seven the average fold increase was 3. In support of this result, the 
ENO2 gene was transcriptionally upregulated 2.6-fold in response to the lower 
concentration of gliotoxin used. 
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Table 3.18 Yeast proteins identified as undergoing an increase or decrease in expression under 16 µg/ml gliotoxin exposure.  
 
Spot 
No. 
 
Protein 
Name 
Fold 
Change 
Change PI Value Molecular Mass 
(Da) 
Peptides 
Matched 
Mascot Score Coverage (%) Protein Function RNA seq 
Results 
1 
 
 
 
Ssb2 1.6 
 
 
 
 
Up- 
 
 
 
 
5.37 66668 11 (2) 558 24 Cytoplasmic ATPase that is a ribosome-
associated molecular chaperone, functions with 
J-protein partner Zuo1p; may be involved in the 
folding of newly-synthesized polypeptide 
chains; member of the HSP70 family; homolog 
of SSB1 
Upregulated 
2 
 
 
 
Eno2 3 
 
 
 
 
Down- 
 
 
 
 
5.67 46942 6 (0) 273 7 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
3 
 
 
 
 
Ssb1 3.6 
 
 
 
 
 
Up- 
 
 
 
 
 
5.32 66732 19 (5) 983 44 Cytoplasmic ATPase that is a ribosome-
associated molecular chaperone, functions with 
J-protein partner Zuo1p; may be involved in 
folding of newly-made polypeptide chains; 
member of the HSP70 family; interacts with 
phosphatase subunit Reg1p 
Upregulated 
4 
 
 
 
Ssa2 2 
 
 
 
 
Up- 
 
 
 
 
4.95 69599 12 (2) 436 16 ATP binding protein involved in protein folding 
and vacuolar import of proteins; member of heat 
shock protein 70 (HSP70) family; associated 
with the chaperonin-containing T-complex; 
present in the cytoplasm, vacuolar membrane 
and cell wall 
Upregulated 
5 
 
 
 
 
Ssb1 1.7 
 
 
 
 
 
Down- 
 
 
 
 
 
5.32 66561 2 (0) 112 4 Cytoplasmic ATPase that is a ribosome-
associated molecular chaperone, functions with 
J-protein partner Zuo1p; may be involved in 
folding of newly-made polypeptide chains; 
member of the HSP70 family; interacts with 
phosphatase subunit Reg1p 
Upregulated 
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6 
 
 
 
 
Ald6 4.2 
 
 
 
 
 
Up- 
 
 
 
 
 
5.31 54779 6 (1) 297 14 Cytosolic aldehyde dehydrogenase, activated by 
Mg2+ and utilizes NADP+ as the preferred 
coenzyme; required for conversion of 
acetaldehyde to acetate; constitutively 
expressed; locates to the mitochondrial outer 
surface upon oxidative stress 
Upregulated 
7 
 
 
Rhr2 2.8 
 
 
 
Up- 
 
 
 
5.35 28100 5 (1) 247 22 Constitutively expressed isoform of DL-
glycerol-3-phosphatase; involved in glycerol 
biosynthesis, induced in response to both 
anaerobic and, along with the Hor2p/Gpp2p 
isoform, osmotic stress 
Upregulated 
8 
 
 
 
Pdc1 2.4 
 
 
 
 
Up- 
 
 
 
 
5.8 61689 5(1) 279 15 Major of three pyruvate decarboxylase 
isozymes, key enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde; subject 
to glucose-, ethanol-, and autoregulation; 
involved in amino acid catabolism 
Upregulated 
9 
 
 
 
Pdc1 2.9 
 
 
 
 
Up- 
 
 
 
 
5.74 46909 4 (2) 234 9 Major of three pyruvate decarboxylase 
isozymes, key enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde; subject 
to glucose-, ethanol-, and autoregulation; 
involved in amino acid catabolism 
Upregulated 
10 
 
 
 
 
Fba1 2.7 
 
 
 
 
 
Up-   
 
 
 
 
 
5.51 39881 4 (0) 199 9 Fructose 1,6-bisphosphate aldolase, required for 
glycolysis and gluconeogenesis; catalyzes 
conversion of fructose 1,6 bisphosphate to 
glyceraldehyde-3-P and dihydroxyacetone-P; 
locates to mitochondrial outer surface upon 
oxidative stress 
Upregulated 
11 
 
 
 
Asc1 2.6 
 
 
 
 
Up- 
 
 
 
 
5.8 34898 5 (1) 268 16 G-protein beta subunit and guanine nucleotide 
dissociation inhibitor for Gpa2p; ortholog of 
RACK1 that inhibits translation; core 
component of the small (40S) ribosomal subunit; 
represses Gcn4p in the absence of amino acid 
starvation 
Upregulated 
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12 
 
 
 
 
 
Eno2 2.8 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 13 (3) 697 26 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
13 
 
 
 
Eno2 3.3 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 4(2) 224 7 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
14 
 
 
 
Eno2 3.2 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 4(2) 224 7 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
15 
 
 
 
Eno2 2.3 
 
 
 
 
Up- 
 
 
 
 
5.67 40942 8 (0) 384 13 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
16 
 
 
Rps3 2.2 
 
 
 
Up- 
 
 
 
9.42 26543 2 (1) 120 16 Protein component of the small (40S)  
ribosomal subunit, has apurinic/apyrimidinic 
(AP) endonuclease activity; essential for 
viability; has similarity to E. coli S3 and rat S3 
ribosomal proteins 
Upregulated 
17 
 
 
 
Eno2 3.7 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 47 (10) 1145 46 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
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18 
 
 
 
Eno2 3 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 11(4) 356 20 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
19 
 
 
 
Eno2 3 
 
 
 
 
Up- 
 
 
 
 
5.67 46942 12 (2) 396 16 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
Upregulated 
20 
 
 
 
Tdh3 2 
 
 
 
 
Up- 
 
 
 
 
6.46 35838 6 (0) 205 17 Glyceraldehyde-3-phosphate dehydrogenase, 
isozyme 3, involved in glycolysis and 
gluconeogenesis; tetramer that catalyzes the 
reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm 
and cell wall 
Upregulated 
21 
 
 
 
Cys3 2.4 
 
 
 
Up- 
 
 
 
6.06 42516 2 (0) 95 5 Cystathionine gamma-lyase, catalyzes one of the 
two reactions involved in the transsulfuration 
pathway that yields cysteine from homocysteine 
with the intermediary formation of cystathionine 
Upregulated 
22 
 
 
 
Tdh3 2.6 
 
 
 
 
Up- 
 
 
 
 
6.46 35838 3 (0) 78 5 Glyceraldehyde-3-phosphate dehydrogenase, 
isozyme 3, involved in glycolysis and 
gluconeogenesis; tetramer that catalyzes the 
reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm 
and cell wall 
Upregulated 
23 
 
 
 
Pgk1 2.2 
 
 
 
 
Up- 
 
 
 
 
7.11 44768 4 (0) 203 9 3-phosphoglycerate kinase, catalyzes transfer of 
high-energy phosphoryl groups from the acyl 
phosphate of 1,3-bisphosphoglycerate to ADP to 
produce ATP; key enzyme in glycolysis and 
gluconeogenesis 
Upregulated 
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24 
 
 
 
 
Cys4 2.6 
 
 
 
 
 
Up- 
 
 
 
 
 
6.25 56074 6 (1) 271 10 Cystathionine beta-synthase, catalyzes synthesis 
of cystathionine from serine and homocysteine, 
the first committed step in cysteine biosynthesis; 
responsible for hydrogen sulfide generation; 
mutations in human ortholog cause 
homocystinuria 
Upregulated 
25 Tdh1 3 
 
Up- 
 
6.25 35825 4 (0) 131 11 Involved in superpathway of glucose 
fermentation 
Upregulated 
26 Ilv5 2.2 
 
Up- 
 
9.06 44585 1 (1) 75 2 Bifunctional acetohydroxyacid reductoisomerase 
and mtDNA binding protein; involved in 
branched-chain amino acid biosynthesis and 
maintenance of wild-type mitochondrial DNA; 
found in mitochondrial nucleoids 
Upregulated 
27 
 
 
 
Tdh3 2.9 
 
 
 
 
Up- 
 
 
 
 
6.46 35838 17(0) 496 26 Glyceraldehyde-3-phosphate dehydrogenase, 
isozyme 3, involved in glycolysis and 
gluconeogenesis; tetramer that catalyzes the 
reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm 
and cell wall 
Upregulated 
28 
 
 
 
Pgk1 1.5 
 
 
 
 
Up- 
 
 
 
 
8 44595 9(0) 314 22 3-phosphoglycerate kinase, catalyzes transfer of 
high-energy phosphoryl groups from the acyl 
phosphate of 1,3-bisphosphoglycerate to ADP to 
produce ATP; key enzyme in glycolysis and 
gluconeogenesis 
Upregulated 
29 
 
 
 
Pgk1 3 
 
 
 
 
Up- 
 
 
 
 
7.11 44768 15 (0) 530 25 3-phosphoglycerate kinase, catalyzes transfer of 
high-energy phosphoryl groups from the acyl 
phosphate of 1,3-bisphosphoglycerate to ADP to 
produce ATP; key enzyme in glycolysis and 
gluconeogenesis 
Upregulated 
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Two proteins were found to be isoforms of Pdc1p, for which the average 
increase was 2.7-fold. The gene encoding this protein underwent a 3.2-fold increase in 
transcription. Finally, ALD6 was transcriptionally increased 1.1-fold in response to 16 
µg/ml gliotoxin while the Ald6p it encodes was upregulated 4.2-fold.      
Only two of the twenty-nine proteins of interest underwent a decrease in 
expression in response to the lower concentration of gliotoxin, these were identified to 
be Eno2p and Ssb1p. The Eno2p downregulatory result is probably due to a flaw in 
identification or inaccuracy in the technique, as Eno2p was largely recorded as being 
upregulated (described above). Ssb1p is one member of a class of cytosolic heat-shock 
proteins, Ssb proteins, that associate with ribosome-bound nascent polypeptides and 
appear to be involved in correct folding of the protein upon emergence from the 
ribosome (Craig et al., 1993, Gautschi et al., 2002, Kim and Craig, 2005). Our finding 
outlining the downregulation of this protein could be indicative of an increase in yeast 
cell death under gliotoxin exposure. It may be the case that cells cannot carry out 
normal functions to the full extent and protein folding may be one of the processes  
negatively effected. However, another protein was also identified as an Ssb1p isoform, 
and this was shown to undergo 3.6-fold upregulation. This second Ssb1p result is more 
in line with RNA sequencing data which reports SSB1 to be upregulated 2.9-fold under 
16 µg/ml gliotoxin exposure. Two-dimensional gel analysis exposed a change in the 
level of another Ssb protein, Ssb2p in the presence of the lower concentration of 
gliotoxin. Ssb2p is 99% identical to Ssb1p (Craig and Jacobsen, 1985, Craig et al., 1993) 
and was found to undergo a 1.6-fold increase in expression in response to the toxin. 
This correlates with the RNA sequencing data which shows the SSB2 gene encoding 
this protein to be upregulated 2.7-fold. Ssa and Ssb proteins are part of the Hsp70p 
family, a 70 kDA cytosolic protein family which is one of the major molecular 
chaperone groups (Ingolia et al., 1982, Werner-Washburne et al., 1987, Craig et al., 
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1993). We found that Ssa2p, one of the four Ssa subfamily members, was increased 2-
fold in response to 16 µg/ml gliotoxin treatment and was transcriptomically elevated 
2.5-fold. Although Ssa and Ssb proteins are part of the Hsp70 protein family, they are 
functionally divergent in many repects, one paramount example being the absolute 
requirement for at least one Ssa protein for cell viability (Werner-Washburne et al., 
1987, Nelson et al., 1992, Chernoff et al., 1999). It may be the case that the lower 
concentration of gliotoxin used enhances both Hsp70 RNA and protein production. 
Another protein found undergo a change in level of expression here was Rhr2p, also 
known as Gpp1p, which is involved in glycerol biosynthesis (Norbeck et al., 1996). 
Absence of RHR2 has previously been shown to result in increased sensitivity to OS 
(Pahl et al., 1996, Pahlman et al., 2001, Wei et al., 2009). We found that in response to 
16 µg/ml gliotoxin, Rhr2p is expressed 2.8-fold more and is transcriptionally 
upregulated 2.7-fold. Upregulation of RHR2 and Rhr2p could be indicative of gliotoxin 
causing cellular OS. As shown in section 3.6.1.1 and clearly depicted in table 3.5, from 
the RNA sequencing data the upregulation of many genes encoding ribosomal subunits 
was observed. The proteomic analysis data here demonstrates the 2.6- and 2.2-fold 
increases in expression of Asc1p and Rps3p respectively. These are both protein 
components of the small ribosomal subunit (Planta and Mager, 1998, Baum et al., 2004) 
and we found that the ASC1 and RPS3 genes encoding these proteins undergo increases 
in transcription of 3.6- and 3.2-fold respectively. This supports the observations made 
from the transcriptomic data, whereby it appears the cells attempt to develop more 
ribosomes when treated with 16 µg/ml gliotoxin. Interstingly, Asc1p is also known to be 
involved in the glucose signalling pathway (Zeller et al., 2007), which may in turn be a 
key intermediate in the upregulation of the glucose fermentation pathway 
aforementioned. The final protein which was found to have altered expression in 
response to this concentration of gliotoxin was Ilv5p. This highly-expressed protein is 
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involved in isoleucine and valine biosynthesis and also plays an important role in 
maintaining mitochondrial genome stability (Petersen and Holmberg, 1986, Zelenaya-
Troitskaya et al., 1995). We found that Ilv5p and ILV5 were upregulated 2.2-fold and 
1.7-fold respectively. Gliotoxin is known to cause DNA damage (Eichner et al., 1988), 
perhaps the increase in production of this protein combats the effects of gliotoxin as 
cells attempt to maintain internal stability.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.80 Comparison of gels containing separated proteins from cells exposed to 
0 and 16 µg/ml gliotoxin.  
 
The gels above contain two-dimensionally separated proteins from cells exposed to 0 
and 16 µg/ml gliotoxin. Differential protein expression represents the yeast global 
proteomic response to this gliotoxin concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.81 Representation of one protein that underwent a decrease in expression, 
Ssb1p (l) and one that underwent an increase in expression, Cys3p (r), in the 
presence of 16 µg/ml gliotoxin. 
 
Figure 3.81 shows an example of one down- and one upregulated protein. It is clear that 
for Ssb1p, the protein spot on the left is more intense than that on the right, illustrating 
5) Ssb1p 21) Cys3p
0 µg/ml gliotoxin0 µg/ml gliotoxin 16 µg/ml gliotoxin 16 µg/ml gliotoxin
0 µg/ml GT exposure 16 µg/ml GT exposure
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downregulation of the protein in the presence of 16 µg/ml gliotoxin. Cys3p is visibly 
more intense in the protein spot in the right as it undergoes an increase in expression 
under the same gliotoxin exposure concentration. 
 
3.6.2.2 Analysis of the effect of 64 µg/ml gliotoxin exposure on global protein 
expression in yeast cells 
 
Separated proteins from cells that were treated with 64 µg/ml gliotoxin were 
compared to wild-type expressed proteins using ProgenesisTM same spot software. 350 
µg of protein was analysed for each sample in triplicate. 22 protein spots were identified 
based on their different levels of expression when cells were exposed to 64 µg/ml 
gliotoxin. Figure 3.82 illustrates the typical pattern of protein spots on one of the gels 
containing two-dimensionally separated proteins. As before, the circled proteins are 
those which were found to have alterations in intensity level when comparing proteins 
from the two treatment cultures. This demonstrated that these proteins underwent a 
change in levels of expression when cells were exposed to 64 µ/ml gliotoxin. 
The circled protein spots were excised from the gel. Peptides were retrieved, 
trypsin digested and underwent LC-MS and Mascot analysis, leading to identification of 
the yeast proteins of interest. Of these 22 differentially expressed proteins, 15 were 
upregulated and 7 were downregulated. These proteins, along with their descriptions are 
listed in table table 3.19. Included in this table is comparison of proteomic alterations 
with that documented by transcriptomics. 
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Figure 3.82 Separated proteins from G600 cells. Spots circled represent proteins that 
undergo an increase or decrease in level of expression in response to 64 µg/ml gliotoxin 
exposure. 
 
 The data outlined in the table below also concurs to some degree with the RNA 
sequencing analysis. With reference to the sulfur amino acid and glutathione 
biosynthesis pathways, the upregulation in response to 64 µg/ml gliotoxin of both 
Cys4p and Met17p was detected at the RNA and protein level. CYS3 underwent a 3.8-
fold increase in transcription and a 1.5-fold increase in protein expression. MET17 was 
upregulated 8.5-fold and the protein it encodes 1.8-fold.  
As was found with proteomic and RNA sequencing data for cells exposed to 16 
µg/ml gliotoxin, some genes and proteins involved in the glucose fermentation pathway 
also underwent an increase in expression in response to 64 µg/ml gliotoxin exposure. 
Three proteins were identified as upregulated Pdc1p and the average fold increase for 
these was 1.6. The gene PDC1 encoding this protein was documented in transcriptome 
data as being upregulated 1.9-fold.
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Table 3.19 Yeast proteins identified as undergoing an increase or decrease in expression under 64 µg/ml gliotoxin exposure. 
 
Spot 
No. 
Protein 
Name 
Fold 
Change 
Change PI Value Molecular 
Mass (Da) 
Peptides 
Matched 
Mascot 
Score 
Coverage 
(%) 
Protein Function RNA seq 
Results 
1 Pdc1 1.6 Up- 5.8 61689 14(2) 602 28 Major of three pyruvate decarboxylase isozymes, key enzyme 
in alcoholic fermentation, decarboxylates pyruvate to 
acetaldehyde; subject to glucose-, ethanol-, and 
autoregulation; involved in amino acid catabolism 
Upregulated 
2 Ecm10 1.6 Up- 5.9 70042 4(1) 69 8 Heat shock protein of the Hsp70 family, localized in 
mitochondrial nucleoids, plays a role in protein translocation, 
interacts with Mge1p in an ATP-dependent manner; 
overexpression induces extensive mitochondrial DNA 
aggregations 
Downregulated 
3 Pdc1 1.5 Up- 5.8 61689 17(3) 771 34 Major of three pyruvate decarboxylase isozymes, key enzyme 
in alcoholic fermentation, decarboxylates pyruvate to 
acetaldehyde; subject to glucose-, ethanol-, and 
autoregulation; involved in amino acid catabolism 
Upregulated 
4 Eno2 1.5 Up- 5.67 46943 5(3) 297 13 Enolase II, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate 
during glycolysis and the reverse reaction during 
gluconeogenesis; expression is induced in response to glucose 
Upregulated 
5 Rph1 4.3 Up- 9.1 71516 4(0) 32 4 JmjC domain-containing histone demethylase which can 
specifically demethylate H3K36 tri- and dimethyl 
modification states; transcriptional repressor of PHR1; Rph1p 
phosphorylation during DNA damage is under control of the 
MEC1-RAD53 pathway 
Downregulated 
6 Adh1 1.3 Down- 6.21 37290 3(0) 108 6 Alcohol dehydrogenase, fermentative isozyme active as 
homo- or heterotetramers; required for the reduction of 
acetaldehyde to ethanol, the last step in the glycolytic 
pathway 
Upregulated 
7 Pgk1 1.3 Down- 7.8 23238 2(0) 99 10 3-phosphoglycerate kinase, catalyzes transfer of high-energy 
phosphoryl groups from the acyl phosphate of 1,3-
bisphosphoglycerate to ADP to produce ATP; key enzyme in 
glycolysis and gluconeogenesis 
Upregulated 
8 Tdh3 2.1 Down- 6.46 35840 4(0) 168 8 Glyceraldehyde-3-phosphate dehydrogenase, isozyme 3, 
involved in glycolysis and gluconeogenesis; tetramer that 
catalyzes the reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm and cell wall 
Upregulated 
2
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9 Ilv5 
 
 
 
 
1.9 Down- 9.1 44515 2(0) 122 5 Bifunctional acetohydroxyacid  reductoisomerase and 
mtDNA binding protein; involved in branched-chain amino 
acid biosynthesis and maintenance of wild-type mitochondrial 
DNA; found in mitochondrial nucleoids 
Upregulated 
10 Pgk1 1.6 Up- 7.1 44769 9(2) 62 13 3-phosphoglycerate kinase, catalyzes transfer of high-energy 
phosphoryl groups from the acyl phosphate of 1,3-
bisphosphoglycerate to ADP to produce ATP; key enzyme in 
glycolysis and gluconeogenesis 
Upregulated 
11 Rps0ap 1.7 Up- 4.65 28065 2(0) 77 5 Protein component of the small (40S) ribosomal subunit, 
nearly identical to Rps0Bp; required for maturation of 18S 
rRNA along with Rps0Bp; deletion of either RPS0 gene 
reduces growth rate, deletion of both genes is lethal 
Upregulated 
12 SceI 1.9 Up- 5.41 70757 3(0) 140 7 I-SceI DNA endonuclease, encoded by the mitochondrial 
group I intron of the 21S_rRNA gene; mediates gene 
conversion that propagates the intron into intron-less copies 
of the 21S_rRNA gene 
N/A 
13 Wtm1 1.9 Up- 5.18 48469 4(1) 214 17 Transcriptional modulator involved in regulation of meiosis, 
silencing, and expression of RNR genes; required for nuclear 
localization of the ribonucleotide reductase small subunit 
Rnr2p and Rnr4p; contains WD repeats 
Downregulated 
14 Ssa1 1.6 Up- 5.5 42014 4(1) 78 11 ATPase involved in protein folding and nuclear localization 
signal (NLS)-directed nuclear transport; member of heat 
shock protein 70 (HSP70) family; forms a chaperone complex 
with Ydj1p; localized to the nucleus, cytoplasm, and cell wall 
Upregulated 
15 Pdc1 1.6 Up- 5.8 60384 4(1) 268 13 Enzyme in alcoholic fermentation, decarboxylates pyruvate to 
acetaldehyde, regulation is glucose- and ethanol-dependent 
Upregulated 
16 Cys4 1.5 Up- 6.25 56045 2(1) 138 6 Cystathionine beta-synthase, catalyzes synthesis of 
cystathionine from serine and homocysteine, the first 
committed step in cysteine biosynthesis; responsible for 
hydrogen sulfide generation; mutations in human ortholog 
cause homocystinuria 
Upregulated 
17 Eno2 2 Up- 5.67 46943 3(2) 220 12 Enolase II, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate 
during glycolysis and the reverse reaction during 
gluconeogenesis; expression is induced in response to glucose 
Upregulated 
18 Met17 1.8 Up- 5.97 48700 1(1) 81 3 Methionine and cysteine synthase (O-acetyl homoserine-O-
acetyl serine sulfhydrylase), required for sulfur amino acid 
synthesis 
Upregulated 
2
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19 Rhr2 1.7 Down- 5.24 28103 2(0) 97 9 Constitutively expressed isoform of DL-glycerol-3-
phosphatase; involved in glycerol biosynthesis, induced in 
response to both anaerobic and, along with the Hor2p/Gpp2p 
isoform, osmotic stress 
Upregulated 
20 Pgk1 1.3 Down- 7.11 44769 13(4) 93 22 3-phosphoglycerate kinase, catalyzes transfer of high-energy 
phosphoryl groups from the acyl phosphate of 1,3-
bisphosphoglycerate to ADP to produce ATP; key enzyme in 
glycolysis and gluconeogenesis 
Upregulated 
21 Eno2 1.7 Up- 5.67 46943 1(1) 83 4 Enolase II, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate 
during glycolysis and the reverse reaction during 
gluconeogenesis; expression is induced in response to glucose 
Upregulated 
22 Tef2 1.4 Down- 9.1 50407 5(2) 90 8 Translational elongation factor EF-1 alpha; also encoded by 
TEF1; functions in the binding reaction of aminoacyl-tRNA 
(AA-tRNA) to ribosomes; may also have a role in tRNA re-
export from the nucleus 
Upregulated 
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 Eno2p identity was assigned to three proteins, all of which were upregulated. 
The average fold increase was calculated to be 1.7, which corresponded with the 3.4-
fold transcriptional increase reported for ENO2 gene.    
 In contrast, the Tdh3 proteomic and transcriptomic responses contradicted one 
another. Tdh3p was found to be 2.1-fold downregulated under 64 µg/ml gliotoxin 
exposure, while the TDH3 gene was upregulated 2.2-fold more than normal. A similar 
scenario was noted for Pgk1p. Three proteins were determined to be Pgk1p. Two of 
these were observed as downregulated and one as upregulated. If the majority result was 
taken, it could be said that this protein undergoes an average 1.3-fold decrease in 
expression in response to the higher toxin concentration. However, this would then 
dispute the transcriptome data which recorded a 2.2-fold increase in the PGK1 gene. 
There were also conflicting results for the alcohol dehydrogenase Adh1p. The protein 
was reported by ProgenesisTM as being 1.3-fold downregulated while the gene ADH1 
gene encoding the protein was found in the RNA sequencing data to be transcriptionally 
upregulated 3-fold. These last three results are indicative of the fact that there is an 
added complication with analysis of effects of the higher concentration of gliotoxin, due 
to the high level of cell death that occurs. Rhr2p was discovered to be downregulated in 
response to the higher level of gliotoxin, while previously it was upregulated under 
exposure to the lower gliotoxin concentration. Transcriptionally, the RHR2 gene was 
upregulated 3.2-fold in response to 64 µg/ml gliotoxin exposure. In section 3.6.2.1, the 
increase in Hsp70 genes and proteins was discussed. When cells were exposed to the 
toxin at 64 µg/ml, two Hsp70 proteins underwent an increase in expression, Ecm10p 
and Ssa1p. The former, unlike the cytosolic Ssa1p, is a mitochondrial Hsp70 protein 
(Baumann et al., 2000) and was increased 1.6-fold proteomically. RNA sequencing 
analysis did record an accurate expression value for ECM1. In cells exposed to the 
higher gliotoxin concentration, Ssa1p was upregulated 1.6-fold and the SSA1 
 207 
transcription level remained relatively stable. Thus when cells are cultured in the 
presence of 64 µg/ml, Hsp70 proteins are not induced to the extent as seen under 16 
µg/ml exposure. Rph1p was identified as the protein which underwent the highest fold 
change here, it was upregulated 4.3-fold. However, it was transcriptionally 
downregulated 1.1-fold. Rph1p is involved in the regulation of the stress response (Jang 
et al., 1999), so perhaps transcriptional downregulation is again indicative of cell death, 
while the increase in production of Rph1p is part of the response to the damaging 
effects of gliotoxin. Alternatively, the downregulation of RPH1 could be a mode of 
negative feedback due to the already hightened levels of the protein encoded by the 
gene. In the comparative analysis of these gels, Ilv5p was, like before, discovered to 
undergo a change in expression, although this time it was seen to be downregulated 1.9-
fold. Trancriptionally, ILV5 only underwent a 1.2-fold upregulation under the higher 
concentration of gliotoxin. Only one ribosomal protein was expressed to a higher degree 
in the presence of 64 µg/ml gliotioxin, Rps0ap was elevated 1.7-fold and RPS0A was 
upregulated 1.8-fold. Another protein with enhanced expression found in this study was 
SceIp. Although no transcriptome data was obtained for the SCEI gene, the protein it 
encodes, an endonuclease that facilitates intron propagation (Dujon, 1989, Perrin et al., 
1993) was proteomically upregulated 1.9-fold. Like SceIp, Wtm1p was found at a level 
1.9-fold higher than in unexposed cells, however, it was transcriptionally downregulated 
1.1-fold. This protein is involved in transcriptional repression, particularly of a meiosis-
specific gene and it also induces amplification of a gene important in the DNA damage 
response (Bowdish and Mitchell, 1993, Pemberton and Blobel, 1997, Tringe et al., 
2006). Thus, the elevated expression of this protein may be in response to genotoxic 
stress caused by gliotoxin. In the presence of 64 µg/ml gliotoxin, Tef2p, translation 
elongation factor EF-1α (Schirmaier and Philippsen, 1984) was one of the seven 
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proteins found to be produced at a reduced rate. It was downregulated 1.4-fold, although 
contrastingly, the transcription of TEF2 was increased 1.9-fold.  
 Figure 3.83 exemplifies gels containing separated proteins from cells that were 
not exposed to gliotoxin and cells that were exposed to 64 µg/ml gliotoxin.  
 
 
 
 
 
 
 
 
Figure 3.83 Comparison of gels containing separated proteins from cells exposed to 
0 and 64 µg/ml gliotoxin.  
 
 In figure 3.84, one protein that underwent an increase in expression and one 
which was upregulated are shown. On the left of the figure there is a sharp decrease in 
intensity of Tdh3p under 64 µg/ml gliotoxin exposure, in comparison the control. 
In contrast, the Pgk1p is visibly more intense in the presence of the higher concentration 
of gliotoxin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.84 Representation of one protein that underwent a decrease in expression, 
Tdh3p (l) and one that underwent an increase in expression, Pgk1p (r), in the 
presence of 64 µg/ml gliotoxin. 
 
Tdh3p Pgk1p
0 µg/ml gliotoxin 0 µg/ml gliotoxin64 µg/ml gliotoxin 64 µg/ml gliotoxin
0 µg/ml GT exposure 64 µg/ml GT exposure
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3.7 Genetic analysis of genes identified  as differentially expressed in response 
to gliotoxin 
 
 A number of genes and proteins were found to be differentially expressed in 
response to gliotoxin exposure, as described above. Further to this, we applied 
functional genetics and phenotypic analyses to assess our findings. Based on data 
obtained from global response analyses, it appears that the induction of sulfur amino 
acid and glutathione biosynthesis pathways is elevated when cells are exposed to 
gliotoxin. This suggests that these pathways are key processes employed by yeast to 
protect against the gliotoxin. 
    
3.7.1 Assessment of growth response to gliotoxin of yeast cells deleted for genes 
involved in sulfur amino acid biosynthesis 
 
 We hypothesised that the importance of the sulfur amino acid biosynthesis 
pathway in resistance to gliotoxin would be reflected in the growth ability of sulfur 
mutants. Comparative growth analysis was carried out using wild-type BY4741 in 
combination with the isogenic ∆met6, ∆met17, ∆cys4 and ∆sam1 mutants, lacking genes 
involved in the said pathway. These strains were phenotypically compared under 0 and 
8 µg/ml gliotoxin exposure, depicted in figure 3.85.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.85 Comparative growth analysis of BY4741, ∆met6, ∆met17, ∆cys4, and 
∆sam1 in the presence of 0 and 8 µg/ml gliotoxin. The above image represents 
cellular growth after 72 hr. incubation at 30ºC. 
SC + 0 µg/ml GT
BY4741
∆cys4
SC + 8 µg/ml GT
∆met6
∆met17
∆sam1
 210 
Repeated performance of this assay revealed no significant change in the level of 
growth in the absence of the above mentioned genes. This demonstrates that cells 
maintain the ability to survive like wild-type when single genes involved in the sulfur 
amino acid biosynthesis pathway are disrupted.  
 
3.7.2 Investigating the role of the transsulfuration pathway in mediating gliotoxin 
effects in yeast 
 
 Results described in previous sections indicate the importance of the sulfur 
amino acid biosynthesis pathway, that contributes to glutathione biosynthesis, in 
response to effects incurred by gliotoxin. Figure 3.86 illustrates the role of 
transsulfuration in glutathione biosynthesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.86 Representation of the importance of transsulfuration in glutathione 
biosynthesis. 
 
 Cystathionine β-synthase- and cystathionine γ-lyase-mediated conversion of 
homocysteine to cystathionine and subsequently to cysteine encompasses the 
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transsulfuration pathway (Ono et al., 1984, Cherest et al., 1993). As glutamate, glycine 
and cysteine form glutathione, homocysteine reserve pools and the emanating 
transsulfuration pathway are key in ensuing glutathione production (Finkelstein, 1998, 
Mosharov et al., 2000). In fact, increasing cysteine levels has been shown to give rise to 
enhanced glutathione production, with the addition of ATP resulting in further elevated 
levels. (Alfafara et al., 1992, Liang et al., 2008, Nisamedtinov et al., 2010). In response 
to gliotoxin, we have shown that CYS3 and CYS4 encoding cystathionine γ-lyase and 
cystathionine β-synthase respectively are upregulated at the RNA and protein levels.      
 We surmised that if the sulfur amino acid and resultant glutathione biosynthesis 
pathways play a pivotal role in protection against gliotoxin, primarily through the 
transsulfuration process, exogenous chemical modification of the pathway would affect 
resistance to the toxin. We also took into consideration the results described in section 
3.3.2 where the ∆gsh1 mutant displayed increased resistance to gliotoxin. In contrast, 
these results suggested that in the absence of γ-glutamylcysteine synthetase (GSH1) and 
consequential glutathione production, cells exhibit increased resistance to gliotoxin. 
Either way, we wanted to investigate the effects of exogenous chemical modification of 
the transsulfuration pathway. Cysteine could not be used in this assay due to the ability 
of gliotoxin to bind to this protein via its sulfhydral group (Pahl et al., 1996, Bertling et 
al., 2010) so alternatively, another intemermediate in glutathione biosynthesis was 
employed, cystathionine. Comparative growth analysis was carried out with strains 
grown under exposure to 12 µg/ml gliotoxin, alone and in combination with 50, 100, 
250 and 350 µM cystathionine. For this assay, wild-type BY4741 and ∆cys3 were 
utilised, and both containing the GliT gene under a constitutive promoter. Figure 3.87 
illustrates the results from this analysis. It can be seen above that as before, GliT 
transformation confers an increase in gliotoxin resistance. The figure clearly 
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demonstrates that as the concentration of cystathionine increases, the ability of both 
BY4741 and ∆cys3 to grow under gliotoxin exposure intensifies. 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.87 Comparative growth analysis of BY4741 and ∆cys3, with and without 
GliT, in the presence of gliotoxin and cystathionine. Plates were incubated at 30ºC 
for 72 hr. 
 
In the presence of gliotoxin and 350 µM exogenous cystathionine, wild-type 
grows at the same rate as that constitutively expressing GliT. Under 12 µg/ml gliotoxin 
exposure, ∆cys3 was completely inhibited, but was able to grow when constitutively 
expressing GliT. With the addition of 350 µM exogenous cystathionine, both strains 
grew considerably better. In general, an acceleration in the rate of growth correlates 
with the addition of exogenous cystathionine. These results demonstrate that through 
increased stimulation of the transsulfuration pathway, cells appear to be protected 
against the detrimental toxic effects of gliotoxin.  
 
3.7.3 Assessment of the utility of GPX2, HXT2, MET32 and ALD6 in yeast 
survival in the presence of gliotoxin 
 
Following global expression analysis, four genes were chosen for further 
evaluation, based on their biological roles and expression levels. To determine the 
importance of these genes in yeast resistance to gliotoxin, comparative growth analysis 
-LEU + 0 µg/ml GT -LEU + 12 µg/ml GT
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cystathionine
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was carried out on mutants deleted for these genes, under cellular exposure to the toxin 
at concentrations of 0 and 8 µg/ml. Expression of the glutathione peroxidase GPX2 is 
Yap1p-controlled and is induced by OS. Its activity catalyses glutathione oxidation and 
reduction of hydroperoxides, such as H2O2, thus playing a role in cellular detoxification 
(Mills, 1957, Galiazzo et al., 1987, Inoue et al., 1999, Avery and Avery, 2001). Due to 
the strong functional link of GPX2 with glutathione, a protein known to play a role in 
protection against OS, and its more than 6-fold increase in expression in response to 64 
µg/ml gliotoxin, the ∆gpx2 phenotype was examined. Additionally, ∆hxt2 was 
phenotypically assessed. HXT2 encodes a yeast hexose transporter induced by low 
glucose concentrations (Ozcan and Johnston, 1999) and the mutant lacking this gene 
was chosen due to the elevated level of HXT2 transcription observed under cellular 
exposure to the higher level of gliotoxin used. MET32 encodes a transcription factor 
involved in regulation of the sulfur amino acid biosynthesis pathway described 
previously (Blaiseau et al., 1997) and BY4741 lacking the gene was thus selected for 
analysis. The importance ALD6, a gene which plays a role in glucose fermentation, 
described in section 3.6.1.4, was also explored via phenotypic analysis of the ∆ald6 
mutant.   
 
Table 3.20 Fold increase in response to gliotoxin exposure of GPX2, HXT2, MET32 
and ALD6 
 
Gene Fold increase under 
exposure to 16 µg/ml 
gliotoxin 
Fold increase under 
exposure to 64 µg/ml 
gliotoxin 
GPX2 1.6 6.4 
HXT2 1.7 8.8 
MET32 1.6 2.9 
ALD6 1.1 3.8 
 
 None of the four mutants described above showed a considerable differential 
growth rate when exposed to 8 µg/ml gliotoxin. However, it should be noted that there 
may be a possible reproducible growth defect seen for ∆ald6. 
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Figure 3.88 Comparative growth analysis of BY4741, ∆gpx2, ∆hxt2, ∆met32 and 
∆ald6 in the presence of 0 and 8 µg/ml gliotoxin. The above image represents cellular 
growth after 72 hr. incubation at 30ºC. 
 
3.7.4 Phenotypic analysis of ∆hbn1, ∆frm2 and ∆hbn1∆frm2 
 Two genes upregulated at the mRNA level on exposure to both 16 and 64 µg/ml 
gliotoxin were HBN1 and FRM2. In response to 16 µg/ml gliotoxin exposure, HBN1 
and FRM2 undergo 3.9- and 1.9-fold upregulation respectively. In the presence of 64 
µg/ml gliotoxin, HBN1 is upregulated 11-fold and FRM2 15.8-fold. 
These two genes are known to genetically interact (de Oliveira et al., 2010). De Oliveira 
et al. (2010) reported that Hbn1p and Frm2p, both putative nitroreductases, are involved 
in yeast cellular protection against OS and the absence of either or both HBN1 and 
FRM2 leads to altered levels of glutathione, superoxide dismutase, catalase and 
glutathione peroxidase. We therefore decided to carry out phenotypic analysis of ∆hbn1, 
∆frm2 and ∆hbn1∆frm2 in the presence of gliotoxin.  
 
3.7.4.1 Creation of ∆hbn1mutant 
The ∆hbn1 strain was not available for purchase from Euroscarf and so was 
created in this study by homologous recombination. HIS5, plus its promoter and 
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terminator sequence was amplified from the pUG27 plasmid by PCR. Primers for this 
reaction were designed so that the amplicon contained regions at both 5’ and 3’ ends 
that were homologous to genomic HBN1 flanking regions, as illustrated in figure 3.89.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.89 Primers used to obtain amplicon for HBN1 replacement with HIS5 by 
homologous recombination. Forward primer is underlined at the top of the figure. 
Reverse complement of reverse primer is underlined at the bottom of the figure. Black 
text represents HBN1 and flanking sequence. Green text depicts regions of pUG27 up- 
and downstream of HIS5. Bold texts indicates start and stop codons of HBN1 gene.   
 
Transformation of the PCR product into BY4741 and selection on SC plates 
lacking histidine led to a number of colonies which potentially contained HIS5 
replacing HBN1. Genomic DNA was then extracted from a number of colonies and a 
diagnostic PCR was performed to determine whether HBN1 had been deleted by 
homologous recombination replacement. Four different PCRs were set up for both the 
potential knockout under examination and a wild-type BY4741 control, as described in 
figure 3.90. 
 
 
 
AGACTGAAGTATCCTATATCAACATATATACAAAAAAACAATCCAATATCA
TGCAGCTGAAGCTTCG
TCTGCTGTTGCAACTTATTTGAAAACTTTAACTGCTCGTCGTACTATTTAC
GCTTTGAAACCGGAGTTACCTGGTGAAATTACTATCAACGACATCCAATC
CGTCGTCCAAACCATCATTAAAGAAACACCCACCGCTTTCAACTCCCAGC
CAAATCGCGCTGTTATCTTGACTGGTGAAACTCACAAAAAAGTTTGGGAC
GAAGTGACTAAGGCTATAGAAAGCCCTGCCGGTCAAAAGAGGCCTGCTT
CAGCAAGGGATGAGGCCTTTGGTTCTGTAATCTTCTTCACCGACGACAA
GGTAACTGAAAAGCTAAAGGCTGACTTCCCAGCGTACGCAGCTGCATTC
CCTAGTTTCGCGGACCATACCTCTGGTGCCGCTCAAATCAACTCGTGGG
TTGCCTTGGAGGCAATGGGCCTGGGTGGTCACCTACAACACTACAATGG
TTACATAAAAGCTGCTTTGCCAAGCAAAATCCCTGAGTCTTGGACCGTAC
AAGCTCAATTAGTCTTCGGTACCCCAGCCGCACCTCCAGGTGAAAAGAC
CTACATCAAAAACGATGTTGAAATCTTCAAT
CAGATCCACTAGTGGCCTATGCTAAGGAACAGTATATAAGTACAGAATT
ATAGGTATAGATTAAATGCGAACGTC
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Figure 3.90 Four different primer sets used for diagnostic PCR and possible 
genotypes. The external forward primer binds 141 bp upstream of the wild-type HBN1 
start codon. The HIS5 internal reverse primer binds 1,041 bp downstream of the 
beginning of the pUG27 region replacing HBN1. Use of these primers in combination 
(primer set 1) in PCR gives rise to a product of 1,182 bp. The external reverse primer 
binds 193 bp downstream of the natural HBN1 stop codon. The HIS5 internal forward 
binds 980 bp upstream from the end of the pUG27 region replacing HBN1. Use of these 
primers in combination (primer set 2) in PCR gives rise to a product of 1,173 bp. 
 
For both the potential knockout and wild-type BY4741, PCRs were performed 
using the sets of primers illustrated above. The results of these reactions are depicted in 
figure 3.91. Lanes 1, 3, 5 and 7 represent PCRs using potential ∆hbn1 genomic DNA 
and lanes 2, 4, 6 and 8 show PCRs using wild-type control DNA. In lane one, there is a 
product of 1,182 bp, resultant from use of primer set one. In the second lane, there is no 
product visible as only the external forward primer bound, there was no HIS5 sequence 
for the reverse primer to anneal. Lane three presents the 1,182 bp product formed from 
PCR using primer set two. There is no product in the fourth lane as only the external 
reverse primer annealed to the DNA in the absence of HIS5. In lane five there can be 
seen a 567 bp product, produced by PCR using both the internal HIS5 primers, primer 
set three. No product resulted from the PCR illustrated in lane six as there was no HIS5 
sequence to which either primer could bind. The HBN1 open reading frame is 582 bp 
and the external forward and reverse primers anneal 141 and 193 bp up- and 
HIS5
Possible genotype 2
= Primer set 1
= Primer set 2
HBN1
= Primer set 3
= Primer set 4
Possible genotype 1
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downstream of this region respectively. Thus, a PCR using these primers, primer set 
four, gives rise to a 916 bp product, as is visible in lane eight. However, the HIS5 region 
used  is 1,454 bp, and HBN1 replacement by this sequence gives rise to a 1,788 bp 
amplicon that can be observed in lane seven. Figure 3.91 confirms successful 
replacement of the HBN1 gene with HIS5. 
 
 
 
 
 
 
Figure 3.91 Diagnostic PCR products that underwent gel electrophoresis, 
illustrating HBN1 knockout in BY4741 background. 1 = ∆hbn1 primer set 1; 2 = WT 
primer set 1; 3 = ∆hbn1 primer set 2; 4 = WT primer set 2; 5 = ∆hbn1 primer set 3; 6 = 
WT primer set 3; 7 = ∆hbn1 primer set 4; 8 = WT primer set 4.   
 
3.7.4.2 Generation of ∆hbn1∆frm2 double knockout 
 BY4741 ∆frm2 was purchased from Euroscarf. The double knockout 
∆hbn1∆frm2 was created by amplification of the novel HIS5 region in BY4741 ∆hbn1 
and transformation into competent BY4741 ∆frm2 followed by selection on SC –his 
plates. This process gave rise to a number of colonies which were tested to determine 
whether or not HBN1 had been deleted. Diagnostic PCRs were performed as before, 
using primer combinations described in figure 3.90 and the amplicons underwent gel 
electrophoresis, as shown in figure 3.92. The diagnostic PCRs demonstrated that HBN1 
had been replaced by HIS5. This was seen firstly by the fact that there are products in 
lanes 1, 3 and 5, of the anticipated sizes and there are no products yielded from the 
control reactions, in lanes 2, 4 and 6, due to the absence of HIS5. Additionally, between 
lanes seven and eight there is an 872 bp dicrepancy in sequence size amplified between 
3 kb
1.5 kb
1 kb
1 2 3 4 5 6 7 8
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external primers. This represents the difference in the size of the HBN1 open reading 
frame and the HIS5 sequence replacing it in the confirmed knockout.  
  
 
 
 
 
 
 
 
 
 
Figure 3.92 Diagnostic PCR products that underwent gel electrophoresis, 
illustrating HBN1 knockout in BY4741 ∆frm2 background. 1 = ∆hbn1∆frm2 primer 
set 1; 2 = WT primer set 1; 3 = ∆hbn1∆frm2 primer set 2; 4 = WT primer set 2; 5 = 
∆hbn1∆frm2 primer set 3; 6 = WT primer set 3; 7 = ∆hbn1∆frm2 primer set 4; 8 = WT 
primer set 4. 
 
3.7.4.3 Comparative growth analysis of BY4741, ∆hbn1, ∆frm2 and ∆hbn1∆frm2  
 The growth of BY4741, ∆hbn1, ∆frm2 and ∆hbn1∆frm2 in the presence of 0 and 
8 µg/ml gliotoxin was subsequently compared, as shown in figure 3.93. Unfortunately, 
no difference in level of resistance or sensitivity was seen for any of the three mutants. 
All grew at the same rate as wild-type and growth of these strains appeared to be 
inhibited to the same extent as wild-type.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.93 Comparative growth analysis of BY4741, ∆hbn1, ∆frm2 and 
∆hbn1∆frm2 in the presence of 0 and 8 µg/ml gliotoxin. The above image represents 
cellular growth after 72 hr incubation at 30ºC. 
 
 To evaluate the similarities in the cellular stress incited by gliotoxin and other 
common oxidative stressors, comparative growth analysis of these strains was then 
3 kb
1.5 kb
1 kb
1 2 3 4 5 6 7 8
BY4741
∆frm2
∆hbn1
∆frm2 ∆hbn1
SC + 0 µg/ml GT SC + 8 µg/ml GT
 219 
carried out in the presence of H2O2. BY4741, ∆hbn1, ∆frm2 and ∆hbn1∆frm2 were 
grown under exposure to 0, 1, 2, 3, 4 and 5 mM H2O2, depicted in figure 3.94. Unlike 
gliotoxin, H2O2 severely inhibits the growth of ∆hbn1 and this was observed at 
concentrations of 3 mM and above. Both ∆frm2 and ∆hbn1∆frm2 exhibit a wild-type 
phenotype in the presence of H2O2. The finding that yeast cells devoid of Hbn1p exhibit 
increased sensitivity to H2O2 but not gliotoxin indicates that there must be a tangible 
difference in the ways in which H2O2 and gliotoxin mediate their deleterious effects.  
 Figure 3.94 suggests that in the absence of Hbn1p, Frm2p mediates H2O2 
toxicity possibly through facilitating the production of a toxic by-product. Hbn1p when 
present may abolish this product or directly inhibit Frm2p activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.94 Comparative growth analysis of BY4741, ∆hbn1, ∆frm2 and 
∆hbn1∆frm2 in the presence of 0, 1, 2, 3, 4 and 5 mM H2O2. The above image 
represents cellular growth after 72 hr incubation at 30ºC. 
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3.8 Discussion 
The inhibitory effects of gliotoxin on S. cerevisiae at the macrobiological level 
have been assessed, through the use of different toxin concentrations and media, and the 
employment of a variety of yeast strains. Undoubtedly, gliotoxin causes deleterious 
effects within the cell resulting in inhibition of growth and increased cell death, in both 
liquid culture and solid media. This has been a paramount observation throughout this 
study. Further to this, it has been ascertained that the A. fumigatus GliT gene, a member 
of a twelve-gene gliotoxin biosynthetic cluster, has the capacity to confer resistance to 
gliotoxin when constitutively expressed in yeast. The protective ability of GliT in S. 
cerevisiae mimics that observed in A. fumigatus (Scharf et al., 2010, Schrettl et al., 
2010). The disulfide bridge present in gliotoxin, to which its toxicity has been attributed 
through redox cycling and conjugation to host thiols, has been identified as a target of 
GliTp (Waring et al., 1995, Hurne et al., 2000, Schrettl et al., 2010). We observed that 
constitutive expression of the GliT gene afforded protection against gliotoxin to strains 
such as wild-type and ∆cys3, deficient in ability to deal with OS. However, it appears 
that carbohydrate source may be a factor in GliTp-induced resistance. Under control of 
the GAL1 promoter, galactose metabolism-induced expression of GliT did not give rise 
to a phenotype exhibiting an increase in resistance to the metabolite. In fact, these 
strains actually demonstrated a slight increase in sensitivity to gliotoxin. This suggests 
that galactose metabolism may undermine the ability of GliTp to elicit protective effects. 
Under constitutive expression, I was able to detect a low level of GliTp using an 
enzymatic assay to indirectly detect gliotoxin reductase activity. It appears that in the 
presence of GliT-pC210, gliotoxin activity is inhibited, thus NADPH oxidase activity 
was not suppressed. In contrast, this was not observed for GliT-pYES2 transformants. 
In this study, the question of whether cellular OS is the predominant detrimental 
consequence of gliotoxin exposure was addressed. Reports have provided evidence that 
 221 
the toxin appears to have the capacity to induce stress of this classification in different 
cell lines (Waring et al., 1995, Zhou et al., 2000, Orr et al., 2004). The results shown 
here have demonstrated that yeast cells do elicit an OS response to gliotoxin and 
transcriptomic, proteomic and functional genetic analyses have illustrated this fact. We 
have shown that some genes involved in the first line of cellular defence against OS are 
critical for optimal survival in the presence of gliotoxin, such as SOD1 and YAP1. 
Without these genes, there is diminished conversion of superoxide to less harmful 
products oxygen and hydrogen peroxide and curtailed regulation of the general OS 
response respectively (McCord and Fridovich, 1969a, Bermingham-McDonogh et al., 
1988, Herrero et al., 2008). Mutant strains lacking these genes display sensitivity to 
gliotoxin, in its presence there is a considerable difference in the growth capacities of 
∆sod1 and ∆yap1, in comparison to wild-type. Of the two, the latter exhibits the highest 
degree of gliotoxin-induced growth inhibition, a phenotype that coheres with YAP1 
function. As a transcription factor involved in the regulation of OS-response genes such 
as TRX2 encoding a thioredoxin isoenzyme and GSH1, which encodes glutathione 
synthetase (Kuge and Jones, 1994, Wu and Moye-Rowley, 1994), Yap1p has substantial 
control over this type of cellular reaction. Although SOD1 is also significantly 
implicated in the OS response, its control is not as extensive as that of YAP1. These 
results were corroborated by further growth analysis of these strains under exposure to a 
common oxidative stressor, H2O2. In the presence of H2O2, a similar result was seen, 
with both ∆yap1 and ∆sod1 showing increased sensitivity in comparison to wild-type. 
Again, the most sensitive strain was ∆yap1, growth of ∆sod1 was less inhibited by H2O2. 
In comparing the suppression imposed on these strains by gliotoxin and H2O2, it was 
noticed that ∆yap1 appears to be more repressed by H2O2 than gliotoxin. Under H2O2 
exposure at a concentration that results in no significant impairment of wild-type 
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growth, ∆yap1 cannot grow. However, when wild-type growth is clearly hindered by 
gliotoxin, growth of ∆yap1 still occurs, albeit at a minimal level.  
Phenotypic analysis of another strain ∆cys3 led to a similar observation. We 
discovered that CYS3, involved in transsulfuration and subsequent glutathione 
biosynthesis (Ono et al., 1984, Ono et al., 1992, Mosharov et al., 2000), is vital for a 
fully functional response to gliotoxin exposure. This supports previous work carried out 
by Chamilos et al. (2008), who also identified CYS3 as a gene that plays a key role in 
resistance to the toxin and have reported that disruption of CYS3 results in cells that 
exhibit an increase in sensitivity. 
 Comparative growth analyses of ∆yap1, ∆sod1 and ∆cys3, described above, 
support previous evidence that gliotoxin can induce conditions characteristic of OS. 
Conversely, ∆gsh1 phenotypic analysis initially appeared to suggest otherwise. This 
mutant is lacking the glutathione synthetase gene that allows cells to synthesise 
glutathione, an important antioxidant that also acts as a reductant facilitating 
glutaredoxin oxidoreductase activity (Grant, 2001). Due to the fact that this gene 
encodes a protein that is key in the OS response, we hypothesised that ∆gsh1 would 
exhibit increased sensitivity to gliotoxin, however the opposite was seen. Phenotypic 
analysis of ∆gsh1 showed that this strain grows considerably more efficiently in the 
presence of gliotoxin than wild-type. Although this appears to directly contrast with 
results for other OS response-deficient mutants this phenotype may be attributed to 
other factors. Bernardo et al. (2001, 2003) reported that the ability of gliotoxin to enter 
into murine cells is limited to the oxidised form. They found that inside the cell, 
gliotoxin is concentrated by reduction to the cell membrane-impermeable form almost 
certainly by glutathione. Subsequent glutathione depletion, associated with gliotoxin-
induced apoptosis and cell death, diminishes the reduction of gliotoxin and the toxin 
effluxes from the cell. The same group also revealed that gliotoxin uptake by cells is 
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negated by the absence of glutathione. Furthermore, research has demonstrated that in 
another cell line, neuroblastoma cells, glutathione stimulates cytotoxicity induced by 
gliotoxin. When intracellular glutathione levels in these cells are depressed, gliotoxin 
cytotoxicity is significantly mitigated (Axelsson et al., 2006). With relevance to our 
results, this provides an explanation for the ∆gsh1 phenotypic description recorded. It is 
quite possible that the absence of GSH1, and thus glutathione, benefits yeast cells when 
exposed to gliotoxin in that the toxin is prevented from becoming concentrated 
intracellularly which would result in additional damage to the cell. Upon efflux, 
gliotoxin can enter neighbouring cells but again cannot be retained within the cell and it 
escapes. Further to this, it may be the case that deletion of CYS3 decreases the cellular 
GSH concentration, sufficient to arrest its protective effects, yet leaving enough GSH to 
retain gliotoxin within the cell leading to increased cell death. ∆gsh1, in the same 
manner as ∆yap1 and ∆sod1, showed increased sensitivity to H2O2, in comparison to 
wild-type, as was expected. It grew somewhat less successfully than ∆sod1, but much 
better than ∆yap1.  
 Further investigation into the S. cerevisiae cellular response induced by 
gliotoxin exposure led us to gather additional evidence in support of gliotoxin being an 
OS-causing agent. Through investigation into the global response of S. cerevisiae to 
gliotoxin, two metabolic pathways were identified as being upregulated in response to 
the toxin, at two different concentrations. Firstly, through RNA sequencing analysis and 
proteomic studies, the sulfur amino acid biosynthesis pathway was identified as one 
which is switched on in response to cellular exposure to gliotoxin. There are eighteen 
genes implicated in this process, which yields cysteine, methionine and S-
adenosylmethionine (SAM/AdoMet). One sub-section of this process is the 
transsulfuration pathway, mentioned above, that involves CYS3 and results in the yield 
of cysteine from homocysteine with cystathionine as an intermediate (Thomas and 
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Surdin-Kerjan, 1997). Due to the fact that cysteine is thus a rate-limiting factor in 
glutathione biosynthesis (Williamson et al., 1982, Penninckx, 2002), the stimulation of 
this pathway indicates that gliotoxin is causing conditions of OS, to which the cells are 
responding. To validate these results, quantitative PCR was performed to assess the 
level of transcription of seven of the eighteen genes under exposure to 16 and 64 µg/ml 
gliotoxin. All seven were confirmed as upregulated in the presence of the lower toxin 
concentration. Under the higher concentration six of the seven were found to undergo an 
increase in transcription, although not all to the same degree as RNA sequencing had 
shown. Generally, the qPCR results correlated well with those from the transcriptome 
analysis, despite some discrepancies in the level of transcriptional change documented. 
Similar results were previously recorded depicting the upregulation of sulfur amino acid 
biosynthesis genes in the S. cerevisiae response to cadmium stresses (Momose and 
Iwahashi, 2001). To further emphasise the importance of the sulfur amino acid 
biosynthesis pathway in yeast response to gliotoxin, the differential expression was 
recorded of a number of genes involved in the mediation of this pathway, under 
exposure to gliotoxin. Similarly to MET10 and MET5, the MET1, MET8 and MET18 
genes all possess sulfite reductase activity, an essential step in sulfur amino acid 
biosynthesis whereby sulfite, which has been formed from the reduction of activated 
sulfate, is reduced to sulfide (Masselot and De Robichon-Szulmajster, 1975, Thomas et 
al., 1992a, Thomas and Surdin-Kerjan, 1997). These three genes are stimulated by two 
different concentrations of gliotoxin, demonstrating the fact that yeast cells, when 
treated with gliotoxin, raise the level of sulfide available for use in sulfur amino acid 
biosynthesis. MET22, encoding a product also involved in sulfate assimilation 
(Masselot and De Robichon-Szulmajster, 1975, Gläser et al., 1993, Murguía et al., 1995) 
is upregulated in response to gliotoxin, as are genes required for transcriptional 
activation of the pathway, MET4, MET31 and MET32 (Thomas et al., 1992b, Blaiseau 
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et al., 1997). The fact that the above cited genes are all upregulated at the transcription 
level indicates that in response to the toxin, the cells are stimulating the sulfur amino 
acid pathway, which can then increase glutathione biosynthesis and protect against OS. 
Conversely, some of the regulatory genes were downregulated when cells were exposed 
to gliotoxin. High cellular levels of SAM, generated from the sulfur amino acid 
biosynthesis pathway, induce MET30 inhibition of sulfate assimilation and thus amino 
acid biosynthesis. This negative feedback occurs through Met4p and Met19p inhibition 
by Met30p (Krems et al., 1995, Thomas et al., 1995). MET19 encodes glucose-6-
phosphate dehydrogenase whose importance in OS resistance has been documented 
(Thomas et al., 1991, Izawa et al., 1998). MET30, MET4 and MET19 were all found to 
be downregulated in response to gliotoxin. Further to previous results described above, 
it was expected that MET30 would be repressed, to prevent inhibition of sulfur 
assimilation in the presence of gliotoxin. It was anticipated that due to MET30 
downregulation, expression of both MET4 and MET19 would not be hindered, however, 
this was not the case. As thioredoxin is reportedly involved in activation of APS kinase, 
encoded by MET14 (Schriek and Schwenn, 1986, Thomas and Surdin-Kerjan, 1997), it 
was of notable interest that genes involved in thioredoxin generation TRX1, TRX2 and 
TRR1 were all considerably upregulated in response to both concentrations of gliotoxin. 
Analysis of the yeast global proteomic response to gliotoxin reinforced some of the 
findings described above. Cys3p, Cys4p and Met17p (also known as Met25p) were 
established as proteins that undergo an increase in production in response to gliotoxin. 
Met17p is critical in the formation of homocysteine, the cornerstone in the sulfur amino 
acid biosynthesis pathway and has when overexpressed been shown to induce higher 
levels of cysteine and glutathione production (Matityahu et al., 2006). The increased 
level of Met17p, in addition to Cys3p and Cys4p, both essential for transsulfuration, 
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signals that on the proteomic response level, the cells are initiating the same reaction to 
gliotoxin exposure as on the transcription level. 
 When cells were exposed to 64 µg/ml gliotoxin, the two genes that underwent 
the highest level of upregulation were CUP1-1 and CUP1-2. Although they were 
transcriptionally stimulated in the presence of 16 µg/ml gliotoxin, they were not to the 
extent observed at the higher concentration. CUP1-1 and CUP1-2 are two copies of 
yeast metallothionein which complements the lack of Sod1p function and when 
overexpressed, enhances resistance to cadmium and copper, thus linking them to the OS 
response (Winge et al., 1985, Jeyaprakash et al., 1991, Tamai et al., 1993). These genes 
are clearly of major importance in cellular reaction to high levels of gliotoxin exposure, 
and the stress induced by this. The fact that CUP1 appears to play a role in the OS 
response only strengthens the supposition that gliotoxin is imposing a stress of this kind 
on our cells.    
 This study has also resulted in the identification of another yeast cellular 
pathway that is induced when cells are exposed to gliotoxin, the glucose fermentation 
pathway. As documented by the RNA sequencing data, only 5 of the 28 genes involved 
in this process are downregulated in response to the toxin, the remaining 23 are 
upregulated. In fact, genes that play a role in gluconeogenesis, fundamentally the 
opposite of fermentation, but not fermentation, are downregulated in response to 
gliotoxin exposure, demonstrating the cell is heavily commissioning fermentation and 
glucose utilisation over gluconeogenesis and glucose production in response to 
gliotoxin. Proteomic analysis yielded results consistent with those from RNA 
sequencing analysis. 25 of the 42 proteins found to be augmented in response to 
gliotoxin, at two different concentrations, play a role in the glucose fermentation 
pathway. Interestingly, this course of action concurs with the induction of the sulfur 
amino acid biosynthesis pathway. Cysteine and glutathione have been found to suppress 
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the level of O2 uptake in the presence of glucose and increase the rate of CO2 production 
through fermentation, thereby controlling the rate of respiration and fermentation within 
the cell (Quastel and Wheatley, 1932). This presents to us the fact that when yeast cells 
are treated with gliotoxin, they react in a way which is typical of an OS response, 
subsequently giving rise to an increase in the level of glucose fermentation. NADPH is 
a product of the glucose fermentation pathway. The fact that NADPH is required for 
fully functional thioredoxin and glutaredoxin systems, which play an important role in 
protection against OS (Holmgren, 1989) provides a possible link for the glucose 
fermentation pathway and the OS response. An intermediate of the glucose fermentation 
pathway is pyruvate, which has been shown to have the ability to protect against 
peroxides such as H2O2 in mammalian cells (Nath et al., 1995, Desagher et al., 1997). 
Stimulation of said pathway may be further indication that gliotoxin induces OS. 
 It must also be acknowledged that of the 172 genes that were found to be 
upregulated more than three-fold under 16 µg/ml gliotoxin exposure, 107 were 
annotated as encoding components of either the small or large ribosomal subunits. As 
Loar et al. (2004) pointed out, from transcription profiling, not all changes in gene 
expression are thought to occur specifically to protect the cells against the stress under 
which the cells have been imposed. Changes may be a result of a cellular effort to adjust 
metabolism under poor growth conditions and this could be what is represented by the 
alteration in the transcription level of ribosomal genes.       
 Gliotoxin was used at concentrations of 16 and 64 µg/ml to explore the global 
response it instigates in S. cerevisiae. The five most common biological processes 
stimulated at the transcription level by the two concentrations were compared. RNA 
metabolic process, ribosome biogenesis, translation and transport were enhanced in the 
presence of both concentrations, however the response to stress was unique to the lower 
concentration and cellular amino acid metabolic process was unique to the higher 
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concentration. Orr et al. (2004) demonstrated using fluorescence dye that gliotoxin can 
cause cellular OS in hepatic cells. In this study a maximum of 50 µM gliotoxin was 
used, which equates to approximately 16 µg/ml, and this ‘high’ concentration was 
deemed to induce ROS, reduce the level of cellular GSH and bring about OS. The fact 
that the same concentration activated a response to stress in our cells falls in line with 
observations by the above mentioned group. Stress imposed on cells by unfolded 
proteins in the endoplasmic reticulum gives rise to ROS and OS conditions, and has 
been shown to activate amino acid metabolism genes (Barbosa-Tessmann et al., 1999, 
Harding et al., 2003, Haynes et al., 2004). Thus, acute stimulation of the cellular amino 
acid metabolic process in our cells under exposure to 64 µg/ml gliotoxin could be 
another result of OS induced by the toxin. Moreover we found GCN4, involved in 
amino acid starvation response (Hinnebusch, 1984, Natarajan et al., 2001), to be 
downregulated under both concentrations of gliotoxin exposure. Additionally, Asc1p 
which functions in repressing Gcn4p, (Hoffmann et al., 1999) was noted to be 
upregulated almost 3-fold in the presence of 16 µg/ml gliotoxin.  
 Four of the five most common cellular components associated with genes that 
underwent a considerable degree of upregulation were the cytoplasm, ribosome, 
mitochondrion and nucleus and these were found to be stimulated by the two 
concentrations of gliotoxin. Uniquely, under the lower and higher concentrations, 
membrane- and nucleolus-associated genes were some of the most highly induced 
respectively. Landolfo et al. (2008, 2010) demonstrated that ROS actually target the 
cellular plasma membrane and through lipid nutrient supplementation, oxidative 
damage was alleviated. They suggested that this was due to additional nutrients aiding 
in the maintenance of membrane integrity, in turn allowing cells to adapt to stressful 
conditions. Perhaps there is a similar situation occurring in yeast cells under exposure to 
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gliotoxin and at the lower concentration they are making an attempt to increase 
membrane-associated proteins in order to abate OS induced by the metabolite. 
 The fact that exposure to the higher gliotoxin concentration induces the 
upregulation of many genes associated with the nucleolus could also be indicative of 
ROS generation. In mammals, OS gives rise to nucleolar stress which in turn initiates 
apoptosis, outlining the stress-sensing function for the nucleolus. The transcription 
factor TIF-IA is essential for this process and functions in ceasing rRNA synthesis 
(Mayer and Grummt, 2005). The TIF-IA yeast homologue Rnr3p has been shown to be 
important in OS signalling and regulation and the crucial role of the nucleolus in 
sensing OS has been demonstrated (Lewinska et al., 2010). Wtm1p which we 
determined to be upregulated in the presence of 64 µg/ml gliotoxin actually plays a role 
in triggering RNR3 stimulation (Tringe et al., 2006), supporting the hypothesis that 
stress of an oxidative manner imposed by gliotoxin is sensed by the nucleolus and 
appropriate responses are initiated. 
 When the most common molecular functions stimulated by the two gliotoxin 
concentrations were compared, transferase activity, structural molecule activity, RNA 
binding activity and hydrolase activity were found to be common to both. In contrast, 
protein binding was uniquely one of the functions most highly stimulated by the lower 
concentration and the same applied to oxidoreductase activity by the higher. Many 
functions associated with protein-binding are implicated in the OS response. RAD59 is a 
gene that encodes a protein involved in protein-binding that was upregulated in 
response to the lower toxin concentration and is key in DNA damage repair (Petukhova 
et al., 1999, Pannunzio et al., 2008). Upregulation of genes such as this one may be 
yeast cells responding to DNA damage caused by gliotoxin, which has been reported 
before (Eichner et al., 1988). Glutaredoxins are just some of the proteins produced that 
exhibit oxidoreductase activity which protect against ROS (Ruoppolo et al., 1997, 
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Luikenhuis et al., 1998) and the fact that oxidoreductase activity is one of the most 
highly stimulated molecular functions in the presence of 64 µg/ml gliotoxin is likely to 
represent the OS response being instigated by the cells. 
 Taken together, the results described above illustrate the manner in which S. 
cerevisiae attempts to react to gliotoxin exposure. Yeast produce a strong OS response 
in the presence of the toxin in many respects, demonstrating that gliotoxin does indeed 
induce stress of this kind as a means to bring about inhibition and ultimately cell death. 
A. fumigatus employs this toxin to effectuate this process in order to colonise its host 
(Gardiner et al., 2005). However, some results did not entirely comply with this model. 
Although it was initially anticipated that ∆gsh1 would display increased sensitivity to 
gliotoxin, we have provided reasons as to why the opposite was observed. TRX2 
encoding a thioredoxin, strongly implicated in the OS response (Kalinina et al., 2008), 
did not appear to be of any considerable importance in protecting cells against the 
effects of gliotoxin. Comparative growth analysis of ∆trx2 and wild-type depicted that 
these two strains do not exhibit differential growth patterns in the presence of gliotoxin. 
The fact that ∆yap1 exhibits increased sensitivity to this mycotoxin, while ∆trx2 does 
not requires consideration, as TRX2 is under the control of the Yap1p transcription 
factor (Kuge and Jones, 1994, Grant et al., 1996). This indicates that it is other genes 
controlled by Yap1p, not thioredoxin-related, that are essential for resistance to 
gliotoxin in yeast. Through comparative growth analysis, GLR1 and GSH2, which are 
required through different functions for maintaining an appropriate level of GSH within 
the cell (Grant et al., 1996, Grant et al., 1997, Inoue et al., 1998, Grant, 2001), also 
failed to demonstrate their prominence in resistance to the toxin, as strains lacking these 
genes grew at a similar rate to wild-type. ∆ctt1 did not show an increase in sensitivity or 
resistance to gliotoxin either, illustrating the lack of importance of catalase T, which 
normally functions in catalysing the conversion of H2O2 to water (Hartig and Ruis, 1986, 
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Jamieson, 1998). However ∆ctt1 has been reported not to be more sensitive to H2O2 
than wild-type strains, but GSH-deficient strains also lacking CTT1 have displayed an 
intensified sensitivity (Grant et al., 1998). TEF3 and TEF4 encode the translation 
elongation factor eEF1Bγ and their deletion has caused increased resistance to OS, in a 
similar manner to Yap1p overexpression (Kinzy et al., 1994, Olarewaju et al., 2004). 
Thus, we expected that ∆tef3 and ∆tef4 would exhibit increased resistance to gliotoxin, 
which was not observed. The evidence presented here suggests that if indeed gliotoxin 
is imposing conditions characteristic of OS on yeast cells, the toxin may either induce 
stress somewhat different to other common oxidative stressors, or, mediate the 
transcriptomic or proteomic reaction instigated in response. 
 But what additional modes of action does gliotoxin utilise and how does this 
prompt cells to respond? We endeavoured to compare the S. cerevisiae genes that are 
up-and downregulated under gliotoxin exposure with those that are stimulated and 
repressed by other toxins to learn more about the metabolite. Comparison and contrast 
was made between gliotoxin and allicin (Yu et al., 2010), citrinin (Iwahashi et al., 2007), 
patulin (Iwahashi et al., 2006) and furfural (Li and Yuan, 2010). Gliotoxin, citrinin, 
patulin and allicin all induced stimulation of the sulfur amino acid biosynthesis pathway 
in yeast, the latter to the least extent. Taking all results together, gliotoxin is probably 
most similar to allicin in the response prompted, many of the same genes are 
transcriptionally altered when cells are exposed to these toxins. 
 Allicin, a garlic derivative, is active against a range of bacteria and fungi, 
including both animal and plant pathogens (Cañizares et al., 2004, Cutler and Wilson, 
2004, Khodavandi et al., 2010). Like gliotoxin, allicin modifies thiol residues on 
proteins (Rabinkov et al., 1998, Hurne et al., 2000) and allicin has been shown to 
induce apoptosis in yeast (Gruhlke et al., 2010). It is possible that gliotoxin acts in a 
similar manner (particularly as it has been shown to induce apoptosis in immune cells 
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(Waring et al., 1988, Zhou et al., 2000, Stanzani et al., 2005)) and much of the 
differential gene expression may result from yeast apoptosis under gliotoxin exposure.         
 To conclude, it appears that gliotoxin does to some extent cause OS in yeast cell 
cultures and many lines of enquiry have presented evidence for this, as described above. 
When the OS response is initiated in cells, it may be the case that normal housekeeping 
functions are negatively affected by this as all cellular effort is going into the stress 
response. For example Ssb1p, which is involved in the correct folding of proteins (Craig 
et al., 1993, Gautschi et al., 2002, Kim and Craig, 2005), is produced to a lesser extent 
when cells are exposed to 16 µg/ml gliotoxin. Through screening the Euroscarf library, 
Chamilos et al. (2008) failed to identify GSH1 as a gene that when deleted alters yeast 
sensitivity to gliotoxin. We assigned importance to this gene using a targeted gene 
approach and through this we have discovered that yeast resistance to gliotoxin is 
extremely sensitive to changes in GSH levels.      
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4.1 Introduction 
The spongiform encephalopathies Creutzfeldt-Jakob disease (CJD), bovine 
spongiform encephalopathy (BSE) and scrapie are just some of the fatal mammalian 
diseases characterised by the aggregation of misfolded proteins called prions (Prusiner, 
1982). Accumulation of misfolded protein is also representative of neurodegenerative 
disorders such as Parkinson’s and Huntington’s Diseases (Gregersen, 2006).  
Mammalian prion diseases are caused by a conversion of the prion protein (PrPC) 
from a soluble functional form to a non-functional protease-resistant form (PrPSc) 
(Prusiner, 1982, McKinley et al., 1983). The appearance of the infectious pathogenic 
PrPSc can occur spontanaeously, through infectious transmission, or as a result of 
mutation in the PRNP prion gene (Prusiner, 1998). PrPC-PrPSc conversion is 
characterised by the refolding of α-helical segments into β-sheets and the assembly of 
PrPSc amyloid plaques in the brain (Roberts et al., 1988, Pan et al., 1993). Amyloid 
plaques are also a distinguishing feature of Alzheimer’s Disease, however these plaques 
are composed of amyloid beta proteins (Roberts et al., 1988).                  
 As analogues to the causative agents of mammalian spongiform 
encephalopathies, the study of yeast prions is of great importance (Wickner, 1994). 
[PSI+] was the first yeast prion discovered and is one of the most widely studied today 
(Cox, 1965). [PSI+] is the prion form of Sup35p, which is a component of the 
translation termination complex (Wickner, 1994, Zhouravleva et al., 1995). In the 
presence of SUQ5, encoding a serine-inserting tRNA, [PSI+] can suppress nonsense 
ochre mutations (Cox, 1965, Liebman et al., 1975, Cox et al., 1988). In this study, this 
phenomenon is utilised in that [PSI+] facilitates the readthrough of the synthetic ade2-1 
mutation resulting in the growth of white cells if present and red cells if absent. 
Due to fact that proteomic conformational changes are key in prion formation, 
many investigations have been carried out to assess the importance of chaperone protein 
 234 
function in prion propagation. It has been determined that the chaperone Hsp104p is 
crucial for yeast cells to propagate [PSI+] and that a delicate balance of Hsp104p must 
be maintained as overexpression and depletion of this protein results in loss of the prion 
(Chernoff et al., 1995). Hsp104p when expressed at wild-type levels, functions in 
disaggregating prion amyloids and cleaving prion seeds which can be passed to 
daughter cells, facilitating prion maintenance (Paushkin et al., 1996). The [PSI+]-curing 
agent GdnHCl functions in preventing the production of new propagons by Hsp104p, 
rendering the cells unable to propagate the prion (Tuite et al., 1981, Eaglestone et al., 
2000).         
Hsp104p functions in rescuing and refolding aggregated proteins through close 
cooperation with other Hsp104p machinery components Hsp70p and Hsp40p (Glover 
and Lindquist, 1998). In terms of priongenesis, Hsp70p and Hsp40p are thus likely to 
also be involved on this basis (Masison et al., 2009).   
The S. cerevisiae Hsp70p family consists of the cytosolic proteins Ssa1p-4p, 
Ssb1p, Ssb2p, Sse1p, Sse2p and Ssz1p, the mitochondrial proteins Ssc1p, Ssq1p and 
Ecm10p and the endoplasmic reticulum-associated proteins Kar2p and Lhs1p (Craig et 
al., 1993, Mukai et al., 1993, Craven et al., 1996, Schilke et al., 1996, Hallstrom et al., 
1998, Baumann et al., 2000). Hsp70p binds and releases proteins in a functional cycle 
termed the ATPase binding cycle. Hsp70p has a well characterised peptide-binding 
domain (PBD) and an ATPase-binding domain (ABD). Whether the PBD adopts an 
open or closed conformation, depends entirely on the ABD. When ATP is bound to the 
ABD, rapid substrate exchange occurs in the adjacent domain. However, when ATP is 
hydrolysed to ADP, the PBD maintains tight adherence to its substrate. Rebinding of 
ATP may then occur, with the reappearance of the PBD open conformation (Masison et 
al., 2009). As the Hsp70p ATP hydrolysis and ADP release is intrinsically slow, the 
cycle is heavily regulated by co-chaperone proteins (Masison et al., 2009). In fact the 
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rate-limiting step, the hydrolysis of ATP, is prompted by associated Hsp40 proteins 
(Mayer et al., 2000, Wittung-Stafshede et al., 2003). S. cerevisiae Hsp40p family 
members include Ydj1p and Sis1p, both of which interact with Hsp70p and regulate the 
ATPase binding cycle (Cyr et al., 1992, Lu and Cyr, 1998). Apj1p is a protein which 
contains a well conserved J-domain, characteristic of the Hsp40p chaperone family and 
when overexpressed disrupts [PSI+] propagation (Kryndushkin et al., 2002, Walsh et al., 
2004). Nucleotide exchange factors (NEFs) also play an important role in regulating the 
ATPase binding cycle, e.g Fes1p and Sse1p, which stimulate ATP binding and thus 
Hsp70p rapid substrate exchange (Kabani et al., 2002, Raviol et al., 2006). Furthermore, 
the Hsp90p co-chaperones Sti1p, Cns1p and Cpr7p function in regulation of this cycle 
(Wegele et al., 2003). Cns1p stimulates the Hsp70p ATPase binding cycle through 
provoking ATP hydrolysis (Dolinski et al., 1998). Cpr7p appears to intensify Hsp70p 
substrate binding (Mayr et al., 2000, Jones et al., 2004).             
The chaperone protein Hsp70p and a number of co-chaperone proteins are 
thought to be involved in prion maintenance for a number of reasons. It has been 
demonstrated that HSP70 mutations impair [PSI+] propagation (Jung et al., 2000, Jones 
and Masison, 2003). Overexpression of SSA1 gives rise to an increase in the level of 
nonsense suppression mediated by [PSI+] (Newnam et al., 1999). It has been suggested 
that disruption of the Hsp70p ATPase binding cycle may hinder prion propagation 
(Jones and Tuite, 2005). When this cycle is disrupted through imbalance of Hsp70p co-
chaperones, the ability of the cell to remain [PSI+] becomes significantly impaired. For 
example, when Fes1p, a nucleotide exchange factor involved in Hsp70p ATPase 
binding cycle regulation is depleted, [PSI+] is weakened (Jones et al., 2004). While 
Sti1p overexpression weakens [PSI+], STI1 deletion favours the [PSI+] phenotype 
(Kryndushkin et al., 2002, Jones et al., 2004). As a result, this cycle could be a potential 
target for anti-prion drugs. 
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Recently, the ability of the ribosome to carry out functional chaperone activity 
has come to light. As part of the large ribosomal subunit, the domain V of the large 
rRNA (25S in S. cerevisiae) has the ability to assist in the re-folding of denatured 
proteins (Das et al., 2008, Fåhraeus and Blondel, 2008). 
Yar1p and Ltv1p are two proteins that have be shown to interact and appear to 
function, distinctly from one another, in 40S ribosomal subunit production (Loar et al., 
2004). It has been demonstrated that deletion of YAR1 and LTV1 in S. cerevisiae causes 
prion instability in [PSI+] strains (M. Blondel, personal communication). This suggests 
that ribosome imbalance induces [PSI+] instability. Thus, the ribosome may somehow 
be linked to prion maintenance within the cell, perhaps through chaperone function. It 
may be the case that loss of LTV1 or YAR1, leading to a decrease in 40S ribosomal 
subunit production (Loar et al., 2004, Seiser et al., 2006) leads to overall ribosome 
instability causing dysfunction and rRNA function disruption, including chaperone 
activity. RPL8A and RPL8B deletion was also found to give rise to prion instability (M. 
Blondel, personal communication). The protein products of these genes encode the 
ribosomal protein L4 of the 60S ribosomal subunit (Arevalo and Warner, 1990, Yon et 
al., 1991, Ohtake and Wickner, 1995).          
Tacrine (TA), 6-aminophenanthridine (6AP) and Guanabenz (GA) are three 
structurally unrelated anti-prion drugs that were identified through a yeast-based prion-
curing screen. All three were show to be active against yeast prions, while only 6AP and 
GA possess prion-curing capacities in mammalian systems (Tribouillard-Tanvier et al., 
2008a, Tribouillard-Tanvier et al., 2008b). The fact that 6AP, GA and other anti-prion 
drug such as Quinacrine (QC) and Chlorpromazine (CPZ) efficiently cure prions in both 
yeast and mammalian systems indicates that there is some degree of conservation in 
prion-controlling mechanisms between the two (Bach et al., 2003, Tribouillard-Tanvier 
et al., 2008b). 6AP and GA appear to exhibit similar effects, acting in trans by 
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disrupting processes involved in prion propagation, rather than directly targeting prions 
in cis (Reis et al., 2011). Both drugs inhibit the ribosomal-mediated protein folding 
activity of the large subunit’s large rRNA, specifically interacting with the domain V.  
Importantly, this does not have an affect on protein synthesis (Tribouillard-Tanvier et 
al., 2008b). 6AP and GA compete with unfolded protein for sites on the ribosome thus 
causing a reduction in the production of refolded protein (Reis et al., 2011).   
Interestingly, exposure of ∆ltv1 and ∆yar1 to 6AP and GA appears to stabilise 
the prion in [PSI+] cells (M. Blondel, personal communication). Taking the above 
described results together, the model depicted in figure 4.1 was constructed. 
TA is a drug currently approved for prescription to treat Alzheimer’s Disease 
(Summers, 2006). As in mammalian prion diseases, Alzheimer’s Disease is 
characterised by the formation of amyloid plaques in the brain of the patient. These 
plaques are composed of amyloid β proteins which are derived from the break-down of 
secreted β amyloid precursor proteins (β APP) (Haass and Selkoe, 1993). TA treatment 
considerably inhibits the secretion of soluble β APP in a number of cell lines (Lahiri et 
al., 1994). 
Regarding prion curing, in contrast to 6AP and GA, little is known about the 
mode of action of TA. Due to the fact that it is not a mammalian prion-curing agent, it is 
thought that its yeast target is too far diverged in mammals (Tribouillard-Tanvier et al., 
2008a). Hsp104p, a key chaperone protein in prion propagation has no known 
mammalian homologue (Jones and Tuite, 2005). This led us to hypothesise that TA may 
target Hsp104p, increasing the rate of [PSI+] curing, particularly as either 
overexpression or deletion of HSP104 eliminates [PSI+] (Chernoff et al., 1995). 
In this study, the principal aim was to gain insight into the prion-curing mode of 
action of TA, using functional genetic techniques, transcriptomics and proteomics.  One 
of the initial aims of this project was to assess if TA uses a similar mode of action to 
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GdnHCl in relation to [PSI+] curing. It was anticipated that the question of whether or 
not TA enhances the uptake of GdnHCl would be addressed. We also wanted to 
investigate the importance of various aspects of chaperone function in prion propagation. 
We endeavoured to use 6AP and GA in a number of provisional assays, to compare the 
effects of these drugs with that of TA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Possible model for [PSI+] curing by 6AP and GA. Efficent prion 
propagation facilitated by 25S rRNA-mediated protein folding may depend on a crucial 
balance of chaperone activity, similarly to Hsp104p. In wild-type cells, 6AP and GA 
appear to cure [PSI+] by inhibiting domain V activity of the 25S-rRNA, as shown on the 
left of the figure (Tribouillard-Tanvier et al., 2008b). It may be the case that the absence 
of LTV1 or YAR1, resulting in ribosomal imbalance (Loar et al., 2004), disrupts the 
delicate balance of 25S rRNA chaperone activity giving rise to prion instability. 6AP or 
GA exposure may then restore the balance by reducing the said chaperone activity.       
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Section 1: Using functional genetics to analyse the prion-curing ability 
of Tacrine, 6-aminophenanthridine and Guanabenz and investigate the 
Tacrine mode of action 
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4.2 Assessing Tacrine, 6-aminophenanthridine and Guanabenz as prion-curing 
agents 
 
   Guanidine hydrochloride (GdnHCl) is commonly used to “cure” prions in yeast 
since its discovery as an anti-prion agent (Tuite et al., 1981). It acts by inhibiting the 
action of Hsp104p, which is involved in cleaving new propagons or prion seeds from 
protein aggregates (Parsell et al., 1994, Jung and Masison, 2001). Tacrine (TA), 6-
aminophenanthridine (6AP) and Guanabenz (GA) do not cure [PSI+] alone, but in 
combination with GdnHCl, can eradicate the prion.   
 
4.2.1 Tacrine cures [PSI+] at relatively low concentrations in combination with 
GdnHCl 
 
  In testing the ability of TA to cure [PSI+], it was demonstrated that relatively 
low concentrations of TA (5 µM) are sufficient to successfully cure the prion in the 
presence of GdnHCl (figure 4.2).  
 
  
 
 
 
 
 
Figure 4.2 Plate streaks depicting TA curing of [PSI+] in G600. Samples were taken 
from a G600 culture and streaked onto YPD containing 1) 5 µM TA + 0 µM GdnHCl, 2) 
0 µM TA + 200 µM GdnHCl and 3) 5 µM TA + 200 µM GdnHCl. Plates were 
incubated at 30ºC for 72 hr. The greater production of red pigment suggests more 
efficient [PSI+] curing. [psi-] phenotypes were confirmed by mating and growth on –ade 
was absent.  
 
To confirm the above result and ensure the curing of [PSI+] was not due to 
GdnHCl alone, single colony plate assays were carried out. Approximately 250 cells 
were plated on YPD containing GdnHCl alone and GdnHCl supplemented with TA 
(figure 4.3). Assessment of single colonies provides a clearer representation of the level 
5 µM TA + 
0 µM GdnHCl
0 µM TA + 
200 µM GdnHCl
5 µM TA + 
200 µM GdnHCl
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of cellular [PSI+] due to more even utilisation of adenine by the cells. There was a 
distinct difference in colony colour of cells exposed to GdnHCl alone and GdnHCl 
combined with TA. TA addition clearly confers a [psi-] phenotype to GdnHCl-exposed 
[PSI+] cells.  
 
 
 
 
 
 
 
Figure 4.3 Single colony assay to assess the curing ability of TA. Approximately 250 
cells were plated evenly on YPD containing 1) 0 µM TA + 200 µM GdnHCl and 2) 5 
µM TA + 200 µM GdnHCl. Plates were incubated at 30ºC for 72 hr. [psi-] phenotypes 
were confirmed by mating and growth on –ade was absent.  
 
 It was necessary to investigate whether or not the cells cured by TA were truly 
[psi-]. From the plates illustrated in figure 4.3, single colonies were removed and 
restreaked onto fresh YPD plates. Cells from plates containing 5 µM TA and 200 µM 
GdnHCl maintain a [psi-] state. Single colonies restreaked from plates containing only 5 
µM TA or 200 µM GdnHCl alone remain predominantly [PSI+] (figure 4.4).   
 
 
 
 
 
 
 
 
Figure 4.4 Examining if cells cured by TA remain [psi-] when grown on YPD. 
Colonies on plate 1) were originally exposed to 200 µM GdnHCl alone, 2) were 
exposed to 5 µM TA alone and 3) were treated with a combination of 5 µM TA and 200 
µM GdnHCl. [psi-] phenotypes were confirmed by mating and growth on –ade was 
absent.  
    
0 µM TA + 200 µM GdnHCl 5 µM TA + 200 µM GdnHCl
Plate 2
1 2 3
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For all plate assays described above, higher concentrations of TA were also 
tested. 10 µM, 15 µM, 20 µM and 30 µM TA with 200 µM GdnHCl did not 
significantly cure [PSI+] better than 5 µM TA (data not shown). Interestingly, it was 
noted when comparing the effects of 20 µM TA + 0 µM GdnHCl and 20 µM TA + 200 
µM GdnHCl, the latter caused much smaller single colonies, suggesting a combination 
of GdnHCl and TA at these concentrations inhibits rapid cell growth.   
 
4.2.2 6-aminophenanthridine cures [PSI+] at relatively low concentrations in 
combination with GdnHCl 
 
Provisional curing experiments were performed for 6AP as for TA and similar 
results were observed (figure 4.5). 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Single colony assay to assess the curing ability of 6AP. Plates were 
incubated at 30ºC for 72 hr. A range of 6AP concentrations were tested, in combination 
with 200 µM GdnHCl. [psi-] phenotypes were confirmed by mating and growth on –ade 
was absent.  
5 µM 6AP 200 µM GdnHCl 10 µM 6AP 200 µM GdnHCl
15 µM 6AP 200 µM GdnHCl 30 µM 6AP 200 µM GdnHCl
0 µM 6AP 200 µM GdnHCl
 243 
Figure 4.5 illustrates the fact that 5 µM 6AP in combination with 200 µM GdnHCl 
cures [PSI+] as efficiently as 30 µM 6AP. 
 
4.2.3 Guanabenz cures [PSI+] at relatively low concentrations in combination 
with GdnHCl 
 
As for TA and 6AP, the ability of GA to cure yeast [PSI+] was assessed. Various 
concentrations were analysed and again, relatively low concentration were found to cure 
the prion as efficiently as higher concentrations. Figure 4.6 shows that 5 µM GA in 
combination with 200 µM GdnHCl cures [PSI+] as efficiently as 30 µM GA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Single colony assay to assess the curing ability of GA. Plates were 
incubated at 30ºC for 72 hr. [psi-] phenotypes were confirmed by mating and growth on 
–ade was absent.  
 
5 µM GA 200 µM GdnHCl 10 µM GA 200 µM GdnHCl
15 µM GA 200 µM GdnHCl 30 µM GA 200 µM GdnHCl
0 µM GA 200 µM GdnHCl
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4.3 Examining the ability of TA to cure prions in the absence of yeast growth 
Regarding the mode of action of TA, one hypothesis was that TA may inhibit 
Hsp104p activity in a similar manner to GdnHCl. It has been demonstrated that active 
cell growth is required for GdnHCl to cure [PSI+] (Byrne et al., 2007). Thus, the 
requirement for cell division in TA curing of [PSI+] was assessed, to investigate if TA is 
similar to GdnHCl in this respect. An experiment was designed to test the curing 
efficacy of TA in the absence of yeast growth (figure 4.7). 
Three G600 cultures were set up, each containing fresh media, GdnHCl and TA. 
Cultures 1 and 2 were incubated at 30ºC overnight and went through nine generations, 
while culture 3 maintained at 4ºC overnight only doubled once. These cells were plated 
on YPD and colour was observed after 48 hr at 30ºC. Colonies grown from culture cells 
1 and 2 were approximately 40% [psi-], while those from culture 3 were 100% [PSI+]. 
This demonstrated that growth is required for TA to cure [PSI+], as although cultures 
had been exposed to the drugs for the same amount of time, only the cells that 
underwent a considerable amount of growth became [psi-]. Media was replenished in 
culture 1 only and fresh drugs were added to all. Samples from each culture were then 
plated at three further time points. As culture 2 did not contain fresh media, efficient 
growth did not occur as for culture 1 and this resulted in a lower number of [psi-] cells. 
Strikingly, the cells in culture 3 remained 100% [PSI+] as during the experiment, cells 
only progressed through one generation. Taken together, this result provides evidence 
that similarly to GdnHCl, active growth is required for TA to exhibit curing effects. 
 
4.4 Curing curve analysis 
As already stated, GdnHCl acts by inhibiting Hsp104p-mediated prion 
propagation. In the absence of prion seed renewal, the propagons are diluted out over 
subsequent generations (Eaglestone et al., 2000). 
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Figure 4.7 Growth of cells is required for TA to cure [PSI+]. Plates were incubated at 
30ºC for 72 hr. Experiment was performed as described in the above text. 
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To investigate whether TA functions in a similar manner, a curing curve technique was 
employed. Unpublished work by Jones et al. has demonstrated that 200 µM GdnHCl 
alone is not sufficient to merit a similar effect to that seen in figure 4.8 and that for 
similar data to be obtained, cells must be exposed to at least 3 mM GdnHCl alone. 
Figure 4.8 illustrates that when cells are exposed to TA in combination with 
GdnHCl, after six generations the percentage of [PSI+] cells begins to fall as cells begin 
to be cured of the prion. After 11 generations the population is virtually completely [psi-
]. This raises the possibility that TA may be preventing prion replication rather than 
abolishing prions, leaving the pre-existing prions to be diluted out over time, in a 
similar manner to GdnHCl. It must also be noted that there is no considerable difference 
in curing capacity between 20, 40 and 60 µM TA, as all give rise to a similar curing 
curve.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Curing curve depicting the percentage [PSI+] remaining after TA 
exposure for 11 generations.    
 
Although little is known about the mode of action utilised by TA to cure yeast 
prions, somewhat more is known about 6AP and GA. Unlike TA, both 6AP and GA 
exhibit anti-prion activity against mammalian prions, in addition to yeast prions 
(Tribouillard-Tanvier et al., 2008a, Tribouillard-Tanvier et al., 2008b). It has been 
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shown that 6AP and GA inhibit ribosomal-mediated protein folding (Tribouillard-
Tanvier et al., 2008b), thus prion maintenance in the cell could be facilitated by rRNA. 
If this is the case, 6AP- and GA-mediated prion curing may be equivalent to GdnHCl 
anti-prion activity in that both inhibit chaperone activity that is essential for prion 
propagation. 
Curing curve analysis was performed to examine the trend associated with [PSI+] 
curing by 6AP and GA. In figure 4.9 it can be seen that after five generations, all three 
concentrations of 6AP begin to exhibit curing effects on G600. By eleven generations, 
almost 80% of cells are [psi-]. The 6AP curing curve is very different to that for TA as 
there is a more rapid decrease in the percentage of [PSI+] cells remaining and the 
decline occurs earlier in the drug exposure.      
 
 
      
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.9 Curing curve depicting the percentage [PSI+] remaining after 6AP 
exposure for 11 generations.   
 
As for TA and 6AP, a curing curve was constructed to illustrate the potency and 
curing trend of GA. The GA curing curve is more similar to that for 6AP than TA, as 
depicted by figure 4.10. Signs of GA activity are observed after five generations and the 
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fall in percentage of [PSI+] cells was rapid. At ten generations almost 80% of cells are 
[psi-].   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Curing curve depicting the percentage [PSI+] remaining after GA 
exposure for 10 generations. 
 
4.5 Employment of [14C]-labelled GdnHCl to test the level of GdnHCl uptake 
by S. cerevisiae 
 
Jones et al. (2003) showed that increased sensitivity to [PSI+] curing by  
GdnHCl can be a result of enhanced cellular uptake of the compound. We utilised [14C]-
labelled GdnHCl with a view to analyse the effects of TA on its uptake. This followed 
the hypothesis that the ability of TA to enhance the effects of GdnHCl may be due to 
the drug inducing a higher level of GdnHCl uptake. It was anticipated that over time, 
the level of [14C] measured for the supernatant would fall and that for the cell pellet 
would rise, representing GdnHCl uptake by the cells. In comparing the levels of [14C]-
labelled GdnHCl in the cell pellets and supernatants of wild-type strains 74D (discussed 
in more detail later) and G600, no real differences were observed between the two 
strains (figure 4.11). Over 75 min., the cellular concentration of [14C]-labelled GdnHCl 
remained relatively constant, as did the concentration in both supernatants. 
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Figure 4.11 Determination of the level of [14C]-labelled GdnHCl in 74D and G600 
cultures. At the indicated intervals, samples were taken from cultures, cells were 
separated from supernatants and the levels of [14C] in both were measured in triplicate.   
 
 The same procedure was carried out using mutant strains and various incubation 
times, including 24 hr. However, an increase in pellet readings representing uptake of 
GdnHCl was never observed. 
 
4.6 Assessing if TA targets Hsp104p using a thermotolerance assay 
Hsp104p plays an essential role in acquired thermotolerance (Sanchez and 
Lindquist, 1990). When yeast cells are exposed to high temperatures such as 52ºC, 
Hsp104p activity allows cells to survive by resolubilising heat-damaged proteins 
(Parsell et al., 1994). We used a well established thermotolerance assay to assess the 
effects of drugs on Hsp104p, whereby cell survival represented functional Hsp104p 
activity. Figure 4.12 depicts the ability of wild-type G600 to withstand a temperature of 
52ºC in the presence of a variety of drug concentrations. Increased cell death occurs 
with longer 52ºC exposure times (A), when 3 mM GdnHCl is applied to the agar, there 
is significant cellular growth inhibition as Hsp104p activity is inhibited (B), the 
presence of 200 µM GdnHCl does not exhibit a significant effect on cellular 
thermotolerance (C), nor does 20 µM TA alone (D). A combination of 20 µM TA and 
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200 µM GdnHCl considerably inhibits the ability of cells to withstand high 
temperatures, however not to the same extent as 3 mM GdnHCl (E). 
 
  
 
    
 
 
 
 
 
 
 
 
Figure 4.12 The effect of TA and GdnHCl on G600 thermotolerance. G600 cells 
were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
  
The same experiment was carried out using G600 deleted for HSP104. Figure 
4.13 represents the ability of G600 to grow at high temperatures when HSP104 has been 
deleted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 The effect of TA and GdnHCl on G600 ∆hsp104 thermotolerance. 
G600 ∆hsp104 cells were incubated at 39ºC and then at 52ºC for 0, 10, 20, 30 and 40 
minutes and plated on YPD containing GdnHCl and TA, as indicated above for 
comparative growth analysis. Plates above were incubated at 30ºC for 48 hr. 
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Images A-E in figure 4.13 are all very similar. G600 ∆hsp104 cells cannot 
survive at 52ºC for more than 10 min due to lack of ability to refold heat-damaged 
proteins. Heat-shocked cells plated on YPD (A) exhibit the same level of growth as 
wild-type treated with 3 mM GdnHCl, illustrated in the previous figure. No drug 
concentrations give rise to differential phenotypes, possibly because all abrogate 
Hsp104p activity, which in this case is absent.   
 Further to this, additional thermotolerance assays were performed to investigate 
if higher levels of TA induced more pronounced effects (figure 4.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 The effect of higher TA concentrations on G600 thermotolerance. 
G600 cells were incubated at 39ºC and then at 52ºC for 0, 10, 20, 30 and 40 minutes and 
plated on YPD containing GdnHCl and TA, as indicated above for comparative growth 
analysis. Plates above were incubated at 30ºC for 48 hr. 
 
In comparing the effects of 20 µM, 50 µM and 100 µM TA alone (B, D, F), 
there are no considerable differences in wild-type yeast growth. It does appear however 
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that in the presence of GdnHCl, 50 µM and 100 µM TA inhibit thermotolerance 
somewhat more than 20 µM (C, E, G), but the difference is small. 
The level of G600 ∆hsp104 thermotolerance was also tested in the presence of 
higher concentrations of TA, alone and combined with GdnHCl (figure 4.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 4.15 The effect of higher TA concentrations on G600 ∆hsp104 
thermotolerance. G600 ∆hsp104 cells were incubated at 39ºC and then at 52ºC for 0, 
10, 20, 30 and 40 minutes and plated on YPD containing GdnHCl and TA, as indicated 
above for comparative growth analysis. Plates above were incubated at 30ºC for 48 hr. 
 
No differences in growth were observed between treatment with 20 µM, 50 µM 
or 100 µM TA. This again suggests that TA may be targeting Hsp104p, as in its absence 
no inhibition is induced.  
 
4.7 Thermotolerance assay using 6AP 
Thermotolerance assays using G600 and G600 ∆hsp104 were performed and 
resultant cellular growth was assessed in the presence of 6AP. As depicted by figure 
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4.16, 20 µM 6AP alone does not affect G600 thermotolerance. Combined with 200 µM 
GdnHCl, there is still no significant inhibition of growth.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 The effect of 6AP and GdnHCl on G600 thermotolerance. G600 cells 
were incubated at 39ºC and then at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on 
YPD containing GdnHCl and 6AP, as indicated above for comparative growth analysis. 
Plates above were incubated at 30ºC for 48 hr. 
 
Thermotolerance assays using G600 and G600 ∆hsp104 were performed and 
resultant cellular growth was assessed in the presence of GA. A similar result was 
obtained for GA as for 6AP.  
 
4.8 Assessing the effect of HSP70-related mutations on the prion-curing 
efficiency of TA, 6AP and GA 
 
Disruption of the Hsp70p ATPase binding cycle, involving a number of co-
chaperones and NEFs as previously discussed, appears to impair prion propagation 
(Jones and Tuite, 2005). The ability of TA, 6AP and GA to cure strains deleted for 
genes involved in the Hsp70p ATPase binding cycle was analysed. We hypothesised 
that if these drugs either directly or indirectly target this cycle, then treating HSP70-
related mutants would exacerbate the prion-curing efficiency of the drugs. 
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Drug spotting assays were designed whereby cells were spread evenly onto YPD 
plates and drugs were spotted onto filter paper discs on plates. As contols, DMSO and 3 
mM GdnHCl was also spotted onto plates. As GdnHCl presence is required for TA, 
6AP and GA curing to be visualised, GdnHCl was added to the plates at concentrations 
of 0, 200 and 500 µM. 
Figure 4.17 demonstrates that TA alone has no visible effect on wildtype. 
However, with increasing concentrations of GdnHCl within the growth media, TA 
curing can be seen. Conversely, TA alone has the ability to cure [PSI+] cells deleted for 
STI1, CPR7 and the double mutant, and this is enhanced by the presence of GdnHCl. It 
appears that the double mutant displays the most exacerbated curing effect. It is 
therefore possible that TA could be affecting the Hsp70p ATPase binding cycle. It 
could be the case that the deletion of Hsp70p co-chaperone genes in combination with 
cellular exposure to TA results in a greater impairment of the binding cycle, giving rise 
to an enhanced [psi-] phenotype. 
It is clear from figures 4.18 and 4.19 that deletion of genes involved in the 
Hsp70p ATPase binding cycle renders cells more susceptible to curing by all three 
drugs. All mutant strains tested, deficient in fully functional Hsp70p ATPase activity, 
were cured by the drugs in the absence of GdnHCl. This contrasted drastically from 
wild-type, which required the presence of GdnHCl to undergo [PSI+] curing by any one 
of the agents. 
Additionally, it appears that GA possesses considerably weaker curing capacity 
than TA or 6AP. For each strain tested, the zone of curing resulting from GA exposure 
is smaller than that induced by either TA or 6AP. It must be considered however that 
this may be specific to the G600 background strain. 
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Figure 4.17 Disc assay for Hsp70p-related mutants assessing the curing activity of 
TA. The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and 
the bottom disc contains 10 mM TA. Plates above were incubated at 30ºC for 72 hr. 
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Figure 4.18 Disc assay for Hsp70p-related mutants assessing the curing activity of 
6AP. The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and 
the bottom disc contains 10 mM 6AP. Plates above were incubated at 30ºC for 72 hr. 
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Figure 4.19 Disc assay for Hsp70p-related mutants assessing the curing activity of 
GA. The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and 
the bottom disc contains 10 mM GA. Plates above were incubated at 30ºC for 72 hr. 
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4.9 Analysis of the G600 Hsp70p and Hsp104p expression levels in response to 
TA, 6AP and GA exposure 
 
Lahiri (1994) reported that TA does not induce a change in the level of Hsp70p 
in mammalian cell lines. Western blot analysis was performed to investigate if the same 
applies to yeast cells. The effects of TA, 6AP and GA on G600 expression of Hsp70p 
and Hsp104p was assessed.  
 Figure 4.20 demonstrates that no detectable differences in the levels of Hsp70p 
and Hsp104p expression are induced by TA, 6AP or GA. Untreated G600 expresses the 
same level of Hsp70p and Hsp104p as cells treated with GdnHCl alone and in 
combination with the said drugs. 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 Western blot representing the expression of Hsp70p (Ssa1p) and 
Hsp104p in response to drug exposure. 1 = untreated G600, 2 = G600 200 µM 
GdnHCl exposure, 3 = G600 200 µM GdnHCl + 20 µM 6AP exposure, 4 = G600 200 
µM GdnHCl + 20 µM GA exposure, 5 = G600 200 µM GdnHCl + 20 µM TA exposure, 
6 = untreated G600, 7 = untreated G600 ∆hsp104.    
 
4.10 Assessment of [PSI+] instability in four mutant strains exhibiting ribosomal 
imbalance 
 
Using the yeast [PSI+] 74D-694 (74D) strain, it has been suggested that deletion 
of YAR1, LTV1, RPL8A and RPL8B confers yeast ribosomal imbalance and [PSI+] 
instability (M. Blondel, personal communication). Wild-type 74D deleted for these 
genes were plated on YPD. Figure 4.21 depicts the spontanaeous appearance of [psi-] 
colonies in the strains deleted for YAR1 and LTV1, but not RPL8A or RPL8B. 
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Figure 4.21 Plates depicting [PSI+] instability in ∆ltv1 and ∆yar1 strains. 1) Top = 
74D, left = ∆yar1, right = ∆ltv1. 2) Top = 74D, left = ∆rpl8b, right = ∆rpl8a. Plates 
were incubated at 30ºC for 48 hr.  
 
4.11 Investigation into the importance of ribosomal subunit balance in [PSI+] 
curing by TA, 6AP and GA  
 
6AP and GA exposure has been reported to stabilise the weak prion in ∆yar1, 
∆ltv1, ∆rpl8a and ∆rpl8b (M. Blondel, personal communication). The effects of TA, 
6AP and GA on [PSI+] in these mutant strains was assessed using disc assays.  
In figures 4.22-4.24, the pinker colonies of the mutant strains will be due to the 
effects of the absence of YAR1/LTV1/RPL8A/RPL8B on [PSI+]. Firstly, figure 4.22 
confirms that TA possesses the capacity to cure [PSI+] in this 74D strain. The mutant 
that cures most similarly to wild-type under TA exposure is ∆yar1. The curing patterns 
of ∆rpl8a and ∆rpl8b also resemble that of 74D. ∆ltv1 however does not appear to 
undergo [PSI+] curing to the same extent as the other strains. Rather than enhance the 
curing induced by TA, the higher GdnHCl concentration appears to repress the 
conversion of cells to a [psi-] state. 
 
 
1 2
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Figure 4.22 Disc assay for ribosome mutants assessing the curing activity of TA. 
The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and the 
bottom disc contains 10 mM TA. Plates were incubated at 30ºC for 72 hr. 
 
 Figures 4.23 and 4.24 demonstrate the ability of 6AP and GA to cure these 
mutants in the 74D background strain.  
74D 
∆yar1 
∆ltv1 
∆rpl8a 
∆rpl8b 
 
YPD 200 µM GdnHCl 500 µM GdnHCl 
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Figure 4.23 Disc assay for ribosome mutants assessing the curing activity of 6AP. 
The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and the 
bottom disc contains 10 mM 6AP. Plates were incubated at 30ºC for 72 hr. 
 
Figure 4.23 demonstrates that 6AP also possesses the capacity to cure [PSI+] in 
the 74D strain. As for TA, ∆yar1, ∆rpl8a and ∆rpl8b all display a similar curing pattern 
to wild-type under 6AP exposure, while that for ∆ltv1 is quite different. It appears that 
6AP has even less of a [PSI+] curing effect on ∆ltv1 than TA, as the curing zones are 
considerably smaller and less red. 
74D 
∆yar1 
∆ltv1 
∆rpl8a 
∆rpl8b 
 
YPD 200 µM GdnHCl 500 µM GdnHCl YPD 200µM GdnHCl 500µM GdnHCl
YPD 200µM GdnHCl 500µM GdnHCl
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Figure 4.24 Disc assay for ribosome mutants assessing the curing activity of GA. 
The top left disc contains DMSO, the top right disc contains 3 mM GdnHCl and the 
bottom disc contains 10 mM GA. Plates were incubated at 30ºC for 72 hr. 
 
Figure 4.24 suggests that GA overall does not possess the ability to cure [PSI+] 
to the extent that TA or 6AP do, in the 74D background. All curing zones are 
significantly smaller. However, a similar conclusion can be drawn from the GA disc 
assay as for TA and 6AP. Yet again, all strains exhibit similar curing patterns, with the 
exception of ∆ltv1.        
74D 
∆yar1 
∆ltv1 
∆rpl8a 
∆rpl8b 
 
YPD 200 µM GdnHCl 500 µM GdnHCl 
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Taking all three disc assays into account, it appears that ribosomal imbalance 
does not exaggerate curing induced by these drugs, as was seen for the Hsp70p-related 
mutants. Also, these results support the previously described work that demonstrated the 
ability of prion-curing drugs to stabilise the prion in these mutant strains. In 
combination with increasing levels of GdnHCl, TA, 6AP and GA all appeared to 
display an agonistic effect on [PSI+]. 
 
4.12 74D, ∆yar1 and ∆ltv1 thermotolerance assays 
Inhibition of both Hsp104p and ribosomal-mediated protein folding are believed 
to cure [PSI+] (Chernoff et al., 1995, Eaglestone et al., 2000, Tribouillard-Tanvier et al., 
2008b). Thus, chaperone activity displayed by Hsp104p and the ribosome appear to be 
involved in prion propagation and [PSI+] maintenance. To address the question of 
whether Hsp104p and ribosomal chaperone activity overlap in relation to acquired 
thermotolerance, thermotolerance assays were performed using ∆hsp104 the mutants 
exhibiting ribosomal imbalance. Figure 4.25 illustrates 74D thermotolerance in the 
presence of GdnHCl and TA. 
 
  
 
 
 
 
 
 
 
 
Figure 4.25 The effect of TA and GdnHCl on 74D thermotolerance. Cells were 
incubated at 39ºC to induce Hsp104p expression to protect against heatshock. Cells 
were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
A) YPD C) 200 µM GdnHClB) 3 mM GdnHCl
D) 20 µM TA E) 20 µM TA + 200 µM GdnHCl
0 mins
0 mins
10 mins
10 mins
20 mins
20 mins
30 mins
30 mins
40 mins
40 mins
52ºC
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 74D is somewhat less tolerant to heatshock than G600, as there is no cellular 
survival after exposure to 52ºC for 40 min (A). Besides that, similar effects on 
thermolerance are induced by TA on 74D as seen for G600. 3 mM GdnHCl 
significantly inhibits thermotolerance (B), while 20 µM TA and 200 µM GdnHCl alone 
and do not obviously affect thermotolerance (C, D). However, exposure to a 
combination of the two results in a slight decrease in growth after heatshock, although 
this is not as pronounced as was observed for G600 (E).       
 As was observed for G600 ∆hsp104, 74D deleted for the HSP104 gene (A) 
displayed a similar level of thermotolerance as wild-type exposed to 3 mM GdnHCl 
(figure 4.26). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 The effect of TA and GdnHCl on 74D ∆hsp104 thermotolerance. Cells 
were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
 
Further to this, no significant inhibition in thermotolerance was induced by drug 
treatment (B-E). 
Moreover, we wanted to investigate the 74D ∆hsp104 level of thermotolerance 
after 52ºC exposure during shorter intervals. Thus we plated cells heatshocked for 0, 2, 
A) YPD C) 200 µM GdnHClB) 3 mM GdnHCl
D) 20 µM TA E) 20 µM TA + 200 µM GdnHCl
0 mins
0 mins
10 mins
10 mins
20 mins
20 mins
30 mins
30 mins
40 mins
40 mins
52ºC
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4, 6, 8 and 10 min. Additionally, the effect on thermotolerance of higher concentrations 
of TA were also assessed, as shown in figure 4.27.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 The effect of higher TA concentrations on 74D ∆hsp104 
thermotolerance. Cells were incubated at 39ºC to induce Hsp104p expression to 
protect against heatshock. Cells were then incubated at 52ºC for 0, 2, 4, 6, 8, 10 minutes 
and plated on YPD containing GdnHCl and TA, as indicated above for comparative 
growth analysis. Plates above were incubated at 30ºC for 72 hr. 
 
 As depicted in the figure above, 100 µM TA in combination with 200 µM 
GdnHCl (F) does not inhibit thermotolerance any more than 20 µM TA with GdnHCl 
does (D). The same figure illustrates that is it only after 8 min at 52ºC that cells begin to 
lose the ability to withstand the high temperature. 
 It can be seen in figure 4.28 that in the absence of LTV1, 74D does not exhibit as 
high a degree of thermotolerance as wild-type (A). 3 mM GdnHCl significantly inhibits 
the growth of this ∆ltv1 (B), and in fact hinders the thermotolerance of this strain more 
than ∆hsp104. Interestingly, ∆ltv1 displays a higher level of thermotolerance than 
A) YPD B) 200 µM GdnHCl
C) 20 µM TA D) 20 µM TA + 200 µM GdnHCl
0 mins
2 mins
4 mins
6 mins
10 mins
52ºC
8 mins
0 mins
2 mins
4 mins
6 mins
10 mins
8 mins
0 mins
2 mins
4 mins
6 mins
10 mins
8 mins
E) 100 µM TA F) 100 µM TA + 200 µM GdnHCl
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∆hsp104 when untreated, but thermotolerance inhibition by 3 mM GdnHCl is more 
acute in ∆ltv1 than ∆hsp104.     
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28 The effect of TA and GdnHCl on 74D ∆ltv1 thermotolerance. Cells 
were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
 
 As illustrated in figure 4.29, the double mutant ∆ltv1∆hsp104 is unable to 
survive after 10 min 52ºC heatshock. 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 The effect of TA and GdnHCl on 74D ∆ltv1∆hsp104 thermotolerance. 
Cells were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
 
A) YPD C) 200 µM GdnHClB) 3 mM GdnHCl
D) 20 µM TA E) 20 µM TA + 200 µM GdnHCl
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In figure 4.30 it can be seen that ∆yar1 appears to be hypersensitive to extreme 
temperatures (A), much moreso than ∆ltv1. With the exception of exposure to 3 mM 
GdnHCl (B), all other treatments seem to affect cell growth quite similarly (C-E). The 
naturally low level of ∆yar1 thermotolerance is highly repressed by 3 mM GdnHCl.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30 The effect of TA and GdnHCl on 74D ∆yar1 thermotolerance. Cells 
were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
      
Interestingly, it appears from figure 4.31, that in general, cells grow better when 
HSP104 is deleted in the ∆yar1 strain. While ∆yar1 does not grow after 10 min. 
incubation at 52ºC, ∆yar1∆hsp104 does (A). ∆yar1∆hsp104 also grows better than 
∆yar1 under 3 mM GdnHCl  exposure (B). A similar result was obtained for cells 
exposed to 20 µM TA and 200 µM GdnHCl after heatshock, as the double mutant 
consistently grew more strongly than ∆yar1 (C-E). From this, there appears to be a 
positive genetic effect from the deletion of HSP104 in ∆yar1. 
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Figure 4.31 The effect of TA and GdnHCl on 74D ∆yar1∆hsp104 thermotolerance. 
Cells were incubated at 39ºC to induce Hsp104p expression to protect against heatshock. 
Cells were then incubated at 52ºC for 0, 10, 20, 30 and 40 minutes and plated on YPD 
containing GdnHCl and TA, as indicated above for comparative growth analysis. Plates 
above were incubated at 30ºC for 48 hr. 
 
4.13 Assessing the effects of YAR1 and LTV1 deletion on heatshock recovery in 
yeast 
 
Luciferase assays were performed to investigate how the absence of LTV1 and 
YAR1 effects yeast chaperone function. As chaperone activity, particularly that of 
Hsp104p, is essential in facilitating cellular recovery after heatshock, this particular 
aspect of chaperone function was examined.      
pDCM90 is a URA3-based plasmid containing a gene for expression of a 
thermolabile bacterial luciferase and was used as a reporter vector allowing analysis of 
luciferase protein function after heatshock. Decanal is a substrate for bacterial luciferase 
and upon reaction light is emitted, which can can be measured using a luminometer. 
pDCM90 was transformed into strains used in this assay, which in culture were 
subsequently incubated at 37ºC to induce heatshock protein expression. Luciferase 
activity was measured at this point and taken to represent full protein activity. Cultures 
were then exposed to 45ºC to subject the cells to heatshock conditions, after which 
luciferase activity was measured again. Cells were incubated at 25ºC to allow recovery 
and luciferase activity measurements were taken at regular intervals. 
A) YPD C) 200 µM GdnHClB) 3 mM GdnHCl
D) 20 µM TA E) 20 µM TA + 200 µM GdnHCl
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Figure 4.32 shows the rate at which luciferase activity recovers over time after 
heatshock, reflecting the ability of chaperone proteins to refold luciferase into its 
functional state. In the absence of LTV1, luciferase activity recovers more rapidly, while 
recovery is fastest in the ∆yar1 strain. This suggests that deletion of LTV1 and YAR1 has 
a positive effect on the chaperone protein activity and the ability of yeast cells to 
efficiently recover after thermostress. Cells deleted for HSP104 are unable to recover 
luciferase function efficiently as Hsp104p plays an important role in yeast 
thermotolerance (Sanchez and Lindquist, 1990). As the absence of LTV1 and YAR1 
have positive effects on luciferase activity recovery, it was anticipated that deletion of 
these genes in the ∆hsp104 backgound would assist in compensating for the lack of 
Hsp104p, however this did not occur. Disruption of both LTV1 and YAR1 function 
appears to exacerbate the inability of ∆hsp104 heatshock recovery. Although ∆yar1 
chaperone activity recovered most rapidly, that of ∆yar1∆hsp104 was the slowest to 
recover. ∆ltv1 recovered second fastest and ∆ltv1∆hsp104 recovered second slowest.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32 Luciferase assay for 74D and HSP104, LTV1 and YAR1 deletion strains. 
Student t-test determined that when comparing control and mutant strain recovery 
readings,  p<0.05 for all but ∆ltv1 at 30, 90 and 120 min., ∆yar1 at 30 and 90 min. and 
∆ltv1∆hsp104 at 0 min. 
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4.14 Analysis of 74D sensitivity to temperature change 
 
Acquired thermotolerance assays performed suggested differences in G600 and 
74D ability to grow at high temperatures. Comparative growth analyses were carried out 
and cells exposed to 30ºC, 37ºC and 39ºC were analysed (figure 4.33). This revealed 
that at 37ºC, 74D growth begins to falter. Although G600 grows well at 39ºC, it appears 
that 74D does not grow at all. It can thus be concluded that 74D is substantially more 
temperature sensitive (TS) than G600.   
 
 
 
 
 
Figure 4.33 Comparative growth analysis of G600 and 74D on YPD at 30ºC, 37ºC 
and 39ºC. Plates above were incubated at the indicated temperature for 48 hr. 
 
 
4.15 Identification of 74D single nucleotide polymorphisms (SNPs) and possible 
implications for temperature sensitivity 
 
Next generation sequencing was performed to obtain data that might account for 
the high level of 74D temperature sensitivity. The genome sequence of 74D was 
retrieved and compared to the reference S. cerevisiae sequenced strain S288C 
(Fitzpatrick et al., paper currently under review). Approximately 25,500 high quality 
SNPs were identified in strain 74D, equating to approximately 5,500 non-synonymous 
amino acid changes. A complete summary list of 74D SNPs, with corresponding amino 
acid changes, are shown in table 4.1. 
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74D
G600
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Table 4.1 SNPs identified in 74D compared to reference strain S288C and 
corresponding amino acid changes. Gene information was obtained from 
www.yeastgenome.org (SGD). 
 
Chromosome Size 
(bp) 
ORFs Total 
number 
of SNPs 
SNPs 
in 
ORFs 
Non- synonymous 
amino acid changes 
I 230,208 117 923 559 200 
II 813,178 456 1443 955 309 
III 316,616 183 614 306 122 
IV 1,531,919 836 2243 1380 482 
V 576,869 324 1156 590 193 
VI 270,148 141 507 245 86 
VII 1,090,947 583 2611 1588 627 
VIII 562,643 321 1678 1080 386 
IX 439,885 241 1907 1065 383 
X 745,741 398 1284 808 310 
XI 666,454 348 1925 1117 365 
XII 1,078,175 578 1752 1118 342 
XIII 924,429 505 1533 978 368 
XIV 784,333 435 1846 1147 411 
XV 1,091,289 598 2619 1659 566 
XVI 948,062 510 1584 1007 361 
mito 85,779 28 212 67 5 
Totals 12,070,898 6,602 25,837 15,669 5,516 
 
Many SNPs that led to non-synonymous changes were identified in chaperone 
and cochaperone proteins, as described in table 4.2. The extreme temperature sensitivity 
of 74D may be attributed to all or some of these mutations. 
 
Table 4.2 Missense mutations in chaperone and cochaperones implicated in prion 
propagation. Gene functions were obtained from www.yeastgenome.org (SGD).   
  
Gene 
name 
Biological functiona Chromosomal SNP 
position(s) 
Non- 
synonymous 
change(s) 
 
SSA1 ATPase involved in protein 
folding and nuclear localization 
signal (NLS)-directed nuclear 
transport; member of heat shock 
protein 70 (Hsp70) family; 
forms a chaperone complex with 
Ydj1; localized to the nucleus, 
cytoplasm, and cell wall 
141,186 A83G 
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HSF1 Trimeric heat shock 
transcription factor, activates 
multiple genes in response to 
stresses that include 
hyperthermia; recognizes 
variable heat shock elements 
(HSEs) consisting of inverted 
NGAAN repeats; 
posttranslationally regulated 
369,170 
369,356 
369,366 
369,603 
369,669 
369,884 
370,320 
370,350 
370,644 
370,650 
370,740 
371,247 
D139N 
F201L 
T204M 
N283S 
S305I 
Q377K 
S522F 
P532L 
W630L 
N632S 
S662W 
A831V 
CPR7 Peptidyl-prolyl cis-trans 
isomerase (cyclophilin), 
catalyzes the cis-trans 
isomerization of peptide bonds 
N-terminal to proline residues; 
binds to Hsp82 and contributes 
to chaperone activity 
491,334 
491,782 
S87L 
L237F 
YDJ1 Protein chaperone involved in 
regulation of the Hsp90 and 
Hsp70 functions; involved in 
protein translocation across 
membranes; member of the 
DnaJ family 
507,059 
506,921 
506,907 
P14S 
P60S 
D64E 
APJ1 Putative chaperone of the 
HSP40 (DNAJ) family; 
overexpression interferes with 
propagation of the [PSI+] prion 
482,040 
482,961 
K217E 
D524N 
STI1 Hsp90 cochaperone, interacts 
with the Ssa group of the 
cytosolic Hsp70 chaperones; 
activates the ATPase activity of 
Ssa1; homolog of mammalian 
Hop protein 
381,777 K242R 
SSE1 ATPase that is a component of 
the heat shock protein Hsp90 
chaperone complex; binds 
unfolded proteins; member of 
the heat shock protein 70 
(Hsp70) family; localized to the 
cytoplasm 
350,651 G541A 
HSP82 Hsp90 chaperone required for 
pheromone signaling and 
negative regulation of Hsf1; 
docks with Tom70 for 
mitochondrial preprotein 
delivery; promotes telomerase 
DNA binding and nucleotide 
addition 
97,732 N298K 
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4.16 Exploration for genes that confer 74D thermotolerance 
 
A high-copy plasmid screen was carried out in an attempt to identify genes that 
when overexpressed confer increased thermotolerance to 74D and overcome the 
extreme temperature sensitivity exhibited by the strain. High-copy yEP13 plasmids 
were transformed into 74D and cells were grown at 39ºC. Transformants were isolated 
that possessed the ability to grow at this temperature, as illustrated in figure 4.34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34 Comparative growth analysis representing strains that retain the 
capacity to survive at 39ºC as a result of high-copy plasmid. Plates were incubated at 
30ºC for 48 hr. Ten strains transformed with high-copy plasmids demonstrate ability to 
grow at 39ºC, unlike 74D.   
  
The transformants that grew well when containing the high-copy yEP13 plasmid 
were isolated and the plasmids were extracted. These plasmids were Agowa sequenced 
to determine what genes they contained. The plasmids were sequenced from the ends 
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inwards to obtain sequence data for the fragment of interest on the plasmid, results for 
which are illustrated in figure 4.35. 
 
 
 
Figure 4.35 Genes encoded that when overexpressed may contribute to the 
abolition of 74D temperature sensitivity.  
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 As illustrated in figure 4.35, there is no overlap of genes that appear to encode 
products that overcome temperature sensitivity. Each plasmid when sequenced was 
found to contain a different variety of genes. This suggests that the temperature 
sensitivity of 74D is complexely attributed to a range of factors. Due to the diversity of 
plasmid sequencing results, no further work could be carried out.    
 
4.17 Comparative expression analysis of heat-shock proteins produced by G600 
and 74D using Western Blot analysis 
 
Western blot analysis was carried out to compare the levels of Hsp70p and 
Hsp104p expressed by G600 and 74D. The effects of 1 hr. 37ºC and 39ºC exposures on 
protein expression were also analysed (figure 4.36).     
 
 
 
 
 
 
 
 
 
Figure 4.36 Western blot illustrating the expression of Hsp70p (Ssa1p) and 
Hsp104p in response to increased temperatures. 1 = G600 ∆hsp104 30ºC incubation, 
2 = G600 30ºC incubation, 3 = G600 30ºC incubation 37ºC last 1 hr, 4 = G600 30ºC 
incubation 39ºC last 1 hr, 5 = 74D ∆hsp104 30ºC incubation, 6 = 74D 30ºC incubation, 
7 = 74D 30ºC incubation 37ºC last 1 hr, 8 = 74D 30ºC incubation 39ºC last 1 hr.      
 
 Figure 4.36 demonstrates that 74D expresses a lower basal level of both Hsp70p 
and Hsp104p than G600. When heat-shock proteins are induced by elevated 
temperatures, both strains produce an augmented level of both Hsp70p and Hsp104p. It 
appears that under incubation at higher temperatures G600 expresses more Hsp70p than 
74D, and a similar level of Hsp104p.  
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Section 2: Investigation into the yeast global expressional response to 
the prion-curing agent Tacrine 
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4.18 Investigation into the global expressional response of S. cerevisiae to TA 
exposure  
 
In order to further understand the way in which yeast respond to the prion-curing 
drug TA, we assessed the global transcriptional and proteomic responses, employing 
RNA sequencing and two-dimensional gel electrophoresis techniques. Since we have 
shown that in wild-type cells, TA requires the presence of GdnHCl to induce an effect, 
the cellular response to GdnHCl alone and in combination with TA was explored. 
 
4.18.1 Using transcriptomics to assess the S. cerevisiae response to TA  
RNA sequencing analysis was carried out on G600 cells and data obtained was 
compared  
1. From untreated samples  
2. From samples treated with 200 µM GdnHCl for 14 generations 
3. From samples treated with 200 µM GdnHCl + 20 µM Tacrine for 14 generations 
and 
4. From untreated samples 
5. From samples treated with 200 µM GdnHCl + 20 µM Tacrine for 1 hr 
6. From samples treated with 200 µM GdnHCl + 20 µM Tacrine for 3 hr 
As for the gliotoxin response data, for each treatment, genes were first grouped into 
those upregulated and downregulated, and then sub-grouped depending on their fold 
change. Genes that displayed >2-fold increase or decrease in expression were further 
assessed. Genes were assigned gene ontology (GO) Identities reflective of the gene 
function and most were designated more than one GO Identity due to multiple functions. 
Go identities are listed in table 3.4. 
Thus, each gene was categorised respective to its biological and molecular functions, 
in addition to the cellular component affected by the expression of the gene. Analysis 
was then carried out to determine the most common GO Identities for each category, 
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associated with genes that have >2-fold up- or downregulation in response to each 
treatment. 
 
4.18.1.1 Analysis of the effect of 200 µM GdnHCl exposure for 14 generations on   
               yeast cells  
 
When yeast cells were treated for 14 generations with 200 µM GdnHCl, 134 
genes were upregulated in excess of 2-fold, 23 of them more than 3-fold. 1175 genes 
were downregulated more than 2-fold, 542 of these over 3-fold. The figures below 
illustrate the cellular components, molecular functions and biological processes 
stimulated or repressed by GdnHCl exposure and the percentages of total changes they 
represent.  
Summary of the overall effects of gene upregulation on cells 
Figures 4.37-4.39 illustrate the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 200 µM GdnHCl exposure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37 The percentage of each cellular component category (200 µM GdnHCl 
14 generation upregulated genes). Genes upregulated more than two-fold were 
assigned cellular component categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
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Figure 4.38 The percentage of each molecular function category (200 µM GdnHCl 
14 generation upregulated genes). Genes upregulated more than two-fold were 
assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39 The percentage of each biological process category (200 µM GdnHCl 
14 generation upregulated genes). Genes upregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
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  The five biological processes, molecular functions and associated cellular 
components most highly stimulated by 200 µM GdnHCl were further grouped. These 
are illustrated in figures 4.40-4.42. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.40 The five associated cellular components most highly upregulated by 
exposure to 200 µM GdnHCl for 14 generations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.41 The five molecular functions most highly upregulated by exposure to 
200 µM GdnHCl for 14 generations. 
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Figure 4.42 The five biological processes most highly upregulated by exposure to 
200 µM GdnHCl for 14 generations. 
 
 Table 4.3 lists the fifty individual genes, and their respective functions, that 
underwent the highest increase in transcription in response to 200 µM GdnHCl. 
 
Table 4.3 The fifty genes most highly upregulated in response to 200 µM GdnHCl 
exposure for 14 generations. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
OLE1 10.73 Delta(9) fatty acid desaturase, required for monounsaturated 
fatty acid synthesis and for normal distribution of 
mitochondria 
MLS1 6.17 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in 
peroxisomes during growth in oleic acid medium 
IZH4 6.17 Membrane protein involved in zinc ion homeostasis, member 
of the four-protein IZH family, expression induced by fatty 
acids and altered zinc levels; deletion reduces sensitivity to 
excess zinc; possible role in sterol metabolism 
IZH1 5.90 Membrane protein involved in zinc ion homeostasis, member 
of the four-protein IZH family; transcription is regulated 
directly by Zap1p, expression induced by zinc deficiency and 
fatty acids; deletion increases sensitivity to elevated zinc 
FBP1 5.09 Fructose-1,6-bisphosphatase, key regulatory enzyme in the 
gluconeogenesis pathway, required for glucose metabolism; 
undergoes either proteasome-mediated or autophagy-
mediated degradation depending on growth conditions; 
interacts with Vid30p 
PCK1 4.81 Phosphoenolpyruvate carboxykinase, key enzyme in 
gluconeogenesis, catalyzes early reaction in carbohydrate 
biosynthesis, glucose represses transcription and accelerates 
mRNA degradation, regulated by Mcm1p and Cat8p, located 
in the cytosol 
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CUP1-1 4.38 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
CUP1-2 4.38 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
FDH1 4.13 NAD(+)-dependent formate dehydrogenase, may protect cells 
from exogenous formate 
SMF2 3.74 Divalent metal ion transporter involved in manganese 
homeostasis; has broad specificity for di-valent and tri-valent 
metals; post-translationally regulated by levels of metal ions; 
member of the Nramp family of metal transport proteins 
SDS23 3.66 One of two S. cerevisiae homologs (Sds23p and Sds24p) of 
the S. pombe Sds23 protein, which is implicated in 
APC/cyclosome regulation; involved in cell separation during 
budding 
PHO89 3.47 Na+/Pi cotransporter, active in early growth phase; similar to 
phosphate transporters of Neurospora crassa; transcription 
regulated by inorganic phosphate concentrations and Pho4p 
ACC1 3.42 Acetyl-CoA carboxylase, biotin containing enzyme that 
catalyzes the carboxylation of acetyl-CoA to form malonyl-
CoA; required for de novo biosynthesis of long-chain fatty 
acids 
YAR035C-A 3.42 Putative protein of unknown function; identified by gene-
trapping, microarray-based expression analysis, and genome-
wide homology searching; predicted to have a role in cell 
budding based on computational "guilt by association" 
analysis 
JEN1 3.27 Lactate transporter, required for uptake of lactate and 
pyruvate; phosphorylated; expression is derepressed by 
transcriptional activator Cat8p during respiratory growth, and 
repressed in the presence of glucose, fructose, and mannose 
ATO2 3.25 Putative transmembrane protein involved in export of 
ammonia, a starvation signal that promotes cell death in aging 
colonies; phosphorylated in mitochondria; member of the TC 
9.B.33 YaaH family; homolog of Ady2p and Y. lipolytica 
Gpr1p 
YAT1 3.25 Outer mitochondrial carnitine acetyltransferase, minor 
ethanol-inducible enzyme involved in transport of activated 
acyl groups from the cytoplasm into the mitochondrial 
matrix; phosphorylated 
MRPL38 3.17 Mitochondrial ribosomal protein of the large subunit; appears 
as two protein spots (YmL34 and YmL38) on two-
dimensional SDS gels 
YDL012C 3.13 Tail-anchored plasma membrane protein containing a 
conserved CYSTM module, possibly involved in response to 
stress; may contribute to non-homologous end-joining 
(NHEJ) based on ydl012c htz1 double null phenotype 
CEM1 3.11 Mitochondrial beta-keto-acyl synthase with possible role in 
fatty acid synthesis; required for mitochondrial respiration 
ACH1 3.06 Protein with CoA transferase activity, particularly for CoASH 
transfer from succinyl-CoA to acetate; has minor acetyl-CoA-
hydrolase activity; phosphorylated; required for acetate 
utilization and for diploid pseudohyphal growth 
GDH3 3.04 NADP(+)-dependent glutamate dehydrogenase, synthesizes 
glutamate from ammonia and alpha-ketoglutarate; rate of 
alpha-ketoglutarate utilization differs from Gdh1p; expression 
regulated by nitrogen and carbon sources 
IDP2 3.04 Cytosolic NADP-specific isocitrate dehydrogenase, catalyzes 
oxidation of isocitrate to alpha-ketoglutarate; levels are 
elevated during growth on non-fermentable carbon sources 
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and reduced during growth on glucose 
ALT1 2.95 Alanine transaminase (glutamic pyruvic transaminase); 
involved in alanine biosynthetic and catabolic processes; the 
authentic, non-tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
MIR1 2.95 Mitochondrial phosphate carrier, imports inorganic phosphate 
into mitochondria; functionally redundant with Pic2p but 
more abundant than Pic2p under normal conditions; 
phosphorylated 
NPL3 2.93 RNA-binding protein that promotes elongation, regulates 
termination, and carries poly(A) mRNA from nucleus to 
cytoplasm; required for pre-mRNA splicing; dissociation 
from mRNAs promoted by Mtr10p; phosphorylated by Sky1p 
in the cytoplasm 
YOR084W 2.90 Oleic acid-inducible, peroxisomal matrix localized lipase; 
transcriptionally activated by Yrm1p along with genes 
involved in multidrug resistance; peroxisomal import is 
dependent on the PTS1 receptor, Pex5p and on self-
interaction 
ICL1 2.88 Isocitrate lyase, catalyzes the formation of succinate and 
glyoxylate from isocitrate, a key reaction of the glyoxylate 
cycle; expression of ICL1 is induced by growth on ethanol 
and repressed by growth on glucose 
GLC3 2.88 Glycogen branching enzyme, involved in glycogen 
accumulation; green fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm in a punctate pattern 
AGP1 2.86 Low-affinity amino acid permease with broad substrate range, 
involved in uptake of asparagine, glutamine, and other amino 
acids; expression is regulated by the SPS plasma membrane 
amino acid sensor system (Ssy1p-Ptr3p-Ssy5p) 
IZH3 2.84 Membrane protein involved in zinc ion homeostasis, member 
of the four-protein IZH family, expression induced by zinc 
deficiency; deletion reduces sensitivity to elevated zinc and 
shortens lag phase, overexpression reduces Zap1p activity 
ADR1 2.83 Carbon source-responsive zinc-finger transcription factor, 
required for transcription of the glucose-repressed gene 
ADH2, of peroxisomal protein genes, and of genes required 
for ethanol, glycerol, and fatty acid utilization 
DLD1 2.83 D-lactate dehydrogenase, oxidizes D-lactate to pyruvate, 
transcription is heme-dependent, repressed by glucose, and 
derepressed in ethanol or lactate; located in the mitochondrial 
inner membrane 
RPN4 2.77 Transcription factor that stimulates expression of proteasome 
genes; Rpn4p levels are in turn regulated by the 26S 
proteasome in a negative feedback control mechanism; RPN4 
is transcriptionally regulated by various stress responses 
REG2 2.76 Regulatory subunit of the Glc7p type-1 protein phosphatase; 
involved with Reg1p, Glc7p, and Snf1p in regulation of 
glucose-repressible genes, also involved in glucose-induced 
proteolysis of maltose permease 
YER185W 2.70 Plasma membrane protein with roles in the uptake of 
protoprophyrin IX and the efflux of heme; expression is 
induced under both low-heme and low-oxygen conditions; 
member of the fungal lipid-translocating exporter (LTE) 
family of proteins 
MSK1 2.68 Mitochondrial lysine-tRNA synthetase, required for import of 
both aminoacylated and deacylated forms of tRNA(Lys) into 
mitochondria and for aminoacylation of mitochondrially 
encoded tRNA(Lys) 
FAA4 2.68 Long chain fatty acyl-CoA synthetase, activates imported 
fatty acids with a preference for C12:0-C16:0 chain lengths; 
functions in long chain fatty acid import; important for 
survival during stationary phase; localized to lipid particles 
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YLR162W 2.67 Putative protein of unknown function; overexpression confers 
resistance to the antimicrobial peptide MiAMP1 
CRC1 2.65 Mitochondrial inner membrane carnitine transporter, required 
for carnitine-dependent transport of acetyl-CoA from 
peroxisomes to mitochondria during fatty acid beta-oxidation 
IXR1 2.65 Protein that binds DNA containing intrastrand cross-links 
formed by cisplatin, contains two HMG (high mobility group 
box) domains, which confer the ability to bend cisplatin-
modified DNA; mediates aerobic transcriptional repression of 
COX5b 
HTA1 2.64 Histone H2A, core histone protein required for chromatin 
assembly and chromosome function; one of two nearly 
identical subtypes (see also HTA2); DNA damage-dependent 
phosphorylation by Mec1p facilitates DNA repair; acetylated 
by Nat4p 
SFC1 2.64 Mitochondrial succinate-fumarate transporter, transports 
succinate into and fumarate out of the mitochondrion; 
required for ethanol and acetate utilization 
GCV1 2.61 T subunit of the mitochondrial glycine decarboxylase 
complex, required for the catabolism of glycine to 5,10-
methylene-THF; expression is regulated by levels of levels of 
5,10-methylene-THF in the cytoplasm 
RKI1 2.60 Ribose-5-phosphate ketol-isomerase, catalyzes the 
interconversion of ribose 5-phosphate and ribulose 5-
phosphate in the pentose phosphate pathway; participates in 
pyridoxine biosynthesis 
CYC1 2.60 Cytochrome c, isoform 1; electron carrier of the 
mitochondrial intermembrane space that transfers electrons 
from ubiquinone-cytochrome c oxidoreductase to cytochrome 
c oxidase during cellular respiration 
COX7 2.58 Subunit VII of cytochrome c oxidase, which is the terminal 
member of the mitochondrial inner membrane electron 
transport chain 
SCS7 2.57 Sphingolipid alpha-hydroxylase, functions in the alpha-
hydroxylation of sphingolipid-associated very long chain 
fatty acids, has both cytochrome b5-like and 
hydroxylase/desaturase domains, not essential for growth 
ODC1 2.56 Mitochondrial inner membrane transporter, exports 2-
oxoadipate and 2-oxoglutarate from the mitochondrial matrix 
to the cytosol for lysine and glutamate biosynthesis and lysine 
catabolism; suppresses, in multicopy, an fmc1 null mutation 
NAB2 2.56 Nuclear polyadenylated RNA-binding protein required for 
nuclear mRNA export and poly(A) tail length control; binds 
nuclear pore protein Mlp1p; autoregulates mRNA levels; 
related to human hnRNPs; nuclear localization sequence 
binds Kap104p 
 
 
Summary of the overall effects of gene downregulation on cells 
Figures 4.43-4.45 illustrate the overall effects on cells induced by genes 
downregulated more than 2-fold in response to 200 µM GdnHCl exposure.  
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Figure 4.43 The percentage of each cellular component category (200 µM GdnHCl 
14 generation downregulated genes). Genes downregulated more than two-fold were 
assigned cellular component categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.44 The percentage of each molecular function category (200 µM GdnHCl 
14 generation downregulated genes). Genes downregulated more than two-fold were 
assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
 
0.33
0.98
1.64
33.11
0.66
0.33
1.97
3.28
0.33
0.66
13.77
6.23
16.72
10.49
0.33
1.97
3.93
2.30
0.98
0 5 10 15 20 25 30 35
cell cortex
cell wall
chromosome
cytoplasm
cytoplasmic membrane-bounded vesicle
cytoskeleton
endomembrane system
endoplasmic reticulum
extracellular region
membrane fraction
membrane
mitochondrial envelope
mitochondrion
nucleus
other
peroxisome
plasma membrane
ribosome
vacuole
C
el
lu
la
r 
C
o
m
po
n
en
t
% Total Expression
9.45
2.36
1.57
5.51
0.79
3.94
5.51
0.79
5.51
20.47
0.79
7.87
0.79
3.15
7.09
11.02
0.79
12.60
0 5 10 15 20 25
DNA binding
RNA binding
enzyme regulator activity
hydrolase activity
isomerase activity
ligase activity
lyase activity
nucleotidyltransferase activity
other
oxidoreductase activity
peptidase activity
protein binding
signal transducer activity
structural molecule activity
transcription regulator activity
transferase activity
translation regulator activity
transporter activity
M
o
le
cu
la
r 
Fu
n
ct
io
n
% Total Expression
 286 
 
Figure 4.45 The percentage of each biological process category (200 µM GdnHCl 
14 generation downregulated genes). Genes downregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.   
 
 
The five most transcriptionally repressed biological processes, molecular 
functions and associated cellular components are depicted  in figures 4.46-4.48. 
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Figure 4.46 The five associated cellular components most highly downregulated by 
exposure to 200 µM GdnHCl for 14 generations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.47 The five molecular functions most highly downregulated by exposure 
to 200 µM GdnHCl for 14 generations. 
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Figure 4.48 The five biological processes most highly downregulated by exposure 
to 200 µM GdnHCl for 14 generations. 
 
 Table 4.4 lists the fifty individual genes, and their respective functions, that 
underwent the most acute decrease in transcription in response to 14 generation 200 µM 
GdnHCl exposure. 
 
Table 4.4 The fifty genes most highly downregulated in response to 200 µM 
GdnHCl exposure for 14 generations. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
PMA1 -58.90 Plasma membrane H+-ATPase, pumps protons out of 
the cell; major regulator of cytoplasmic pH and plasma 
membrane potential; part of the P2 subgroup of cation-
transporting ATPases 
HXT4 -27.44 High-affinity glucose transporter of the major 
facilitator superfamily, expression is induced by low 
levels of glucose and repressed by high levels of 
glucose 
ENO2 -25.37 Enolase II, a phosphopyruvate hydratase that catalyzes 
the conversion of 2-phosphoglycerate to 
phosphoenolpyruvate during glycolysis and the reverse 
reaction during gluconeogenesis; expression is induced 
in response to glucose 
PGK1 -24.49 3-phosphoglycerate kinase, catalyzes transfer of high-
energy phosphoryl groups from the acyl phosphate of 
1,3-bisphosphoglycerate to ADP to produce ATP; key 
enzyme in glycolysis and gluconeogenesis 
RPS22A -23.82 Protein component of the small (40S) ribosomal 
subunit; nearly identical to Rps22Bp and has similarity 
to E. coli S8 and rat S15a ribosomal proteins 
TOS4 -23.17 Forkhead Associated domain containing protein and 
putative transcription factor found associated with 
chromatin; target of SBF transcription factor; 
expression is periodic and peaks in G1; similar to 
PLM2 
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BSC1 -21.17 Protein of unconfirmed function, similar to cell surface 
flocculin Muc1p; ORF exhibits genomic organization 
compatible with a translational readthrough-dependent 
mode of expression 
YGR272C -19.46 Essential protein required for maturation of 18S rRNA; 
null mutant is sensitive to hydroxyurea and is delayed 
in recovering from alpha-factor arrest; green 
fluorescent protein (GFP)-fusion protein localizes to 
the nucleolus 
PCL1 -19.44 Cyclin, interacts with cyclin-dependent kinase Pho85p; 
member of the Pcl1,2-like subfamily, involved in the 
regulation of polarized growth and morphogenesis and 
progression through the cell cycle; localizes to sites of 
polarized cell growth 
DCD1 -19.28 Deoxycytidine monophosphate (dCMP) deaminase 
required for dCTP and dTTP synthesis; expression is 
NOT cell cycle regulated 
EXG1 -18.74 Major exo-1,3-beta-glucanase of the cell wall, 
involved in cell wall beta-glucan assembly; exists as 
three differentially glycosylated isoenzymes 
GPM1 -17.48 Tetrameric phosphoglycerate mutase, mediates the 
conversion of 3-phosphoglycerate to 2-
phosphoglycerate during glycolysis and the reverse 
reaction during gluconeogenesis 
INM1 -16.58 Inositol monophosphatase, involved in biosynthesis of 
inositol and in phosphoinositide second messenger 
signaling; INM1 expression increases in the presence 
of inositol and decreases upon exposure to antibipolar 
drugs lithium and valproate 
HXK2 -16.45 Hexokinase isoenzyme 2 that catalyzes 
phosphorylation of glucose in the cytosol; predominant 
hexokinase during growth on glucose; functions in the 
nucleus to repress expression of HXK1 and GLK1 and 
to induce expression of its own gene 
AAC3 -16.07 Mitochondrial inner membrane ADP/ATP translocator, 
exchanges cytosolic ADP for mitochondrially 
synthesized ATP; expressed under anaerobic 
conditions; similar to Pet9p and Aac1p; has roles in 
maintenance of viability and in respiration 
PDC1 -15.70 Major of three pyruvate decarboxylase isozymes, key 
enzyme in alcoholic fermentation, decarboxylates 
pyruvate to acetaldehyde; subject to glucose-, ethanol-, 
and autoregulation; involved in amino acid catabolism 
ARO7 -15.43 Chorismate mutase, catalyzes the conversion of 
chorismate to prephenate to initiate the 
tyrosine/phenylalanine-specific branch of aromatic 
amino acid biosynthesis 
CDC19 -15.11 Pyruvate kinase, functions as a homotetramer in 
glycolysis to convert phosphoenolpyruvate to 
pyruvate, the input for aerobic (TCA cycle) or 
anaerobic (glucose fermentation) respiration 
RPL33B -14.71 Ribosomal protein L37 of the large (60S) ribosomal 
subunit, nearly identical to Rpl33Ap and has similarity 
to rat L35a; rpl33b null mutant exhibits normal growth 
while rpl33a rpl33b double null mutant is inviable 
FBA1 -14.56 Fructose 1,6-bisphosphate aldolase, required for 
glycolysis and gluconeogenesis; catalyzes conversion 
of fructose 1,6 bisphosphate to glyceraldehyde-3-P and 
dihydroxyacetone-P; locates to mitochondrial outer 
surface upon oxidative stress 
FEN1 -14.09 Fatty acid elongase, involved in sphingolipid 
biosynthesis; acts on fatty acids of up to 24 carbons in 
length; mutations have regulatory effects on 1,3-beta-
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glucan synthase, vacuolar ATPase, and the secretory 
pathway 
YPL033C -13.93 Protein of unknown function; involved in regulation of 
dNTP production; null mutant suppresses the lethality 
of lcd1 and rad53 mutations; expression is induced by 
Kar4p 
YOR051C -13.69 Nuclear protein that inhibits replication of Brome 
mosaic virus in S. cerevisiae, which is a model system 
for studying replication of positive-strand RNA viruses 
in their natural hosts; deletion increases stop codon 
readthrough 
TKL1 -13.23 Transketolase, similar to Tkl2p; catalyzes conversion 
of xylulose-5-phosphate and ribose-5-phosphate to 
sedoheptulose-7-phosphate and glyceraldehyde-3-
phosphate in the pentose phosphate pathway; needed 
for synthesis of aromatic amino acids 
TDH3 -13.01 Glyceraldehyde-3-phosphate dehydrogenase, isozyme 
3, involved in glycolysis and gluconeogenesis; 
tetramer that catalyzes the reaction of glyceraldehyde-
3-phosphate to 1,3 bis-phosphoglycerate; detected in 
the cytoplasm and cell wall 
YBR238C -12.56 Mitochondrial membrane protein with similarity to 
Rmd9p; not required for respiratory growth but causes 
a synthetic respiratory defect in combination with 
rmd9 mutations; transcriptionally up-regulated by 
TOR; deletion increases life span 
URA7 -12.39 Major CTP synthase isozyme (see also URA8), 
catalyzes the ATP-dependent transfer of the amide 
nitrogen from glutamine to UTP, forming CTP, the 
final step in de novo biosynthesis of pyrimidines; 
involved in phospholipid biosynthesis 
IMD4 -12.26 Inosine monophosphate dehydrogenase, catalyzes the 
first step of GMP biosynthesis, member of a four-gene 
family in S. cerevisiae, constitutively expressed 
CLB2 -12.24 B-type cyclin involved in cell cycle progression; 
activates Cdc28p to promote the transition from G2 to 
M phase; accumulates during G2 and M, then targeted 
via a destruction box motif for ubiquitin-mediated 
degradation by the proteasome 
RPS17B -12.10 Ribosomal protein 51 (rp51) of the small (40s) subunit; 
nearly identical to Rps17Ap and has similarity to rat 
S17 ribosomal protein 
PHM6 -12.07 Protein of unknown function, expression is regulated 
by phosphate levels 
ALD5 -11.93 Mitochondrial aldehyde dehydrogenase, involved in 
regulation or biosynthesis of electron transport chain 
components and acetate formation; activated by K+; 
utilizes NADP+ as the preferred coenzyme; 
constitutively expressed 
SUR4 -11.86 Elongase, involved in fatty acid and sphingolipid 
biosynthesis; synthesizes very long chain 20-26-carbon 
fatty acids from C18-CoA primers; involved in 
regulation of sphingolipid biosynthesis 
ANB1 -11.78 Translation elongation factor eIF-5A, previously 
thought to function in translation initiation; similar to 
and functionally redundant with Hyp2p; undergoes an 
essential hypusination modification; expressed under 
anaerobic conditions 
FRM2 -11.38 Protein of unknown function, involved in the 
integration of lipid signaling pathways with cellular 
homeostasis; expression induced in cells treated with 
the mycotoxin patulin; has similarity to bacterial 
nitroreductases 
 291 
RAX2 -11.36 N-glycosylated protein involved in the maintenance of 
bud site selection during bipolar budding; localization 
requires Rax1p; RAX2 mRNA stability is regulated by 
Mpt5p 
ALG12 -11.36 Alpha-1,6-mannosyltransferase localized to the ER; 
responsible for the addition of the alpha-1,6 mannose 
to dolichol-linked Man7GlcNAc2, acts in the dolichol 
pathway for N-glycosylation 
RNR1 -11.15 Major isoform of the large subunit of ribonucleotide-
diphosphate reductase; the RNR complex catalyzes 
rate-limiting step in dNTP synthesis, regulated by 
DNA replication and DNA damage checkpoint 
pathways via localization of small subunits 
TPI1 -10.97 Triose phosphate isomerase, abundant glycolytic 
enzyme; mRNA half-life is regulated by iron 
availability; transcription is controlled by activators 
Reb1p, Gcr1p, and Rap1p through binding sites in the 
5' non-coding region 
ATX2 -10.71 Golgi membrane protein involved in manganese 
homeostasis; overproduction suppresses the sod1 
(copper, zinc superoxide dismutase) null mutation 
SPO19 -10.71 Meiosis-specific prospore protein; required to produce 
bending force necessary for proper assembly of the 
prospore membrane during sporulation; identified as a 
weak high-copy suppressor of the spo1-1 ts mutation 
RHR2 -10.68 Constitutively expressed isoform of DL-glycerol-3-
phosphatase; involved in glycerol biosynthesis, 
induced in response to both anaerobic and, along with 
the Hor2p/Gpp2p isoform, osmotic stress 
DTD1 -10.56 D-Tyr-tRNA(Tyr) deacylase, functions in protein 
translation, may affect nonsense suppression via 
alteration of the protein synthesis machinery; 
ubiquitous among eukaryotes 
YLR301W -10.56 Protein of unknown function that interacts with Sec72p 
TDH2 -10.51 Glyceraldehyde-3-phosphate dehydrogenase, isozyme 
2, involved in glycolysis and gluconeogenesis; 
tetramer that catalyzes the reaction of glyceraldehyde-
3-phosphate to 1,3 bis-phosphoglycerate; detected in 
the cytoplasm and cell wall 
RAD53 -10.40 Protein kinase, required for cell-cycle arrest in 
response to DNA damage; activated by trans 
autophosphorylation when interacting with 
hyperphosphorylated Rad9p; also interacts with ARS1 
and plays a role in initiation of DNA replication 
HGH1 -10.40 Nonessential protein of unknown function; predicted to 
be involved in ribosome biogenesis; green fluorescent 
protein (GFP)-fusion protein localizes to the 
cytoplasm; similar to mammalian BRP16 (Brain 
protein 16) 
NRK1 -10.13 Nicotinamide riboside kinase, catalyzes the 
phosphorylation of nicotinamide riboside and nicotinic 
acid riboside in salvage pathways for NAD+ 
biosynthesis 
CYB5 -10.02 Cytochrome b5, involved in the sterol and lipid 
biosynthesis pathways; acts as an electron donor to 
support sterol C5-6 desaturation 
ERG25 
 
-9.92 
 
C-4 methyl sterol oxidase, catalyzes the first of three 
steps required to remove two C-4 methyl groups from 
an intermediate in ergosterol biosynthesis; mutants 
accumulate the sterol intermediate 4,4-
dimethylzymosterol 
 
 292 
4.18.1.2 Analysis of the effect of 200 µM GdnHCl + 20 µM TA exposure for 14 
generations on yeast cells  
 
When yeast cells were treated for 14 generations with 200 µM GdnHCl in 
combination with 20 µM TA, 100 genes were upregulated more than 2-fold, and of 
these, 12 more than 3-fold. 1363 genes were downregulated over 2-fold, 696 of these in 
excess of 3-fold. The figures below illustrate the cellular components, molecular 
functions and biological processes stimulated or repressed by GdnHCl + TA exposure 
and the percentages of total changes they represent. 
 
Summary of the overall effects of gene upregulation on cells 
Figures 4.49-4.51 depict the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 200 µM GdnHCl + 20 µM TA exposure.  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.49 The percentage of each cellular component category (200 µM GdnHCl 
+ 20 µM TA 14 generation upregulated genes). Genes upregulated more than two-
fold were assigned cellular component categories. The number of genes in each 
category was expressed as a percentage of the number of total genes.   
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Figure 4.50 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 14 generation upregulated genes). Genes upregulated more than two-
fold were assigned molecular function categories. The number of genes in each category 
was expressed as a percentage of the number of total genes.   
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Figure 4.51 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 14 generation upregulated genes). Genes upregulated more than two-fold 
were assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes.  
 
 The five biological processes, molecular functions and associated cellular 
components most highly stimulated by a combination of 200 µM GdnHCl + 20 µM TA 
were investigated. These are illustrated in figures 4.52-4.54. 
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Figure 4.52 The five associated cellular components most highly upregulated by 
exposure to 200 µM GdnHCl + 20 µM TA for 14 generations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.53 The five molecular functions most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 14 generations. 
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Figure 4.54 The five biological processes most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 14 generations. 
 
 Table 4.5 lists the fifty individual genes, and their respective functions, that 
underwent the highest increase in transcription in response to 200 µM GdnHCl + 20 µM 
TA exposure for 14 generations. A substantial level of overlap was seen for genes that 
are upregulated in response to GdnHCl alone for 14 generations, and GdnHCl combined 
with TA. 
 
Table 4.5 The fifty genes most highly upregulated in response to 200 µM GdnHCl 
+ 20 µM TA exposure for 14 generations. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
OLE1 9.25 Delta(9) fatty acid desaturase, required for monounsaturated 
fatty acid synthesis and for normal distribution of mitochondria 
MRPL38 4.52 Mitochondrial ribosomal protein of the large subunit; appears as 
two protein spots (YmL34 and YmL38) on two-dimensional 
SDS gels 
IZH1 4.35 Membrane protein involved in zinc ion homeostasis, member of 
the four-protein IZH family; transcription is regulated directly 
by Zap1p, expression induced by zinc deficiency and fatty 
acids; deletion increases sensitivity to elevated zinc 
IZH4 4.15 Membrane protein involved in zinc ion homeostasis, member of 
the four-protein IZH family, expression induced by fatty acids 
and altered zinc levels; deletion reduces sensitivity to excess 
zinc; possible role in sterol metabolism 
ALT1 4.08 Alanine transaminase (glutamic pyruvic transaminase); 
involved in alanine biosynthetic and catabolic processes; the 
authentic, non-tagged protein is detected in highly purified 
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mitochondria in high-throughput studies 
GLC3 3.92 Glycogen branching enzyme, involved in glycogen 
accumulation; green fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm in a punctate pattern 
SDS23 3.64 One of two S. cerevisiae homologs (Sds23p and Sds24p) of the 
S. pombe Sds23 protein, which is implicated in APC/cyclosome 
regulation; involved in cell separation during budding 
ATO2 3.45 Putative transmembrane protein involved in export of ammonia, 
a starvation signal that promotes cell death in aging colonies; 
phosphorylated in mitochondria; member of the TC 9.B.33 
YaaH family; homolog of Ady2p and Y. lipolytica Gpr1p 
CEM1 3.38 Mitochondrial beta-keto-acyl synthase with possible role in 
fatty acid synthesis; required for mitochondrial respiration 
SMF2 3.28 Divalent metal ion transporter involved in manganese 
homeostasis; has broad specificity for di-valent and tri-valent 
metals; post-translationally regulated by levels of metal ions; 
member of the Nramp family of metal transport proteins 
GCV1 3.13 T subunit of the mitochondrial glycine decarboxylase complex, 
required for the catabolism of glycine to 5,10-methylene-THF; 
expression is regulated by levels of levels of 5,10-methylene-
THF in the cytoplasm 
NPL3 
 
3.05 
 
RNA-binding protein that promotes elongation, regulates 
termination, and carries poly(A) mRNA from nucleus to 
cytoplasm; required for pre-mRNA splicing; dissociation from 
mRNAs promoted by Mtr10p; phosphorylated by Sky1p in the 
cytoplasm 
 
PIR3 2.95 O-glycosylated covalently-bound cell wall protein required for 
cell wall stability; expression is cell cycle regulated, peaking in 
M/G1 and also subject to regulation by the cell integrity 
pathway 
GDH3 2.92 NADP(+)-dependent glutamate dehydrogenase, synthesizes 
glutamate from ammonia and alpha-ketoglutarate; rate of alpha-
ketoglutarate utilization differs from Gdh1p; expression 
regulated by nitrogen and carbon sources 
MLS1 2.90 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in peroxisomes 
during growth in oleic acid medium 
SPI1 2.89 GPI-anchored cell wall protein involved in weak acid 
resistance; basal expression requires Msn2p/Msn4p; expression 
is induced under conditions of stress and during the diauxic 
shift; similar to Sed1p 
ADE13 2.84 Adenylosuccinate lyase, catalyzes two steps in the 'de novo' 
purine nucleotide biosynthetic pathway; expression is repressed 
by adenine and activated by Bas1p and Pho2p; mutations in 
human ortholog ADSL cause adenylosuccinase deficiency 
YOR161W-B 2.77 Identified by gene-trapping, microarray-based expression 
analysis, and genome-wide homology searching 
ACH1 2.75 Protein with CoA transferase activity, particularly for CoASH 
transfer from succinyl-CoA to acetate; has minor acetyl-CoA-
hydrolase activity; phosphorylated; required for acetate 
utilization and for diploid pseudohyphal growth 
YDL012C 2.72 Tail-anchored plasma membrane protein containing a conserved 
CYSTM module, possibly involved in response to stress; may 
contribute to non-homologous end-joining (NHEJ) based on 
ydl012c htz1 double null phenotype 
MTD1 2.70 NAD-dependent 5,10-methylenetetrahydrafolate 
dehydrogenase, plays a catalytic role in oxidation of 
cytoplasmic one-carbon units; expression is regulated by Bas1p 
and Bas2p, repressed by adenine, and may be induced by 
inositol and choline 
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YPR013C 2.69 Putative zinc finger protein; YPR013C is not an essential gene 
BDH2 2.65 Putative medium-chain alcohol dehydrogenase with similarity 
to BDH1; transcription induced by constitutively active PDR1 
and PDR3 
PCK1 2.63 Phosphoenolpyruvate carboxykinase, key enzyme in 
gluconeogenesis, catalyzes early reaction in carbohydrate 
biosynthesis, glucose represses transcription and accelerates 
mRNA degradation, regulated by Mcm1p and Cat8p, located in 
the cytosol 
SNZ1 2.60 Protein involved in vitamin B6 biosynthesis; member of a 
stationary phase-induced gene family; coregulated with SNO1; 
interacts with Sno1p and with Yhr198p, perhaps as a 
multiprotein complex containing other Snz and Sno proteins 
YAT1 2.59 Outer mitochondrial carnitine acetyltransferase, minor ethanol-
inducible enzyme involved in transport of activated acyl groups 
from the cytoplasm into the mitochondrial matrix; 
phosphorylated 
CAT5 2.59 Protein required for ubiquinone (Coenzyme Q) biosynthesis; 
localizes to the matrix face of the mitochondrial inner 
membrane in a large complex with ubiquinone biosynthetic 
enzymes; required for gluconeogenic gene activation 
MET13 2.58 Major isozyme of methylenetetrahydrofolate reductase, 
catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate in the methionine biosynthesis pathway 
RPN4 2.55 Transcription factor that stimulates expression of proteasome 
genes; Rpn4p levels are in turn regulated by the 26S proteasome 
in a negative feedback control mechanism; RPN4 is 
transcriptionally regulated by various stress responses 
MSK1 2.47 Mitochondrial lysine-tRNA synthetase, required for import of 
both aminoacylated and deacylated forms of tRNA(Lys) into 
mitochondria and for aminoacylation of mitochondrially 
encoded tRNA(Lys) 
FMP46 2.46 Putative redox protein containing a thioredoxin fold; the 
authentic, non-tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
MIR1 2.42 Mitochondrial phosphate carrier, imports inorganic phosphate 
into mitochondria; functionally redundant with Pic2p but more 
abundant than Pic2p under normal conditions; phosphorylated 
VHR1 2.42 Transcriptional activator, required for the vitamin H-responsive 
element (VHRE) mediated induction of VHT1 (Vitamin H 
transporter) and BIO5 (biotin biosynthesis intermediate 
transporter) in response to low biotin concentrations 
SHR5 2.41 Subunit of a palmitoyltransferase, composed of Shr5p and 
Erf2p, that adds a palmitoyl lipid moiety to heterolipidated 
substrates such as Ras1p and Ras2p through a thioester linkage; 
palmitoylation is required for Ras2p membrane localization 
IRC9,YAK1 2.37 Cytosolic serine hydroxymethyltransferase, converts serine to 
glycine plus 5,10 methylenetetrahydrofolate; major isoform 
involved in generating precursors for purine, pyrimidine, amino 
acid, and lipid biosynthesis 
YOR329W-A 2.36 Peripheral membrane protein located at Vid (vacuole import 
and degradation) vesicles; regulates fructose-1,6-bisphosphatase 
(FBPase) targeting to the vacuole; promotes proteasome-
dependent catabolite degradation of FBPase 
VID24 2.36 Mitochondrial protein; may interact with ribosomes based on 
co-purification experiments; similar to E. coli and human 
mitochondrial S12 ribosomal proteins 
YNR036C 2.36 Lactate transporter, required for uptake of lactate and pyruvate; 
phosphorylated; expression is derepressed by transcriptional 
activator Cat8p during respiratory growth, and repressed in the 
presence of glucose, fructose, and mannose 
JEN1 2.35 Substrate of the Hub1p ubiquitin-like protein that localizes to 
the shmoo tip (mating projection); mutants are defective for 
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mating projection formation, thereby implicating Hbt1p in 
polarized cell morphogenesis 
HBT1 2.35 Protein that binds DNA containing intrastrand cross-links 
formed by cisplatin, contains two HMG (high mobility group 
box) domains, which confer the ability to bend cisplatin-
modified DNA; mediates aerobic transcriptional repression of 
COX5b 
IXR1 2.34 Mitochondrial ribosomal protein of the large subunit 
MRPL4 2.32 Glucokinase, catalyzes the phosphorylation of glucose at C6 in 
the first irreversible step of glucose metabolism; one of three 
glucose phosphorylating enzymes; expression regulated by non-
fermentable carbon sources 
GLK1 2.32 Membrane protein involved in zinc ion homeostasis, member of 
the four-protein IZH family, expression induced by zinc 
deficiency; deletion reduces sensitivity to elevated zinc and 
shortens lag phase, overexpression reduces Zap1p activity 
IZH3 2.31 Na+/Pi cotransporter, active in early growth phase; similar to 
phosphate transporters of Neurospora crassa; transcription 
regulated by inorganic phosphate concentrations and Pho4p 
PHO89 2.31 Putative protein of unknown function; YMR206W is not an 
essential gene 
YMR206W 2.31 Nucleotide exchange factor for the endoplasmic reticulum (ER) 
lumenal Hsp70 chaperone Kar2p, required for protein 
translocation into the ER; homolog of Yarrowia lipolytica 
SLS1; GrpE-like protein 
SLS1 2.29 Mitochondrial membrane protein that coordinates expression of 
mitochondrially-encoded genes; may facilitate delivery of 
mRNA to membrane-bound translation machinery 
NDI1 2.29 NADH:ubiquinone oxidoreductase, transfers electrons from 
NADH to ubiquinone in the respiratory chain but does not 
pump protons, in contrast to the higher eukaryotic multisubunit 
respiratory complex I; phosphorylated; homolog of human 
AMID 
YGR035C 2.28 Putative protein of unknown function, potential Cdc28p 
substrate; transcription is activated by paralogous transcription 
factors Yrm1p and Yrr1p along with genes involved in 
multidrug resistance 
FBP1 2.27 Fructose-1,6-bisphosphatase, key regulatory enzyme in the 
gluconeogenesis pathway, required for glucose metabolism; 
undergoes either proteasome-mediated or autophagy-mediated 
degradation depending on growth conditions; interacts with 
Vid30p 
 
 
Summary of the overall effects of gene downregulation on cells 
Genes which were transcriptionaly repressed under 200 µM GdnHCl + 20 µM 
TA exposure were also explored. Figures 4.55-4.57 depict the overall effects on cells 
induced by genes downregulated more than 2-fold in response to 200 µM GdnHCl + 20 
µM TA exposure.  
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Figure 4.55 The percentage of each cellular component category (200 µM GdnHCl 
+ 20 µM TA 14 generation downregulated genes). Genes downregulated more than 
two-fold were assigned cellular component categories. The number of genes in each 
category was expressed as a percentage of the number of total genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.56 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 14 generation downregulated genes). Genes downregulated more than 
two-fold were assigned molecular function categories. The number of genes in each 
category was expressed as a percentage of the number of total genes. 
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Figure 4.57 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 14 generation downregulated genes). Genes downregulated more than 
two-fold were assigned biological process categories. The number of genes in each 
category was expressed as a percentage of the number of total genes. 
 
 
  
 The five biological processes, molecular functions and associated cellular 
components most repressed by a combination of 200 µM GdnHCl + 20 µM TA were 
explored. These are illustrated in figures 4.58-4.60. 
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Figure 4.58 The five associated cellular components most highly downregulated by 
exposure to 200 µM GdnHCl + 20 µM TA for 14 generations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.59 The five molecular functions most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 14 generations. 
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Figure 4.60 The *five biological processes most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 14 generations. *The 5th and 6th most repressed 
biological processes are represented by the same number of genes and are thus both 
included. 
 
 Table 4.6 lists the fifty individual genes, and their respective functions, that 
underwent the most acute decrease in transcription in response to 200 µM GdnHCl + 20 
µM TA exposure for 14 generations. 
Table 4.6 The fifty genes most highly downregulated in response to 200 µM 
GdnHCl + 20 µM TA exposure for 14 generations. Gene functions were obtained 
from www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
PMA1 -61.79 Plasma membrane H+-ATPase, pumps protons out of the cell; 
major regulator of cytoplasmic pH and plasma membrane 
potential; part of the P2 subgroup of cation-transporting ATPases 
CYB5 -50.91 Cytochrome b5, involved in the sterol and lipid biosynthesis 
pathways; acts as an electron donor to support sterol C5-6 
desaturation 
RPS22A -35.29 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps22Bp and has similarity to E. coli S8 and rat S15a 
ribosomal proteins 
RPL33B -34.027 Ribosomal protein L37 of the large (60S) ribosomal subunit, 
nearly identical to Rpl33Ap and has similarity to rat L35a; rpl33b 
null mutant exhibits normal growth while rpl33a rpl33b double 
null mutant is inviable 
DTD1 -33.14 D-Tyr-tRNA(Tyr) deacylase, functions in protein translation, may 
affect nonsense suppression via alteration of the protein synthesis 
machinery; ubiquitous among eukaryotes 
YGR272C -26.17 Essential protein required for maturation of 18S rRNA; null 
mutant is sensitive to hydroxyurea and is delayed in recovering 
from alpha-factor arrest; green fluorescent protein (GFP)-fusion 
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protein localizes to the nucleolus 
TOS4 -23.74 Forkhead Associated domain containing protein and putative 
transcription factor found associated with chromatin; target of 
SBF transcription factor; expression is periodic and peaks in G1; 
similar to PLM2 
YER053C-A -21.85 Putative protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the endoplasmic reticulum 
HXT4 -20.90 High-affinity glucose transporter of the major facilitator 
superfamily, expression is induced by low levels of glucose and 
repressed by high levels of glucose 
RPS17B -20.41 Ribosomal protein 51 (rp51) of the small (40s) subunit; nearly 
identical to Rps17Ap and has similarity to rat S17 ribosomal 
protein 
BRN1 -19.45 Subunit of the condensin complex; required for chromosome 
condensation and for clustering of tRNA genes at the nucleolus; 
may influence multiple aspects of chromosome transmission 
EXG1 -17.48 Major exo-1,3-beta-glucanase of the cell wall, involved in cell 
wall beta-glucan assembly; exists as three differentially 
glycosylated isoenzymes 
RNR1 -17.11 Major isoform of the large subunit of ribonucleotide-diphosphate 
reductase; the RNR complex catalyzes rate-limiting step in dNTP 
synthesis, regulated by DNA replication and DNA damage 
checkpoint pathways via localization of small subunits 
CLB2 -17.07 B-type cyclin involved in cell cycle progression; activates Cdc28p 
to promote the transition from G2 to M phase; accumulates during 
G2 and M, then targeted via a destruction box motif for ubiquitin-
mediated degradation by the proteasome 
FEN1 -16.52 Fatty acid elongase, involved in sphingolipid biosynthesis; acts on 
fatty acids of up to 24 carbons in length; mutations have 
regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, 
and the secretory pathway 
INM1 -16.16 Inositol monophosphatase, involved in biosynthesis of inositol 
and in phosphoinositide second messenger signaling; INM1 
expression increases in the presence of inositol and decreases 
upon exposure to antibipolar drugs lithium and valproate 
JJJ3 -15.75 Protein of unknown function, contains a J-domain, which is a 
region with homology to the E. coli DnaJ protein 
ENO2 -15.67 Enolase II, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate during 
glycolysis and the reverse reaction during gluconeogenesis; 
expression is induced in response to glucose 
RPL21A -15.33 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl21Bp and has similarity to rat L21 ribosomal 
protein 
MCM16 -14.89 Protein involved in kinetochore-microtubule mediated 
chromosome segregation; binds to centromere DNA 
IMD4 -14.59 Inosine monophosphate dehydrogenase, catalyzes the first step of 
GMP biosynthesis, member of a four-gene family in S. cerevisiae, 
constitutively expressed 
RPS1B -14.51 Ribosomal protein 10 (rp10) of the small (40S) subunit; nearly 
identical to Rps1Ap and has similarity to rat S3a ribosomal 
protein 
RPL6B -14.45 Protein component of the large (60S) ribosomal subunit, has 
similarity to Rpl6Ap and to rat L6 ribosomal protein; binds to 
5.8S rRNA 
RPL42B -14.42 Protein component of the large (60S) ribosomal subunit, identical 
to Rpl42Ap and has similarity to rat L44; required for propagation 
of the killer toxin-encoding M1 double-stranded RNA satellite of 
the L-A double-stranded RNA virus 
YRO2 -14.40 Putative protein of unknown function; the authentic, non-tagged 
protein is detected in a phosphorylated state in highly purified 
mitochondria in high-throughput studies; transcriptionally 
regulated by Haa1p 
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ATX2 -14.40 Golgi membrane protein involved in manganese homeostasis; 
overproduction suppresses the sod1 (copper, zinc superoxide 
dismutase) null mutation 
RPS28B -14.08 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps28Ap and has similarity to rat S28 ribosomal 
protein 
RAX2 -14.04 N-glycosylated protein involved in the maintenance of bud site 
selection during bipolar budding; localization requires Rax1p; 
RAX2 mRNA stability is regulated by Mpt5p 
ACM1 -13.92 Pseudosubstrate inhibitor of the anaphase-promoting 
complex/cyclosome (APC/C), that suppresses APC/C [Cdh1]-
mediated proteolysis of mitotic cyclins; associates with Cdh1p, 
Bmh1p and Bmh2p; cell cycle regulated protein 
YLR063W -13.86 Putative S-adenosylmethionine-dependent methyltransferase; 
green fluorescent protein (GFP)-fusion protein localizes to the 
cytoplasm; YLR063W is not an essential gene 
GPM3 -13.86 Homolog of Gpm1p phosphoglycerate mutase, which converts 3-
phosphoglycerate to 2-phosphoglycerate in glycolysis; may be 
non-functional derivative of a gene duplication event 
RPS9B -13.78 Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps9Ap and has similarity to E. coli S4 and rat S9 
ribosomal proteins 
HXK2 -13.75 Hexokinase isoenzyme 2 that catalyzes phosphorylation of 
glucose in the cytosol; predominant hexokinase during growth on 
glucose; functions in the nucleus to repress expression of HXK1 
and GLK1 and to induce expression of its own gene 
PGK1 -13.53 3-phosphoglycerate kinase, catalyzes transfer of high-energy 
phosphoryl groups from the acyl phosphate of 1,3-
bisphosphoglycerate to ADP to produce ATP; key enzyme in 
glycolysis and gluconeogenesis 
URA7 -13.44 Major CTP synthase isozyme (see also URA8), catalyzes the 
ATP-dependent transfer of the amide nitrogen from glutamine to 
UTP, forming CTP, the final step in de novo biosynthesis of 
pyrimidines; involved in phospholipid biosynthesis 
GPM1 -13.43 Tetrameric phosphoglycerate mutase, mediates the conversion of 
3-phosphoglycerate to 2-phosphoglycerate during glycolysis and 
the reverse reaction during gluconeogenesis 
RPC17 -13.34 RNA polymerase III subunit C17; physically interacts with C31, 
C11, and TFIIIB70; may be involved in the recruitment of pol III 
by the preinitiation complex 
RPS12 -13.30 Protein component of the small (40S) ribosomal subunit; has 
similarity to rat ribosomal protein S12 
RPL31A -13.29 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl31Bp and has similarity to rat L31 ribosomal 
protein; associates with the karyopherin Sxm1p; loss of both 
Rpl31p and Rpl39p confers lethality 
NCE103 -13.25 Carbonic anhydrase; poorly transcribed under aerobic conditions 
and at an undetectable level under anaerobic conditions; involved 
in non-classical protein export pathway 
BSC1 -13.18 Protein of unconfirmed function, similar to cell surface flocculin 
Muc1p; ORF exhibits genomic organization compatible with a 
translational readthrough-dependent mode of expression 
ARO7 -12.96 Chorismate mutase, catalyzes the conversion of chorismate to 
prephenate to initiate the tyrosine/phenylalanine-specific branch 
of aromatic amino acid biosynthesis 
RPL34A -12.61 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl34Bp and has similarity to rat L34 ribosomal 
protein 
NRK1 -12.48 Nicotinamide riboside kinase, catalyzes the phosphorylation of 
nicotinamide riboside and nicotinic acid riboside in salvage 
pathways for NAD+ biosynthesis 
HOM3 -12.43 Aspartate kinase (L-aspartate 4-P-transferase); cytoplasmic 
enzyme that catalyzes the first step in the common pathway for 
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methionine and threonine biosynthesis; expression regulated by 
Gcn4p and the general control of amino acid synthesis 
PCL1 -12.20 Cyclin, interacts with cyclin-dependent kinase Pho85p; member 
of the Pcl1,2-like subfamily, involved in the regulation of 
polarized growth and morphogenesis and progression through the 
cell cycle; localizes to sites of polarized cell growth 
FRM2 12.17 Protein of unknown function, involved in the integration of lipid 
signaling pathways with cellular homeostasis; expression induced 
in cells treated with the mycotoxin patulin; has similarity to 
bacterial nitroreductases 
RPL2B 11.88 Protein component of the large (60S) ribosomal subunit, identical 
to Rpl2Ap and has similarity to E. coli L2 and rat L8 ribosomal 
proteins; expression is upregulated at low temperatures 
RPL27A 11.67 Protein component of the large (60S) ribosomal subunit, nearly 
identical to Rpl27Bp and has similarity to rat L27 ribosomal 
protein 
MSH2 11.59 Protein that forms heterodimers with Msh3p and Msh6p that bind 
to DNA mismatches to initiate the mismatch repair process; 
contains a Walker ATP-binding motif required for repair activity; 
Msh2p-Msh6p binds to and hydrolyzes ATP 
 
 
4.18.1.3 Comparison of the effect of 200 µM GdnHCl alone and in combination 
with 20 µM TA for 14 generations on yeast cells 
 
 Cells were exposed to these compounds for 14 generations due to the fact that  
TA, in the presence of GdnHCl at these concentrations fully cures [PSI+]. Further to the 
results illustrated above, RNA sequencing data was compared. We attempted to search 
for yeast responses induced by a combination of GdnHCl and TA, but not by GdnHCl 
alone. It was anticipated that this would provide an indication of the type of impact 
caused by TA in yeast cultures, and perhaps offer insight into the mode of action of the 
drug. Figures 4.61-4.63 depict comparisons of the biological processes, cellular 
components and molecular functions stimulated by GdnHCl and TA. 
 As illustrated by figure 4.61, ribosome biogenesis, RNA metabolic process, 
transport, translation and cell cycle are the five biological processes most highly 
stimulated by GdnHCl alone, and in combination with TA. 
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Figure 4.61 Comparison of the five most common biological processes of genes 
with >2-fold upregulation. 
 
 Figure 4.62 demonstrates that when cells are treated with GdnHCl alone, genes 
involved with the cytoplasm, nucleus, membrane, ribosome and mitochondrion are most 
highly upregulated. With the addition of TA, genes involved with the nucleolus are 
most highly upregulated, and not those associated with the mitochondrion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.62 Comparison of the five most common associated cellular components 
of genes with >2-fold upregulation. 
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Cellular exposure to GdnHCl alone and in combination with TA results in 
induction of the same most common molecular functions. As shown in figure 4.63, 
these are transferase activity, hydrolase activity, structural molecule activity, RNA 
binding and protein binding. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.63 Comparison of the five most common molecular functions of genes 
with >2-fold upregulation. 
 
Downregulated gene GO identities were also compared and contrasted, as 
illustrated in figures 4.64-4.66. In the case of genes downregulated in response to 
treatment with GdnHCl alone and in combination with TA, there are considerably more 
differences. Three of the five biological processes most repressed under exposure are 
common to both treatments and these are transport, RNA metabolic process and 
transcription. However, cellular lipid metabolic process and heterocycle metabolic 
process are two of the higest biological processes inhibited by GdnHCl alone, but not in 
combination with TA. In contrast, response to chemical stimulus, generation of 
precursor metabolites and energy and mitochondrion organisation are all highly 
repressed by GdnHCl + TA exposure, but not by GdnHCl alone.  
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Figure 4.64 Comparison of the *five most common biological processes of genes 
with >2-fold downregualation. *In response to GdnHCl + TA exposure, the 5th and 6th 
most repressed biological processes are represented by the same number of genes and 
are thus both included. 
 
 Genes associated with the membrane, cytoplasm, mitochondrial envelope, 
mitochondrion and nucleus are those most highly downregulated by exposure to 
GdnHCl alone and combined with TA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.65 Comparison of the five most common associated cellular components 
of genes with >2-fold downregulation. 
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 Figure 4.66 demonstrates that oxidoreductase activity, transferase activity, DNA 
binding and protein binding are all some of the most highly inhibited functions by both 
treatments. However, repression of transporter activity is specific to GdnHCl treatment 
alone, while downregulation of transcription regulator activity is specific to GdnHCl 
treatment in combination with TA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.66 Comparison of the five most common molecular functions of genes 
with >2-fold downregulation. 
 
Following this analysis, an attempt was made to identify genes that are 
upregulated upon GdnHCl exposure and further upregulated in the presence of GdnHCl 
and TA combined. It was anticipated that if a specific pathway was identified that was 
stimulated in the presence of GdnHCl alone and further so in the presence of both 
GdnHCl and TA, it might provide evidence that TA enhances the curing effects of 
GdnHCl, either directly or indirectly. A number of genes displaying this pattern of 
expression were identified and are described in table 4.7.  
Few genes were identified that were that were downregulated under GdnHCl 
exposure and considerably moreso in the presence of a combination of GdnHCl and TA.     
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Table 4.7 Expression levels of a number of genes upregulated by GdnHCl alone and furthermore by GdnHCl and TA combined. Gene 
functions were obtained from www.yeastgenome.org (SGD). 
Gene 
Name 
Function Basal expression level Expression level 
under 200 µM 
GdnHCl exposure 
(14 generations) 
Expression level 
under 200 µM 
GdnHCl + 20 µM 
TA exposure (14 
generations) 
MRPL38 Mitochondrial ribosomal protein of the large subunit;  69.43 215.48 314.14 
ALT1 Alanine transaminase (glutamic pyruvic transaminase);  
involved in alanine biosynthetic and catabolic processes; the 
authentic, non-tagged protein is detected in highly purified 
mitochondria in high-throughput studies 
84.27 249.43 344.00 
PIR3 O-glycosylated covalently-bound cell wall protein required for 
cell wall stability; expression is cell cycle  
regulated, peaking in M/G1 and also subject to regulation by 
the cell integrity pathway 
697.16 861.49 2063.50 
SPI1 GPI-anchored cell wall protein involved in weak acid 
resistance; basal expression requires Msn2p/Msn4p;  
expression is induced under conditions of stress and during the 
diauxic shift; similar to Sed1p 
2278.04 4990.85 6603.60 
CAT5 Protein required for ubiquinone (Coenzyme Q) biosynthesis; 
localizes to the matrix face of the  
mitochondrial inner membrane in a large complex with 
ubiquinone biosynthetic enzymes;  
required for gluconeogenic gene activation 
77.42 141.75 200.64 
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BDH2 Putative medium-chain alcohol dehydrogenase with similarity 
to BDH1; transcription induced  
by constitutively active PDR1 and PDR3 
499.11 930.11 1326.29 
HBT1 Substrate of the Hub1p ubiquitin-like protein that localizes to 
the shmoo tip (mating projection);  
mutants are defective for mating projection formation, thereby 
implicating Hbt1p in polarized  
cell morphogenesis 
540.09 581.27 1269.92 
GLK1 Glucokinase, catalyzes the phosphorylation of glucose at C6 in 
the first irreversible step of  
glucose metabolism; one of three glucose phosphorylating 
enzymes; expression regulated  
by non-fermentable carbon sources 
2622.84 4872.50 6098.06 
CMK1 Calmodulin-dependent protein kinase; may play a role in stress 
response, many CA++/calmodulan  
dependent phosphorylation substrates demonstrated in vitro, 
amino acid sequence similar to  
Cmk2p and mammalian Cam Kinase II 
143.84 214.11 312.65 
ADE1 N-succinyl-5-aminoimidazole-4-carboxamide ribotide 
(SAICAR) synthetase, required for  
'de novo' purine nucleotide biosynthesis; red pigment 
accumulates in mutant cells deprived of  
adenine 
285.98 478.53 610.86 
ADE17 Enzyme of 'de novo' purine biosynthesis containing both 5-
aminoimidazole-4-carboxamide ribonucleotide  
transformylase and inosine monophosphate cyclohydrolase 
activities, isozyme of Ade16p; ade16 ade17 mutants require 
adenine and histidine 
291.74 370.34 547.34 
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4.18.1.4 Analysis of the effect of 1 hr 200 µM GdnHCl + 20 µM TA exposure on 
yeast cells  
 
S. cerevisiae cultures were treated with 200 µM GdnHCl + 20 µM TA for 1 hr, 
after which the genes differentially expressed were investigated. In response to this 
treatment, 164 genes were upregulated more than 2-fold, 45 of these more than 3-fold. 
421 genes were downregulated more than 2-fold, 157 of these in excess of 3-fold.  
 
Summary of the overall effects of gene upregulation on cells 
Figures 4.67-4.69 depict the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 200 µM GdnHCl + 20 µM TA exposure for 
1 hr.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Figure 4.67 The percentage of each cellular component category (200 µM GdnHCl  
+ 20 µM TA 1 hr upregulated genes). Genes upregulated more than two-fold were 
assigned cellular component categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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Figure 4.68 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 1 hr upregulated genes). Genes upregulated more than two-fold were 
assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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Figure 4.69 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 1 hr upregulated genes). Genes upregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
 
The five biological processes, molecular functions and associated cellular 
components most highly stimulated by exposure to 200 µM GdnHCl + 20 µM TA for 1 
hr were further grouped. These are illustrated in figures 4.70-4.72. 
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Figure 4.70 The five associated cellular components most highly upregulated by 
exposure to 200 µM GdnHCl + 20 µM TA for 1 hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.71 The five molecular functions most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 1 hr. 
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Figure 4.72 The five biological processes most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 1 hr. 
 
 Table 4.8 lists the fifty individual genes, and their respective functions, that 
underwent the highest level of transcriptional upregulation in response to 200 µM 
GdnHCl + 20 µM TA exposure for 1 hr. 
Table 4.8 The fifty genes most highly upregulated in response to 200 µM GdnHCl 
+ 20 µM TA exposure for 1 hr. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
CUP1-2 17.54 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably amplified 
in different strains, with two copies, CUP1-1 and CUP1-2, in the 
genomic sequence reference strain S288C 
CUP1-1 17.54 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably amplified 
in different strains, with two copies, CUP1-1 and CUP1-2, in the 
genomic sequence reference strain S288C 
PCL1 7.63 Cyclin, interacts with cyclin-dependent kinase Pho85p; member of 
the Pcl1,2-like subfamily, involved in the regulation of polarized 
growth and morphogenesis and progression through the cell cycle; 
localizes to sites of polarized cell growth 
MF(ALPHA)1 7.16 Mating pheromone alpha-factor, made by alpha cells; interacts with 
mating type a cells to induce cell cycle arrest and other responses 
leading to mating; also encoded by MF(ALPHA)2, although 
MF(ALPHA)1 produces most alpha-factor 
CLN1 6.22 G1 cyclin involved in regulation of the cell cycle; activates Cdc28p 
kinase to promote the G1 to S phase transition; late G1 specific 
expression depends on transcription factor complexes, MBF 
(Swi6p-Mbp1p) and SBF (Swi6p-Swi4p) 
CWP2 5.99 Covalently linked cell wall mannoprotein, major constituent of the 
cell wall; plays a role in stabilizing the cell wall; involved in low 
pH resistance; precursor is GPI-anchored 
HTB2 5.51 Histone H2B, core histone protein required for chromatin assembly 
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and chromosome function; nearly identical to HTB1; Rad6p-Bre1p-
Lge1p mediated ubiquitination regulates transcriptional activation, 
meiotic DSB formation and H3 methylation 
IMD2 5.51 Inosine monophosphate dehydrogenase, catalyzes the rate-limiting 
step in GTP biosynthesis, expression is induced by mycophenolic 
acid resulting in resistance to the drug, expression is repressed by 
nutrient limitation 
MAL12 5.50 Maltase (alpha-D-glucosidase), inducible protein involved in 
maltose catabolism; encoded in the MAL1 complex locus; 
hydrolyzes the disaccharides maltose, turanose, maltotriose, and 
sucrose 
CTT1 5.08 Cytosolic catalase T, has a role in protection from oxidative damage 
by hydrogen peroxide 
SRL1 5.01 Mannoprotein that exhibits a tight association with the cell wall, 
required for cell wall stability in the absence of GPI-anchored 
mannoproteins; has a high serine-threonine content; expression is 
induced in cell wall mutants 
NRM1 4.87 Transcriptional co-repressor of MBF (MCB binding factor)-
regulated gene expression; Nrm1p associates stably with promoters 
via MBF to repress transcription upon exit from G1 phase 
KNH1 4.72 Protein with similarity to Kre9p, which is involved in cell wall beta 
1,6-glucan synthesis; overproduction suppresses growth defects of a 
kre9 null mutant; required for propionic acid resistance 
YDR246W-A 4.68 Putative protein of unknown function; identified by fungal 
homology and RT-PCR 
PMA2 4.64 Plasma membrane H+-ATPase, isoform of Pma1p, involved in 
pumping protons out of the cell; regulator of cytoplasmic pH and 
plasma membrane potential 
YNR073C 4.32 Putative mannitol dehydrogenase 
MAL32 4.25 Maltase (alpha-D-glucosidase), inducible protein involved in 
maltose catabolism; encoded in the MAL3 complex locus; 
functional in genomic reference strain S288C; hydrolyzes the 
disaccharides maltose, turanose, maltotriose, and sucrose 
YFR032C 4.13 Putative protein of unknown function; non-essential gene identified 
in a screen for mutants with increased levels of rDNA transcription; 
expressed at high levels during sporulation 
HHF2 3.95 Histone H4, core histone protein required for chromatin assembly 
and chromosome function; one of two identical histone proteins 
(see also HHF1); contributes to telomeric silencing; N-terminal 
domain involved in maintaining genomic integrity 
DSF1 3.84 Deletion suppressor of mpt5 mutation 
CYC1 3.79 Cytochrome c, isoform 1; electron carrier of the mitochondrial 
intermembrane space that transfers electrons from ubiquinone-
cytochrome c oxidoreductase to cytochrome c oxidase during 
cellular respiration 
YHR126C 3.76 Putative protein of unknown function; transcription dependent upon 
Azf1p 
SIM1 3.74 Protein of the SUN family (Sim1p, Uth1p, Nca3p, Sun4p) that may 
participate in DNA replication, promoter contains SCB regulation 
box at -300 bp indicating that expression may be cell cycle-
regulated 
YHP1 3.65 One of two homeobox transcriptional repressors (see also Yox1p), 
that bind to Mcm1p and to early cell cycle box (ECB) elements of 
cell cycle regulated genes, thereby restricting ECB-mediated 
transcription to the M/G1 interval 
HHF1 3.61 Histone H4, core histone protein required for chromatin assembly 
and chromosome function; one of two identical histone proteins 
(see also HHF2); contributes to telomeric silencing; N-terminal 
domain involved in maintaining genomic integrity 
SCW4 3.61 Cell wall protein with similarity to glucanases; scw4 scw10 double 
mutants exhibit defects in mating 
CCW12 3.57 Cell wall mannoprotein, mutants are defective in mating and 
agglutination, expression is downregulated by alpha-factor 
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CLB1 3.52 B-type cyclin involved in cell cycle progression; activates Cdc28p 
to promote the transition from G2 to M phase; accumulates during 
G2 and M, then targeted via a destruction box motif for ubiquitin-
mediated degradation by the proteasome 
YGR107W 3.50 Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data 
ALD3 3.44 Cytoplasmic aldehyde dehydrogenase, involved in beta-alanine 
synthesis; uses NAD+ as the preferred coenzyme; very similar to 
Ald2p; expression is induced by stress and repressed by glucose 
YEL007W 3.43 Putative protein with sequence similarity to S. pombe gti1+ 
(gluconate transport inducer 1) 
ENO1 3.38 Enolase I, a phosphopyruvate hydratase that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate during 
glycolysis and the reverse reaction during gluconeogenesis; 
expression is repressed in response to glucose 
GAS3 3.37 Putative 1,3-beta-glucanosyltransferase, has similarity to Gas1p; 
localizes to the cell wall 
ADH4 3.35 Alcohol dehydrogenase isoenzyme type IV, dimeric enzyme 
demonstrated to be zinc-dependent despite sequence similarity to 
iron-activated alcohol dehydrogenases; transcription is induced in 
response to zinc deficiency 
YHL018W 3.33 Putative protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to mitochondria and is induced in 
response to the DNA-damaging agent MMS 
PDS1 3.26 Securin, inhibits anaphase by binding separin Esp1p; blocks cyclin 
destruction and mitotic exit, essential for meiotic progression and 
mitotic cell cycle arrest; localization is cell-cycle dependent and 
regulated by Cdc28p phosphorylation 
HXK1,YFR052C-
A 
3.21 Hexokinase isoenzyme 1, a cytosolic protein that catalyzes 
phosphorylation of glucose during glucose metabolism; expression 
is highest during growth on non-glucose carbon sources; glucose-
induced repression involves the hexokinase Hxk2p 
YMR144W 3.20 Putative protein of unknown function; localized to the nucleus; 
YMR144W is not an essential gene 
GPD1 3.19 NAD-dependent glycerol-3-phosphate dehydrogenase, key enzyme 
of glycerol synthesis, essential for growth under osmotic stress; 
expression regulated by high-osmolarity glycerol response 
pathway; homolog of Gpd2p 
WSC4 3.19 ER membrane protein involved in the translocation of soluble 
secretory proteins and insertion of membrane proteins into the ER 
membrane; may also have a role in the stress response but has only 
partial functional overlap with WSC1-3 
YPL014W 3.17 Putative protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm and to the nucleus 
YOX1 3.15 Homeodomain-containing transcriptional repressor, binds to 
Mcm1p and to early cell cycle boxes (ECBs) in the promoters of 
cell cycle-regulated genes expressed in M/G1 phase; expression is 
cell cycle-regulated; potential Cdc28p substrate 
SWI5 3.12 Transcription factor that activates transcription of genes expressed 
at the M/G1 phase boundary and in G1 phase; localization to the 
nucleus occurs during G1 and appears to be regulated by 
phosphorylation by Cdc28p kinase 
GDH1 3.09 NADP(+)-dependent glutamate dehydrogenase, synthesizes 
glutamate from ammonia and alpha-ketoglutarate; rate of alpha-
ketoglutarate utilization differs from Gdh3p; expression regulated 
by nitrogen and carbon sources 
YMR003W 3.00 Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency 
of mitochondrial genome loss 
ALD2 2.00 Cytoplasmic aldehyde dehydrogenase, involved in ethanol 
oxidation and beta-alanine biosynthesis; uses NAD+ as the 
preferred coenzyme; expression is stress induced and glucose 
repressed; very similar to Ald3p 
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YOS1 2.00 Integral membrane protein required for ER to Golgi transport; 
localized to the Golgi, the ER, and COPII vesicles; interacts with 
Yip1p and Yif1p 
ECO1 2.00 Acetyltransferase required for sister chromatid cohesion; modifies 
Smc3p at DNA replication forks during S-phase; modifies Mcd1p 
in response to double-strand DNA breaks during G2/M; mutations 
in human homolog ESCO2 cause Roberts syndrome 
MSN4 2.00 Transcriptional activator related to Msn2p; activated in stress 
conditions, which results in translocation from the cytoplasm to the 
nucleus; binds DNA at stress response elements of responsive 
genes, inducing gene expression 
SGO1 2.02 Component of the spindle checkpoint, involved in sensing lack of 
tension on mitotic chromosomes; protects centromeric Rec8p at 
meiosis I; required for accurate chromosomal segregation at 
meiosis II and for mitotic chromosome stability 
 
 
Summary of the overall effects of gene downregulation on cells 
Figures 4.73-4.75 depict the overall effects on cells induced by genes 
downregulated more than 2-fold in response to 200 µM GdnHCl + 20 µM TA exposure 
for 1 hr.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.73 The percentage of each cellular component category (200 µM GdnHCl 
+ 20 µM TA 1 hr downregulated genes). Genes downregulated more than two-fold 
were assigned cellular component categories. The number of genes in each category 
was expressed as a percentage of the number of total genes. 
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Figure 4.74 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 1 hr downregulated genes). Genes downregulated more than two-fold 
were assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.75 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 1 hr downregulated genes). Genes downregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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The five biological processes, molecular functions and associated cellular 
components most downregulated by exposure to 200 µM GdnHCl + 20 µM TA for 1 hr 
were further grouped. These are illustrated in figures 4.76-4.78. 
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Figure 4.76 The *five associated cellular components most highly downregulated 
by exposure to 200 µM GdnHCl + 20 µM TA for 1 hr. *The 5th and 6th most 
repressed associated cellular components are represented by the same number of genes 
and are thus both included. 
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Figure 4.77 The five molecular functions most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 1 hr. 
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Figure 4.78 The five biological processes most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 1 hr. 
 
 Table 4.9 lists the fifty individual genes, and their respective functions, that 
underwent the most acute transcriptional downregulation in response to 200 µM 
GdnHCl + 20 µM TA exposure for 1 hr. 
Table 4.9 The fifty genes most highly downregulated in response to 200 µM 
GdnHCl + 20 µM TA exposure for 1 hr. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
ADY2 -22.82 Acetate transporter required for normal sporulation; 
phosphorylated in mitochondria 
FRM2 -21.65 Protein of unknown function, involved in the integration of lipid 
signaling pathways with cellular homeostasis; expression 
induced in cells treated with the mycotoxin patulin; has 
similarity to bacterial nitroreductases 
BSC1 -12.31 Protein of unconfirmed function, similar to cell surface 
flocculin Muc1p; ORF exhibits genomic organization 
compatible with a translational readthrough-dependent mode of 
expression 
COX2 -11.51 Subunit II of cytochrome c oxidase, which is the terminal 
member of the mitochondrial inner membrane electron transport 
chain; one of three mitochondrially-encoded subunits 
SAM1 -11.25 S-adenosylmethionine synthetase, catalyzes transfer of the 
adenosyl group of ATP to the sulfur atom of methionine; one of 
two differentially regulated isozymes (Sam1p and Sam2p) 
JJJ3 -9.53 Protein of unknown function, contains a J-domain, which is a 
region with homology to the E. coli DnaJ protein 
DBP2 -9.52 Essential ATP-dependent RNA helicase of the DEAD-box 
protein family, involved in nonsense-mediated mRNA decay 
and rRNA processing 
CIT2 -9.14 Citrate synthase, catalyzes the condensation of acetyl coenzyme 
A and oxaloacetate to form citrate, peroxisomal isozyme 
involved in glyoxylate cycle; expression is controlled by Rtg1p 
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and Rtg2p transcription factors 
SPL2 -8.90 Protein with similarity to cyclin-dependent kinase inhibitors; 
downregulates low-affinity phosphate transport during 
phosphate limitation; overproduction suppresses a plc1 null 
mutation; GFP-fusion protein localizes to the cytoplasm 
SFC1 -8.40 Mitochondrial succinate-fumarate transporter, transports 
succinate into and fumarate out of the mitochondrion; required 
for ethanol and acetate utilization 
DLD3 -7.74 D-lactate dehydrogenase, part of the retrograde regulon which 
consists of genes whose expression is stimulated by damage to 
mitochondria and reduced in cells grown with glutamate as the 
sole nitrogen source, located in the cytoplasm 
CHA1 -7.71 Catabolic L-serine (L-threonine) deaminase, catalyzes the 
degradation of both L-serine and L-threonine; required to use 
serine or threonine as the sole nitrogen source, transcriptionally 
induced by serine and threonine 
GUA1 -7.04 GMP synthase, an enzyme that catalyzes the second step in the 
biosynthesis of GMP from inosine 5'-phosphate (IMP); 
transcription is not subject to regulation by guanine but is 
negatively regulated by nutrient starvation 
YIL057C -6.51 Protein of unknown function involved in energy metabolism 
under respiratory conditions; expression induced under carbon 
limitation and repressed under high glucose 
PCK1 -6.48 Phosphoenolpyruvate carboxykinase, key enzyme in 
gluconeogenesis, catalyzes early reaction in carbohydrate 
biosynthesis, glucose represses transcription and accelerates 
mRNA degradation, regulated by Mcm1p and Cat8p, located in 
the cytosol 
CGR1 -6.43 Protein involved in nucleolar integrity and processing of the 
pre-rRNA for the 60S ribosome subunit; transcript is induced in 
response to cytotoxic stress but not genotoxic stress 
YPR036W-A -6.39 Protein of unknown function; transcription is regulated by 
Pdr1p 
RKI1 -6.33 Ribose-5-phosphate ketol-isomerase, catalyzes the 
interconversion of ribose 5-phosphate and ribulose 5-phosphate 
in the pentose phosphate pathway; participates in pyridoxine 
biosynthesis 
DSE1 -6.21 Daughter cell-specific protein, may regulate cross-talk between 
the mating and filamentation pathways; deletion affects cell 
separation after division and sensitivity to alpha-factor and 
drugs affecting the cell wall 
LTV1 -6.16 Component of the GSE complex, which is required for proper 
sorting of amino acid permease Gap1p; required for ribosomal 
small subunit export from nucleus; required for growth at low 
temperature 
ERO1 -6.07 Thiol oxidase required for oxidative protein folding in the 
endoplasmic reticulum 
MLS1 -6.03 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in peroxisomes 
during growth in oleic acid medium 
PHO89 -6.01 Na+/Pi cotransporter, active in early growth phase; similar to 
phosphate transporters of Neurospora crassa; transcription 
regulated by inorganic phosphate concentrations and Pho4p 
RMT2 -5.74 Arginine N5 methyltransferase; methylates ribosomal protein 
Rpl12 (L12) on Arg67 
OSW1 -5.44 Protein involved in sporulation; required for the construction of 
the outer spore wall layers; required for proper localization of 
Spo14p 
NCE103 -5.36 Carbonic anhydrase; poorly transcribed under aerobic 
conditions and at an undetectable level under anaerobic 
conditions; involved in non-classical protein export pathway 
YAT2 -5.27 Carnitine acetyltransferase; has similarity to Yat1p, which is a 
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carnitine acetyltransferase associated with the mitochondrial 
outer membrane 
YGR067C -5.19 Putative protein of unknown function; contains a zinc finger 
motif similar to that of Adr1p 
SSF1 -5.15 Constituent of 66S pre-ribosomal particles, required for 
ribosomal large subunit maturation; functionally redundant with 
Ssf2p; member of the Brix family 
AAC3 -5.09 Mitochondrial inner membrane ADP/ATP translocator, 
exchanges cytosolic ADP for mitochondrially synthesized ATP; 
expressed under anaerobic conditions; similar to Pet9p and 
Aac1p; has roles in maintenance of viability and in respiration 
UTP6 -5.00 Nucleolar protein, component of the small subunit (SSU) 
processome containing the U3 snoRNA that is involved in 
processing of pre-18S rRNA 
YGR272C -4.96 Essential protein required for maturation of 18S rRNA; null 
mutant is sensitive to hydroxyurea and is delayed in recovering 
from alpha-factor arrest; green fluorescent protein (GFP)-fusion 
protein localizes to the nucleolus 
MRD1 -4.86 Essential conserved protein that is part of the 90S preribosome; 
required for production of 18S rRNA and small ribosomal 
subunit; contains five consensus RNA-binding domains 
NOP15 -4.85 Constituent of 66S pre-ribosomal particles, involved in 60S 
ribosomal subunit biogenesis; localizes to both nucleolus and 
cytoplasm 
YOR338W -4.85 Putative protein of unknown function; YOR338W transcription 
is regulated by Azf1p and its transcript is a specific target of the 
G protein effector Scp160p; identified as being required for 
sporulation in a high-throughput mutant screen 
ENA1 -4.81 P-type ATPase sodium pump, involved in Na+ and Li+ efflux 
to allow salt tolerance 
YBL028C -4.78 Protein of unknown function that may interact with ribosomes; 
green fluorescent protein (GFP)-fusion protein localizes to the 
nucleolus; predicted to be involved in ribosome biogenesis 
NOP14 -4.75 Nucleolar protein, forms a complex with Noc4p that mediates 
maturation and nuclear export of 40S ribosomal subunits; also 
present in the small subunit processome complex, which is 
required for processing of pre-18S rRNA 
HCA4 -4.75 Putative nucleolar DEAD box RNA helicase; high-copy number 
suppression of a U14 snoRNA processing mutant suggests an 
involvement in 18S rRNA synthesis 
DIP5 -4.58 Dicarboxylic amino acid permease, mediates high-affinity and 
high-capacity transport of L-glutamate and L-aspartate; also a 
transporter for Gln, Asn, Ser, Ala, and Gly 
DSE2 -4.49 Daughter cell-specific secreted protein with similarity to 
glucanases, degrades cell wall from the daughter side causing 
daughter to separate from mother; expression is repressed by 
cAMP 
PUT1 -4.45 Proline oxidase, nuclear-encoded mitochondrial protein 
involved in utilization of proline as sole nitrogen source; PUT1 
transcription is induced by Put3p in the presence of proline and 
the absence of a preferred nitrogen source 
RPF1 -4.43 Nucleolar protein involved in the assembly and export of the 
large ribosomal subunit; constituent of 66S pre-ribosomal 
particles; contains a sigma(70)-like motif, which is thought to 
bind RNA 
HIT1 -4.36 Protein of unknown function, required for growth at high 
temperature 
NIP7 -4.32 Nucleolar protein required for 60S ribosome subunit biogenesis, 
constituent of 66S pre-ribosomal particles; physically interacts 
with Nop8p and the exosome subunit Rrp43p 
FAL1 -4.27 Nucleolar protein required for maturation of 18S rRNA, 
member of the eIF4A subfamily of DEAD-box ATP-dependent 
RNA helicases 
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OLI1 -4.18 F0-ATP synthase subunit c (ATPase-associated proteolipid), 
encoded on the mitochondrial genome; mutation confers 
oligomycin resistance; expression is specifically dependent on 
the nuclear genes AEP1 and AEP2 
YGR271C-A -4.18 Essential protein required for maturation of 18S rRNA; null 
mutant is sensitive to hydroxyurea and is delayed in recovering 
from alpha-factor arrest; green fluorescent protein (GFP)-fusion 
protein localizes to the nucleolus 
DRS1 -4.18 Nucleolar DEAD-box protein required for ribosome assembly 
and function, including synthesis of 60S ribosomal subunits; 
constituent of 66S pre-ribosomal particles 
FAF1 -4.14 Protein required for pre-rRNA processing and 40S ribosomal 
subunit assembly 
 
4.18.1.5 Analysis of the effect of 3 hr 200 µM GdnHCl + 20 µM TA exposure on 
yeast cells  
 
In response to 200 µM GdnHCl + 20 µM TA exposure for 3 hr, 175 S. 
cerevisiae genes were upregulated more than 2-fold, 50 of these over 3-fold. The same 
treatment led to 571 genes being downregulated more than 2-fold, 163 of these more 
than 3-fold.  
Summary of the overall effects of gene upregulation on cells 
Figures 4.79-4.81 depict the overall effects on cells induced by genes 
upregulated more than 2-fold in response to 200 µM GdnHCl + 20 µM TA exposure for 
3 hr.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.79 The percentage of each cellular component category (200 µM GdnHCl 
+ 20 µM TA 3 hr upregulated genes). Genes upregulated more than two-fold were 
assigned cellular component categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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Figure 4.80 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 3 hr upregulated genes). Genes upregulated more than two-fold were 
assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.81 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 3 hr upregulated genes). Genes upregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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The five biological processes, molecular functions and associated cellular 
components most induced by exposure to 200 µM GdnHCl + 20 µM TA for 3 hr were 
further explored. These are illustrated in figures 4.82-4.84. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.82 The five associated cellular components most highly upregulated by 
exposure to 200 µM GdnHCl + 20 µM TA for 3 hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.83 The five molecular functions most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 3 hr. 
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Figure 4.84 The five biological processes most highly upregulated by exposure to 
200 µM GdnHCl + 20 µM TA for 3 hr. 
 
 Table 4.10 lists the fifty individual genes, and their respective functions, that 
underwent the highest level of transcriptional upregulation in response to 200 µM 
GdnHCl + 20 µM TA exposure for 3 hr. 
Table 4.10 The fifty genes most highly upregulated in response to 200 µM GdnHCl 
+ 20 µM TA exposure for 3 hr. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
MF(ALPHA)1 18.97 Mating pheromone alpha-factor, made by alpha cells; interacts 
with mating type a cells to induce cell cycle arrest and other 
responses leading to mating; also encoded by MF(ALPHA)2, 
although MF(ALPHA)1 produces most alpha-factor 
ARO10 14.35 Phenylpyruvate decarboxylase, catalyzes decarboxylation of 
phenylpyruvate to phenylacetaldehyde, which is the first 
specific step in the Ehrlich pathway 
ICL1 9.97 Isocitrate lyase, catalyzes the formation of succinate and 
glyoxylate from isocitrate, a key reaction of the glyoxylate 
cycle; expression of ICL1 is induced by growth on ethanol and 
repressed by growth on glucose 
MLS1 8.17 Malate synthase, enzyme of the glyoxylate cycle, involved in 
utilization of non-fermentable carbon sources; expression is 
subject to carbon catabolite repression; localizes in peroxisomes 
during growth in oleic acid medium 
PMA2 7.89 Plasma membrane H+-ATPase, isoform of Pma1p, involved in 
pumping protons out of the cell; regulator of cytoplasmic pH 
and plasma membrane potential 
YJL045W 6.83 Minor succinate dehydrogenase isozyme; homologous to 
Sdh1p, the major isozyme reponsible for the oxidation of 
succinate and transfer of electrons to ubiquinone; induced 
during the diauxic shift in a Cat8p-dependent manner 
KNH1 6.59 Protein with similarity to Kre9p, which is involved in cell wall 
beta 1,6-glucan synthesis; overproduction suppresses growth 
defects of a kre9 null mutant; required for propionic acid 
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resistance 
MDH2 6.22 Cytoplasmic malate dehydrogenase, one of three isozymes that 
catalyze interconversion of malate and oxaloacetate; involved in 
the glyoxylate cycle and gluconeogenesis during growth on 
two-carbon compounds; interacts with Pck1p and Fbp1 
PDC6 5.73 Minor isoform of pyruvate decarboxylase, decarboxylates 
pyruvate to acetaldehyde, involved in amino acid catabolism; 
transcription is glucose- and ethanol-dependent, and is strongly 
induced during sulfur limitation 
FBP1 5.50 Fructose-1,6-bisphosphatase, key regulatory enzyme in the 
gluconeogenesis pathway, required for glucose metabolism; 
undergoes either proteasome-mediated or autophagy-mediated 
degradation depending on growth conditions; interacts with 
Vid30p 
ADH2 5.41 Glucose-repressible alcohol dehydrogenase II, catalyzes the 
conversion of ethanol to acetaldehyde; involved in the 
production of certain carboxylate esters; regulated by ADR1 
ARO9 5.26 Aromatic aminotransferase II, catalyzes the first step of 
tryptophan, phenylalanine, and tyrosine catabolism 
CYC1 5.21 Cytochrome c, isoform 1; electron carrier of the mitochondrial 
intermembrane space that transfers electrons from ubiquinone-
cytochrome c oxidoreductase to cytochrome c oxidase during 
cellular respiration 
PCK1 5.14 Phosphoenolpyruvate carboxykinase, key enzyme in 
gluconeogenesis, catalyzes early reaction in carbohydrate 
biosynthesis, glucose represses transcription and accelerates 
mRNA degradation, regulated by Mcm1p and Cat8p, located in 
the cytosol 
YER158C 4.99 Protein of unknown function, has similarity to Afr1p; 
potentially phosphorylated by Cdc28p 
ACS1 4.89 Acetyl-coA synthetase isoform which, along with Acs2p, is the 
nuclear source of acetyl-coA for histone acetlyation; expressed 
during growth on nonfermentable carbon sources and under 
aerobic conditions 
CWP2 4.63 Covalently linked cell wall mannoprotein, major constituent of 
the cell wall; plays a role in stabilizing the cell wall; involved in 
low pH resistance; precursor is GPI-anchored 
PIR3 4.44 O-glycosylated covalently-bound cell wall protein required for 
cell wall stability; expression is cell cycle regulated, peaking in 
M/G1 and also subject to regulation by the cell integrity 
pathway 
SIP18 4.29 Phospholipid-binding protein; expression is induced by osmotic 
stress 
ACO1 4.21 Aconitase, required for the tricarboxylic acid (TCA) cycle and 
also independently required for mitochondrial genome 
maintenance; phosphorylated; component of the mitochondrial 
nucleoid; mutation leads to glutamate auxotrophy 
CWP1 4.11 Cell wall mannoprotein that localizes specifically to birth scars 
of daughter cells, linked to a beta-1,3- and beta-1,6-glucan 
heteropolymer through a phosphodiester bond; required for 
propionic acid resistance 
TMA7 4.02 Protein of unknown that associates with ribosomes; null mutant 
exhibits translation defects, altered polyribosome profiles, and 
resistance to the translation inhibitor anisomcyin 
CIT3 4.00 Dual specificity mitochondrial citrate and methylcitrate 
synthase; catalyzes the condensation of acetyl-CoA and 
oxaloacetate to form citrate and that of propionyl-CoA and 
oxaloacetate to form 2-methylcitrate 
RPL28 3.99 Ribosomal protein of the large (60S) ribosomal subunit, has 
similarity to E. coli L15 and rat L27a ribosomal proteins; may 
have peptidyl transferase activity; can mutate to cycloheximide 
resistance 
ALD6 3.93 Cytosolic aldehyde dehydrogenase, activated by Mg2+ and 
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utilizes NADP+ as the preferred coenzyme; required for 
conversion of acetaldehyde to acetate; constitutively expressed; 
locates to the mitochondrial outer surface upon oxidative stress 
SPS100 3.84 Protein required for spore wall maturation; expressed during 
sporulation; may be a component of the spore wall; expression 
also induced in cells treated with the mycotoxin patulin 
ATO3 3.84 Plasma membrane protein, regulation pattern suggests a 
possible role in export of ammonia from the cell; 
phosphorylated in mitochondria; member of the TC 9.B.33 
YaaH family of putative transporters 
ACS2 3.80 Acetyl-coA synthetase isoform which, along with Acs1p, is the 
nuclear source of acetyl-coA for histone acetylation; mutants 
affect global transcription; required for growth on glucose; 
expressed under anaerobic conditions 
OLE1 3.65 Delta(9) fatty acid desaturase, required for monounsaturated 
fatty acid synthesis and for normal distribution of mitochondria 
NCA3 3.62 Protein that functions with Nca2p to regulate mitochondrial 
expression of subunits 6 (Atp6p) and 8 (Atp8p ) of the Fo-F1 
ATP synthase; member of the SUN family; expression induced 
in cells treated with the mycotoxin patulin 
SIP4 3.60 C6 zinc cluster transcriptional activator that binds to the carbon 
source-responsive element (CSRE) of gluconeogenic genes; 
involved in the positive regulation of gluconeogenesis; 
regulated by Snf1p protein kinase; localized to the nucleus 
YLR162W 3.44 Putative protein of unknown function; overexpression confers 
resistance to the antimicrobial peptide MiAMP1 
PST1 3.40 Cell wall protein that contains a putative GPI-attachment site; 
secreted by regenerating protoplasts; up-regulated by activation 
of the cell integrity pathway, as mediated by Rlm1p; 
upregulated by cell wall damage via disruption of FKS1 
CUP1-1 3.38 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
CUP1-2 3.38 Metallothionein, binds copper and mediates resistance to high 
concentrations of copper and cadmium; locus is variably 
amplified in different strains, with two copies, CUP1-1 and 
CUP1-2, in the genomic sequence reference strain S288C 
YGL260W 3.34 Putative protein of unknown function; transcription is 
significantly increased in a NAP1 deletion background; deletion 
mutant has increased accumulation of nickel and selenium 
ARG1 3.31 Arginosuccinate synthetase, catalyzes the formation of L-
argininosuccinate from citrulline and L-aspartate in the arginine 
biosynthesis pathway; potential Cdc28p substrate 
YLR164W 3.30 Mitochondrial inner membrane of unknown function; similar to 
Tim18p and Sdh4p; expression induced by nitrogen limitation 
in a GLN3, GAT1-dependent manner 
ICS2 3.23 Protein of unknown function; null mutation does not confer any 
obvious defects in growth, spore germination, viability, or 
carbohydrate utilization 
SPO19 3.18 Meiosis-specific prospore protein; required to produce bending 
force necessary for proper assembly of the prospore membrane 
during sporulation; identified as a weak high-copy suppressor of 
the spo1-1 ts mutation 
YAT1 3.18 Outer mitochondrial carnitine acetyltransferase, minor ethanol-
inducible enzyme involved in transport of activated acyl groups 
from the cytoplasm into the mitochondrial matrix; 
phosphorylated 
RNH203 3.16 Ribonuclease H2 subunit, required for RNase H2 activity; 
related to human AGS3 that causes Aicardi-Goutieres syndrome 
PDH1 3.15 Mitochondrial protein that participates in respiration, induced 
by diauxic shift; homologous to E. coli PrpD, may take part in 
the conversion of 2-methylcitrate to 2-methylisocitrate 
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SSA3 3.15 ATPase involved in protein folding and the response to stress; 
plays a role in SRP-dependent cotranslational protein-
membrane targeting and translocation; member of the heat 
shock protein 70 (HSP70) family; localized to the cytoplasm 
CDA1 3.15 Chitin deacetylase, together with Cda2p involved in the 
biosynthesis ascospore wall component, chitosan; required for 
proper rigidity of the ascospore wall 
PUT4 3.12 Proline permease, required for high-affinity transport of proline; 
also transports the toxic proline analog azetidine-2-carboxylate 
(AzC); PUT4 transcription is repressed in ammonia-grown cells 
ASH1 3.12 Zinc-finger inhibitor of HO transcription; mRNA is localized 
and translated in the distal tip of anaphase cells, resulting in 
accumulation of Ash1p in daughter cell nuclei and inhibition of 
HO expression; potential Cdc28p substrate 
MMR1 3.04 Phosphorylated protein of the mitochondrial outer membrane, 
localizes only to mitochondria of the bud; interacts with Myo2p 
to mediate mitochondrial distribution to buds; mRNA is 
targeted to the bud via the transport system involving She2p 
SPS4 3.029 Protein whose expression is induced during sporulation; not 
required for sporulation; heterologous expression in E. coli 
induces the SOS response that senses DNA damage 
RPP1B 3.00 Ribosomal protein P1 beta, component of the ribosomal stalk, 
which is involved in interaction of translational elongation 
factors with ribosome; accumulation is regulated by 
phosphorylation and interaction with the P2 stalk component 
 
Summary of the overall effects of gene downregulation on cells 
Figures 4.85-4.87 depict the overall effects on cells induced by genes 
downregulated more than 2-fold in response to 200 µM GdnHCl + 20 µM TA exposure 
for 3 hr.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.85 The percentage of each cellular component category (200 µM GdnHCl 
+ 20 µM TA 3 hr downregulated genes). Genes downregulated more than two-fold 
were assigned cellular component categories. The number of genes in each category 
was expressed as a percentage of the number of total genes. 
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Figure 4.86 The percentage of each molecular function category (200 µM GdnHCl 
+ 20 µM TA 3 hr downregulated genes). Genes downregulated more than two-fold 
were assigned molecular function categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
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Figure 4.87 The percentage of each biological process category (200 µM GdnHCl + 
20 µM TA 3 hr downregulated genes). Genes downregulated more than two-fold were 
assigned biological process categories. The number of genes in each category was 
expressed as a percentage of the number of total genes. 
 
The five biological processes, molecular functions and associated cellular 
components most repressed by exposure to 200 µM GdnHCl + 20 µM TA for 3 hr were 
further graphed. These are illustrated in figures 4.88-4.90. 
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Figure 4.88 The five associated cellular components most highly downregulated by 
exposure to 200 µM GdnHCl + 20 µM TA for 3 hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.89 The *five molecular functions most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 3 hr. *The 5th and 6th most repressed molecular 
functions are represented by the same number of genes and are thus both included. 
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Figure 4.90 The five biological processes most highly downregulated by exposure 
to 200 µM GdnHCl + 20 µM TA for 3 hr. 
 
 Table 4.11 lists the fifty genes, and their respective functions, that were the most 
transcriptionally downregulated in response to 200 µM GdnHCl + 20 µM TA exposure 
for 3 hr. 
 
Table 4.11 The fifty genes most highly downregulated in response to 200 µM 
GdnHCl + 20 µM TA exposure for 3 hr. Gene functions were obtained from 
www.yeastgenome.org (SGD). 
 
Gene 
 
Fold Change Gene Function 
FRM2 -30.67 Protein of unknown function, involved in the integration of lipid 
signaling pathways with cellular homeostasis; expression 
induced in cells treated with the mycotoxin patulin; has 
similarity to bacterial nitroreductases 
HXT4 -28.61 High-affinity glucose transporter of the major facilitator 
superfamily, expression is induced by low levels of glucose and 
repressed by high levels of glucose 
SAM1 -19.10 S-adenosylmethionine synthetase, catalyzes transfer of the 
adenosyl group of ATP to the sulfur atom of methionine; one of 
two differentially regulated isozymes (Sam1p and Sam2p) 
CHA1 -13.31 Catabolic L-serine (L-threonine) deaminase, catalyzes the 
degradation of both L-serine and L-threonine; required to use 
serine or threonine as the sole nitrogen source, transcriptionally 
induced by serine and threonine 
AAD6 -11.68 Putative aryl-alcohol dehydrogenase with similarity to P. 
chrysosporium aryl-alcohol dehydrogenase, involved in the 
oxidative stress response; expression induced in cells treated 
with the mycotoxin patulin 
ERO1 -11.53 Thiol oxidase required for oxidative protein folding in the 
endoplasmic reticulum 
AAD16 -10.86 Putative aryl-alcohol dehydrogenase with similarity to P. 
chrysosporium aryl-alcohol dehydrogenase; mutational analysis 
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has not yet revealed a physiological role 
CYC7 -10.73 Cytochrome c isoform 2, expressed under hypoxic conditions; 
electron carrier of the mitochondrial intermembrane space that 
transfers electrons from ubiquinone-cytochrome c 
oxidoreductase to cytochrome c oxidase during cellular 
respiration 
AQR1 -10.47 Plasma membrane multidrug transporter of the major facilitator 
superfamily, confers resistance to short-chain monocarboxylic 
acids and quinidine; involved in the excretion of excess amino 
acids 
YBR238C -9.91 Mitochondrial membrane protein with similarity to Rmd9p; not 
required for respiratory growth but causes a synthetic 
respiratory defect in combination with rmd9 mutations; 
transcriptionally up-regulated by TOR; deletion increases life 
span 
SER2 -8.63 Phosphoserine phosphatase of the phosphoglycerate pathway, 
involved in serine and glycine biosynthesis, expression is 
regulated by the available nitrogen source 
OYE3 -8.29 Conserved NADPH oxidoreductase containing flavin 
mononucleotide (FMN), homologous to Oye2p with different 
ligand binding and catalytic properties; has potential roles in 
oxidative stress response and programmed cell death 
DAN1 -8.18 Cell wall mannoprotein with similarity to Tir1p, Tir2p, Tir3p, 
and Tir4p; expressed under anaerobic conditions, completely 
repressed during aerobic growth 
MUP1 -7.97 High affinity methionine permease, integral membrane protein 
with 13 putative membrane-spanning regions; also involved in 
cysteine uptake 
HXT3 -7.96 Low affinity glucose transporter of the major facilitator 
superfamily, expression is induced in low or high glucose 
conditions 
ATX2 -7.60 Golgi membrane protein involved in manganese homeostasis; 
overproduction suppresses the sod1 (copper, zinc superoxide 
dismutase) null mutation 
HBN1 -7.32 Putative protein of unknown function; similar to bacterial 
nitroreductases; green fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and nucleus; protein becomes 
insoluble upon intracellular iron depletion 
OYE2 -7.24 Conserved NADPH oxidoreductase containing flavin 
mononucleotide (FMN), homologous to Oye3p with different 
ligand binding and catalytic properties; may be involved in 
sterol metabolism, oxidative stress response, and programmed 
cell death 
VID24 -6.99 Peripheral membrane protein located at Vid (vacuole import 
and degradation) vesicles; regulates fructose-1,6-bisphosphatase 
(FBPase) targeting to the vacuole; promotes proteasome-
dependent catabolite degradation of FBPase 
AAC3 -6.76 Mitochondrial inner membrane ADP/ATP translocator, 
exchanges cytosolic ADP for mitochondrially synthesized ATP; 
expressed under anaerobic conditions; similar to Pet9p and 
Aac1p; has roles in maintenance of viability and in respiration 
HXK2 -6.69 Hexokinase isoenzyme 2 that catalyzes phosphorylation of 
glucose in the cytosol; predominant hexokinase during growth 
on glucose; functions in the nucleus to repress expression of 
HXK1 and GLK1 and to induce expression of its own gene 
YGL157W -6.13 NADPH-dependent aldehyde reductase, utilizes aromatic and 
alophatic aldehyde substrates; member of the short-chain 
dehydrogenase/reductase superfamily 
GSH1 -6.05 Gamma glutamylcysteine synthetase catalyzes the first step in 
glutathione (GSH) biosynthesis; expression induced by 
oxidants, cadmium, and mercury 
ATR1 -6.04 Multidrug efflux pump of the major facilitator superfamily, 
required for resistance to aminotriazole and 4-nitroquinoline-N-
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oxide 
MUP3 -5.80 Low affinity methionine permease, similar to Mup1p 
FLR1 -5.67 Plasma membrane multidrug transporter of the major facilitator 
superfamily, involved in efflux of fluconazole, diazaborine, 
benomyl, methotrexate, and other drugs; expression induced in 
cells treated with the mycotoxin patulin 
ADE4 -5.63 Phosphoribosylpyrophosphate amidotransferase (PRPPAT; 
amidophosphoribosyltransferase), catalyzes first step of the 'de 
novo' purine nucleotide biosynthetic pathway 
GRC3 -5.60 Polynucleotide kinase present on rDNA that is required for 
efficient transcription termination by RNA polymerase I; 
required for cell growth; mRNA is cell-cycle regulated 
SCW11 -5.59 Cell wall protein with similarity to glucanases; may play a role 
in conjugation during mating based on its regulation by Ste12p 
YFL054C -5.54 Putative channel-like protein; similar to Fps1p; mediates 
passive diffusion of glycerol in the presence of ethanol 
YGR035C -5.47 Putative protein of unknown function, potential Cdc28p 
substrate; transcription is activated by paralogous transcription 
factors Yrm1p and Yrr1p along with genes involved in 
multidrug resistance 
AAD4 -5.37 Putative aryl-alcohol dehydrogenase with similarity to P. 
chrysosporium aryl-alcohol dehydrogenase, involved in the 
oxidative stress response; expression induced in cells treated 
with the mycotoxin patulin 
GTT2 -5.32 Glutathione S-transferase capable of homodimerization; 
functional overlap with Gtt2p, Grx1p, and Grx2p 
INM1 -5.16 Inositol monophosphatase, involved in biosynthesis of inositol 
and in phosphoinositide second messenger signaling; INM1 
expression increases in the presence of inositol and decreases 
upon exposure to antibipolar drugs lithium and valproate 
PFK27 -5.15 6-phosphofructo-2-kinase, catalyzes synthesis of fructose-2,6-
bisphosphate; inhibited by phosphoenolpyruvate and sn-
glycerol 3-phosphate, expression induced by glucose and 
sucrose, transcriptional regulation involves protein kinase A 
YNL024C -4.97 Putative protein of unknown function with seven beta-strand 
methyltransferase motif; green fluorescent protein (GFP)-fusion 
protein localizes to the cytoplasm; YNL024C is not an essential 
gene 
YLR301W -4.94 Protein of unknown function that interacts with Sec72p 
MIG1 -4.93 Transcription factor involved in glucose repression; sequence 
specific DNA binding protein containing two Cys2His2 zinc 
finger motifs; regulated by the SNF1 kinase and the GLC7 
phosphatase 
JJJ3 -4.89 Protein of unknown function, contains a J-domain, which is a 
region with homology to the E. coli DnaJ protein 
STE14 -4.77 Farnesyl cysteine-carboxyl methyltransferase, mediates the 
carboxyl methylation step during C-terminal CAAX motif 
processing of a-factor and RAS proteins in the endoplasmic 
reticulum, localizes to the ER membrane 
HOR2 -4.74 One of two redundant DL-glycerol-3-phosphatases 
(RHR2/GPP1 encodes the other) involved in glycerol 
biosynthesis; induced in response to hyperosmotic stress and 
oxidative stress, and during the diauxic transition 
YKL071W -4.66 Putative protein of unknown function; expression induced in 
cells treated with the mycotoxin patulin, and also the quinone 
methide triterpene celastrol; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm 
PMP2 -4.61 Proteolipid associated with plasma membrane H(+)-ATPase 
(Pma1p); regulates plasma membrane H(+)-ATPase activity; 
nearly identical to PMP1 
PGA3 -4.60 Putative cytochrome b5 reductase, localized to the plasma 
membrane; may be involved in regulation of lifespan; required 
for maturation of Gas1p and Pho8p, proposed to be involved in 
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protein trafficking 
AGA1 -4.57 Anchorage subunit of a-agglutinin of a-cells, highly O-
glycosylated protein with N-terminal secretion signal and C-
terminal signal for addition of GPI anchor to cell wall, linked to 
adhesion subunit Aga2p via two disulfide bonds 
CST26 -4.57 Protein required for incorporation of stearic acid into 
phosphatidylinositol; affects chromosome stability when 
overexpressed 
COX5B -4.53 Subunit Vb of cytochrome c oxidase, which is the terminal 
member of the mitochondrial inner membrane electron transport 
chain; predominantly expressed during anaerobic growth while 
its isoform Va (Cox5Ap) is expressed during aerobic growth 
GPX2 -4.45 Phospholipid hydroperoxide glutathione peroxidase induced by 
glucose starvation that protects cells from phospholipid 
hydroperoxides and nonphospholipid peroxides during 
oxidative stress 
SPI1 -4.44 GPI-anchored cell wall protein involved in weak acid 
resistance; basal expression requires Msn2p/Msn4p; expression 
is induced under conditions of stress and during the diauxic 
shift; similar to Sed1p 
YNL134C -4.40 Putative protein of unknown function with similarity to 
dehydrogenases from other model organisms; green fluorescent 
protein (GFP)-fusion protein localizes to both the cytoplasm 
and nucleus and is induced by the DNA-damaging agent MMS 
 
 
4.18.1.6 Investigation into the differential effects of GdnHCl and TA exposure 
time on yeast cells 
 
 I was interested at this point in assessing the effects induced by GdnHCl and 
TA under different lengths of exposure. RNA sequencing data was compared from cells 
exposed to 200 µM GdnHCl + 20 µM TA for 1 hr, 3 hr and 14 generations, as 
summarised in previous sections. The five most commonly stimulated and repressed 
molecular functions, biological processes and associated cellular components were 
compared and contrasted. This provides insight into the ways in which different 
exposure times affect the S. cerevisiae drug response.  
 Figures 4.91-4.93 depict comparisons of the biological processes, cellular 
components and molecular functions stimulated by GdnHCl and TA upon 1 hr., 3 hr. 
and 14 generation exposures. It appears that there are differences in responses induced 
by cellular exposure to GdnHCl and TA for 1 hr. and 3 hr. As shown in figure 4.91, 
RNA metabolic process, ribosome biogenesis and transport are all some of the most 
highly stimulated processes under 1 hr., 3 hr. and 14 generation exposures. Genes 
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involved in translation are greatly stimulated by GdnHCl and TA exposure for 1 hr and 
14 generations, but not 3 hr. Transcription and cell cycle appear to be induced upon 1 hr. 
and 14 generation exposure respectively, while genes involved in the response to stress 
and chemical stimulus are stimulated only under 3 hr. exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.91 Comparison of the five most common biological processes of genes 
with >2-fold upregulation. 
 
 Genes associated with the cytoplasm, nucleus and membrane are all some of 
those most highly expressed upon 1 hr., 3 hr. and 14 generation exposure to GdnHCl 
and TA, as illustrated in figure 4.92. Genes associated with the nucleolus are highly 
upregulated under the 1 hr. and 14 generation exposures only, while plasma membrane-
associated genes are acutely induced solely under 3 hr exposure. The high upregulation 
of mitochondrion-associated genes occurs only upon 1 hr. and 3 hr. exposures, while 
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genes involved in ribosome function are only acutely expressed upon 14 generation 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.92 Comparison of the five most common associated cellular components 
of genes with >2-fold upregulation. 
 
 Transferase and hydrolase activity are among the most induced functions when 
cells are treated to these agents for 1 hr., 3 hr. and 14 generations (figure 4.93). 
Oxidoreductase and transporter activity are most highly stimulated under the two 
shorter exposure times. Genes involved in RNA binding are highly upregulated upon 1 
hr. and 14 generation treatments, while those that play a role in protein binding are 
acutely induced in response to 3 hr. and 14 generation exposures. Structural molecule 
activity is only highly stimulated under treatment for 14 generations.  
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Figure 4.93 Comparison of the five most common molecular functions of genes 
with >2-fold upregulation. 
 
Downregulated gene GO identities were also compared and contrasted, as 
illustrated in figures 4.94-4.96. Figure 4.94 depicts the great difference in genes that are 
repressed upon 1 hr., 3 hr. and 14 generation exposure to GdnHCl and TA. RNA 
metabolic process is the only biological process greatly inhibited in response to all 
exposure times. Response to stress, cellular carbohydrate metabolic process, 
chromosome organisation and cell cycle are all inhibited upon 1 hr. exposure. 
Heterocycle metabolic process, ribosome biogenesis, cellular amino acid metabolic 
process and translation are the most repressed processes upon treatment for 3 hr. In 
contrast, genes involved in transport, transcription, generation of precursor metabolites 
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and energy, response to chemical stimulus and mitochondrion organistaion are all 
acutely repressed under 14 generation treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.94 Comparison of the *five most common biological processes of genes 
with >2-fold downregulation. *In response to 14 generation exposure the 5th and 6th 
most repressed biological processes are represented by the same number of genes and 
are thus both included. 
 
Upon comparison of the cellular components associated with the most acutely 
donwregulated genes, it was found that those associated with the cytoplasm, nucleus, 
mitochondrion and membrane are common to all three exposure times (figure 4.95). 
 Cell wall- and chromosome-associated genes are only highly repressed under 
drug treatment for 1 hr. Ribosome-associated genes are only highly inhibited under 
exposure for 3 hr., while genes involved in the mitochondrial envelope are only those 
most repressed under the 14 generation treatment. 
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Figure 4.95 Comparison of the *five most common associated cellular components 
of genes with >2-fold downregulation. *In response to 1 hr exposure the 5th and 6th 
most repressed associated cellular components are represented by the same number of 
genes and are thus both included. 
 
 As illustrated in figure 4.96, oxidoreductase and transferase activity are both 
some of the most repressed functions under drug exposure for 1 hr., 3 hr. and 14 
generations. Upon 1 hr. yeast cell treatment, DNA binding is most inhibited, which is 
also common to 14 generation exposure. Other molecular functions inhibited under this 
treatment are transcription regulator activity and protein binding.  Upon drug exposure 
for 3 hr., RNA binding and transporter activity are those most hindered, in addition to 
hydrolase and structural molecule activity, which are both also acutely inhibited under 1 
hr. exposure.  
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Figure 4.96 Comparison of the *five most common molecular functions of genes 
with >2-fold downregulation. *In response to 3 hr. exposure the 5th and 6th most 
repressed molecular functions are represented by the same number of genes and are thus 
both included. 
 
 
4.18.1.7 Assessing the effects of TA on heatshock and related genes using 
transcriptomics    
 
    It is known that heatshock proteins and related co-chaperones are involved in 
prion propagation (Jones and Tuite, 2005). Disruption of normal chaperone protein 
activity, particularly that of Hsp70p can disturb prion propagation (Jung et al., 2000, 
Jones and Masison, 2003, Jones et al., 2004). It was thus considered that the curing of 
[PSI+] by TA may involve alterations in chaperone function or chaperone expression 
levels. Further to this, the expression levels of a number of genes encoding proteins 
with chaperone-related function were assessed under GdnHCl and TA exposure (table 
4.12).    
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200 µM GdnHCl
1 hr exposure 
20 µM TA + 
200 µM GdnHCl
3 hr exposure
20 µM TA + 
200 µM GdnHCl
14 generation exposure
Oxidoreductase Activity
Protein Binding
Transcription 
Regulator 
Activity
Five Most Common Molecular Functions 
of Genes with >2-fold Downregulation
Structural Molecule Activity
Transferase Activity
Hydrolase Activity
DNA Binding
RNA binding
Transporter Activity
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The majority of the genes in the table below have been previously discussed. 
CDC37, like STI1 encodes a Hsp90p co-chaperone and the two are known to interact 
with one another (Kimura et al., 1997, Abbas-Terki et al., 2002). Cells deleted for 
HSP26 and HSP42 have been shown to accumulate protein aggregates (Petko and 
Lindquist, 1986, Haslbeck et al., 2004). Hsp26p and Hsp42p encoded by these genes 
are small heatshock proteins (sHSPs) that are involved in the suppression of cytosolic 
protein aggregation (Haslbeck et al., 2004). It has been reported that Hsp26p co-
aggregates with misfolded proteins, thereby facilitating their disaggregation and 
reactivation by Hsp104p, Hsp70p and Hsp40p (Cashikar et al., 2005). This provides a 
possible link for sHSPs and prion propagation.  
 
Table 4.12 Expression levels of a number of genes possibly involved in [PSI+] 
propagation in the presence of GdnHCl and TA. 
 
Gene 
 
Control 14 gen Gdn 14 gen Gdn + 
TA 
 
1hr Gdn + 
TA 
3hr Gdn + TA 
APJ1 44.18 90.23 75.54 36.59 56.82 
CDC37 104.68 54.10 49.93 113.45 65.76 
CNS1 40.76 19.94 12.85 10.77 16.42 
CPR7 19.77 4.977 3.85 16.64 11.28 
ECM10 N/A N/A N/A N/A N/A 
FES1 76.61 63.44 46.11 48.53 112.31 
HSP104 705.00 224.57 382.18 860.98 798.13 
HSP26 6677.16 2513.75 5033.54 7950.32 13825.5 
HSP42 672.22 586.49 726.93 830.18 764.81 
HSP82 772.31 235.18 370.91 543.59 817.02 
KAR2 570.35 138.76 116.47 186.38 235.16 
LHS1 53.31 18.19 17.93 24.94 23.65 
SSA1 1214.19 168.49 319.47 1373.99 1396.94 
SSA2 799.88 88.80 176.41 20.27 725.72 
SSA3 300.07 129.80 214.15 297.10 945.95 
SSA4 233.94 59.69 79.36 245.03 138.58 
SSB1 326.94 85.72 47.05 224.71 357.90 
SSB2 336.71 139.75 76.53 282.77 461.26 
SSC1 1497.55 2658.25 2913.65 1332.14 1440.8 
SSE1 360.65 167.19 127.61 164.28 241.92 
SSE2 301.94 217.88 N/A 455.17 340.52 
SSQ1 63.24 N/A 78.93 60.81 42.41 
SSZ1 122.36 63.92 51.38 76.31 N/A 
STI1 392.04 194.60 227.42 N/A 482.27 
YDJ1 214.95 55.35 38.51 93.22 192.82 
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Hsp82p and Hsc82p are the two S. cerevisiae Hsp90 proteins (Borkovich et al., 
1989, Gross et al., 1990). As previously described, Hsp90 proteins work in conjunction 
with Hsp70 members to carry out correct protein folding and maintain cell viability 
(Wegele et al., 2004). The fact that Hsp70p and Hsp90p closely cooperate and many co-
chaperones are common to both families of heatshock proteins suggests that Hsp90p 
may also have a regulatory function linked to prion propagation. Kar2p and Lhs1p are 
endoplasmic reticulum-associated Hsp70 proteins (Rose et al., 1989, Craven et al., 1996) 
and the mammalian Bip protein, homologous to Kar2p has been shown to prevent PrP 
aggregation and facilitate PrPSc proteosomal degradation (Normington et al., 1989, Jin 
et al., 2000).  
 
4.18.2 Using two-dimensional gel electrophoresis to assess the S. cerevisiae 
response to TA 
  
In addition to analysing the global transcriptional response of yeast to TA, the 
proteomic response was explored. 2D gel electrophoresis was employed to achieve this. 
Protein was extracted, precipitated and quantified, from untreated control cells, cells 
exposed to 200 µM GdnHCl and cells exposed to 200 µM GdnHCl + 20 µM TA. The 
cells were exposed to the compounds for 14 generations as we knew this to be enough 
time to fully cure [PSI+].  
Proteins were separated based on their isoelectric point, followed by their mass 
and coomassie stained. ProgenesisTM same spot software was used to identify proteins 
differentially expressed. Protein expression patterns were sought that depicted 
differential expression upon the two treatments. 15 protein spots of interest, illustrated 
in figure 4.97 were selected, extracted and identified using Liquid Chromatography 
Mass Spectrometry (LC-MS).   
Table 4.13 lists the 15 proteins identified that were expressed at different levels 
in response to treatment with GdnHCl alone and in combination with TA.  
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Figure 4.97 Separated proteins from G600 cells. Spots circled represent proteins that 
undergo an increase or decrease in level of expression in response to 200 µM GdnHCl 
and 200 µM GdnHCl + 20 µM TA exposure. 
 
 
Spot no. 1, Ilv2p is downregulated in response to GdnHCl alone, but upregulated 
in the presence of both GdnHCl and TA (figure 4.98). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.98 Ilv2p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 7.215e-004. 
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Spot no. 2, Ssb1p follows the same pattern of expression as Ilv2p whereby 
expression decreases under exposure to GdnHCl alone and increases in the presence of 
both GdnHCl and TA (figure 4.99).  
 
 
   
 
 
 
 
 
 
 
 
Figure 4.99 Ssb1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.014. 
 
 
Spot no. 3, Ssa2p was found to be upregulated in response to GdnHCl and 
further increased in when TA was present (figure 4.100). 
 
 
 
 
 
 
 
 
Figure 4.100 Ssa2p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.013. 
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Table 4.13 Yeast proteins identified as undergoing an increase or decrease in expression under GdnHCl and TA treatment. *Fold change is the 
sum of changes between the control and GdnHCl alone, and GdnHCl alone and with the addition of TA.  
 
Spot No. Protein 
Name 
Sum of 
fold 
changes* 
Change 
C-GdnHCl 
Change 
Gdn-TA 
PI Value Molecular 
Mass (Da) 
Peptides 
Matched 
Mascot 
Score 
Coverage (%) Protein Function 
1 
 
 
 
Ilv2 
 
 
 
15.6 
 
 
 
Down- Up- 8.95 
 
 
 
75064 
 
 
 
10(3) 
 
 
 
420 
 
 
 
12 
 
 
 
Acetolactate synthase, catalyses the first common step  
in isoleucine and valine biosynthesis and is the target of 
several classes of inhibitors, localizes to the mitochondria; 
expression of the gene is under general amino acid control 
2 Ssb1 50.7 Down- Up- 5.32 42078 5(0) 195 9 Cytoplasmic ATPase that is a ribosome-associated 
molecular chaperone, functions with J-protein partner 
Zuo1p; may be involved in folding of newly-made 
polypeptide chains; member of the HSP70 family; interacts 
with phosphatase subunit Reg1p 
3 
 
 
 
 
 
Ssa2 
 
 
 
 
42.1 
 
 
 
 
Up- Up- 4.95 
 
 
 
 
69601 
 
 
 
 
5(1) 
 
 
 
 
256 
 
 
 
 
10 
 
 
 
 
ATP binding protein involved in  
protein folding and vacuolar import of proteins; member of 
heat shock protein 70 (HSP70) family; associated with the 
chaperonin-containing T-complex; present in the cytoplasm, 
vacuolar membrane and cell wall 
4 
 
 
 
 
Ssb1 
 
 
 
 
16.5 
 
 
 
 
Down- Up- 5.32 
 
 
 
 
66735 
 
 
 
 
4(0) 
 
 
 
 
199 
 
 
 
 
5 
 
 
 
 
Cytoplasmic ATPase that is a ribosome-associated 
molecular chaperone, functions with J-protein partner 
Zuo1p; may be involved in folding of newly-made 
polypeptide chains; member of the HSP70 family; interacts 
with phosphatase subunit Reg1p 
5 
 
Asn2 
 
6.6 
 
Down- Up- 5.48 
 
65085 
 
5(0) 
 
168 
 
5 
 
Asparagine synthetase, isozyme of Asn1p;  
catalyzes the synthesis of L-asparagine from L-aspartate in 
the asparagine biosynthetic pathway 
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6 
 
 
 
 
 
Ssa2 
 
 
 
 
21.4 
 
 
 
 
Up- Up- 4.95 
 
 
 
 
69601 
 
 
 
 
10(2) 
 
 
 
 
413 
 
 
 
 
12 
 
 
 
 
ATP binding protein involved in  
protein folding and vacuolar import of proteins; member of 
heat shock protein 70 (HSP70) family; associated with the 
chaperonin-containing T-complex; present in the cytoplasm, 
vacuolar membrane and cell wall 
7 
 
 
 
 
Ade17 
 
 
 
 
9.4 
 
 
 
 
Down- Down- 6.12 
 
 
 
 
65571 
 
 
 
 
3(1) 
 
 
 
 
201 
 
 
 
 
5 
 
 
 
 
Enzyme of 'de novo' purine biosynthesis  
containing both 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase and inosine monophosphate 
cyclohydrolase activities, isozyme of Ade16p; ade16 ade17 
mutants require adenine and histidine 
8 
 
 
 
 
Pdc1 
 
 
 
5.8 
 
 
 
Up- Up- 5.8 
 
 
 
61689 
 
 
 
4(1) 
 
 
 
146 
 
 
 
4 
 
 
 
Major of three pyruvate decarboxylase  
isozymes, key enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde; subject to 
glucose-, ethanol-, and autoregulation; involved in amino 
acid catabolism 
9 
 
 
 
 
Pdc1 
 
 
 
11.8 
 
 
 
Down- Up- 5.8 
 
 
 
61689 
 
 
 
2(0) 
 
 
 
89 
 
 
 
3 
 
 
 
Major of three pyruvate decarboxylase  
isozymes, key enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde; subject to 
glucose-, ethanol-, and autoregulation; involved in amino 
acid catabolism 
10 Aro8 13.3 Up- Up- 5.68 56375 2(0) 83 4 Aromatic aminotransferase I, expression  
is regulated by general control of amino acid biosynthesis 
11 
 
 
Imd3 
 
 
17.7 
 
 
Down- Up- 7.04 
 
 
56955 
 
 
2(0) 
 
 
78 
 
 
3 
 
 
Inosine monophosphate dehydrogenase,  
catalyzes the first step of GMP biosynthesis, member of a 
four-gene family in S. cerevisiae, constitutively expressed 
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12 Adh1 
 
 
93.9 Down- Up- 5.94 
 
 
37290 
 
 
2(0) 90 4 Alcohol dehydrogenase, fermentative  
isozyme active as homo- or heterotetramers; required for the 
reduction of acetaldehyde to ethanol, the last step in the 
glycolytic pathway 
13 
 
 
 
 
Adh1 
 
 
14.1 
 
 
 
Up- Up- 5.94 
 
 
37290 
 
 
8(0) 
 
 
304 
 
 
15 
 
 
Alcohol dehydrogenase, fermentative  
isozyme active as homo- or heterotetramers; required for the 
reduction of acetaldehyde to ethanol, the last step in the 
glycolytic pathway 
14 Tdh3  Up- Up- 6.46 35840 2(0) 77 5 Glyceraldehyde-3-phosphate dehydrogenase, isozyme  
3, involved in glycolysis and gluconeogenesis; tetramer that 
catalyzes the reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm and cell 
wall 
15 Rhr2  Up- Up- 5.35 28103 5(1) 255 20 Constitutively expressed isoform of DL-glycerol-3- 
phosphatase; involved in glycerol biosynthesis, induced in 
response to both anaerobic and, along with the 
Hor2p/Gpp2p isoform, osmotic stress 
 Spot no. 4, another Ssb1p isoform, is downregulated in response to GdnHCl 
alone and under cellular exposure to both GdnHCl and TA in combination it is highly 
upregulated (figure 4.101). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.101 Ssb1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.012. 
 
 Spot no. 5, identified as Asn2p is downregulated in the presence of GdnHCl and 
upregulated under GdnHCl and TA combined exposure (figure 4.102). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.102 Asn2p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.009. 
 
 Spot no. 6, Ssa2p is upregulated under exposure to both treatments (figure 
4.103).   
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Figure 4.103 Ssa2p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.043. 
 
 
 Ade17p was found to be represented by spot no. 7, and the expression of this 
protein is repressed in the presence of GdnHCl alone and further inhibited in the 
presence of a combination of GdnHCl and TA (figure 4.104). 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.104 Ade17p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.034 
 
 Spot no. 8, identified as Pdc1p is upregulated upon GdnHCl exposure and its 
expression increases further upon TA addition (figure 4.105). 
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Figure 4.105 Pdc1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.020. 
 
 Protein spot no. 9 was also identified as Pdc1p. In this instance, Pdc1p was seen 
to be downregulated in the presence of GdnHCl alone and highly upregulated with the 
addition of TA (figure 4.106). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.106 Pdc1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.043. 
 
 The protein represented by spot no. 10 was identified as Aro8p. Proteomic study 
demonstrated that this protein is upregulated under exposure to GdnHCl alone and then 
furthermore in the presence of a combination of both GdnHCl and TA (figure 4.107). 
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Figure 4.107 Aro8p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.032. 
  
The expression of protein spot no. 11, Imd3p decreases upon exposure to 
GdnHCl but is highly stimulated under the addition of TA (figure 4.108).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.108 Imd3p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.007. 
 
 The expression of Adh1p, represented by spot no. 12 is heavily repressed in the 
presence of GdnHCl alone but highly induced under exposure to both GdnHCl and TA 
(figure 4.109).   
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Figure 4.109 Adh1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.003. 
 
 Spot no. 13 was also identified as Adh1p. As for spot 12, this was found to be 
highly expressed in the presence of a combination of GdnHCl and TA. Unlike spot 12, 
expression was upregulated under exposure to GdnHCl alone (figure 4.110).   
  
 
 
 
 
 
 
 
 
 
Figure 4.110 Adh1p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.040. 
 
 Tdh3p, found to be represented by spot no. 14 is upregulated upon GdnHCl 
exposure and furthermore with the addition of TA (figure 4.111).  
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Figure 4.111 Tdh3p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.042. 
 
 Spot no. 15 was identified as Rhr2p. This appears to be stimulated in the 
presence of GdnHCl alone and induced to a higher level under exposure GdnHCl and 
TA in combination (figure 4.112).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.112 Rhr2p expression in response to GdnHCl and TA. ProgenesisTM 
calculated p = 0.046. 
 
 Figure 4.113 below presents gels containing separated proteins from cells that 
were untreated, exposed to 200 µM GdnHCl and treated with 200 µM GdnHCl + 20 µM 
TA. 
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Figure 4.113 Comparison of gels containing separated proteins from untreated 
cells, and cells exposed to GdnHCl and TA.  
 
Figure 4.114 provides an example of proteins found to be differentially 
expressed upon drug exposure. 
 
 
 
 
 
 
 
Figure 4.114 Illustration of differential Ssb1p and Ade17p expression in response 
to GdnHCl and TA exposure. 
 
 Protein spot no. 2 Ssb1p as depicted in figure 4.114 is downregulated in the 
presence of GdnHCl alone and upregulated under exposure to a combination of GdnHCl 
and TA. The figure above illustrates the visible difference in spot intensity. Ade17p is 
repressed under cellular exposure to GdnHCl alone and further decreased with the 
addition of TA.  
 
4.19 Discussion 
 
Much of the work described in this chapter was carried out to learn more about 
the mode of action of TA. Although commonly prescribed for decades to treat 
Alzheimer’s Disease (Summers, 2006), TA was recently identified as an agent 
displaying prion-curing capacity in yeast (Tribouillard-Tanvier et al., 2008a). Unlike 
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two other drugs 6AP and GA identified in a similar screen, TA was found to be inactive 
against mammalian prions (Bach et al., 2003, Tribouillard-Tanvier et al., 2008a, 
Tribouillard-Tanvier et al., 2008b). It was thus hypothesised that the yeast TA target 
may be too far diverged in the mammalian system for the drug to be effective 
(Tribouillard-Tanvier et al., 2008b). 
In this study, it was demonstrated that TA, 6AP and GA all have the ability to 
cure [PSI+] in wild-type S. cerevisiae, but only in the presence of GdnHCl. It therefore 
appears that a certain level of background curing by GdnHCl is required before the anti-
prion effects of the drugs can be observed in wild-type. Importantly, the concentration 
of GdnHCl that facilitates [PSI+] curing by the drugs does not cure the prion when 
supplied alone. This can be seen in figures 4.3, 4.5 and 4.6. It was noted that relatively 
low concentrations, such as 5 µM, of all three drugs is sufficient to elicit effects.  
When [PSI+] cells are treated wth an effective level of GdnHCl, the cleavage of 
new propagons by Hsp104p is prevented, halting priongenesis, and the remaining prion 
seeds are diluted out over time (Paushkin et al., 1996, Eaglestone et al., 2000, Ferreira 
et al., 2001). Based on the curing curves constructed in this study, it appears that 6AP, 
GA and TA function in a similar manner, preventing prion propagation, allowing 
residual propagons to be diluted out over subsequent generations. Although it is thought 
that 6AP and GA cure [PSI+] through a different mode of action to TA, methods may be 
similar in this respect. Like GdnHCl, the way in which these three drugs cure [PSI+] 
may also be a result of chaperone function inhibition. It is already known that 6AP and 
GA decrease the level of ribosomal chaperone activity. Although structurally unrelated, 
6AP and GA cure prions through a similar in trans mode of action (Reis et al., 2011). 
Both compete with unfolded protein for the domain V of the large rRNA of the large 
ribosomal subunit and inhibit ribosomal-mediated protein folding (Tribouillard-Tanvier 
et al., 2008b, Reis et al., 2011). The analogous TA curing curve implies this agent may 
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also inhibit chaperone activity, hindering prion propagation. Perhaps TA is inhibiting a 
chaperone that is diverged or undiscovered in mammals, as suggested by Tribouillard-
Tanvier et al. (2008a). To date, no Hsp104p homologue has been discovered in 
mammals (Jones and Tuite, 2005), it was thus hypothesised that TA may target 
Hsp104p, as GdnHCl does, and like TA, GdnHCl does not cure mammalian prions. The 
TA curing curve data correlates well with the result from another assay demonstrating 
that growth is required for TA to cure [PSI+]. Cell cultures exposed to TA (in 
combination with GdnHCl) in which cells did not grow remained [PSI+], while cells 
that underwent growth began to cure (figure 4.7). Data from both assays depicted TA 
prion curing over time, associated with cell growth.                    
Although similarities were observed in 6AP, GA and TA curing curves, some 
differences were also seen. Both 6AP and GA appear to cure [PSI+] in the wild-type 
background faster than TA, suggesting that they are more potent prion-curing agents 
than TA. However, when comparing the level of curing after 11 generations, TA 
exposure results in a greater percentage of cured cells than 6AP or GA. These 
discrepancies in drug curing patterns highlights a probable difference in the way in 
which 6AP and GA cure [PSI+], in comparison to TA. This difference may simply be a 
disparity in the chaperone activity targeted by the respective drugs. 
Further to these results, thermotolerance assays were carried out. Hsp104p is key 
in enabling cells to withstand heatshock (Sanchez and Lindquist, 1990). It was reasoned 
that if TA does target Hsp104p, inhibiting its function, this may be reflected in the level 
of cellular thermotolerance. After Hsp104p induction by incubation at 39ºC and 
subsequent heatshock at 52ºC, a clear growth gradient was observed for wild-type cells 
on YPD (figure 4.11). Prolonged heatshock resulted in increased cell death. Exposure to 
3 mM GdnHCl following heatshock strongly inhibited cell growth, illustrating 
inhibition of Hsp104p activity by GdnHCl, thus hindering thermotolerance. Neither 20 
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µM TA nor 200 µM GdnHCl alone effected wild-type cellular thermotolerance, 
demonstrating the neither alone exert any considerable influence on Hsp104p. However, 
growth of heatshocked cells exposed to a combination of both is hindered. This implies 
that TA may inhibit Hsp104p, as it enhances the effect of a low, ineffective level of 
GdnHCl. It may be the case that together, TA and GdnHCl have an accumulative effect 
on Hsp104p, resulting in clear inhibition.  
Thermotolerance assays using G600 ∆hsp104 showed no difference in growth of 
heat-shocked cells, regardless of drug exposure (figure 4.12). Due to the absence of 
HSP104, drugs cannot take effect, supporting the hypothesis that TA targets Hsp104p.   
Thermotolerance assays were also performed using 6AP and GA. This allowed 
comparisons to be made to the inhibitory effects of TA on Hsp104p. In contrast to TA, a 
combination of 20 µM 6AP/GA and 200 µM GdnHCl did not appear to result in the 
inhibition of Hsp104p (figure 4.15). This suggests that 6AP and GA do not amplify the 
effects of GdnHCl, and do not target Hsp104p and again highlights a difference in the 
modes of action of 6AP/GA and TA.       
Following thermotolerance assay results that demonstrated an apparent 
accumulative effect of GdnHCl and TA on Hsp104p, it was hypothesised that TA may 
function in increasing the rate of GdnHCl uptake by cells. An attempt was made to 
monitor the uptake of [14C]-labelled GdnHCl in the presence and absence of TA. 
Unfortunately, the assay was unsuccessful.    
 Upon environmental stress, Hsp104p works through collaboration with 
Hsp70p and Hsp40p to rescue denatured, aggregated proteins (Glover and Lindquist, 
1998). Taking into account that TA appears to cure [PSI+] in a similar manner to 
GdnHCl, the effects of this drug on Hsp70p activity was also investigated. Hsp70 
protein family members have a peptide-binding domain (PBD) which maintains tight 
association with its substrate when ADP is bound to the adjacent ATPase-binding 
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domain (ABP). In contrast, when ATP is bound, rapid substrate exchange takes place 
(Masison et al., 2009). This ATPase binding cycle is regulated by a number of co-
chaperones and NEFs such as Ydj1p, Sis1p, Fes1p, Sse1p, Sti1p, Cns1p and Cpr7p (Cyr 
et al., 1992, Dolinski et al., 1998, Lu and Cyr, 1998, Kabani et al., 2002, Wegele et al., 
2003, Hainzl et al., 2004, Jones et al., 2004, Raviol et al., 2006). The importance of 
Hsp70p and the ATPase binding cycle in prion propagation has been demonstrated and 
is of particular interest due to the high level of conservation between yeast and 
mammals (Chernoff et al., 1995, Newnam et al., 1999, Jones et al., 2004). In this study, 
wild-type and mutant strains lacking genes involved in the Hsp70p ATPase binding 
cycle were exposed to TA alone and in the presence of GdnHCl (figure 4.17). As 
expected, it was seen that TA alone does not cure [PSI+] in wild-type G600, but clear 
zones of TA curing were seen in the presence of 200 µM and 500 µM background 
GdnHCl. Very different results were obtained for Hsp70p-associated mutants. TA cures 
∆ssa1 [PSI+] in the absence of background GdnHCl, however 3 mM GdnHCl appears to 
have the same effect as 10 mM TA. When 200 µM and 500 µM GdnHCl are present TA 
curing is enhanced. Similar results were seen for ∆cpr7, ∆sti1 and ∆fes1, however that 
for the double mutant ∆sti1∆cpr7 was somewhat different. In the presence of 500 µM 
background GdnHCl, the TA zone of ∆sti1∆cpr7 [PSI+] curing was greater than that for 
either of the single mutants. This suggests that an exacerbated disruption of the Hsp70p 
ATPase binding cycle renders cells more sensitive to curing by TA.  
The same experiment was performed using 6AP and GA, so that the effects of 
these drugs could be compared to that of TA (figures 4.18 and 4.19). Comparable 
results were obtained for 6AP curing of [PSI+] in these strains. In the absence of 
background GdnHCl, 6AP did not cure [PSI+] in wild-type G600 but it did in the 
mutant strains. It does appear however that 6AP is to a small degree more potent than 
TA in curing prions in Hsp70p-related mutant strains. The [PSI+] curing capacity of GA 
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in these strains was also observed. Interestingly, GA seemed to be the weakest anti-
prion agent as the curing zones induced in both wild-type and mutant strains was 
considerably smaller than those for TA and 6AP. The fact that all three drugs alone have 
the ability to cure [PSI+] in these mutant strains suggests that any of these drugs might 
target Hsp70p or the ATPase binding cycle. It may be the case that the drugs are 
inhibiting an already weakend ATPase binding cycle and exhibiting intensified [PSI+] 
curing. The fact that 6AP and GA alone cure [PSI+] in Hsp70p-related mutants may 
indicate a possible link between Hsp70p- and ribosomal-mediated protein folding. 
Importantly, it was clearly demonstrated in these assays that in a suitable background 
strain, TA, 6AP and GA have the ability to cure [PSI+]. Following the observation that 
TA has the ability to cure [PSI+] in the absence of GdnHCl, it can be assumed that this 
drug does not solely function through enhancing the uptake of GdnHCl, as was 
previously hypothesised.               
 To further investigate if any of these drugs target Hsp104p or Hsp70p, Western 
blot analysis was performed. The expression levels of Ssa1p and Hsp104p under drug 
exposure was assessed. Untreated wild-type cells express the same level of both Ssa1p 
and Hsp104p as those treated with GdnHCl alone and in combination with TA, 6AP and 
GA. This indicates that TA, 6AP and GA do not directly affect the level of these 
chaperone proteins and correlates with results published by Lahiri et al. (1994), who 
showed that TA does not induce changes in the expression level of mammalian Hsp70p. 
If any of these drugs do induce [PSI+] curing through targeting Hsp70p or Hsp104p, 
they may do so by altering chaperone protein activity rather than direct expression 
levels.   
 Additional investigation into the mode of action of TA involved assessing the 
genes that are up- and downregulated in response to exposure. RNA sequencing data 
was analysed and the cellular transcriptomic responses to 200 µM GdnHCl and 200 µM 
 365 
GdnHCl + 20 µM TA were compared (exposure for 14 generations). Genes that 
underwent more than 2-fold increase or decrease in transcription were assessed. It must 
be noted that many more genes are downregulated than upregulated in response to both 
treatments.  
It appears that whether the cells are exposed to 200 µM GdnHCl alone, or in 
combination with 20 µM TA, the cells respond in the same way at a general biological 
level. The five most highly induced biological processes are common to both treatments 
(4.61). The RNA metabolic process is stimulated, to increase the amount of RNA 
available, prerequisite to protein production, presumably as a general response to the 
above described compounds. The fact that ribosome biogenesis and translation are 
stimulated adds weight to this hypothesis, increasing potential for augmented protein 
production. Transport, also seen to be provoked, is important subsequently for carriage 
of synthesised proteins to regions where function might occur. The importance of the 
cell cycle becomes clear at this point, as it is necessary for cells to undergo duplication 
to increase the opportunity to respond to both TA and GdnHCl. 
The cellular response at the molecular function level to both treatments is also 
quite similar (4.63). Transferase activity involves the transfer of a functional group from 
one molecule to another, e.g. transfer of a phosphate group to a molecule from ATP by 
a kinase (Parson, 1993). The fact that transferase activity is upregulated could denote 
that GdnHCl and TA are creating stressful conditions for the cell. Kinases have 
previously been shown to be transcriptionally upregulated in response to osmotic, 
oxidative and heavy metal stress in Candida albicans (Enjalbert et al., 2006) and 
environmental stress in Schizosaccharomyces pombe (Berlanga et al., 2010). It is 
already known that GdnHCl is toxic to yeast at concentrations of above 3-5 mM and 
thus causes an inhibition of growth (Jung et al., 2002). The 200 µM concentration, 
albeit 15-25 times lower that that found by others to be toxic, could bring about stress 
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that would precede cell death in cultures exposed to 3-5 mM GdnHCl. As illustrated by 
figures 4.61 and 4.63, it is difficult to assess the impact TA has on the cell, as TA and 
GdnHCl combined at these concentrations don’t initiate biological or molecular 
responses that aren’t seen under GdnHCl exposure alone.  
Genes associated with the cytoplasm, nucleus, membrane and ribosome are 
some of the most highly induced in the presence of GdnHCl alone and combined wih 
TA. However, GdnHCl alone stimulates genes associated with the mitochondrion, while 
GdnHCl and TA together stimulate nucleolus-associated genes (figure 4.62). rRNA is 
transcribed and assembled within the nucleolus (Parson, 1993). The fact that under 
exposure to GdnHCl and TA combined, nucleolus-associated genes are most highly 
upregulated, suggests the cells strive to respond to those compounds by increasing 
protein production, be it proteins involved in regular housekeeping functions or specific 
proteins that enable survival in the presence of the drugs.     
When comparing the biological processes carried out by the most acutely 
downregulated genes, a greater difference was observed. Genes associated with 
transport, RNA metabolic process and transcription are highly downregulated under 
exposure to both GdnHCl alone and in combination with TA. However, cellular lipid 
and heterocycle metabolic processes are only acutely repressed in the presence of 
GdnHCl alone. In contrast, the response to chemical stimulus, generation of precursor 
metabolites and energy and mitochondrion organisation are all greatly inhibited when 
TA is added to GdnHCl. Heterocycle metabolism involves ‘chemical reactions and 
pathways involving heterocyclic compounds, those with a cyclic molecular structure’ 
(SGD www.yeastgenome.org). However GdnHCl does not possess a cyclic structure. 
A high degree of overlap was observed from expression data in genes that are 
up- and downregulated in response to GdnHCl alone and in combination with TA for 14 
generations. For example, three of the four genes most upregulated in response to 
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GdnHCl exposure are also some of the four genes most stimulated in the presence of 
GdnHCl and TA combined.     
It was important not only to look at the cellular response to GdnHCl and TA 
after 14 generations, when [PSI+] cells have been completely cured by a combination of 
the two. Cellular responses after 1 hr. and 3 hr. exposures provides insight into the way 
in which yeast initially react to the presence of the drugs. The RNA sequencing data 
depicting the complete yeast cellular response to GdnHCl and TA combined for 14 
generations was also used in assessing the differential effects induced by various 
exposure times. Comparisons were made of the genes differentially expressed under 
exposure to 200 µM GdnHCl + 20 µM TA for 1 hr., 3 hr. and 14 generations. All three 
exposure times induced an increase in the expression of genes involved in RNA 
metabolic process, ribosome biogenesis and transport. The shortest exposure time 
caused an upregulation in transcription- and translation-associated genes, the latter also 
common to the 14 generation treatment, while the 3 hr. exposure induced genes that 
play a role in response to chemical stimulus and stress. Uniquely, the 14 generation 
exposure acutely induced genes involved in the cell cycle (4.91). 
Genes associated with the nucleolus were only highly upregulated upon 1 hr. 
and 14 generation exposure, while those associated with the plasma membrane where 
only highly stimulated under 3 hr. exposure, as shown in figure 4.92. Cytoplasm-, 
nucleus-, and membrane-associated genes were some of the most highy upregulated 
genes in response to all treatments. Conversely, genes associated with the 
mitochondrion were only highly stimulated under the two shorter exposures, while 
those involved with ribosome function were found to be most induced upon 14 
generation treatment. 
As regards molecular function, transferase and hydrolase activity were 
commonly induced under the three different exposures. Oxidoreductase and transporter 
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activity were stimulated under 1 hr. and 3 hr. exposures, while RNA binding was 
acutely induced upon 1 hr. and 14 generation exposures. Protein binding was commonly 
upregulated upon 3 hr. and 14 generation treatments and structural molecule activity 
was uniquely one of the most highly stimulated functions under the longest exposure 
(figure 4.93).  
Interestingly, very little correlation was observed in biological processes 
repressed upon GdnHCl + TA exposure for 1 hr., 3 hr. and 14 generations (figure 4.94). 
Only RNA metabolic process was highly inhibited in response to all treatments. Genes 
most heavily downregulated upon 1 hr. treatment function in the response to stress, 
cellular carbohydrate metabolic process, chromosome organisation and cell cycle. 
Those downregulated upon 3 hr. exposure play a role in heterocycle metabolic process, 
ribosome biogenesis, cellular amino acid metabolic process and translation. The 
processes most hindered under exposure for 14 generations were transport, transcription, 
generation of precursor metabolites and energy, response to chemical stimulus and 
mitochondrial organisation. 
A higher degree of correlation was observed in the comparison of cellular 
components associated with genes highly repressed upon exposure 1 hr., 3 hr. and 14 
generation exposure. Genes associated with the cytoplasm, nucleus, mitochondrion and 
membrane were heavily downregulated under all exposures (figure 4.95). Cell wall- and 
chromosome-associated genes were among those most repressed during the shortest 
exposure, while ribosome-associated genes were seen to be inhibited most heavily 
during the 3 hr. exposure. Conversely, genes involved with the mitochondrial envelope 
were acutely downregulated upon the 14 generation treatment. 
In response to GdnHCl + TA exposure for 1 hr., 3 hr. and 14 generations, genes 
involved in oxidoreductase and transferase activity were all highly repressed (figure 
4.96). Hydrolase and structural molecule activity were severely inhibited under the two 
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shorter treatments, while DNA binding genes were acutely downregulated upon 1 hr. 
and 14 generation exposures. Specific to the 3 hr. treatment, genes related to RNA 
binding and transporter activity were transcriptionally repressed. Transcription regulator 
activity and protein binding-associated genes were severly downregulated upon 14 
generation exposure only.       
Taking these results together, it appears that exposure to GdnHCl and TA 
combined may be conferring some kind of cellular stress. The biological process termed 
response to stress is acutely stimulated under 3 hr. exposure. Individual genes involved 
in the stress response can be some of the most highly upregulated genes in the presence 
of these agents. For example, CUP1-1 and CUP1-2 are upregulated almost 18-fold 
under the 1 hr. treatment (table 4.8). CUP1-1 and CUP1-2 are two copies of a gene 
encoding a metallothionein that confers resistance to cells against copper and cadmium 
(Winge et al., 1985, Jeyaprakash et al., 1991). In response to 3 hr. exposure, these genes 
are again among the 50 most highly upregulated genes. However, after exposure for 14 
generations, these genes do not fall into the 50 most highly upregulated gene category. 
This may imply that when cells are initially exposed to GdnHCl and TA combined, they 
are subjected to stress on some level, which they begin to respond to and eventually 
adapt to. The fact that the concentrations of these agents used elicit effects but do not 
kill cells may facilitate this response and adaptation.        
Examining the expression levels of a number of genes involved or related in 
some way to prion propagation yielded interesting results (table 4.12). Ydj1p is a 
member of the Hsp40 protein family (Cyr et al., 1994). It interacts with Hsp70p and 
plays a role in regulating the ATPase binding cycle, thus facilitating Hsp70p activity 
and prion propagation (Cyr et al., 1992, Masison et al., 2009). When cells are exposed 
to 200 µM GdnHCl alone for 14 generations, YDJ1 is downregulated 3.9-fold. With the 
addition of 20 µm TA, it is further repressed 1.4-fold. Similar patterns were observed 
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for other genes encoding Hsp70p ATPase cycle regulators. The CNS1 gene product acts 
as a co-chaperone for both Hsp90p and Hsp70p, stimulating ATPase activity of the 
latter (Dolinski et al., 1998, Hainzl et al., 2004). CNS1 was found to be downregulated 
2-fold under exposure to GdnHCl alone and downregulated 1.6-fold further in the 
presence of GdnHCl and TA combined. Similar patterns of transcriptional repression 
were observed for other genes CPR7, FES1 and SSE1, which act as Hsp70p ATPase 
binding cycle regulators (Kabani et al., 2002, Raviol et al., 2006, Masison et al., 2009). 
The fact that these genes are all heavily downregulated upon GdnHCl exposure alone 
can perhaps be explained. GdnHCl is known to inhibit Hsp104p-mediated prion 
propagation (Ferreira et al., 2001). Moosavi et al. (2010) demonstrated that [PSI+] 
curing by Hsp104p overexpression requires Hsp70p co-chaperones and suggested that 
these proteins regulate Hsp104p activity or alter its binding ability. It may be the case 
that in this study, when Hsp104p activity was inhibited by GdnHCl, the cells responded 
by downregulating the expression of Hsp70p co-chaperones as they were not required 
for Hsp104p regulation. If TA does target Hsp104p, this response may be enhanced 
with the addition of TA. Alternatively, the exacerbated decrease in YDJ1, CNS1, CPR7, 
FES1 and SSE1 expression under GdnHCl + TA exposure may be indicative that TA 
targets the Hsp70p ATPase binding cycle.  
Following two-dimensional gel electrophoresis and LC-MS, analysis of proteins 
differentially expressed under 200 µM GdnHCl and 20 µM TA exposure led to the 
identification of a number of proteins displaying similar patterns of expression. A 
number of spots determined to be Ssa2p (two spots), Pdc1p, Aro8p, Adh1p, Tdh3p and 
Rhr2p were shown to be upregulated in response to GdnHCl exposure alone and further 
elevated in the presence of GdnHCl and TA combined (figures 4.100, 4.103, 4.105, 
4.107, 4.110-4.112). Ssa2p as described above is a member of the Hsp70 Stress Seventy 
subclass A (Craig et al., 1993), and the fact that expression of this protein is upregulated 
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in this manner may suggest that TA cures [PSI+] by targeting Hsp70p expression in 
combination with GdnHCl. It may be the case that TA and GdnHCl negatively affect 
Hsp70p and in response to this the cells increase Ssa2p production.     
Pdc1p is a pyruvate decarboxylase, and along with the alcohol dehydrogenease 
Adh1p and the glyceraldehyde-3-phosphate dehydrogenase Tdh3p, plays a role in the 
glucose fermentation pathway (Lutstorf and Megnet, 1968, Bennetzen and Hall, 1982, 
Schmitt and Zimmermann, 1982, McAlister and Holland, 1985, Pronk et al., 1996). The 
increases in expression of these proteins in response to GdnHCl alone and in 
combination with TA suggest that glucose fermentation may be stimulated in response 
to these agents. As was discussed in chapter 3, the increased activation of this process 
may be a result of cellular oxidative stress. 
Rhr2p, which was shown to be upregulated in response to GdnHCl and TA, is a 
glycerol-3-phosphatase that is involved in yeast stress responses (Norbeck et al., 1996, 
Pahlman et al., 2001). The fact that this protein is increasingly expressed in response to 
these agents supports the hypothesis that they may induce cellular stress. Interestingly, 
this protein has been shown to physically interact with other Hsp70 family members 
Ssa1p, Ssb1p and Sse1p (Gong et al., 2009). If TA and GdnHCl exposure does result in 
an alteration of Hsp70p expression, the upregulation of Rhr2p may be implicated in the 
differential chaperone expression. 
Aro8p is an aminotransferase (Iraqui et al., 1998) that undergoes an increase in 
expression in response to GdnHCl and TA. This protein is also known to interact 
physically with Sse1p (Gong et al., 2009) and may be thus involved somehow in 
[PSI+]-curing by GdnHCl and TA. 
Other proteins were also found to undergo interesting patterns of differential 
expression. Ade17p is responsible for catalysing part of the de novo purine biosynthesis 
pathway (Tibbetts and Appling, 2000) and was the only protein downregulated upon 
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GdnHCl exposure and furthermore with the addition of TA (figure 4.104). A number of 
proteins were downregulated in the presence of GdnHCl alone and then upregulated 
under exposure to GdnHCl and TA combined. Protein spots representing Ilv2p, Ssb1p 
(two spots), Asn2p, Pdc1p, Imd3p and Adh1p all followed this pattern of expression 
(figures 4.98, 4.99, 4.101, 4.102, 4.106, 4.108, 4.109). Ilv2p plays a role in isoleucine 
and valine biosynthesis and physically interacts with Ssb2p, a Stress Seventy B Hsp70 
subclass member (Falco et al., 1985, Craig et al., 1993, Krogan et al., 2006). 
Interestingly, the second member of the Ssb Hsp70 subfamily, Ssb1p (Craig et al., 
1993), was found to exhibit the same expression pattern as Ilv2p under GdnHCl and TA 
exposure. These results suggest that in response to GdnHCl alone, the Hsp70 Ssa 
proteins are generally upregulated and the Ssb proteins downregulated, and with the 
addition of TA, expression of both subfamilies is upregulated. Thus, it appears that 
exposure to GdnHCl alone induces differential expression of Stress Seventy proteins but 
in combination with TA, these proteins are largely upregulated.  
Asn2p is a synthetase required in the asparagine biosynthesis pathway (Dang et 
al., 1996), while Imd3p is an inosine monophosphate dehydrogenase (Escobar-
Henriques and Daignan-Fornier, 2001). Both are downregulated under exposure to 
GdnHCl alone and upregulated in the presence of GdnHCl and TA combined. Although 
protein spots consistently upregulated were identified as Pdc1p and Adh1p, additional 
spots displaying the same expression pattern as Asn2p were determined to be Pdc1p and 
Adh1p. Although these patterns do not fully correlate, both demonstrate that Pdc1p and 
Adh1p are highly stimulated in the presence of GdnHCl and TA combined.      
Additional work performed to investigate possible targets of TA involved ethyl 
methanesulfonate (EMS) mutagenesis, whereby the G600 genome was randomly 
mutagenised in an attempt to identify gene(s) that when disrupted alter [PSI+]-curing by 
TA. A high-copy plasmid screen was also carried out with the aim of identifying gene(s) 
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that when overexpressed alter [PSI+]-curing by TA. More than 500 colonies were 
screened in each of these experiments but no genes of interest were identified.    
In investigating the mode of action of TA, four mutant strains lacking LTV1, 
YAR1, RPL8A and RPL8B, deficient in ribosomal stability and reported to display [PSI+] 
instability were employed (M. Blondel, personal communication). Exposure of these 
strains to 6AP or GA has been shown to confer stability to the weak [PSI+] prion (M. 
Blondel, personal communication). The fact that ribosomal imbalance is stabilised by 
6AP and GA supports the findings that these drugs target ribosomal chaperone activity 
(Tribouillard-Tanvier et al., 2008b), and further implicates ribosome function in prion 
propagation. As for wild-type 74D strain, [PSI+] curing by TA, 6AP and GA in ∆ltv1, 
∆yar1, ∆rpl8a and ∆rpl8b requires the presence of a relatively low concentration of 
GdnHCl (figures 4.22-4.24). Drug-mediated [PSI+] curing in these strains is not 
enhanced and similar zones of curing to wild-type were observed in disc assays. It did 
however appear that [PSI+] in the ∆ltv1 background did not cure as efficiently as the 
other strains tested, particularly under 6AP exposure. Therefore, it appears that 6AP 
stabilises the prion to the greatest extent in the absence of LTV1.   
The fact that Hsp104p- and ribosomal-mediated chaperone activity are both 
involved in prion propagation has been previously discussed. Further to this, it was of 
interest to assess if their roles in maintaing [PSI+] overlap, and analyse the effects of 
both HSP104 and LTV1/YAR1 deletion on the yeast phenotype. In this study only ∆ltv1 
and ∆yar1 were found to exhibit weak [PSI+] and the spontanaeous appearance of [psi-] 
colonies (figure 4.21), and were thus the only strains used for further investigation. To 
learn more, the question of whether these functions overlap in relation to acquired 
thermotolerance was addressed. 74D ∆hsp104 displayed an identical phenotype to wild-
type upon 3 mM GdnHCl exposure (figures 4.25-4.26). This demonstrates that in the 
74D background strain 3 mM GdnHCl inhibits Hsp104p activity to the same extent as if 
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the HSP104 gene were absent. ∆ltv1 exhibited a higher level of induced 
thermotolerance than ∆hsp104, although a certain level of this was attributed to 
Hsp104p as when the cells were treated with 3 mM GdnHCl, growth was inhibited 
mimicking the ∆hsp104 phenotype (figure 4.28). Exposure to 200 µM GdnHCl and 20 
µM TA combined also inhibits ∆ltv1 thermotolerance while either drug alone at these 
concentrations does not. In the absence of both LTV1 and HSP104, cells do not survive 
at all after a 10 minute heatshock, illustrating the severly low level of acquired 
thermotolerance (figure 4.29). Neither TA nor GdnHCl had any effect of the virtually 
absent induced thermotolerance of the ∆ltv1∆hsp104 strain. This suggests that LTV1 
and HSP104 exhibit an accumulative effect in conferring thermotolerance to S. 
cerevisiae. The fact that ∆ltv1∆hsp104 did not grow to the same extent as ∆ltv1 exposed 
to 3 mM, as was expected, raises the possibility that Ltv1p and Hsp104p synergy is 
required for a comprehensive acquired heatshock response.  
The phenotype of ∆yar1 was somewhat different to that of ∆ltv1, demonstrating 
that although both mutants exhibit ribosome instability, the cells appear to be affected 
differently. ∆yar1 was unable to grow after the 10 min. heatshock, displaying an acute 
lack of acquired thermotolerance, even though HSP104 was present (figure 4.30). 3 mM 
GdnHCl exposure appeared to be the only treatment that affected the growth of this 
strain and was seen to inhibit cell growth further, resulting in only a small level of cell 
growth prior to heatshock. Interestingly, the deletion of HSP104 in ∆yar1 appears to 
induce a positive genetic effect, as in the absence of HSP104, ∆yar1 appears to grow 
better (figure 4.31). There is a small amount of ∆yar1∆hsp104 growth after the 10 
minute heatshock on YPD, although not upon drug exposure. Also when exposed to 3 
mM GdnHCl, ∆yar1∆hsp104 undergoes a much higher level of growth than ∆yar1. This 
is accounted for by the absence of Hsp104p, the GdnHCl target (Ferreira et al., 2001). 
Although it seems that Ltv1p and Hsp104p work in union with one another to facilitate 
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thermotolerance, Yar1p and Hsp104p may not. Ultimately, it appears that in the absence 
of Yar1p, Hsp104p in some way renders the cells more vulnerable to heatshock. 
 Due to ambiguity surrounding thermotolerance assay results, luciferase assays 
were performed that enabled further investigation into the effects of LTV1 and YAR1 
deletion on heatshock recovery. In contrast to results from thermotolerance assays, 
luciferase assays suggested that the absence of YAR1 and LTV1 facilitates a much more 
rapid recovery of luciferase, following denaturation (figure 4.32). Following heatshock, 
the cells that demonstrated the fastest luciferase activity recovery, representative of 
chaperone activity, were ∆yar1 cells. These cells exhibited more than 100% of their 
initial pre-heatshock luciferase activity after 60 min. As Hsp104p plays an essential role 
in heatshock recovery and acquired thermotolerance (Sanchez and Lindquist, 1990), this 
implies that the absence of YAR1 allows exacerbated Hsp104p activity. ∆yar1∆hsp104 
was in fact the strain that displayed the lowest level of luciferase activity recovery 
following heatshock, suggesting that it is uniquely Hsp104p that facilitates the rapid 
recovery observed for ∆yar1. Similar results were obtained for ∆ltv1 and ∆ltv1∆hsp104. 
After ∆yar1, ∆ltv1 was the second most rapidly recovering strain with regards to 
luciferase activity, exhibiting restored chaperone activity considerably faster than wild-
type, while ∆ltv1∆hsp104 was the second slowest recovering strain. This again is 
suggestive of ribosomal imbalance facilitating accelerated chaperone recovery and in 
turn allowing refolding of proteins into their functional state, but only in the presence of 
Hsp104p. These results are more consistent than those obtained from the 
thermotolerance assays, however there is confliction. Returning to the initial model 
illustrated in figure 4.1, the luciferase assay results may be explained. Ribosomal 
imbalance may lead to excess chaperone activity which increases the rate of luciferase 
recovery. Perhaps this activity enhances Hsp104p function either directly or indirectly. 
Further to this, the absence of both YAR1/LTV1 and HSP104 may then severely hinder 
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the ability of cells to recover following heatshock, which is subsequently exemplified 
by the low level of luciferase activity. 
While assessing the effects of LTV1 and YAR1 absence on functional chaperone 
activity and prion propagation, it was observed that the wild-type 74D background 
strain phenotypically differed from G600 in some respects. 74D is substantially more 
TS than G600 and unlike the latter, does not survive following incubation at 39ºC for 48 
hr (figure 4.33). As Hsp104p and Hsp70p are heavily implicated in enabling cells to 
withstand thermostress (Sanchez and Lindquist, 1990, Glover and Lindquist, 1998), it 
was hypothesised that 74D may produce a lower basal level of these chaperone proteins 
than G600. Western blot analysis was thus performed to investigate the expression 
levels of these proteins upon cellular incubation at 30ºC, 37ºC and 39ºC (figure 4.36). 
For both strains, it was found that 1 hr. incubation at 37ºC caused an increase in 
expression of both Hsp104p and Ssa1p. 1 hr. incubation at 39ºC induced a further 
increase in the level of these proteins. Thus, it appears that both strains are able to 
acquire thermotolerance through pre-incubation at 37ºC and 39ºC, however 74D cannot 
survive prolonged exposure to the latter temperature. This experiment also 
demonstrated that 74D does indeed produce a somewhat lower basal level of both 
Hsp104p and Ssa1p than G600, which may contribute to temperature sensitivity.     
To further investigate, the 74D genome was sequenced and compared with that 
of the S288C reference strain. Approximately 5, 500 non-synonymous amino acid 
changes were identified in the 74D genome, a number of them in genes encoding 
chaperones and cochaperones, including SSA1, CPR7, and STI1 (tables 4.1-4.2). 
Although no non-synonymous amino acid changes were found in HSP104, which is of 
great importance in acquired thermotolerance (Sanchez and Lindquist, 1990), changes 
were found in the Hsp70p family SSA1 gene, that is required for Hsp104p-mediated 
protein folding (Glover and Lindquist, 1998). 
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 Additionally, a high-copy plasmid screen was performed with the aim of 
identifying gene(s) that when overexpressed reduce 74D temperature sensitivity. A 
number of genes were found whose overexpression resulted in similar 74D growth to 
that of G600 (figure 4.34). It was anticipated at this point that a certain level of overlap 
would be observed and that a number of genes might encode products involved in the 
same pathway or process. However, when the identity of these genes were revealed, 
there appeared to be no overlap and thus no specific function could be said to be 
responsible in part for 74D temperature sensitivity.      
 In overall conclusion, differences in the TA mode of action compared to that of 
6AP and GA are highlighted in this chapter. While results suggest that TA may target 
Hsp104p, as GdnHCl does (Ferreira et al., 2001), they suggest that 6AP and GA do not. 
The hypothesis that TA functions solely through enhancing GdnHCl uptake also 
appears to be invalidated. Disruption of Hsp70p activity enhances [PSI+] curing by all 
drugs and eliminates the requirement for background GdnHCl curing, suggesting that 
any one of the three drugs may target Hsp70p and its regulators. TA and GdnHCl 
combined appear to induce cellular stress, implying that cells must adapt when treated 
with these drugs to enable survival. There are differences in results relating to the 
effects of LTV1 and YAR1 absence on acquired cellular thermotolerance. Regardless, 
LTV1 or YAR1 deletion alone and in combination with HSP104 deletion severely 
impacts upon the way in which cells recover and survive following heatshock. Thus it 
can be concluded that ribosomal imbalance has an acute affect on heatshock and 
chaperone activity, which may subsequently have implications for prion-propagation.  
 
 
 
      
 
 
 
 
 
 
 
 
 
Chapter 5   Discussion and future work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 378 
Part 1 Using Saccharomyces cerevisiae as a model organism to 
investigate the eukaryotic response to the toxic fungal metabolite 
gliotoxin 
 
 
As a secondary metabolite that assists in facilitating host colonisation by a 
number of fungal species, including A. fumigatus (Weindling and Emerson, 1936, 
Müllbacher and Eichner, 1984), gliotoxin is an interesting toxin. In this study, S. 
cerevisiae, a commonly used model organism, was employed to investigate the 
eukaryotic response to gliotoxin. The detrimental effects of gliotoxin were clearly 
evident as it inhibited the growth of yeast strains in both solid and liquid culture. As this 
distinct consequence of gliotoxin exposure was observed, RNA sequencing and 
proteomic analysis were utilised to investigate the eukaryotic cellular response induced 
as a result of exposure to gliotoxin. 
To our knowledge, analysis of the yeast global response to gliotoxin had not 
been performed prior to this study, although Chamilos et al. (2008) had previously 
carried out a genomewide screen to identify S. cerevisiae genes associated with 
gliotoxin resistance or sensitivity. 
Previous work has indicated that the presence of gliotoxin gives rise to OS in 
mammalian cells, particularly as the toxin can undergo redox cycling (Trown and 
Bilello, 1972, Eichner et al., 1988, Orr et al., 2004). The findings discussed here have 
supported these observations as wild-type S. cerevisiae increased the expression of a 
large number of proteins that play a role in the OS response. This stimulation often 
occured at both the transcription level and the proteomic level. For example, genes 
involved in the sulfur amino acid biosynthesis pathway, both directly and through its 
regulation, were upregulated considerably in response to two concentrations of gliotoxin, 
as demonstrated by RNA sequencing analysis. This led to increased protein expression 
in some cases which was possible to detect using 2-dimensional gel electrophoresis. 
This sulfur amino acid biosynthesis pathway must be fully functional before glutathione 
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can be produced which has been significantly implicated in protection against OS 
(Williamson et al., 1982, Dormer et al., 2000, Mosharov et al., 2000, Penninckx, 2000). 
Moreover, mutant analysis also demonstrated the importance of the OS response in 
resistance to gliotoxin. In agreement with Chamilos et al. (2008), ∆cys3 was seen to be 
hyper-sensitive to gliotoxin, due to disruption of the transsulfuration pathway, a 
subsection of the sulfur amino acid biosynthesis pathway that generates cysteine (Ono 
et al., 1992, Cherest et al., 1993). ∆sod1 and ∆yap1 also displayed increased sensitivity 
to gliotoxin, ∆yap1 more acutely than ∆sod1, due to the absence of cytosolic superoxide 
dismutase and important transcriptional regulation of a wide range of OS responses 
(Bermingham-McDonogh et al., 1988, Schnell et al., 1992, Lee et al., 1999). These 
mutants also exhibited increased sensitivity to H2O2, highlighting the possible similarity 
in deleterious effects imposed on cells by both gliotoxin and H2O2. The fact that 
cysteine and glutathione suppress the uptake of O2 in the presence of glucose, favouring 
fermentation (Quastel and Wheatley, 1932) may be one of the reasons why many 
proteins involved in glucose fermentation were found to be upregulated in response to 
gliotoxin. Alternatively, it may be the requirement of the thioredoxin and glutaredoxin 
OS defence systems for NADPH produced during the process (Holmgren, 1989), that 
drives the system.  
GSH is one of the most important proteins in preventing cellular oxidative 
damage (Penninckx, 2002). However, the absence of GSH1, encoding a protein that 
catalyses the first step in yeast GSH biosynthesis (Ohtake and Yabuuchi, 1991, Wu and 
Moye-Rowley, 1994) has afforded elevated cellular resistance to gliotoxin. As 
discussed previously, this may be due to rapid efflux of gliotoxin from the cells in the 
absence of GSH. The ∆cys3 mutant, producing much lower levels of GSH than wild-
type may synthesise enough GSH to allow retention of gliotoxin within the cell, yet not 
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enough to confer efficient protection to cells. This proposed model is illustrated in 
figure 5.1.  
   
   
 
 
 
 
 
 
 
 
 
Figure 5.1 Proposed model demonstrating how changes in GSH levels affect yeast 
growth in the presence of gliotoxin. A) When normal levels of GSH are produced, 
gliotoxin enters the cell and is reduced by GSH, becoming cell membrane impermeable 
and thus causing damage. However, the high levels of GSH assist in protecting the cells 
against the deleterious toxin effects. B) When the transsulfuration pathway is disrupted, 
less GSH is produced, yet there is enough to retain gliotoxin intracellularly, facilitating 
damage. The decrease in GSH results in less cellular protection against gliotoxin. C) In 
the absence of ∆gsh1, no GSH is produced. Therefore, gliotoxin cannot be retained in 
the cell and no deleterious effects can be elicited.       
 
Taking all results into account, the yeast response elicited by gliotoxin in this 
study is largely characteristic of cellular OS and the majority of mutant analyses have 
supported this finding. Thus, we come to the conclusion that gliotoxin exposure is likely 
to impose OS on S. cerevisiae. Importantly, the damaging effects caused by the toxin 
which result in yeast growth inhibition can be arrested by the constitutive expression of 
the A. fumigatus GliT gene (figure 5.2). 
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Figure 5.2 Principal effects of gliotoxin on S. cerevisiae. 
 
 
To further validate the conclusion that gliotoxin induces conditions of OS in 
yeast cultures, additional advanced genetics must be applied. To extensively elucidate 
the proteins required by S. cerevisiae to withstand gliotoxin exposure it would be 
necessary to create double mutants deficient in more than one OS defence system. It has 
been demonstrated in this study that ∆sod1 displays increased sensitivity to gliotoxin, 
emphasising the importance of superoxide dismutase in protection against the toxin. 
Sod1p is involved in the dismutation of the superoxide anion O2- to the less damaging 
H2O2 and O2 (McCord and Fridovich, 1968, McCord and Fridovich, 1969a). Yeast 
deleted for the CTT1 gene in this study did not appear to display increased sensitivity to 
gliotoxin. As the catalase T protein encoded by this gene catalyses the decomposition of 
H2O2 to O2 and H2O (Loew, 1900, Hartig and Ruis, 1986), which may be viewed as the 
next step of detoxification after SOD activity, it would be of interest to assess the 
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growth of ∆sod1∆ctt1 in the presence of gliotoxin, compared to wild-type and the single 
mutants. 
A number of mutants deleted for genes involved in the sulfur amino acid 
biosynthesis pathway have exhibited a wild-type growth rate in the presence of 
gliotoxin. However, ∆cys3 displayed increased sensitivity. 
As the sulfur amino acid biosynthesis and glucose fermentation pathways are 
both highly stimulated by gliotoxin exposure, disruption of both pathways followed by 
mutant analysis would be interesting. This would determine if stimulation of the glucose 
fermentation pathway is a direct consequence of gliotoxin exposure or if it is a result of 
increased sulfur amino acid biosynthesis.     
To further advance our understanding of the way in which S. cerevisiae responds 
to gliotoxin, it might be of interest to investigate gliotoxin-induced apoptosis. It has 
been reported that gliotoxin induces apoptosis in immune cells, while the garlic-
derivative allicin achieves a similar result in yeast cells (Waring et al., 1988, Zhou et al., 
2000, Stanzani et al., 2005, Gruhlke et al., 2010). It is known that ROS act as apoptosis-
regulators in yeast (Madeo et al., 1999), thus much of the data illustrating the yeast 
response to gliotoxin may be indicative of Programmed Cell Death due to OS. A 
comparison of the yeast cellular response to gliotoxin and allicin could potentially yield 
some interesting results and provide insight into gliotoxin-induced apoptosis in yeast.  
To test the hypothesis depicted in figure 5.1, it would be of interest to measure 
the levels of intracellular GSH. Subsequent to this, the location of oxidised gliotoxin in 
these strains could be monitored and compared, perhaps using [14C]-labelled gliotoxin. 
This could provide evidence for the requirement for GSH in facilitating gliotoxin-
induced cellular OS. 
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Part 2 Investigation into the mode of action of the prion-curing drug 
Tacrine 
 
 
One of the main aims of this study was to gain further insight into the mode of 
action of TA. Along with this drug, 6AP and GA have been shown to exhibit prion-
curing activity in yeast (Bach et al., 2006, Tribouillard-Tanvier et al., 2008a, 
Tribouillard-Tanvier et al., 2008b). Due to the fact that 6AP and GA have been studied 
in more detail than TA, these drugs were utilised to compare the effects of TA with.  
The work discussed here provides support for previous findings identifying TA, 
6AP and GA as yeast prion-curing agents. Although a certain level of background 
curing by GdnHCl is required for any of these drugs to cure wild-type [PSI+] in yeast, it 
has been demonstrated in this study that in a suitable background strain, the effects of 
TA, 6AP and GA alone can be seen.  
Unlike 6AP and GA, TA is known to be inactive against mammalian prions 
(Tribouillard-Tanvier et al., 2008a), highlighting the fact that its mode of action differs 
to that of 6AP and GA and the results obtained in this study comply. It appears that all 
three drugs cure [PSI+] through chaperone activity inhibition. While it has been reported 
that 6AP and GA inhibit ribosomal-mediated protein folding (Tribouillard-Tanvier et al., 
2008b), the work presented here suggests that TA may also function through targeting 
chaperone activity, specifically that of Hsp104p. GdnHCl is known to prevent [PSI+] 
propagation through inhibition of Hsp104p activity (Chernoff et al., 1995, Ferreira et al., 
2001). Thermotolerance assays have illustrated that a combination of GdnHCl and TA, 
at concentrations that are alone ineffective at inhibiting Hsp104p activity, clearly have 
the capacity to inhibit the chaperone. This implies that TA may also hinder Hsp104p 
activity, in a similar manner to GdnHCl. Interestingly, these results were not observed 
upon performing the same assay using 6AP and GA, suggesting that the ability to 
enhance the effects of GdnHCl is unique to TA.  
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The difference in modes of action of 6AP and GA compared to that of TA is 
supported by results from curing curve analysis. The curing curves indicate that all 
drugs prevent prion propagation, and similarly to GdnHCl, facilitate the dilution of the 
prion out of cells over time. However, the curing patterns of 6AP and GA are different 
to that of TA. TA effects only appear after 7 generations, while 6AP and GA seem to 
have a direct effect after 5 generations. This implies that although 6AP and GA may 
have different targets to TA, they are more potent agents. No further results dispute that 
6AP is more potent that TA, however disc assays suggest that GA is the least potent 
compound as the smallest zone of curing was observed for this drug.  
Despite the fact that the results discussed here and published by other groups 
suggest that 6AP and GA, and TA target ribosomal and Hsp104p chaperone function 
respectively, disc assays propose that any or all of these drugs may also target Hsp70p 
or its ATPase binding cycle. This is apparent as disruption (through gene deletion) of 
the ATPase binding cycle magnifies the curing capacities of all 3 drugs. The fact that 
the expression of many Hsp70p cochaperone genes is downregulated upon TA exposure 
adds weight to this hypothesis. Perhaps the presence of TA disrupts the regulation of the 
Hsp70p ATPase binding cycle. If it is the case that TA, 6AP, or GA cure [PSI+] through 
targeting Hsp104p or Hsp70p, they do not mediate their effects through altering the 
expression levels of these proteins. Western blot analysis has demonstrated that the 
expression levels of these proteins remain stable under drug exposure. 
Results obtained from investigating the S. cerevisiae response to 20 µM TA 
combined with 200 µM GdnHCl suggests that a combination of the two imposes 
cellular stress upon yeast cells. After 1 hr. exposure to TA and GdnHCl combined, the 
cells mount a stress response, which decreases after 3 hr. exposure and furthermore 
under treatment for 14 generations. This implies that these concentrations of TA and 
GdnHCl induce cellular stress, to which cells adapt over time. Support is provided by 
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the fact 2-dimensional gel electrophoresis illustrates that the glucose fermentation 
pathway appears to be stimulated in the presence of TA and GdnHCl combined. As 
discussed in chapter 3, stimulation of glucose fermentation may be linked to conditions 
of OS.           
Prion-curing drugs such as 6AP and GA function through targeting ribosomal 
activity (Tribouillard-Tanvier et al., 2008b). Ribosomal instability caused by the 
deletion of YAR1 or LTV1 does not cure [PSI+] but destabilises it, leading to the 
appearance of spontaneous [psi-] colonies (M. Blondel, personal communication). The 
results under discussion here show that ∆ltv1 [PSI+] is less sensitive to curing by all 
three drugs, supporting the previous findings that exposure of this strain to 6AP and GA 
stabilises the weakened prion (M. Blondel, personal communication). In this study, it 
was demonstrated that the absence of LTV1 and YAR1 (alone and in combination with 
HSP104) severely alters chaperone activity and cellular recovery and survival post 
heatshock. It appears that Hsp104p acts synergistically with both Ltv1p and Yar1p to 
facilitate induced thermotolerance, and that Yar1p plays a more important role than 
Ltv1p in allowing cellular survival following heatshock. Interestingly, the recovery of 
luciferase activity occurs more rapidly when cells are deleted for YAR1 or LTV1. 
However, when these genes are deleted in the ∆hsp104 background the luciferase 
recovery rate is lower than even that for ∆hsp104. Despite the apparent confliction of 
results from thermotolerance and luciferase assays, the results cannot be compared. 
Thermotolerance assays involve the assessment of the whole cellular response, leading 
to cell survival. Thus, it must be considered that a range of proteins contribute to the 
observed result. Conversely, luciferase assays examine the refolding activity of one 
protein, thus, the two assays do not equate.           
It is reasonable to believe that TA may target Hsp104p and mediate its effects 
through regulation of Hsp104p activity. The fact that in a suitable background strain, 
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TA has been shown to cure [PSI+] in the absence of GdnHCl suggests that this drug 
does not function solely through enhancing the uptake of GdnHCl. Ideally, the [14C]-
labelled GdnHCl assay should be attempted again to confirm this, perhaps using fresh 
materials. If the assay procedure is perfected and fully functional, TA could be utilised 
and its ability to enhance the uptake of GdnHCl could be tested.  
It would be interesting to investigate whether or not TA interacts with Hsp104p. 
To accomplish this, and also to assess the molecular basis of TA-mediated effects 
through protein interaction, a relatively new technique could be applied. West et al. 
(2010) described a method involving protein chemical modification and mass 
spectrometry, which they employed to identify the complete set of targets of the 
immunosuppressant cyclosporin A. This technique could potentially be utilised to 
identify the yeast targets of TA and could provide great insight into the drug’s mode of 
action. Following this, mutant analyses could be performed, to assess the ability of TA 
to cure [PSI+] cells in the absence of possible TA targets. This would potentially give a 
similar result to that which would have been achieved had EMS mutagenesis been 
successful.       
 Regarding ∆ltv1 and ∆yar1 mutant studies, future work should involve 
performing Western Blot analysis to assess the expression levels of Hsp70p and 
Hsp104p in these mutant strains under TA, 6AP and GA exposure. Additionally, the 
viability of the double mutant ∆ltv1∆yar1 requires consideration. If this strain is shown 
to be viable, it should be employed in luciferase and thermotolerance assay performance.   
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